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Abstract 
Communication within and between cells is called signalling; elucidation of cell signalling in 
diseases, especially metastatic cancers, creates opportunities for developing therapeutic 
interventions. Signalling initiation occurs when a cell surface receptor binds a ligand; the signal 
then transmits via phosphorylation events through cytosolic signalling proteins to nuclear or 
effector proteins that orchestrate a cellular response. G-protein coupled receptors (GPCRs) are 
one type of receptor; a sub-family of GPCRs are chemokine receptors, their ligands, chemokines, 
can trigger directional migration. Homeostatic chemokine-triggered migration can be hijacked by 
cancer cells to facilitate metastasis. This study explored various poorly understood aspects of 
chemokine signalling that may support metastasis with the aim of identifying therapeutic targets.  
Methodology employed THP-1, Jurkat and MCF7 cell-lines, the manipulation of signalling by 
antagonists, siRNA knockdown or plasmid modification, followed by calcium and chemotaxis 
assays, protein visualisation using immunofluorescence, flow cytometry and western blot.  
Investigations found that in THP-1 cofilin phosphorylation temporally relates to CXCL12-
stimulation and to chemotactic migration. In THP-1, but not Jurkat, JAK2 and STAT3 signalling 
support chemotaxis to CXCL12 and CCL2. Various NSAIDs, Aspirin and Paracetamol drug-
specifically influenced chemokine-induced migration and cofilin activity. Rac1, FAK/Pyk2 and Pi3K 
were found important for chemotaxis to CXC- but not CC-chemokines and to modulate cofilin 
phosphorylation. Rac1 inhibitor NSC23766 was found to compete with CXCR4 ligands. Many 
signalling proteins involved in cancer, including GRKs, Src, Raf, MEK, ERK, Cdc42, ROCK, β-catenin 
and p38MAPK were shown to positively influence chemotactic migration, also Arrestin-2 to 
support chemotaxis to CXCL12, and Arrestin-3 chemotaxis to CCL3. Dynamin inhibitors and siRNA 
knockdown produced chemokine, cell type, and dynamin domain-specific responses, Dynamin’s 
G-domain being important for CXCL12- and PH domain for CCL3-induced migration. PKC’s role in 
malignancies was found contradictory and isoform specific; PKCε and PKCδ supporting chemotaxis 
to CXCL12 but not CCL3, whereas PKCα and PKCζ influenced migration to both CXCL12 and CCL3. 
This thesis offers novel insights into the complexities of chemokine-induced migration. It 
examines many key signalling proteins implicated in cancer; reports that NSC23766 offers promise 
as a lead compound for developing CXCR4 biased antagonists; and offers possible mechanisms, 
through cofilin phosphorylation and effects on cell migration, for the mixed epidemiology 
reported for different NSAID’s with respect to their influences on cancer incidence and 
progression, and suggests Ibuprofen may offer anti-metastatic efficacy. 
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Chapter 1: Introduction 
Most of us have heard of cancer, many will understand that early detection can offer cure, this is 
because survival rate is dramatically dashed by metastasis, the movement of a cancer cell from its 
primary site to a secondary niche which supports its growth and division. Cancers are diverse; 
they comprise normal cells with acquired genetic instability and abnormalities that render them 
refractory to normal controlling influences on their growth, lifespan and location [1, 2]. 
Metastasis can occur in response to ‘come hither’ signals from amongst others chemokines, small 
proteins secreted by immune and other cells [3]. The signalling networks driving metastasis are 
only partially understood, some component proteins and pathways have been identified but the 
full network and its spatiotemporal dynamics represents a major objective in oncology research.  
Cancer touches most people’s lives at some point, either their own or someone dear to them; 
developing new therapies requires us to listen in and try to understand the conversations within 
and between our cells, contributing to our understanding of this signalling dialogue was the aim 
of my research. 
This chapter aims to acquaint the reader with the basics and some of the intricacies of 
chemokines, chemokine receptors and immune cells; and introduce key signalling proteins 
relevant to the research work reported in later chapters. 
1.1: Cells 
Eukaryotic cells are the basic structural and functional unit of the human body. Within each cell 
are many components each of which perform unique functions, figure 1. There are many different 
types of cells in humans together making up the different tissues; muscular, nervous, epithelial or 
connective. Some cells are dynamic and motile, cell movement often involves crawling over the 
extracellular matrix. This enables fibroblasts to move into wounds to support healing, and 
neutrophils and macrophages to respond to tissue invasion by pathogens. However with cancer 
cell movement facilitates metastasis  [4]. 
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Figure 1.1: Cancer cells may contain many of the components of normal cells but often display 
reduced cytoplasm, an abnormal shape, plus multiple or enlarged dark staining nucleus with an 
irregular nuclear border, a nucleus containing clumpy chromatin and multiple nucleoli.  
Cancer cells are normal cells that have acquired some or all of the following characteristics: 
Immortality so they are able to undergo repeated replication and resist apoptosis; DNA mutations 
and genome instability; an ability to induce angiogenesis, promote inflammation, avoid 
destruction by immune cells, and evade growth suppressors, also they may produce sustained 
proliferative signalling. Cancer cells also lose their ability to differentiate and have dysregulated 
cellular energetics [5]. For example a cell may become cancerous due to dysregulation of amino 
acid and glucose metabolism in response to abnormal growth factor signalling. Activation of a 
signalling pathway known as Pi3K/Akt may be key to this initial creation and support of a cancer 
cell because such signalling can trigger the reprogramming of mitochondrial metabolism [2]. 
Healthy cells compete for growth factors that govern their uptake of nutrients and maximise their 
ATP production via oxidative phosphorylation in mitochondria. However when growth factors are 
present in excess cells can increase their nutrient uptake and start using anabolic glycolysis, the 
energy production method commonly found in cancer cells. Nutrient supply appears key to cancer 
initiation [6]. Transcription factors are proteins that regulate the function of genes, oncogenes are 
genes that in some circumstances make a cell cancerous. Myc is an oncogene that can support 
this cancer initiation by promoting mitochondrial production of glutamine, a good carbon source 
and nitrogen donor, aiding macromolecule production and thus cell proliferation. Hence cancer 
can initiate from oncogene-directed metabolic reprogramming allowing anabolic growth, and cell 
proliferation [1]. 
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1.2: Cell communication 
Cells within any multicellular organism need to communicate with each other and respond to 
their environment. Cells talk to each other using small peptides or ions which, like words, can pass 
on an instruction or message and produce a physiological response. This talking is called cell 
signalling. Cell signalling can occur within cells (autocrine signalling), between neighbouring cells 
over short distances (paracrine signalling), or between cells or a collection of cells (a tissue) over 
longer distances (endocrine signalling). Intracellular communication between areas of the cell 
itself occurs via signalling pathways composed of membrane or cytosolic proteins. Passing the 
message (stimulus) between these proteins frequently involves protein phosphorylation which 
may activate or inactivate the next protein/s in the pathway. A cell’s architecture is fundamental 
to its morphology and its mobility; signalling can modify a cell’s morphology causing temporally 
and spatially transient changes in protein complexes within the many intracellular domains. The 
signalling cascade can initiate cellular responses e.g. activation of transcription factors, or cell 
movement [7, 8].  
Immune cells employ a communication process facilitated by small protein signalling molecules 
that are secreted from one cell and detected by another cell or cells. Cells detect these signalling 
molecules, also called ligands, using receptors which are usually transmembrane proteins located 
within their plasma membrane. There are many different receptors, and each ligand will have 
affinity for and bind one or more receptors. Each receptor may bind one or more ligand. After 
binding the ligand/receptor pair can activate one or more intracellular signalling ‘pathways’ within 
the cell, usually producing an end response. Responses can include stimulating the cell to move 
up a chemical gradient which is termed cell migration [9, 10]. 
1.3: Cancer and metastasis 
Cancer is where abnormal cells undergo uncontrolled division, often invading nearby normal 
tissues. Metastasis is the spread of these cells to a distant secondary site in the body. In cancer 
communication within and between cells goes wrong. Stem cells exist in a ‘niche’; changes in their 
microenvironment or various transcription factors and signalling can activate them to make 
progenitor cells which then differentiate to generate tissues as required. When this goes wrong 
uncontrolled growth can initiate a benign tumour which may over time become cancerous. 
Cancer may also initiate through somatic mutation triggered by environmental stimulus, such as 
UV light or carcinogenic chemicals, or may arise from congenital insults, genetic defects, 
inflammation, ageing, and/or infection by virus or parasite [3, 11].  
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Cancer is not one disease; cancers are individual, complex and usually heterogeneous, so for 
example only some of the cells within a tumour will be capable of endless self-renewal i.e. 
malignant. Tumours are complex microenvironments composed of cohabiting malignant, healthy 
and immune cells. No two people’s cancers are the same, as their oncogenic, genetic, epigenetic 
and immunological phenotypes will differ [11].  
1.3.1: Cell signalling in metastasis 
Cell-cell communication in cancers encompasses many feedback loops that can activate or inhibit 
cell growth [3, 11]. The prevention of cancer progression, the migration of malignant cells from 
the localised primary tumour to secondary locations, requires a better understanding of cell 
signalling within malignant cells and between tumours and healthy tissues, as it is this 
communication that facilitates cell migration. Elucidating signalling pathways supporting 
metastasis is challenging, but considerable progress has been made, for example the 
dysregulation of calcium homeostasis has long been recognised as a casualty of cancer [12], with 
intracellular calcium dynamics modulating organelle functions, oncogenesis and ultimately cell 
death [13, 14]. Much is known about the role of cell energetics, glycolysis and mitochondrial 
respiration as mediators in cancer progression [2], and that mutations of receptors, key initiators 
of many signalling pathways, can also contribute to malignancy [15].  However to develop new 
therapies we need a better understanding of cell signalling.  Immunotherapies, such as the 
checkpoint inhibitors, Programmed Death Protein-1 (PD-1) and Cytotoxic T Lymphocyte 
associated Antigen-4 (CLTA-4), are amongst the most innovative of the new treatments available 
for cancer. They are monoclonal antibodies that by binding inhibitory surface receptors on the 
cancer cells re-target cytotoxic T-cells to destroy cancer cells [16].  
1.4: G-Protein Coupled Receptors 
The surfaces of most cells bristle with a multitude of different receptors which enable the cell to 
communicate with its environment. Contributing to this array is the family of G-Protein Coupled 
Receptors (GPCRs), of which there are over 800 distinctly different members [17]. GPCRs mediate 
responses to many different stimuli (agonists) which may arrive in the form of light, peptides, 
proteins, or sugars. Examples include hormones, neurotransmitters and immune system 
messaging proteins called cytokines. GPCRs are membrane proteins consisting of a peptide chain 
with a conserved basic tertiary structure that consists of seven hydrophobic transmembrane 
regions. When an agonist binds the GPCR, it undergoes a conformational change favouring its 
coupling with three intracellular heterotrimeric guanine nucleotide-binding proteins (G-proteins), 
Gα, Gβ and Gγ. Guanine exchange factors (GEFs) then promote GDP exchange for GTP on the Gα 
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subunit; this allows Gα-GTP and Gβγ to dissociate and interact with various effector proteins. The 
extracellular stimulus is translated into tightly regulated, highly specific, intracellular signalling 
cascades [18, 19]. GPCRs can be regulated by receptors becoming refractory to stimulus 
(desensitisation), receptor internalisation by endocytosis, and by longer term down-regulation of 
receptors. The desensitisation can be through the action of kinases; protein kinase A (PKA), 
protein kinase C (PKC), and G-protein receptor kinases (GRKs) which may trigger binding of β-
arrestins, halt G-protein activation and trigger desensitisation of GPCR [20, 21].  
1.5: Chemokines  
Cytokines are small secreted proteins that influence cell behaviour through modulation of cell 
signalling. Chemokines are a large subfamily of chemotactic cytokines [22]. Cell signalling allows 
cells to sense and respond to their environment and maintain homeostasis. Aberrant signalling 
between and within cells can initiate and perpetuate cancers [23]. Chemotactic chemokines can 
play a role in homeostasis. These small 8-12 kDa basic proteins regulate cell migration when they 
interact with and activate a specialist type of GPCR termed a Chemokine Receptor. Spatial and 
temporal expression of chemokines regulate the trafficking and locations of many cell types 
including leukocytes [24, 25].  
There are four sub-families of chemokines classified by the arrangement of the initial two 
cysteines (C) with respect to non-cysteine residues (X) within each chemokine amino acid 
sequence. The largest two of these four families are the CXC chemokines, where one amino acid 
separates the first two cysteines at the N-terminal of the peptide chain, and the CC chemokines, 
where cysteines are adjacent. The other two families, known as XC and CXXXC, have very few 
members [26]. Although there is promiscuity in interactions between chemokines and their 
cognate GPCR, many restrict their ligand-binding to favoured partners [24, 25]. Leukocytes can 
express many different chemokine receptors. This differential expression allows the recruitment 
of specific cell types to specific tissues or locations providing a tailored appropriate immune 
response to the infective or inflammatory insult [26].  
1.6: Chemokine receptors 
Chemokine receptors are subdivided into CC, CXC, XC and CXXXC with respect to their favoured 
ligands [25]. There are at least 18 Gαi-coupling chemokine receptors and 5 non-chemotactic 
Atypical Chemokine Receptors (ACKRs). ACKRs may undertake roles such as recycling or 
scavenging chemokines to maintain chemotactic gradients. Interestingly some chemokines have 
dual roles, as they can also act as classical receptor antagonists, antagonising ligand-receptor 
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interactions and responses. For example CXCL11 acts as a CCR5 antagonist and so hinders the 
binding of CCR5 ligand CCL3 [27, 28]. Some chemokine receptors are also the target of non-
chemokine ligands e.g. macrophage migration inhibitory factor (MIF) is a cytokine that binds 
CXCR4 [29] as does extracellular ubiquitin [30] and nuclear protein HMGB1 [31]. 
On chemokine receptor activation the signal passes to GPCR-associated G-proteins, subunits α, β 
and γ. The GDP on the Gα subunit is phosphorylated to GTP, Gα dissociates from Gβγ and, 
depending on stimulus, subunits trigger particular intracellular signalling proteins and pathways. 
There are at least four Gα subtypes Gαs, Gαi/o, Gαq/11, Gα12/13. Chemokine chemotaxis purportedly 
mainly follows Gαi or Gα12/13 signalling and can involve Rho family GTPases, RhoA, Rac1 and Cdc42 
[18, 32, 33]. Signalling cascades can be triggered through both Gα and Gβγ and involve 
phospholipase C (PLC) isoforms. Diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) 
produced in response to PLC signalling can trigger many converging or diverging signalling 
pathways within the cell; for example PLCβ signalling via phosphoinositide 3-kinase (Pi3K) to 
phosphatase Slingshot (SSH), which can activate a small protein called cofilin which remodels the 
key cytoskeletal protein actin enabling leukocyte polarization and cell chemotaxis [34]. 
1.7: Inflammatory and homeostatic chemokines 
Chemokines can also be classified into functional groups such as ‘inflammatory chemokines’, 
including CXCL9, CXCL10, CXCL11, which can act to produce increased inflammation. 
Inflammatory CC chemokines include CCL3 (MIP-1α) and CCL2 (MCP-1), figure 1.2. ‘Homeostatic 
chemokines’ is another classification. Many CC chemokines are coded on chromosome 17q12 and 
CXC chemokines on 4q13.3. However homeostatic chemokines are coded at other loci, for 
example CXCL12, on 10q11.21. [35]. CXCL12 is usually constitutively expressed in lymphoid tissues 
and can mediate homeostatic chemotaxis of lymphocytes and other cells. However CXCL12 can be 
upregulated and become inflammatory in disease including in cancers. Dysregulated chemokine 
or chemokine receptor expression can trigger or worsen prognosis in diseases including those 
involving inflammation or malignancy [3, 36]. 
A             B  
Figure 1.2: Examples of (A) CC and (B) CXC chemokine receptors and their ligands.  
CCR1 CCR4 CCR5 CCR2
CCL3 CCL2
CXCR4 CXCR7 CXCR3
CXCL12 CXCL11 CXCL9
CXCL10
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1.8: Receptors CXCR4, CXCR7 (aka ACKR3) and their ligand CXCL12 
CXCL12 is typical amongst homeostatic chemokines in binding only two chemokine receptors, 
each with non-redundant specific roles. CXCL12 binds CXCR4 and CXCR7, CXCL11 binds CXCR3 but 
also binds CXCR7 which is an ACKR. Atypical receptors are still seven transmembrane proteins but 
do not signal like classical chemokine receptors. They can lack the DRYLAIV motif in their second 
intracellular loop which aids coupling to Gαi G-proteins [37, 38]. CXCR7 is well conserved across 
species [39]. It is known to dimerize with CXCR4 and may moderate the effects of CXCL12 binding 
CXCR4. CXCR7 may produce atypical signalling, not via G-proteins [40], and can act as a CXCL12 
sink [41]. Interestingly although CXCR7 is not highly expressed in healthy tissues in an adult it is 
frequently present in malignant cells and through MAPK signalling can promote neo-angiogenesis 
[40]. CXCR4-CXCL12 signalling is key in keeping hematopoietic stem cells in the bone marrow [42]. 
Unfortunately this ability of CXCR4-CXCL12 signalling to support homing of stem cells can be 
hijacked by tumour cells, as CXCL12 can aid metastasis and the formation of secondary tumours 
[43]. 
1.9: ELR-positive and -negative CXC chemokines 
CXC chemokines can further be classified on the absence or presence of the glutamic acid-leucine-
arginine (ELR) sequence occurring just prior to the CXC sequence. ELR-positive CXC chemokines 
mainly promote angiogenesis (examples include CXCL1, CXCL5 and CXCL8) whereas ELR-negative 
CXCs mainly inhibit angiogenesis [44]. CXCL9 (aka MIG), CXCL10 (aka IP-10) and CXCL11 (aka ITAC) 
are all ELR-negative and inhibit angiogenesis. They also attract anti-tumour T-lymphocytes and so 
may cause tumour regression [45-47]. CXCL9, CXCL10 and CXCL11 all bind CXCR3 which has three 
splice variants CXCR3-A, CXCR3-B and CXCR3-alt. CXCR3-A supports proliferation and chemotaxis, 
whereas CXCR3-B inhibits migration, proliferation and can trigger apoptosis [48, 49].   
1.10: Chemokines and T-lymphocytes (T-cells) 
Chemotaxis is when a cell senses a chemokine and moves or ‘taxis’ towards it up the chemokine 
concentration gradient. In homeostasis this draws leukocytes towards damaged or infected cells 
releasing chemokines [50]. Chemokines can recruit effector T-cells including CD8+ T-cells 
(cytotoxic T-cells) and T-helper CD4+ cells type 1 and 2 (TH1 and TH2). Both types are T-helper cells 
supporting and regulating adaptive immune system function. TH1 and TH2 differ in the cytokines 
and type of immune responses they produce. Chemokines can also recruit Natural Killer (NK) cells 
which can engage with and cause apoptosis in malignant cells. TH1 and NK cells express CXCR3, 
the receptor for ligands CXCL9 and CXCL10; these chemokines draw TH1 and NK cells into the 
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tumour microenvironment, figure 1.3. The presence of TH1 and NK cells can improve patient 
prognosis and reduce metastasis [51, 52], and their presence in tumours improves outcomes as 
they increase CD8+ T-cell secretion of interferon-γ and reduce metabolism of the 
chemotherapeutic agent cisplatin by tumour-associated fibroblasts [53].  
 
Figure 1.3: Immune cells can be recruited into the tumour microenvironment by chemokines; T-
reg and Plasmacytoid Dendritic Cells (pDC) are recruited by CXCL12 and CD8+ T-cells, and T-helper 
cells and NK cells by CXCL9 and CXCL10. Monocytes differentiate into M1 and M2 macrophages. 
M1 macrophages stimulate the immune system, are microbiocidal and cause tumour cytotoxicity, 
whereas M2 macrophages support tumour growth by promoting matrix remodelling and 
angiogenesis [43, 54-56]. 
Human T-helper-17 cell (TH17) function in human tumours is somewhat controversial [57] but 
they do express CXCR4 [58] which may aid their recruitment and retention in inflamed and 
malignant tissues where there are high levels of CXCL12. TH17 can recruit CD8
+ T-cells, dendritic, 
and NK cells [59-62] into the tumour micro-environment; this is clinically helpful [63].  
Tumour metastasis frequently occurs in the bone marrow, an immunosuppressive 
microenvironment that can aid malignant cell survival and growth. Regulatory T-cells (T-regs) aka 
suppressor T-cells maintain self-tolerance, preventing autoimmune disease, but also suppress 
immune responses to malignant cells [64]. T-regs can be recruited into the bone marrow and 
tumour microenvironments by CXCL12 as they express CXCR4. Increasing T-reg bone marrow load 
promotes an immune suppressive environment favouring implantation and growth of bone 
metastasis [65, 66].  
NK cells express chemokine receptors including CXCR3, CCR2 and CCR5 [67]; CCR2 aids the 
movement of NK cells into tumours [68]. NK cells can activate CD8+ and other T-cells to attack and 
kill tumour cells. NK cells are part of the non-specific innate immune system. They have a single 
invariant antigen receptor which recognises a specific glycolipid antigen enabling them to activate 
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CD8+ T-cells to target and kill MHC-positive tumour cells, whereas the NK cells themselves can kill 
MHC-negative tumour cells [55]. 
1.11: Chemokines and B-lymphocytes (B-cells) 
B-lymphocytes mature in the bone marrow and can develop into memory B-cells or plasma cells 
producing antibodies. Both form part of humoral immunity and the Adaptive Immune System. B-
cells can act as Antigen Presenting Cells (APCs) and secrete cytokines [69], including some 
chemokines, and may also express CXCR4. Hence they may be recruited by CXCL12 into tumour 
microenvironments where they may improve prognosis [70, 71]. In lymphatic tissues associated 
with tumours B-cells may express chemokines which helpfully increase T-cell responses. B-cells 
can also serve as APCs in the tumour microenvironment and may positively or negatively 
influence anti-tumour immunity [72]. 
CXCL12 can recruit Plasmacytoid Dendritic Cells (pDC), which are part of the innate immune 
system. pDCs produce interferons and some chemokines including CXCL10 and CCL3 which attract 
immune cells to sites of infection or inflammation, and they also present antigens to CD4+ T-
helper cells.  pDCs also express chemokine receptors including CXCR3, CXCR4, CCR2 and CCR5. 
pDCs need to express CCR2 and CCR5 to egress from the bone marrow whereas CXCR4 expression 
allows their retention in the bone marrow stroma where their development occurs, but also 
allows their attraction into CXCL12-producing tumour environments where they can impair T-cell 
destruction of malignant cells and so hinder prognosis [56, 73]. pDCs also produce pro-
inflammatory cytokines and trigger immune tolerance favouring cancer progression [74].  
1.12: Tumour-associated macrophages, CCL2 and CCL3 
Macrophages are large phagocytic leukocytes that develop from monocytes produced by stem 
cells in the bone marrow. Macrophages express CCR2 and so can respond to CCL2 and be 
attracted into tumours [75]. High numbers of Tumour Associated Macrophages (TAM) correlate 
with poor prognosis [76] as they can inhibit helpful T-cell activation [77], increase resistance to 
chemotherapy [78] and support metastasis [76]. This is because TAMs secrete CCL2, which can 
induce CCL3 secretion from metastasis-associated macrophages at metastatic sites; this can aid 
growth of secondary tumours [79]. However in some circumstances macrophages may aid 
survival. They can assist tumour-associated antigen T-cell ‘cross-priming’ by phagocytosing dead 
malignant cells then cross-presenting cancer antigens to cytotoxic T-cells, promoting the T-cells to 
attack live malignant cells [80]. Depending on the treatment employed macrophages may support 
or antagonise cancer therapy [81]. This is because TAMs can be influenced by their environment 
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to differentiate into an inflammatory (M1) or pro-tumour (M2) state. Bacterial 
lipopolysaccharides and interferon-γ induce macrophage polarization into M1-subtypes that can 
kill cancer cells. However when entering tumours macrophages encounter cytokines such as 
interleukin-10 that can polarise them into M2-subtypes which can support tumour growth [54]. 
CCL2 is frequently produced by malignant tumours and the level of production correlates with 
macrophage infiltration. Excess CCL2 production can lead to TAM accumulation and tumour 
destruction, whereas modest accumulations can cause inflammation and tumour initiation. TAMs 
themselves may also produce CCL2 [82-84]. 
CCL2 and CCL3 can support tissue invasion as they stimulate the secretion of Matrix 
Metalloproteases (MMP), including MMP9, by monocytes. Matrix metalloproteases are molecular 
scissors, as they aid intracellular matrix penetration by migrating cells [85]. Circulating monocytes 
are precursors of macrophages [77]. CCL2 released from a tumour can recruit monocytes 
expressing CCR2 [86] from the blood. Treatment with the anti-CCL2 antibody, Carlumab, prevents 
this and reduces metastasis e.g. from breast to lung. However once Carlumab is withdrawn 
metastasis is accelerated. This could be due to a feedback mechanism accelerating tissue 
production of CCL2 [87], or that blocking CCL2 accumulates monocytes in the bone marrow which 
are released upon Carlumab withdrawal, allowing mass monocyte infiltration into metastatic 
tumours [88], which also increases local vascular endothelial growth factor (VEGF) and CXCL8 
(interleukin-8) levels. CCL2 and CCL3 also support metastasis and angiogenesis, as the formation 
of new blood vessels allows tumours to grow [89]. However, even if TAM accumulation could be 
effectively prevented neutrophil accumulation may take its place, and have equally detrimental 
pro-tumour and pro-metastatic effects [85, 90]. Additionally CCL2 stimulates JAK2 and p38 
mitogen-activated protein kinase (MAPK) signalling supporting metastasis [91]. CCL2 can also 
promote proliferation via activation of Rho GTPases [92], Epithelial Mesenchymal Transition 
(EMT) [93], and the survival and motility of cancer cells [92]. EMT is the process where epithelial 
cells lose their polarity, cell-cell adhesiveness, become migratory and invasive by gaining 
mesenchymal multipotent and stem-cell like properties. EMT is essential for embryogenesis but 
the process in later life facilitates metastasis of tumours [94]. 
CCL2 and CCL3 signalling can recruit macrophages into malignant tissues. These chemokines 
target CCR1, CCR2 and CCR5. Blocking this recruitment may inhibit accumulation of 
immunosuppressive leukocytes in the tumour microenvironment, stall metastasis and tumour 
neoangiogenesis [75, 79]; indeed, reducing macrophage load may increase anti-PD-L1 
immunotherapy success [82]. However blocking chemokine production alone appears ineffective 
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[87], but may work synergistically with developing therapies such as cancer vaccines. For example 
CCL2 inhibition in mouse models potentiates cancer vaccines in lung cancer [95]. Recently clinical 
trials were conducted with a CCR2 antagonist CCX872-b [96], however treatment did not have a 
control so the benefits of adding CCX872-b to standard 5-fluorouracil, leucovorin, irinotecan, 
oxaliplatin regimens are not easily analysed. An anti-CCR2 monoclonal antibody Plozalizumab 
(MLN1202), which stops CCL2 binding CCR2, that reached phase-2 trials for bone metastasis has 
been withdrawn, although in trials for arthrosclerosis Plozalizumab did appear to reduce C-
reactive protein levels, a marker for inflammation [97].  
1.13: Tumorigenic signalling complexities, CXCL9, CXCL10, CXCL11 and CXCL12. 
CXCL9, CXCL10 and CXCL11 chemotaxis and signalling through CXCR3 can be key in orchestrating 
anti-tumour immune responses such TH1 T-cell polarisation, the recruitment of cytotoxic T-cells, 
NK cells and IFNγ production [98]. However these chemokines can also support metastasis and 
cell proliferation [99]. This converse situation illustrates the difficulty of designing effective 
immunotherapies. Immune cell chemotaxis is dependent on chemokine gradient and chemokine 
receptor expression but also on other modulators present in vivo for example CXCL9, CXCL10 and 
CXCL11 expression by monocytes and malignant cells is upregulated by cytokines such as TNFγ, 
and Tumour necrosis factor alpha (TNFα) [100, 101]. Additionally there are the CXCR3-A and 
CXCR3-B receptor subtypes whose responses differ [49] as well as factors such as CXCL9, CXCL10 
and CXCL11 acting as antagonists to CCR3 which itself stimulates TH2 polarization [102]. 
CXCL12 can work synergistically with VEGF to produce angiogenesis to support tumours [60]. 
CXCL12 supports malignant cell survival and proliferation [103], plus CXCL12-CXCR4 signalling 
promotes metastasis, invasion of cancer cells [104] and possibly radiation resistance [105]. When 
CXCL12 binds CXCR7, the receptor may act as a scavenger [106] but CXCL12-CXCR7 may also signal 
in malignant and associated endothelial cells via non-G-protein pathways e.g. CXCR7 is reportedly 
able to signal via ERK1/2 and p38 MAPK-kinase, Gαi-independently in Jurkat [107], and via 
JAK2/STAT3 upregulating β- and N-cadherin [108]. β-catenin is involved in transcription, and along 
with N-cadherin, in cell-cell adhesion and migration. β-catenin expression and signalling can be 
upregulated in cancers and is reported to suppress chemokine expression and so the attraction 
and activation of effector T-cells. β-catenin signalling is tumorigenic, as it supports EMT and 
changes in cancer cells to a stem-cell-like phenotype [109].  
Conversely CXCR7 signalling in astrocytes is reported to involve pertussis toxin sensitive Gαi/o G-
proteins, and stimulate ERK1/2 and Akt via β-arrestin-2 triggered internalisation [110, 111]. 
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CXCL12-CXCR7 signalling may support angiogenesis by increasing VEGF levels [112]. Inhibiting 
CXCR7 can inhibit T-cell chemotaxis [106]. CXCR7 expressed in malignant cells may increase 
survival, growth, adhesion and invasion of breast [113], prostate [114], and lung cancer cells [115] 
although CXCR7 expression may also aid lung repair after insult [116]. MCF7 breast cancer cells 
have been shown to express CXCR4, and at lower levels CXCR7. Knocking out CXCR7 with small 
interfering RNAs (siRNA) modestly reduced proliferation in MCF7, but no further inhibition of 
proliferation was observed if both CXCR4 and CXCR7 were depleted with siRNAs, suggesting 
proliferation in this cell-line involves CXCR4-CXCR7 dimerization. Interestingly MCF7 were found 
to strongly express both CXCL12 and CXCL11 [117]. The generally observed upregulation of CXCR7 
in cancer cells compared to healthy cells may be a disease response aimed at repair. 
1.14: Oncogenic and epigenetic influences on chemokines  
DNA methylation of genes can modulate the expression of chemokines such as CXCL9 and CXCL10 
in malignant cells, and so influence the trafficking of cytotoxic and NK cells into cancerous tissues 
that may be critically important for the success of some immunotherapies such as PD-L1 inhibitors 
[118]. These are immune checkpoint inhibitors; they facilitate the immune system attacking the 
cancer cells but leaving healthy tissue alone. PD-1 is a checkpoint protein on T-cells; cancer cells 
can carry PD-L1, a protein which when it binds PD-1 stops the T-cells attacking and destroying 
them. Monoclonal antibodies that bind either PD-1 or PD-L1 block the interaction and the T-cells 
remain able to attack and destroy the cancer cells. Examples of PD-L1 monoclonal antibodies 
include Pembrolizumab and Nivolumab [119]. Drugs aiming to reprogram epigenetic signatures 
may restore chemokine expression and so also T-cell movement into tumours [118].  
CXCR4 in malignant cells carrying a point mutation, making the receptor functionally active, 
showed increased signalling and chemotaxis to CXCL12, but conversely the mutation slowed 
tumour growth. Inhibition of this mutated CXCR4 with AMD3100, a small molecule CXCR4 
antagonist, reversed this slowdown but only in vitro not in vivo [120]; chemokine gradients may 
have contributed to this outcome. Other genetic mutations can also increase CXCR4 expression, 
for example, in rhabdomyosarcoma fusion of PAX3 and FKHR genes occurs, which increases the 
cancer cells’ invasiveness [121]. Hypoxia is a common feature in central zones of solid tumours, 
and it can stimulate CXCL12 [122] and CCL2 expression [123]. Transcription factors such as 
Hypoxia-Inducible Factor 1 (HIF1) mediate malignant cell responses to hypoxia [124]. HIF1 may 
bind the promoter region of CXCL12 gene-inducing translation of CXCL12 mRNA. Hypoxia can also 
stimulate both malignant cells and TAMs to express CXCR4 [125, 126] and inhibit expression of 
13 
 
CXCR7 [127]. Blocking CXCL12-CXCR4 signalling may be therapeutic in cancers as the signalling 
supports cell proliferation, invasiveness, angiogenesis and metastasis [128, 129].  
1.15: Chemokine receptor CXCR4 and metastasis  
CXCL12/CXCR4 aberrant signalling is heavily implicated in cancer, tumour angiogenesis and the 
survival and metastasis of malignant cells [130, 131]. The expression of CXCR4 is reportedly 
upregulated in many malignancies [132]. However CXCR4 can also be essential to maintain health. 
For example in B-cells CXCR4 expression facilitates immune responses to infection and 
autoimmune diseases [133]. Somatic homeostasis may also involve immune modulation by the 
sympathetic nervous system, for example adrenaline stimulation of B2-aderenergic receptors 
may, through interaction with CCR7 and CXCR4 receptors, cause retention of lymphocytes in 
lymph nodes, resulting in reduced peripheral tissue concentrations of antigen-carrying T-cells in 
inflammatory diseases [134]. CXCR4 is therefore an attractive target for therapeutic manipulation. 
Blocking CXCR4/CXCL12 signalling with small molecule inhibitors has been shown to inhibit 
metastasis [135]. A simplification of the complex signalling through the CXCL12/CXCR4 axis in 
metastasis is illustrated in figure 1.4. 
 
Figure 1.4: CXCR4/CXCL12 signalling supports tumour cell spread from primary to secondary 
locations [136-140]. 
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1.15.1: Structure of CXCR4 and its interactions with CXCL12  
The CXCR4/CXCL12 axis influences so many complex physiological activities that the simple 
interaction of CXCL12 with CXCR4 would offer insufficient specificity. It is known that the cell 
context, along with both CXCR4 oligmerization and CXCL12 oligmerization, adds levels of control 
[141, 142]. CXCR4 is a class A GPCR [143]. Dimerization of CXCR4 has been shown by 
investigations of crystal structures with small antagonists, fluorescence resonance energy 
transfer, bioluminescence and other techniques to be key in functional selectivity, and in the gain 
of function of mutated CXCR4 in cancers and WHIM syndrome where there are heterozygous 
mutations of CXCR4 [144]. Recent research and crystal structures suggests that CXCR4 may 
interact with CXCL12 in 1:1, 2:2 or 2:1 CXCR4:CXCL12 ratios [145, 146].   
GPCRs have seven transmembrane helices which in CXCR4 are arranged in a goblet shape in such 
a way that two sub-pockets capable of accommodating ligands are available. These are known as 
the major pocket formed by helices 3, 4, 5, 6 and 7, and the minor pocket formed by helices 1, 2, 
3 and 7 [147]. The G-protein binding site lies in the centre of the helices on the cytosolic side, 
figure 1.5. 
 
 
Figure 1.5: Basic goblet structure of the 
CXCR4 receptor. Major pocket - red 
star, minor pocket - blue star, G-protein 
binding site - green star, 
transmembrane domains (TM) - black, 
extracellular loop 2 (ECL2) - purple, 
ECL3 - green. Residues thought essential 
for CXCL12 binding - red, and for 
CXCL12 activation - blue [147-153]. 
Chemokine receptor activation may follow the chemokine binding to the N-terminal, major and 
minor pockets, triggering receptor conformation change and activation precipitating the binding 
of a G-protein to the intracellular site. Research on CXCR4 suggest the major and minor pockets 
are connected [147]. These pockets have been analysed using ligand structure activity and 
mutagenesis studies which allow their mapping. It has been found some CXCR4 ligands such as 
AMD3100 and AMD11070, figure 1.6, bind the major and minor pockets and their interface  [147, 
149]. 
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(A) AMD3100          (B) AMD11070 
Figure 1.6: Structures of CXCR4 inhibitors AMD3100 and AMD11070  
Chemokine receptors, including CXCR4, differ from other class A GPCRs in the position of their 
helix bundle, extracellular, and ligand binding domains. Various standard sequences found in 
other GPCRs in specific locations, and the generic numbering system developed for GPCRs (which 
relies on conserved motifs and sequences e.g. DRY in transmembrane helix 3 (TM3) does not 
translate completely to chemokine GPCRs [145, 154, 155]. 
CXCL12 itself may function differently when in monomeric or dimeric form. CXCL12 acts as a 
partial agonist incapable of inducing chemotaxis when dimeric, but still able to induce intracellular 
calcium flux [156-158]. Several residues are thought essential for CXCL12 binding, namely Asp97 
in TM2, Asp187 in extracellular loop 2 (ECL2) and Glu288 in TM7. Others, such as Glu179 to 
Asp182, Asp187 and Tyr190 in ECL2, and Glu268 in ECL3 and Glu288 are thought important for 
CXCR4 signalling [150-153].  
Research has employed NMR as well as site-directed mutagenesis studies. NMR studies show the 
first eight residues of CXCL12 N-terminus contain two amino acids that are essential for CXCR4 
activation, namely Lys1 and Pro2 which may interact with CXCR4’s Asp187 (ECL2) and Glu288 
(TM7).  Investigations so far have led to the theory that CXCL12 interacts with CXCR4 in a two-step 
process. Firstly the CXCL12 motif between amino acids 12 and 17, ‘RFFESH’ (Arg-Phe-Phe-Glu-Ser-
His), binds CXCR4’s N-terminus followed by CXCL12’s N-terminus between amino acids 1 and 8. 
This locates into a transmembrane helix of CXCR4 triggering conformation change and activation 
[146, 150-153, 158-162]. Put together the extensive research completed supports the importance 
of the purported minor and major sub-pockets located in CXCR4’s transmembrane cavities for 
CXCL12 binding. With the minor pocket formed by helices one, two, three, and seven [147], where 
ECL2’s residues Glu179, Asp187, Tyr190 and Asp193, plus ECL3’s Glu268 along with Trp94 and 
Asp97 (both in TM2) are key. The major pocket is surrounded by helices three, four, five, six and 
seven, with Asp171 (TM4), Tyr255 and Asp262 (both in TM6) being important. Also considered to 
contribute are Tyr116 (TM3) and Glu288 (TM7) which sit at the edge of the major and minor sub-
pockets. The CXCL12 N-terminal Lys1 and Pro2 are thought to sit in CXCR4’s minor sub-pocket in 
contact with Asp97 (TM2), Asp187 (ECL2) and Glu288 (TM7), three key activation residues, figure 
1.7. What has also been explored is how one CXCL12 protomer could successfully bind a CXCR4 
dimer. It is suggested that CXCL12’s Lys1 and Pro2 could continue to occupy one CXCR4’s minor 
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sub-pocket and still be in contact with activators Asp97 (TM2), Asp187 (ECL2) plus Glu288 (TM7) 
in a CXCR4 dimer. CXCL12 may remain longer in contact with a CXCR4 homodimer than a CXCR4 
monomer, and also be in contact for longer when CXCL12:CXCR4  stoichiometry is 1:2 than would 
occur with 1:1 [147, 148].  
 
Figure 1.7: CXCR4 sequence with key binding residues for CXCL12 in red, TM = transmembrane 
region, ICL = intracellular loop, ECL = extracellular loop. 
 
Having briefly explored the role of chemokines, chemokine receptors and the immune system in 
metastatic signalling, next key individual proteins will be introduced that are involved in 
transferring the message from an activated chemokine receptor onwards into a cell. 
1.16: Introduction to Dynamin and Dynamin Like Proteins (DLPs) 
For a receptor to internalise an endocytic vesicle needs to form from the cell membrane. This 
requires the recruitment of several cytosolic proteins including the GTPase dynamin. Dynamin is 
purported to aid the scission of vesicles from the membrane by forming helical oligomers around 
the necks of budding vesicles, before GTP hydrolysis creates conformational change in the 
dynamin polymer producing vesicle/membrane fission. However this is not dynamin’s only role in 
cellular function [163, 164]. Dynamins are also involved in cytokinesis, organelle division, 
pathogen resistance and transport vesicle budding [165]. 
There are three dynamin mammalian genes producing at least twenty-five distinct splice forms of 
dynamin: eight variants of dynamin-1, mainly found in neurons; four variants of dynamin-2 which 
is ubiquitous; and thirteen variants of dynamin-3 mainly found in brain and testis [166],  
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suggesting varying specialist roles for dynamin throughout the body. Different isoforms can 
uniquely interact with specific proteins, for example dynamin-1 is found in presynaptic neuronal 
tissue and is involved with axon growth, whereas dynamin-3 is found in dendritic spines where it 
purportedly mediates remodelling [167, 168].  The main differences in dynamin-1, -2 and -3 are in 
the last 150 residues in the C-terminus proline-rich domain. Dynamin isoforms interact with 
various proteins and lipids with varying affinities and oligomerizational ability producing tissue-
specific regulation [169].  
Dynamin-1, -2, and -3 are members of the DLPs membrane remodelling GTPase family. Other DLP 
members include Dynamin-related protein-1 (Drp-1) and mitofusin (Mfn) both found in 
mitochondrial outer membranes. Drp-1 is involved in mitochondrial fission, whereas Mfn 
mediates mitochondrial fusion along with a DLP called Optic Atropy-1 (OPA-1) found in 
mitochondrial inner membrane [170], figure 1.8.  
 
Figure 1.8: Dynamics of dynamin and dynamin-like proteins (DLPs) in a migrating cell [163, 170, 
171].  
 
1.16.1: Dynamin family proteins structure and domains 
The dynamin monomers reside in the cytosol. Dynamin structural regions from the N-terminal 
consist of a G-domain, a stalk region, a Pleckstrin Homology (PH) domain, a GTPase Effector 
Domain (GED), and at the C-terminal a Proline-Rich Domain (PRD), figures 3.3 and 3.4. 
Phospholipids binding dynamin’s PH domain can stimulate its activity, and dynamin’s GTPase 
activity can be stimulated by oligomerization of the protein via interactions of GTPase domains, 
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the middle domains, and the GEDs. Stimulation also follows binding of SH3-domain proteins to 
dynamin’s PRD [165]. Crystallographic studies show dynamin can form hairpin-like dimers, with 
the PH and GTPase domains sitting either side of a pocket, and juxtaposed BSE (stalks) interacting 
in a criss-cross arrangement. The PRDs do not appear in the crystal structure as they project out 
of the polymerized helix, figures 1.9 and 1.10.  
 
Figure 1.9: Regions of the crystal structure of a dynamin dimer [172, 173]. 
 
BSE – Bundle Signalling element  
or ‘neck’.  
PH – Pleckstrin Homology, aids lipid 
membrane binding. 
GED – GTPase Effector Domain, aids 
ring assembly. 
PRD – Proline-Rich Domain, aids 
interaction with SH3 domain proteins 
MLS – Mitochondrial leader sequence 
PTD – Predicted Transmembrane 
Domain  
Figure 1.10: Structural elements of Dynamin and Dynamin-Like Proteins (DLPs) [163, 165]. 
1.16.2: Dynamin polymerization 
Dynamin monomers form dimers, the basic unit, through interactions of the stalk regions, [174] 
then dimers themselves interact, forming oligomers. Different oligomeric rings of dynamin can 
link through the G-domains [175]. The PH domains, “the feet”, bind lipid membranes positioning 
the PRD region facing the cytosol, so ideally placed to interact with other proteins. The PH domain 
has affinity for acidic membrane phospholipids such as phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2) aka PIP2 [176]. Curvature of the membrane itself may attract dynamin [177].  
Antagonising the PH domain is known to impair clathrin-mediated endocytosis [178]. There are 
also hydrophobic (lipid binding) loops protruding from the PH domain, figure 3.2, which may 
promote curvature of the oligomer and membrane interactions [179]. The PRD domain strongly 
supports dynamin’s interaction and co-ordination with SH3-motifs in other proteins, helps to 
draw dynamin to endocytic locations, and co-ordinate endocytosis [180]. 
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1.16.3: Membrane fission 
Dynamin’s mode of membrane fission has been extensively investigated over many years [177, 
181, 182] and there is consensus that dynamin can, in the presence of GTP, constrict or twist 
membranes facilitating fission. The oligomer must circle the membrane tube and connects with 
itself via the G-domains, as GTPase activity depends on G-domain dimerization. G-domain dimer 
GTP hydrolysis then produces a lever-like movement of dynamin’s BSE domains which propagates 
along the dynamin subunits, thus narrowing the dynamin helix diameter constricting the 
membrane tube [183], figure 1.11.  
  
Figure 1.11: Mechanism of dynamin-mediated vesicle and membrane fission [163, 183]. 
Fission is thought not to occur solely due to shearing or tearing as tube radius decrease occurs too 
slowly [184]. Helix disassembly may trigger membrane destabilisation and fission [185], although 
this is still debated [184]. Other DLPs share some of dynamin’s structural features and mode of 
action [186, 187]. Membrane severing can in vitro be achieved by dynamin alone, in vivo this may 
also involve other proteins and processes, such as actin polymerization or myosin providing 
membrane tension thus supporting membrane fission [188].  
Dynamins catalyse scission but also may modulate clathrin-coated pit maturation. Over 
expressing dynamin-1 mutants, with GTPase domains inactivated, was found to accelerate 
clathrin-mediated endocytosis; how is not clear [189]. Dynamin-1 can alone curve membranes 
and catalyse fission. Dynamin-2 cannot shape membranes alone, it appears to need other curve-
generating proteins to produce fission [190]. Dynamin-1 and dynamin-2 mRNA are equally 
present in non-neuronal tissues, however dynamin-1 may be phosphorylated and so inactivated 
by GSK3β which itself is constitutively active [191]. Inhibiting GSK3β can activate both dynamin-1 
and clathrin-mediated endocytosis [192].      
1.16.4: Endocytosis plays a key role in regulation of intracellular signalling  
Endocytosis involves the inward budding of vesicles from the plasma membrane. Endocytosis 
allows the passage of components between cellular compartments but also mediates cellular 
signalling  [193].  Vesicle cargo can include GPCRs with bound ligands. Endocytosis of the receptor 
can terminate signalling [194] or initiate signalling cascades from endosome complexes. 
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Endosomes can be classified as early, recycling or late endosomes. The pathway followed by 
endocytic vesicles and their intracellular fate can qualitatively and quantitatively control 
downstream signalling and hence cellular responses [193, 195]. This signalling can reciprocally 
also regulate both further receptor endocytosis, and the endocytic pathways followed by 
subsequent endocytic vesicles [196, 197]. This crosstalk can mediate cancer prognosis by 
modulating migratory, proliferative and survival signals supporting metastasis [198].   
1.16.5: Influences of cargo on endosome fate 
Signalling from endosomes has been shown to influence post-uptake sorting decisions, between 
recycling to the membrane and degradation pathways [199]. Coated pits reportedly may 
themselves trigger signalling pathways e.g. through JAK2 and Akt [200], and even surviving flat 
clathrin lattices may act as signalling platforms [201], as do caveolar micro-domains which can 
support catabolic oxidative mitochondrial metabolism and cell signalling effects favouring 
malignancy [202]. Endosomes may contain signalling platforms that trigger Grb2-mSOS-Ras 
signalling [203] and determine signal strength and specificity [204]. For example endosomes 
containing APPL1 scaffolding protein can signal from Akt to GSK3β, whereas Akt signalling from 
the plasma membrane can follow the mTOR pathway [205].  
1.16.6: Dynamin, β-arrestins and the Rho GTPases 
When GPCRs signal through trimeric G-proteins the stimulated G-protein is inactivated by GPCR 
kinases, β-arrestin recruitment may follow [206].  β-arrestins can also act as adaptors linking G-
proteins to clathrin-coated pits and clathrin-mediated endocytosis. However, MAPK pathway 
signalling may continue from early endosomes via β-arrestins acting as scaffolds, or from 
GPCR/arrestin complexes [207, 208]. This secondary signalling may vary in specificity and strength 
from the original issuing from the GPCR/ligand at the plasma membrane [209], and be controlled 
by GPCR type. GPCRs may use PDZ-domain/s to interact with the actin cytoskeletal components 
and delay clathrin coated pit maturation and dynamin recruitment and/or receptor ubiquitination 
[197, 210]. This appears relevant for CXCR4 [211], and for CCR5 signalling as both receptors 
contain a C-terminus PDZ-binding sequence [212].  Endocytosis can be modulated by Ras and Rho 
GTPases. Rho GTPases support actin-dependent clathrin-independent endocytosis [209], but Rac 
and Rho activation may actin-independently inhibit clathrin-mediated endocytosis [213]. 
1.16.7: Dynamin’s role in Clathrin-dependent endocytosis  
Clathrin-mediated endocytosis is one of several endocytic pathways [214]. It requires Adaptor 
Protein Complex-2 (AP2) to recruit clathrin proteins to the plasma membrane [215]. Supported by 
other endocytic assessor proteins a clathrin-coated pit develops around its cargo until it has 
formed a narrow neck connecting it to the plasma membrane. This neck triggers recruitment and 
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assembly of dynamin which triggers scission [216]. The endocytic vesicle may then fuse with 
others containing similar or different cargoes. These are early phosphatidylinositol-3-phosphate 
(PI3P) rich endosomes, which carry interacting scaffold proteins such as EEA1 or APPL1 that 
mediate endosome maturation and sort endosomes into three possible pathways [217]. Receptor 
cargoes can be (i) rapidly recycled back to the plasma membrane, (ii) slowly recycled to the 
membrane via perinuclear recycling endosomes or (iii) retained, ubiquitinated and degraded 
when endosomes fuse with lysosomes, this terminates signalling and down-regulates receptors 
[171]. 
Clathrin-dependent endocytosis is important in signalling from many receptors. It appears 
involved in the building of multi-protein clathrin-containing pits which enable surface receptors 
and their ligand to be internalised [218]. Dynamin may help modulate cell signalling by regulating 
receptor endocytosis, so clearance of receptors from the cell surface, and the formation of signal 
transduction complexes in endosomes [195, 219].  
1.16.8: Dynamin’s role in clathrin-independent endocytosis 
The endocytic protein endophilin-A recruits dynamin [220] and may play a subsidiary role in 
clathrin-mediated endocytosis, as may cofilin, a small protein controlling actin polymerization 
[188]. Endophilin-A also controls a clathrin-independent endocytic pathway, it carries an SH3-
domain that strongly binds proline-rich motifs in some GPCRs, and is involved in some receptor-
ligand stimulated endocytosis. Endophilin-A, but not clathrin, is found at the leading edge in some 
cells undergoing chemotaxis, whereas in non-migrating cells endophilin-A and clathrin-coated pits 
are equally present. Endophilin-A, F-actin and dynamin are all in plentiful supply at the leading 
edge of cells, and all participate in rapid β-arrestin-independent formation of clathrin-
independent endophilin-A assemblies which facilitate receptor endocytosis, following GPCR 
stimulation [221]. Endophilin-A may interact with dynamin to produce the pulling-force needed 
for scission [222]. Such endophilin-A-rich endocytic vesicles then can be tracked from the 
membrane to perinuclear area. Growth factors can also facilitate this rapid endophilin-A-
mediated endocytosis, or hinder it if absent. Fast endophilin-A-mediated endocytosis appears 
important in chemotaxis, and may also play a role in Raf, MEK, ERK (MAPK) and growth factor 
signalling, which produces chemotaxis. Although not affected by clathrin-knockdown or inhibition, 
endophilin-A-mediated endocytosis is hampered by dynamin knockdown or mutation (K44A 
dominant negative mutant), or dynamin inhibition using Dyngo4a, Dynasore, MitMAB and 
OctMAB. Endophilin-A-mediated budding and endocytosis is also inhibited by the inhibition of 
actin polymerization, Pi3K, Rho or Rac, whereas inhibiting Cdc42 increased endophilin-A-rich 
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vesicle formation. Overall endophilin-A-mediated endocytosis appears dependent on dynamin, 
actin, cholesterol, Rac, Rho, Pi3K and PAK1 [221]. 
Receptor-ligand binding may stimulate Pi3K to produce phosphatidylinositol(3,4,5)-triphosphate 
(aka PtdIns(3,4,5)P3 and PIP3) from PtdIns(4,5,)P2 (aka PIP2). PIP3 is plentiful at a cell’s leading 
edge. Once produced PIP3 is hydrolysed back to PIP2 by phosphatase PTEN [223]. PTEN inhibition 
increases leading edge endophilin-A levels, this is Pi3K-dependent. SHIP1 and SHIP2 hydrolyse PIP3 
to PtdIns(3,4)P2 [224], this reduces leading edge endophilin-A levels. A PtdIns(3,4)P2-binding 
protein lamellipodin binds endophilin-A at the leading edge, triggering fast endophilin-A-mediated 
endocytosis [225], figure 1.12.  
 
 
Figure 1.12: Dynamin contributes to both clathrin-dependent and endophilin-mediated 
endocytosis. Endophilin controls a leading edge fast-acting clathrin-independent pathway 
dependent on dynamin, Rac and actin that facilitated endocytosis of some GPCRs. SHIP1 
dephosphorylates P(3,4,5)P3 forming P(3,4)P2, SHIP2 recruits lamellipodin which summons 
endophilin [221, 223, 225]. 
1.16.9: Dynamin and DLPs in disease 
Aberrant dynamin and DLP’s function has been linked to many diseases including cancer. Dynamin 
has been found to be upregulated in malignant cells, and to support increased cell migration in 
vitro and metastasis in vivo [226]. Dynamin interacts with microtubules and focal adhesion kinase 
to modulate cell migration [227], while also affecting lamellipodia formation [228]. Dynamin does 
this through interaction with a GTPase, Rac1’s guanine exchange factor (GEF) Vav1. Vav1 along 
with other GEFs activates Rac1 [229]. Rac1 then regulates actin dynamics including the branching 
important in lamellipodia formation [230]. In T-cells dynamin-2 was shown to directly interact 
with Vav1 [231]. Vav1 is an oncogene expressed in many cancers [232, 233]. CXCL12 can activate 
JAK-Vav-Rac1 signalling in melanoma cells which then supports metastasis [234]. However in the 
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absence of active dynamin Vav1 interacts instead with Hsc70 chaperone protein which directs 
Vav1 to lysosomes for degradation [229]. 
Mutations in DLP Drp-1 has been found to drive mitosis in twenty-nine different cancer types and 
to modulate chemotherapy sensitivity of primary tumours. Relapse in ovarian cancers treated 
with platinum-based chemotherapy has been linked to Drp-1/mitochondrial-driven mitosis [235]. 
Inhibition of Drp-1 has been shown to reduce migration and invasion of thyroid cancer cells [236].  
1.16.10: Dynamin in cancer development and progression 
Cancer features unregulated cell proliferation, migration and endocytosis; signalling controls 
these factors and the survival of cancer cells. Endosomal signalling can enhance metastasis e.g. 
aberrant sorting decisions favouring endosome recycling over degradation for proliferative 
signalling cargoes [199]. 
Mutations and loss of proteins that ubiquitinate receptors in endosomes can change the fate of 
oncogenic receptors directed to lysosomes, causing them to be recycled back to the plasma 
membrane and prolong signalling. If this signalling supports cell proliferation and/or migration it 
can favour cancer and metastasis. Scaffolding proteins, cargo and dynamin can all influence the 
fate of the endosome [194, 198]. Mechanisms include upregulation of dynamin which can by 
increasing clathrin-coated pit initiation and maturation support aberrant clathrin mediated 
endocytosis [192].  
Proliferative signalling can be produced by the Pi3K/PIP2/PIP3/Akt/mTOR pathway. PTEN tumour 
suppressor inhibits the PIP2 to PIP3 step, whereas Akt inhibits constitutively active GSK3β which 
when active suppresses dynamin-1. Overactive dynamin-1 enhances clathrin-coated pit initiation 
and clathrin-mediated endocytosis. Akt-GSK3β signalling is upregulated in endosomes with APPL1 
scaffolds [192]. Activated dynamin-1 appears to support APPL1 endosome production and Akt 
signalling [196]. Akt inhibitors can be shown to dynamin-1-dependently inhibit clathrin-mediated 
endocytosis [192]. Dynamin-1 is controlled by phosphorylation so its activity and expression do 
not necessarily correlate. The calcium-dependent phosphatase calcineurin can dephosphorylate 
and so activate dynamin-1 [171]. Thus dynamin recruitment can regulate the initiation and 
maintenance of clathrin-coated pits, and increase endocytic activity which itself may correlate 
with metastatic potential. 
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1.16.11: Drp-1, mitochondrial division and cancer 
Mitochondrial fusion is aided by the DLP Mfn isoforms Mfn1 and Mfn2 along with OPA1 [237], 
which create links between fusing mitochondria. Mfn2 also aids mitochondrial-Endoplasmic 
Reticulum (ER) linkage facilitating mitochondrial calcium uptake [238]. 
Mitochondria undergo division and fusion, governed by genes in the cell nucleus [239]. Disorders 
of mitochondrial dynamics can contribute to the pathology of cancer, since mitochondrial fission 
and fusion fine-tunes cell-cycle progression, majorly influencing ATP production, reactive oxygen 
species production, oxygen sensitivity and apoptosis [240]. Mitochondria associate with the ER 
facilitating localised peaks in calcium signalling [241], which can trigger apoptosis [242]. 
Calmodulin-dependent kinase links the phosphorylation of Drp-1 to calcium levels [243]. Defective 
mitochondria are disposed of by enclosing in autophagic vacuoles which then merge with 
lysosomes in a process called mitophagy [244]. Mitophagy is more efficient with smaller 
organelles created by mitochondria fission. Smaller mitochondria also more efficiently accelerate 
cell proliferation. Fission is facilitated by Drp-1 [245]. Drp-1 monomers co-operate, creating a ring-
like structure which constricts and divides the mitochondrion [246].  
In cancer there is excess proliferation along with apoptosis resistance. Respiration shifts from 
oxidative metabolism to aerobic glycolysis, this is called the ‘Warburg Effect’. Mitochondrial 
pyruvate dehydrogenase kinase activation contributes to this by suppressing oxidative 
metabolism and inhibiting pyruvate dehydrogenase making the cell less susceptible to apoptosis 
[247, 248]. ATP production and mitochondrial division is needed before mitosis, these processes 
are co-ordinated as the cell cycles from stage G1 to S. Drp-1 inhibition triggers mitochondrial 
hyperfusion into larger mitochondria, which facilitates increased ATP production  [249]. DNA 
replication then occurs and cyclin E accumulates. Cyclin B1- cyclin-dependent kinase 1 (CDK1) 
initiates mitosis and activates Drp-1 via phosphorylation of its Ser616, this triggers mitochondria 
fission facilitating cell division [250]. Drp-1 is controlled by various kinases. Drp-1 activity, so 
mitochondrial replication, is increased by phosphorylation at Ser616, and decreased by 
phosphorylation of Drp-1 Ser637 [251], figure 1.13. 
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Figure 1.13: Drp-1 influences  
mitochondria fission/fusion  
dynamics during the cell 
cycle [249, 252]. 
 
 
Drp-1 inhibition can inhibit tumour growth, increasing spontaneous apoptosis and decreasing cell 
proliferation and metastasis [252, 253] and change cell morphology to a more rounded shape 
unsuited to migration [254].  
Once initiated the signalling from a chemokine receptor is transmitted through various membrane 
and cytosolic proteins. A key protein often involved in this signal transduction is Protein Kinase C.  
1.17: Protein Kinase C (PKC) 
Homeostatic PKC signalling is exquisitely complex and in cancer this complexity increases. PKC 
responses can be modulated by chemokines. Differences in distribution of PKC isoforms in normal 
and malignant leukocytes have been reported [255, 256], hence PKC assays using cancer cell-lines 
may produce differing results to those in non-malignant cells. 
Activating PKCs can protect against induced lung metastasis and reduce tumour growth (in mice) 
[257] and produce temporary remission from leukaemia in humans [258]. Hence in human 
cancers PKCs can act as tumour suppressors, however they can also act as oncogenes [259, 260] 
1.17.1: PKC structure, isoforms, location and function  
PKC is transcribed from nine PKC genes producing twelve isoforms as some genes produce splice 
variants. All isoforms contain a C-terminal kinase and a variable N-terminal auto-inhibitory 
regulatory domain that determines both the PKC subfamily, and through interactions with its 
respective C-terminal kinase moiety, if the protein is active or not [261]. PKC isoforms are 
classified as conventional (isoforms α, β, and γ), novel (δ, ε, η, and θ) and atypical (ζ and ι), figure 
1.14. PKC enzymes contain a catalytic C-terminal ATP binding domain, and a regulatory unit that 
keeps PKC inactive until triggered and controls its subcellular location.  
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Figure 1.14: PKC isoenzymes, domains and activators [261, 262]. 
Diacylglycerol (DAG) can activate conventional and novel, but not atypical PKC isoforms. DAG is a 
lipid metabolism intermediate, its level in cells is modulated by PLC activation [263]. Conventional 
PKCs all have a C2 domain that calcium dependently binds phospholipids along with two cysteine-
rich zinc finger regions C1a and C1b at the amino-terminus.  Conventional PKCs remain in the 
cytosol until activated by the activation of DAG; they then translocate to the membrane to bind 
DAG [264]. 
Novel PKCs also have C1 and C2 domains but with the C2 nearest the N-terminus, and their C2 
region lacks calcium binding regions so membrane translocation is not controlled by calcium or 
phospholipids but occurs just as efficiently as with conventional PKCs as their affinity for DAG is 
greater [265, 266].  
Atypical PKC’s activation is independent of DAG and calcium, their C1 domain is activated by PIP3 
[267] or ceramide [268, 269]. Also they also have a PB1 motif at their N-terminal which reacts 
with other PB1 containing proteins and 3-phosphoinositide-dependent protein kinase 1 (PDPK1) 
[270, 271]. Partition Defective Protein (PAR)-6 and PKCζ interact through their PB1 domains [272], 
PAR6 links PKCζ to Rho GTPases Rac1 and Cdc42 involved in Ras oncogenic transformation and cell 
polarity [273, 274].  
1.17.2: PKC’s phosphorylation of chemokine receptors 
GPCR phosphorylation is a complex process involving many kinases. There is considerable 
redundancy with several kinases each able to phosphorylate several, usually C-terminal, sites. 
CXCL12/CXCR4 activation is no exception and purportedly involves multiple kinases including 
GPCR kinases (GRKs) and PKC isoforms [275-277]. CXCR4 C-terminal has three threonines and 
fifteen serines. Research has demonstrated phosphorylation of seven serines following CXCR4 
stimulation by GRKs and PKC [278]. Other studies support phosphorylation by PKC of CXCR4 
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following CXCL12 binding [279]. Also CXCL12 induced CXCR4 C-tail phosphorylation can be 
inhibited by GRK, PKCα PKCδ or PKCζ inhibition [280]. 
1.17.3: PKC activation 
PKC resides in the cytosol until activated by agonist interaction with receptor [262]. Activation 
triggers conformational changes allowing PKC to interact in specific cellular locations with defined 
substrates, which substrate is governed by PKC C1a domain [281]. With conventional PKCα, PIP2 
hydrolysis leads to PKC activation, firstly by calcium binding PKCα C2 domain facilitating 
interactions with membrane phospholipids and PKCα activation by binding DAG embedded in 
membrane [282, 283].  
The novel PKCs including PKCδ and PKCε do not bind calcium but have a greater affinity for DAG 
than conventional PKC’s so primarily move to and signal from Golgi membranes which are richer 
in DAG than cell membranes [261]. Atypical PKCs including PKCζ have a lower catalytic activity 
than DAG-regulated novel or conventional PKCs; atypicals bind scaffold proteins e.g. PAR6 via PB1 
Domains [284, 285]. Different scaffolds produce different PKC activity levels e.g. PAR6 activates, 
whereas PAR3 binds atypical PKC’s active site preventing substrate access and activation [286].  
Scaffolding proteins can modulate PKC location and signalling. PKC N-terminal regions contain 
regulatory regions that produce different isoform responses to different activators [287]. PKC 
isoforms can be activated by the same stimulus but then be directed to different cellular 
locations, for example Golgi, nuclear envelope, endoplasmic reticulum or specific cytoskeletal 
components inside mitochondria or the nucleus [288]. At these locations various scaffolding, 
adaptor or targeting proteins link the PKC with their substrates so can translate the extracellular 
signal to specific cellular microenvironments [289]. These PKC binding proteins include actin, 
importins, heat shock proteins (HSP), 14-3-3 proteins, receptors for activated C-kinase (RACKs), A-
kinase-anchoring protein (AKAPs) and Annexins, figure 1.15.  
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Figure 1.15: PKC isoenzymes interact with scaffolding proteins which can selectively modulate the 
PKCs location and signalling, for example an annexin or anchoring protein such as RACK1 can 
regulate recruitment of specific PKC isoenzyme to the membrane or other subcellular location 
where PKC may phosphorylate nearby substrates [287-289]. 
1.17.4: PKCs role in cancers 
Conventional and novel PKC inactivation is governed by metabolism and decay of DAG these PKCs 
then return to their auto-inhibited conformation and reside in the cytosol [290]. With atypical 
PKCs other PKC isoforms may be involved in their inactivation [291]. 
Abnormal PKC expression has been implicated in many pathophysiologies including cancers [292, 
293]. However PKC is not a simple proto-oncogene, it actually supports homeostasis, but 
modifying PKC regulation may support malignancies [262]. This includes through Raf-1 signalling 
triggering Mitogen-Activation Protein Kinase (MAPK) promoted metastasis, and proliferation 
normally prevented by PKC regulation [294].  In cancers loss of function (LOF) or loss of normal 
signalling of PKC isoforms is common and gain of function (GOF) rare [261]. LOF mutations are 
generally heterozygous and can be dominant negative which then adversely influences global PKC 
signalling, i.e. one isoenzyme mutation may suppress other PKC isoenzyme signalling [259]. This 
may be due to common elements in PKC isoenzyme activation being sequestered by the mutated 
PKC e.g. PDPK1 [295]. It has been observed that PKCα has reduced function in pituitary tumours 
[296] and that PKCα inhibitors enzastaurin and aprinocarsen worsened outcomes when given with 
chemotherapy for lung cancers [297]. PKC signalling can suppress oncogenic mutated K-Ras 
signalling, and can inhibit oncogenic signalling by promoting internalisation of receptors such as 
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Epidermal Growth Factor Receptor (EGFR) and HER2 (Human-EFGR-2) which promote cell growth 
and survival [298-300]. Functional PKC can also keep growth factor receptor signalling in check, 
PKC may inhibit receptors, including GPCRs by phosphorylation of their cytoplasmic loops in a 
dynamin-dependent manner [301]. PKCα can also inhibit K-Ras, so may suppress malignant cell 
growth by suppressing oncogenes, as K-Ras is frequently mutated in cancers where there is LOF of 
PKC [259, 302].  
The gene for PKCδ is deleted in many skin cancers, re-expression in a mouse model suppresses 
malignant cell growth [303]. However PKCδ is implicated in promoting pancreatic cancers [260] 
and in cell-lines PKCδ depletion can induce apoptosis and PKCδ upregulation protects from 
apoptosis [304], so depending on oncogene expression PKCδ can promote malignant growth, 
survival and ERK signalling downstream of PKCδ [305] or inhibit it. Results of PKC investigations in 
malignant cell-lines may therefore be cell-type specific. 
1.17.5: PKCs as oncoproteins and as tumour suppressors 
Novel PKCs may act as oncoproteins e.g. PKCδ has roles in survival and apoptosis, opposing 
receptor-initiated apoptosis, and supporting apoptosis triggered by DNA damage [306, 307]. PKCδ 
increased expression may worsen outcome in HER2 positive breast cancer, but in endometrial 
cancers decreased PKCδ expression correlates with higher grade tumour, hence PKCδ can drive 
some cancers and inhibit others. Hormone sensitivity may govern if PKC GOF or LOF favours 
malignant cell survival [308, 309].  
PKCε expression can be elevated in prostate and breast cancers [310] and ablation of PKCε may 
inhibit prostate cancer development and metastasis (in mice). Inhibiting PKCε can cause Gi/S cell 
cycle arrest. PKCε can phosphorylate Signal Transducers and Activator of Transcription-3 (STAT3) 
Ser727 triggering nuclear translocation; hence PKCε can regulate transcription factors including, 
STAT3 activity in some cancers. STAT3 activation also links to COX-2 activation [311] so 
inflammation. STATs are transcription factors phosphorylated by receptor associated Janus 
Kinases (JAKs), which respond to specific cytokines, including chemokines, producing cell 
migration, proliferation and survival [312]. 
1.18: JAK STAT Signalling.  
The JAK family contains the ubiquitously distributed JAK1, JAK2 and Tyk2, plus JAK3 which is found 
mostly in hematopoietic cells. The STATs are intracellular transcription factors influencing cell 
immunity, differentiation, proliferation and apoptosis. The STAT family consists of STAT1-STAT4, 
STAT5 (A & B) and STAT6. STAT3 is often activated in tumours and has been implicated in in 
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cancer progression. STAT3 appears important in immune responses to malignancy and in 
resistance to chemotherapy. GPCR’s activation of STAT3 via JAK2 is associated with cancer [312-
316]. STAT3 appears to hold a key role in cancer initiation, progression and prognosis, and is often 
elevated in blood and breast malignancies [317, 318]. 
Tyrosine phosphorylation by JAKs is purportedly required for most cytokine responses. JAKs’ 
association with cytokine receptors is enhanced by cytokine ligand binding, and JAK responses 
include tyrosine phosphorylation of their associated receptor, this opens docking sites for both 
STATs and PLC; activated PLC signalling can then trigger calcium release from intracellular 
reservoirs [319-321]. JAKs’ phosphorylation of receptor tyrosines facilitates STAT phosphorylation, 
dimerization, transfer to nucleus and initiation of transcription [312]. 
Gαi can be inactivated by pertussis toxin (PTX). PTX is an A-B toxin, the A subunit ribosylates and 
uncouples α subunits of Gαi from the receptor, the B protomer reportedly can bind cell surface 
proteins including Toll-like receptor 4 and activate intracellular signalling cascades [322] hence 
PTX can be used to investigate the involvement of Gαi in CXCR4/CXCL12 signalling. Vila-Coro et al. 
(1999) published evidence that CXCR4/CXCL12 signalling involved Gαi, JAK phosphorylation, JAK 
phosphorylation of CXCR4 dimers, STAT association with CXCR4 and subsequent dimerization via 
SH2-phosphotrosyl interactions then movement to the nucleus [323]. 
1.18.1: JAK2 in malignancies  
JAK2 gene mutations are common in myeloproliferative neoplasms. STAT signalling downstream 
of JAK kinases is reportedly enhanced in malignant cells [324].  JAK2 mutations have been shown 
to increase chemotactic responses of CXCR4 to CXCL12 and also both retention and maintenance 
of haematopoietic stem cells in bone marrow, plus their movement to extramedullary sites 
producing myelofibrosis. Normally haematopoietic stem cells and haematopoietic stem 
progenitor cells divide and differentiate in the bone marrow but in myeloproliferative neoplasms 
extramedullary haematopoiesis occurs for example in the spleen [325]. CXCR4 functions to retain 
haematopoietic stem cells in the bone medullary this can be antagonised by CXCR4 inhibitors 
including AMD3100 (Plerixafor) [326]. In myeloproliferative neoplasms CXCR4 sensitivity may be 
increased even in CXCR4 downregulation [327]. JAK2 mutations or cytokines may trigger 
oncogenic activation synergistically with CXCR4/CXCL12 signalling facilitating Pi3K signalling and 
chemotaxis [328]. A JAK1/2 inhibitor ruxolitinib is currently licenced for treating 
myeloproliferative neoplasm polycythemia vera [329]. 
PKC and JAK2 signalling may influence metastasis, but the process of cell migration is co-ordinated 
by Rho GTPases regulating cell polarity, adhesion, actin polymerization and cytoskeletal dynamics. 
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1.19: Rho GTPases in cell migration 
Rho GTPases are members of the Ras family of proteins and are molecular switches, they are ‘off’ 
when GDP-bound and ‘on’ when in GTP-bound conformation but are also modulated by post-
translational modifications and influenced by other proteins when in complexes [330]. Active Rho 
GTPases interact with effectors downstream to initiate various signalling pathways [331]. Location 
is key for Rho GTPases. Although Rho GTPases have sequence and structural homology each can 
control specific cellular responses within tightly controlled spatial-temporal activation and 
signalling [332].  
There are over twenty Rho GTPase family members, each with several isoforms, three Rho 
GTPases involved with the actin cytoskeleton are RhoA, Rac1 and Cdc42. RhoA is involved with 
contraction at the cell’s rear related to actomycin, Cdc42 with filopodia formation at the leading 
edge, and Rac1 with lamellipodia and membrane ruffles  [331, 333]. Rac1 regulates lamellipodia 
formation and so is key to cell motility; it is most active at a cells leading edge [334]. 
Rho GTPases can undergo lipid modification of their C-terminal. Usually this is prenylation, the 
addition of farnesyl or geranylgeranyl unit to a C-terminal cysteine commonly the Cis in terminal 
CAAX motif.  This may be followed by S-palmatoylation at a nearby cysteine. The effect of 
prenylation is to allow the GTPase to insert and anchor in a cell or organelle membrane. For 
example Rac1 palmitoylation increases the GTPase stability and activity, and may determine the 
subcellular location of the protein. Rac1 is prenylated at Cys189, then palmitoylated at Cys178 [335], 
figure 1.16. 
 
Figure 1.16: Human Rac1 sequence, showing Switch I and Switch II regions, C-terminus cysteines 
Cys178 and Cys189 (underlined), and W56 Rac1 active peptide (used in chapter 8) residues in red.  
MQAI--KCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDG
KPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWY
PEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKE
IGAVKYLECSALTQRGLKTVFDEAIRAVLCPPPVKKR -- KRKCLLL
- 48
- 98
- 148
- 192
Switch I
Switch II
C-terminus
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1.19.1: Controllers of Rho GTPases GDIs, GAPs and GEFs 
Cellular activity and levels of Rho GTPases are also controlled by epigenetic and microRNA 
regulation, phosphorylation, and in the case of Rac1, addition of ubiquitin-like proteins 
(sumoylation) which help to keep Rac1 in an active state, or subject to ubiquitination and 
degradation in proteasomes [330].  Rho GTPases can be activated by GPCRs including chemokine 
receptors [336].  
There are three controllers of Rho GTPases. (i)  Firstly Rho-specific guanine nucleotide dissociation 
inhibitors (Rho GDIs), these can bind GDP-bound Rho GTPases and can sequester them in the 
cytosol by masking the COOH prenylation [337]. There are at least three known Rho GDI 
mammalian isoforms each containing two key motifs, the N-terminal domain which binds Rho 
GTPases’ Switch I and Switch II regions, see figure 1.16, and the C-terminus domain which through 
interactions with Rho GTPases including the Switch II region facilitate the release of Rho GTPases 
from lipid membranes [338-340]. (ii) Secondly there are GTPase-Activating Proteins (Rho GAPs) 
which by augmenting the speeding up of the intrinsic GTPase-hydrolysis turn the GTPase ‘off’. 
Several Rho GAPs have been identified, many exhibiting Rho GTPase specificity, including 
ARHGAP15 and FilGAP which act on Rac1 [341, 342]. (iii) Finally there are guanine nucleotide 
exchange factors (Rho GEFs) which promote activation of the GTPase and so exchange of GDP for 
GTP [338].  
There are seventy or more Rho GEFs classified into two families, DOCK and DBL, depending on 
structure; they interact with GTPase Switch regions as do GAPs and GDIs [330, 343]. Rho GEFs are 
usually regulated by phosphorylation, which may activate or inhibit depending on GEF. 
Phosphorylation produces 14-3-3 protein docking sites. 14-3-3 proteins usually inhibit GEF 
activity. 14-3-3ζ binds GEF T-lymphoma invasion and metastasis-inducing protein-1 (Tiam1) 
recruiting Tiam1 to adhesion complexes where it activates Rac1 supporting cell migration and 
chemotaxis [344]. Tiam1 is a pro-invasion factor of T-lymphocytes. It activates Rac1 but also 
influences polarity in migrating cells, by binding PAR3 in the PAR polarity complex, which includes 
PAR3, PAR6 and atypical PKC. Tiam1 promotes the PAR complex which regulates cell front-rear 
polarization and the formation of cell-cell junctions [345].  Inhibition of TIAM1 can support 
migration indirectly by promoting cell-cell junction disassembly. Also inhibition of PKC can inhibit 
chemotaxis.  Tiam1 therefore exhibits some control over chemotaxis via the PAR complex. 
Research suggests different cell-lines appear to have different GEFs activating Rac1. In 
lymphocytes Rac activation can be triggered via Rac-specific GEF DOCK2 only found in 
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hematopoietic cells. In HER2 positive breast cancers Rac1 was found activated through Akt 
signalling stimulating Tiam1 and via PKC signalling inhibiting a Rac1 guanine nucleotide 
dissociation inhibitor, RhoGDI2 [346-350].  
Additionally GTPase Rac1 can be regulated by phosphorylation, including by focal adhesion kinase 
(FAK) or SRC on Tyr64, and by AKT on Ser71, both raise levels of GDP-bound Rac1. Tyr64 and Ser71 lie 
in the Rac1’s Switch II region, figure 1.16; phosphorylation of these residues appears to hinder 
GTP binding [351, 352]. ERK can trigger Rac1 phosphorylation at Thr108 causing Rac1 translocation 
into nucleus where it is unavailable to GEFs, and can interact with NFκB and β-catenin and may 
support Wnt signalling plus RhoA-governed malignant cell invasion [353-356].  
 
1.20: Pi3K and FAK signalling in metastasis 
Sequences of events following a cell surface receptor sensing a chemokine gradient can include 
phosphoinositide-3-kinase (Pi3K) signalling which triggers the formation of PIP3 at the cell’s 
leading edge and actin cytoskeleton reorganisation resulting in lamellipodia formation [357].  This 
involves a dense intracellular matrix of actin filaments forming within the lamellipodium which 
can move the cell membrane forward, but also supports the formation of adhesion complexes 
that link to and grip the extracellular matrix (ECM) meshwork giving the cell traction to flow 
forward [358]. Adhesion complexes are dynamic structures composed of scaffolding proteins such 
as integrins that bind to ECM fibronectin and to actin via proteins such as paxillin and talin [359]. 
These adhesion complexes grip the ECM as the cell flows past their location, then are 
disassembled when located near the uropod, by microtubules transporting calpains and FAK to 
the complex [227, 360]. FAK phosphorylation of paxillin, and calpain’s severing of talin, effectively 
then disunite the ECM link. Adhesion complex proteins and FAK may then undergo ubiquitination 
or be recycled back to the leading edge [361, 362]. Membrane phospholipids to expand the 
lamellipodium leading edge in response to chemotactic chemokines can be supplied by polarized 
microtubule exocytosis and facilitated by autophagy. Autophagy includes facilitated degradation 
of focal adhesion proteins and actin remodelling proteins. Chemokine receptors such as CXCR4 
have been implicated in the control of autophagic flux facilitating metastasis [363].  
Thus metastasis involves cell polarisation and leading edge formation involving Rho family 
members Cdc42, Rac and Rho interacting with Pi3K signalling and FAK phosphorylation, however 
another key protein involved with actin filament dynamics is cofilin. 
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1.21: Signalling linking cofilin to chemotactic metastasis 
Actin filament remodelling is essential for cells to physically migrate. Actin filaments mainly grow 
from ‘barbed’ ends. Such actin dynamics can be modulated by cofilin, a small 19 kDa protein 
which forms co-filaments with actin, initiating actin severing and depolymerisation and so 
providing a source of actin initiation barbed ends along with monomers which can be recycled to 
growing actin filaments at a cell’s leading edge which then push the cell membrane forward, 
facilitating chemotaxis. This is an ATP-dependent process; cofilin has high affinity for ADP-actin 
and low affinity for ATP-actin and so functions to break-up old filaments [364, 365]. 
Studies show cofilin expression is upregulated in many solid tumours, in adherent cell-lines 
including A549 and HeLa, and in malignant leukocytes and suspension cell-lines including Jurkat 
and HL60. Cofilin has also been shown to aid EMT and metastasis. Chemotaxis has been shown to 
positively correlate with cofilin expression [366-372].  
1.21.1: Cofilin phosphorylation and dynamics 
Active cofilin binds actin filaments, disassembling them from the minus end by modifying the 
actin twist causing filament strain followed by filament fragmentation. Cofilin is activated by 
dephosphorylation on Ser3, which lies in its actin-binding site [373, 374], by phosphatases 
including PP1/PP2, Calcineurin and Slingshot, activation can be modulated by signalling including 
through Pi3K [375, 376]. Cofilin is inactivated by LIM kinase (LIMK) phosphorylation, which is 
mediated by Rho GTPases [377]. However cofilin’s cellular activities are multi-layered and 
complex; for example, cofilin may have feedback effects on stimulated receptors by interacting 
with phospholipase D1, as phosphorylated cofilin can stimulate phospholipase D1 activity 
triggering cellular responses such as calcium mobilisation and apoptosis, membrane hydrolysis, 
and actin stress fibre formation [378]. Cofilin phosphorylation is also influenced by pH, ROS and 
membrane lipids. Only un-phosphorylated cofilin can sever actin [377, 379].  
Three isoforms of Slingshot occur in humans, SSH1L, SSH2L and SSH3L. The activities of slingshot 
phosphatases are influenced by regulatory proteins including 14-3-3ζ. 14-3-3 proteins bind 
phosphorylated Slingshot sequestering the phosphatase in the cytoplasm away from F-actin in the 
lamellipodia and cell protrusions [380]. Protein Kinase D (PKD) can phosphorylate serines in the 
carboxy-terminus of Slingshot, and this induces 14-3-3 scaffold proteins to bind and sequester 
Slingshot in the cytoplasm, reducing active Slingshot levels in lamellipodia. Reducing phosphatase 
activity on cofilin can increase local levels of phosphocofilin occur in lamellipodia. Slingshot also 
dephosphorylates and inactivates LIMK1. 14-3-3 bound Slingshot may then dephosphorylate 
LIMK1 in the cytosol, leaving active cofilin in the actin-rich lamellipodia in migrating cells [381-
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383]. In metabolic stress, which can be triggered by high cholesterol or blood glucose, 14-3-3ζ 
undergoes S-glutathionylation and degradation by caspases. This frees Slingshot to activate 
cofilin, stimulating actin turnover plus remodelling, and has been found to increase THP-1 
sensitivity towards CCL2 [384].  
There are two LIMK subtypes, LIMK1 and LIMK2; they are serine-threonine specific and both 
contain many cysteine residues and two zinc fingers. LIMKs can be regulated by Rho GTPases 
[385]. LIMKs are involved in a wide range of cellular processes including mediating the actin 
cytoskeletal structure via phosphorylation of cofilin [386]. LIMK can activated by several routes 
including: phosphorylation of a threonine in LIMK’s catalytic domain [385, 387, 388]; 
phosphorylation of Ser323; and inactivated by caspase-3 proteolysis of LIMK Asp-240 [389, 390], 
figure 1.17. 
 
 
 
 
 
 
 
 
 
Figure 1.17: Some of  
the many signalling 
pathways modulating  
LIMK activation 
[385, 387-390]. 
 
Both LIMK and cofilin have been shown to moderate other signalling pathways; and 
dephosphorylated cofilin to localise to mitochondria [391]. If dephosphorylated cofilin 
translocates to mitochondria it raises membrane permeability allowing cytochrome C release, 
caspase 9 Apat-1 cleavage and activation, then caspase-3 activation and cell apoptosis [391]. 
Overall the literature suggests the many influences on cofilin activation may interact and are 
often cell type specific.  
Cofilin phosphorylation state is not a direct measure of cofilin activity, although total 
phosphorylation has been shown to increase following ligand stimulation of cells [392].  This is 
explained as the active cofilin (un-phosphorylated) and phosphocofilin may be in different cellular 
‘locations’ such as the cytosol, the F-actin location between cytosol and membrane, and at the 
membrane. Cofilin does not evenly spread throughout the cell, it clusters. Where clusters are 
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juxtaposed to older actin filaments un-phosphorylated cofilin can sever actin, forming new barbed 
ends and monomers which trigger actin polymerization, that is key to cell migration and 
metastasis [373, 379, 393]. Also cofilin’s protein sequence contains nuclear location signals which 
allow cofilin to carry depolymerized actin into the nucleus [394]. In the nucleus cofilin may form 
actin rod-like structures [395], and be phosphorylated by LIMK1 [396]; the transported actin may 
remodel chromatin [397] and bind RNA polymerase modulating gene transcription [398]. Hence 
cofilin may indirectly influence gene expression. 
1.21.2: Phospholipid phosphatidylinositol-(4,5)-bisphosphate influences on cofilin 
Cofilin activity can be assisted by actin-interacting protein (Aip1) and adenylyl cyclase-associated 
protein (CAP). Aip1 and cofilin form a complex that can stop severed actin reannealing by capping 
barbed ends. An Aip1:cofilin:CAP complex then frees cofilin from ADP-actin to continue severing 
[399]. PIP2 in the cell membrane can also sequester the Ser
3 site of cofilin, rending notionally 
‘active’ un-phosphorylated cofilin inactive. The cofilin-PIP2 complex is transient and dynamic, with 
membrane PIP2 rapidly binding then releasing active cofilin. PLCγ activation causes a decrease in 
levels of PIP2, and so reduces the amount available that can bind cofilin i.e. decreases binding but 
not the release of cofilin; hence this can effectively increase the actual levels of active cofilin near 
the membrane juxtaposed to plentiful F-actin [379, 400, 401]. CXCL12/CXCR4 signalling through 
Pi3K, Rho and Rho-associated protein kinase (ROCK) pathways can activate LIMK and PLCγ. 
Whereas LIMK causes generalised cofilin phosphorylation throughout the cytosol, PLCγ acts 
locally near the membrane increasing levels of active cofilin, as explained above, near the 
receptors receiving CXCL12 stimulus, supporting directional lamellipodium formation towards the 
chemokine stimulus [379, 402-405]. Additionally, a pH rise may cause a decrease in PIP2/cofilin 
affinity and increases PLCγ activation of cofilin [406], figure 1.18.  
 
Figure 1.18: Signalling resulting in phospholipid PIP2 sequestering cofilin [379, 402-406]. 
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Cofilin activity upregulation in cancer cells can be a major driver of metastasis and hamper DNA 
repair [407, 408]. Prostaglandin E2 (PGE2) can stimulate PTEN to dephosphorylate so activate 
cofilin [409]. Hence blocking PGE2 production using Non-Steroidal Anti-inflammatory Drugs 
(NSAIDs) may, via inhibition of cofilin, inhibit cell migration.  
1.22: Non-Steroidal-Anti-inflammatory Drugs (NSAIDs) and metastasis  
The connection between inflammation and cancer is well established; inflammation is purportedly 
highly tumorigenic and links to chemokine chemotaxis [410, 411]. NSAIDs are reported to have 
useful prophylactic effects for some solid tumours, although effects on haematopoietic 
malignancies risk are less clear [412]; also they may affect metastatic spread [413].  
1.22.1: Selective and non-selective NSAIDs 
Commonly prescribed NSAIDs include ibuprofen, naproxen, aspirin and celecoxib. Ibuprofen, 
aspirin and naproxen are non-selective inhibitors of prostaglandin-endoperoxide synthase 1 and 2 
more commonly known as cyclooxygenase 1 (COX1) and 2 (COX2), whereas celecoxib is a selective 
COX2 inhibitor [414]. All NSAIDs inhibit COX1 or COX2 or both, these enzymes catalyse the 
conversion of Arachidonic Acid (AA) to Prostaglandin H2 (PGH2). The fatty acid AA is produced by 
hydrolysis of the fatty acid/glycerol bond in membrane phospholipids by one of the many 
phospholipase A2 isoenzymes [415]. COX enzymes have cyclooxygenase and peroxidase actions; 
they catalyse the cyclization of AA to unstable 15-hydroxyperoxide then their peroxidase action 
produces PGH2. PGH2 is also unstable and so is converted by isomerases to prostaglandins (PGD2, 
PGE2 or PGF2), prostacyclin (PGI2) or thromboxanes (TXA2, TXB2) depending on tissue isomerase/s 
present. Many of these derivatives have inflammatory, pyretic or nociceptive effects [416]. PGE2 is 
also produced by cancer cells as COX2 expression is induced by inflammatory and mitogenic 
stimuli, such as cytokines and growth factors. PGE2 supports inflammatory T-cell Th17 activity, and 
recruits monocytes and neutrophils. Also COX2 derived PGE2 can promote angiogenesis [417].  
1.22.2: Paracetamol’s complex mode of action 
Paracetamol is widely used in pain management, it also inhibits COX enzymes but its mode of 
action is complex; it appears to act locally [418]; peripherally [419] including through cannabinoid 
receptors; centrally in the spine [420] including via serotonin 5-HT3 receptors coupling to Gs and 
cAMP production; and in the brain via transient receptor potential vanilloid subtype 1 (TRPV1) 
non-selective Ca2+ channels [421]. Paracetamol weakly inhibits prostaglandin synthesis with more 
COX2 than COX1 activity, it has weaker analgesic effects than NSAIDs and few anti-inflammatory 
effects [422]. Paracetamol appears to inhibit the peroxidase function of COX enzymes only when 
low, not high, levels of AA are available, and hence fails to effectively suppress inflammation. 
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Paracetamol also non-selectively inhibits other peroxidases. In monocytes paracetamol can 
reduce COX2 activity by 80% [423]. Centrally paracetamol has an anti-nociceptive effect on 5-HT3 
serotonin receptors; this can be blocked with 5-HT3 antagonists [424, 425]. PGE2 modulates 
nociceptive signals via the serotoninergic anti-nociceptive system [426] so paracetamol’s 
analgesic effect may be directly on 5-HT3 receptors or via cyclooxygenases, figure 1.19.  
  
 
 
 
Figure 1.19: Modes of action of paracetamol, 
ibuprofen, naproxen and celecoxib [423, 424, 
427, 428]. 
Paracetamol can be de-acetylated to p-aminophenol which interacts with AA to form N-
arachidonoyl phenylamine aka N-arachidonoyl aminophenol, which, by inhibiting the degradation 
and uptake of anandamide, can (i) indirectly increase activity of cannabinoid receptors [428] 
inhibiting endogenous cannabinoid reuptake, (ii) activate TRPV1 channels, agonists of which can 
inactivate nociceptive nerve fibres, cause vasodilation and modulate thermoregulation reducing 
temperature [427, 429, 430], (iii) inhibit cyclooxygenases and (iv) inhibit selective transport and 
internalisation of anandamide by neurones [431]. Anandamide concentration appears key to 
paracetamol’s efficacy [432, 433]. Endogenous cannabinoids have an anti-nociceptive action on 
spinal cord and brain pain pathways [427]. If cannabinoid receptors are inhibited paracetamol’s 
analgesic and antipyretic effect is blocked [434]. Paracetamol may also inhibit formation of the 
neurotransmitter nitrous oxide (NO). Substance P and NMDA receptors activate NO synthesis, NO 
acts on the nociceptive pathways in the spinal cord leading to the brain [435, 436].  
 
1.22.3: Leukocytes and PGE2 
Prostaglandins such as PGE2 are inflammatory mediators; macrophage response to cytokines 
includes the secretion of PGE2 which through autocrine signalling regulates their activity. PGE2 can 
be produced by many tissues, and its production can be increased in cancer [437]. Raised PGE2 
levels can be immunosuppressive [438], additionally PGE2 has been shown to increase cell 
proliferation, migration and angiogenesis [439]. COX1 contributes to homeostasis, and is 
constitutively expressed in most cell types whereas COX2 can be induced in macrophages by 
mediators of inflammation. PKCα regulates macrophage PGE2 responses to bacterial 
lipopolysaccharides and interferon-gamma via modulation of COX2 expression [440]. 
 
COX1 COX2
Paracetamol
Celecoxib
Ibuprofen
Naproxen
Nitric oxide 
(NO)
Cannabinoid 
signalling
Serotonin 5HT3
receptors
Pain transmission through 
spinal pathways
+
+
Aspirin
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PGE2 suppresses leukocyte activation and binds G-protein coupled E-prostanoid receptors 1 to 4 
(EP1-EP4). EP1 receptors increase Gq G-protein and Ca
2+ responses; EP2 and EP4 receptors 
through Gs G-proteins increase Adenylyl Cyclase and cAMP levels; and EP3 receptors through Gi G-
proteins reduce cAMP levels [441]. COX2 is the target of transcription factor Activator Protein-1 
(AP-1). AP-1 consists of cFos and cJun subunits expressed in response to stimuli including 
cytokines [442]. COX2 is one of the rate limiting enzymes in PGE2 production; excess PGE2 inhibits 
macrophage and NK cell tumouricidal activity [443].  
 
1.22.4: COX1 and COX2, inflammation and cancer 
COX1 is constitutively active whereas COX2 isoform expression is inducible, for example, by 
mitogens or cytokines as COX2 is involved in inflammation [444]. NSAIDs may be therapeutic in 
malignant cells exhibiting certain mutations such as in Pi3K signalling [445]. Non-selective NSAIDs 
inhibit both COX1 and COX2 and may inhibit proliferation and accelerate apoptosis [446]. High 
levels of COX2 which is overexpressed in some cancers correlates with angiogenesis and 
mutagenesis [447]. Although epidemiological evidence shows aspirin and some NSAIDs can 
protect against tumour development or progression in the gut, dose and duration appear critical 
[448, 449], and the mechanisms need further elucidation. COX1 and COX2 are coded on separate 
genes [450].  
 
Prostaglandins are involved in cellular differentiation; PGE2 production by COX2 appears 
important for colorectal cancer initiation and progression via stimulation of malignant cell 
proliferation, survival, invasiveness and tumour angiogenesis [451, 452]. NSAIDs may hamper 
colorectal carcinogenesis by stimulating apoptosis or programmed cell death, as PGE2 stimulates 
Pi3K/Akt pathways that protect colon cancer from apoptosis [453]. The Akt substrate GSK3β 
inactivates cJun and cMyc oncogenic transcription factors and negatively regulates Wnt signalling 
and β-catenin proto-oncoprotein and so suppresses tumour initiation [454]. Regular NSAIDs or 
aspirin may halve bowel cancer risk [455], and reduce polyp formation in familial adenomatous 
polyposis [456].  
 
Chemotherapy with cisplatin and radiation treatments may leave patients more vulnerable to the 
metastatic spread of tumour cells, spared by these therapies, as responses can include production 
of chemotactic cytokines, and tumour cell growth in damaged tissues. This vulnerability may be 
ameliorated by ibuprofen treatment [457], possibly due to ibuprofen’s ability to inhibit PGE2 
production, and modulate calcium dynamics in remaining malignant cells [458].  
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NSAIDs may have a COX-independent mechanism of opposing various malignancies. Non-selective 
NSAIDs irreversibly acetylate COX1 and competitively inhibit COX2 [459], but different NSAIDs 
may act at different concentrations in different tissues e.g. Aspirin at low dose relatively 
selectively inhibits COX1 in platelets but above 500 μM only inhibits COX2 [460, 461]. Inhibition of 
COX1 purportedly can cause gut ulceration, but COX2 expressed in the presence of damage may 
support mucosal integrity [462]. There is a link between inflammation and cancer, and pro-
inflammatory IL-1β and TNFα are potent inducers of COX2. Chronic inflammation can trigger 
malignant transformation. PGE2 levels are reported to positively correlate with metastatic 
potential of breast cancers [463]. Smoking can induce COX2 expression and PGE2 release in 
metastatic breast cancer via phospholipid A2-dependent pathways that support cell proliferation 
and migration [415]. PGE2 may be able to inhibit apoptosis, reduce cellular adhesion, increase 
motility, promote immunosuppression and angiogenesis [464, 465]. PGE2 may promote anti-
apoptotic effects via Pi3K-Akt & PPARδ signalling [466]; support VEGF expression which itself 
stimulates cell proliferation [467]; and induce cell proliferation by Raf/MEK/ERK and Pi3K/Akt 
signalling [468] that itself supports motility and invasion and through ERK2/JNK1 signalling 
angiogenesis [469].  
COX2-produced PGE2 is the principle prostaglandin produced in solid tumours [470, 471]. In mice 
if EP1, EP2 and EP4 are deleted or blocked by antagonists the animals resist carcinogen-mediated 
cancers [472-474]. EP1, EP2 and EP4 over-expression occurs in breast cancers [475]. COX2/PGE2 
may contribute to breast cancer growth via EP1-PKC or PKA signalling upregulating aromatase, an 
enzyme which catalyses oestrogen biosynthesis in adipose tissues; if adjacent to tumours this can 
support malignancy [476, 477]. 
1.22.5: NSAIDs COX-independent antineoplastic effects 
Individual NSAIDs may have COX-independent prostaglandin-independent antineoplastic effects, 
e.g. celecoxib can induce expression of cyclins A, B and D causing cell cycle arrest in G1 phase 
[478], this may occur due to inhibition of PKB/Akt or PDK-1 [479]. Celecoxib can also activate 
apoptosis by the intrinsic pathway, i.e. cytochrome C release by mitochondria activating caspases-
3, 8, and 9 [480, 481].  
NSAIDs have also shown anti-tumour effects on COX2-null cell lines as NSAIDs independently of 
COX2 inhibition can stimulate the transcription and translation of 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) which degrades inflammatory prostaglandins so physiologically 
antagonises COX2. 15-PGDH may inhibit colon malignancy [482]. NSAIDs may raise levels of 15-
PGDH by (i) down-regulation of matrix metalloproteinase-9 (MMP-9) which can degrade 15-PGDH 
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and (ii) by upregulating Tissue inhibitor of metalloproteinase-1 (TIMP-1) an inhibitor of MMP-9 
[483]. Ibuprofen is reported to upregulate metalloprotease-13 (MMP-13) and Paracetamol to 
suppress it [484]. Ibuprofen may also down regulate MMP-2, MMP-9 [485], as well as TNFα 
stimulated IL-6 and IL-8 [486]. Finally NSAIDs’ purported anti-cancer effects include inhibition of 
calcium ATPases preventing cytosolic calcium re-uptake and so elevating intracellular calcium 
concentrations [487].  
 
1.23: Research objectives 
Malignant cell migration facilitates metastasis, frequently the final fatal stage in cancer 
progression. Interest is growing in modulation of chemokine signalling as a therapeutic tool in 
cancer. For example, a CXCR4 peptide antagonist (LY2510924) has been used in clinical trials as 
adjunct therapy, with a variety of established chemotherapeutic agents, but as yet there have 
been no positive outcomes reported. Sadly LY2510924 reduced overall survival (OS) time in 
metastatic renal cell carcinoma from 12 to 8 months when added to Sunitinib [488]; and reduced 
OS time from 11 to 9 months in small cell lung cancer when added to carboplatin and etoposide 
therapy [489]. These results confirm further elucidation and understanding of chemokine 
signalling is urgently required.  
Hypothesis: Many chemokines, including CCL3 and CXCL12 along with their cognate receptors, 
are instrumental in supporting metastasis. 
Aim: Elucidate the importance of key intracellular signalling proteins in CCL3- and CXCL12-
triggered cancer cell migration.  
Objective: To use small molecule antagonism, siRNA knockdown or plasmid modification of 
chemokine receptors and important intracellular signalling proteins to further elucidate these 
proteins role in chemokine-induced cell migration in vitro, as this may relate to metastasis in vivo. 
The focus was on CXCL12-, CCL3- and CCL2-induced chemotaxis in THP-1 monocyte, and Jurkat T-
cell suspension cell-lines also CXCL12- and CCL3-stimulated random motility (chemokinesis) in 
MCF7 a breast-cancer adherent cell-line.  
Limitations: The investigations in this thesis solely used cancer cell-lines to understand the 
fundamentals of these specific chemokine signalling pathways, the identities of the cell-lines were 
presumed to be as supplied from ATCC. Cell-lines offer easy access and excellent reproducibility 
as a first step before expanding into patient samples or animal models both of which also have 
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their limitations. Malignant cells are unique to each and every patient so tissue samples must be 
drawn from many different patients to get a clear picture of inhibitor effects. Animal models, 
usually mice, are also very useful, more homogeneous; however the important differences in the 
chemokine systems of mice and men are a limiting factor. Cell-lines can establish the importance 
of a signalling protein in chemotactic signalling laying the groundwork for further investigations in 
animal models and patient samples which precede clinical trials in people. For example this was 
the route that has led to the now extensive clinical use of tyrosine kinase inhibitors in the 
treatment of many cancers [490].  
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Chapter 2: Materials and Methodology 
 
2.1: Reagents 
2.1.1: Small Molecule Inhibitors 
 
Table 2.1: Small Molecule Inhibitors (solvent DMSO unless otherwise stated) 
Small molecule Inhibitor Supplier Experimental conc. 
   
Dynamin Inhibitors 
MitMAB  Ascent Scientific 10 μM 
OctMAB Ascent Scientific 5 μM 
Dynasore Abcam 40, 60, 80 μM 
Dyngo 4a Abcam 80 μM 
RTIL-13™ Abcam 2.5, 5, 10 μM 
RhodadynC10™ Abcam 20 μM 
Pyrimidyn-7™ Abcam 10 μM 
   
PKC Inhibitors 
Rottlerin (solvent ethanol) Tocris 2-4 μM 
Staurosporine Tocris 10 nM 
GF109203X (solvent ethanol) Tocris 5 μM 
   
PKD Inhibitor   
CID755673 Tocris 5 μM 
   
Raf-1 Inhibitor   
L779450 Abcam 0.5, 1, 5 μM 
   
cAMP Activator   
Forskolin Abcam 20, 50 μM 
   
ERK/MEK inhibitors   
SL327 Abcam 1 μM 
PD98059 Abcam 10, 25 μM 
   
Rac Inhibitors  
NSC23766  (solvent water) Abcam 12.5, 25, 50, 100 μM 
EHT1864 Cambridge Biosciences 10 μM 
   
FAK/Pyk2 Inhibitors  
PF-562271 Abcam 10 -25 μM  
FAK Inhibitor PF-228 Sigma-Aldrich 10 μM 
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Table 2.1 continued: Small Molecule Inhibitors (solvent DMSO unless otherwise stated) 
Small molecule Inhibitor Supplier Experimental conc. 
 
Kinase Inhibitors 
SB203580 Abcam 10 μM 
β-ARK-1 Calbiochem 1 – 2 μM 
Bosutinib Selleck Biochem 0.5, 1, 2.5, 5, 10 μM 
H89 HCL Abcam 0.5, 1 μM 
Y27632 Tocris 1, 5, 10 μM 
   
Pi3K Inhibitors   
AS605240 Tocris 1, 5 μM 
LY294002 Tocris 10 μM 
   
GRK Inhibitor   
Ipyrimidine (4-Amino-5-
ethoxymethyl-2-methylpyrimidine) Abcam 1, 5 μM 
   
JAK2 II Inhibitor 
Hexabromocyclohexane (HBC) Calbiochem 10 μM 
   
STAT3 III Inhibitor 
WP1066 Calbiochem 2 μM 
   
STAT3 VIII Inhibitor 
5,15-Diphenylporphyrin (5,15-DPP) Calbiochem 10 μM 
   
β-catenin Inhibitor   
FH535 Abcam 1, 5 μM 
   
Cdc 42 Inhibitors 
ZCL278 Abcam. 10, 20 μM 
   
Phospholipase C Inhibitors 
U73122 Tocris 10 μM 
 
NSAIDs 
Celecoxib Sigma-Aldrich 50 μM 
Ibuprofen Aspar Pharmaceuticals 290 μM 
Naproxen (solvent water) Aspar Pharmaceuticals 217 μM 
Aspirin (solvent water) Aspar Pharmaceuticals 555 μM 
Paracetamol  Aspar Pharmaceuticals 130 μM 
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Table 2.2: Small Molecule Inhibitors and Receptor Antagonists (solvent DMSO unless otherwise 
stated) 
Small molecule inhibitor Supplier Experimental conc. 
 
CXCR4 antagonist 
  
ATI2341 (solvent water) Tocris  10 μM 
   
CCR1/CCR3 antagonist   
J113863 Tocris  1 nM, 20 nM 
   
CCR5 antagonist   
Maroviroc Tocris  50 nM 
   
Gβγ Inhibitor   
Gallein Tocris  10 μM 
   
Cytoskeletal Inhibitors 
Nocodazole Sigma-Aldrich 7.5 μM 
   
 
2.1.2: Peptides and Chemokines 
 
Table 2.3: Peptide Inhibitors (solvent water) 
Peptide Sequence Experimental Conc. 
   
Rac-1 active peptide (W56) VDGKPVNLGLWDTAG 280 – 560 μM 
Rac-1 control peptide (F56) VDGKPVNLGLFDTAG 280 – 560 μM 
   
 
Table 2.4: Chemokines (solvent water) 
Chemokines (Human) Supplier Experimental Conc. 
   
CXCL9 PeproTech London, UK 1 – 5 nM 
CXCL11 PeproTech London, UK 1 – 5 nM 
CXCL12 PeproTech London, UK 0.1 – 10 nM 
CXCL14 PeproTech London, UK 1 – 600 nM 
CCL2 PeproTech London, UK 1 – 5 nM 
CCL3 (2-70) (D26A) [491] British Biotech Oxford UK* 1 – 10 nM 
   
*Generously donated by Lloyd Czaplewski of British Biotech (Oxford, UK). CCL3 (2–70) (D26A) a 
form of CCL3 which has reduced aggregation propensity but similar affinity for CCR5 as well as 
ability to stimulate both calcium mobilisation and chemotaxis as endogenous CCL3, although CCL3 
(2–70) (D26A) has a reduced gene sequence [492]. 
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2.1.3: Bacterial Plasmids 
Table 2.5: Bacterial Plasmids 
Plasmid Source / Addgene plasmid reference  
  
β-arrestin 1 aka Arrestin-2 pcDNA3 arr2 (arrestin-2) a gift from Eamond Kelly [493] 
β-arrestin 2 aka Arrestin-3 pcDNA3 arr3 (arrestin-3) a gift from Eamond Kelly [493] 
eGFP control 
 
pEGFP.C2 (Clontech, France) plasmid DNA coding green 
fluorescent protein at the C-terminus 
Arrestin-2 mutant 
 
 
PcDNA3-arr2 mutant – arrestin-2 component is mutated by 
substitution of a valine for an aspartic acid at the start of the 
arrestin sequence i.e. β-arrestin-1-V53D  [494] 
dsRed-Mito Mitochondrial targeting sequence fused to 5’ of DsRed vector 
has CMV pormoter, pUC, fI and SV40 origins of replication. 
Kanamycin / G418 resistance (Clontech, France) 
  
 
Plasmids above were produced by cloning arrestin DNA into pEGFP-N1 plasmids (Clontech, 
France) using a Hind III/Apa I digest. pEGFP.C2 plasmids (Clontech, France) were used as  
transfection controls.   
 
2.1.4: Antibodies 
Table 2.6: Primary Antibodies 
Primary Antibody  Species Supplier Dilution* 
 
Cofilin #3312 mAb (Immunofluorescence) 
 
Rabbit 
 
Cell Signaling Tech. 
 
1 in 1000 
Cofilin (D3F9)XPTM mAb (Western Blots) Rabbit Cell Signaling Tech. 1 in 5000 
Phospho-cofilin (Ser3) (77G2) #3313 mAb  Rabbit Cell Signaling Tech. 1 in 1000 
Dynamin-2 Ab65556 mAb Rabbit Abcam 1 in 1000 
β-actin (C4) sc47778 mAb Mouse Santa Cruz Biotech 1 in 5000 
β-Arrestin-1/2 Antibody (A-1): sc-74591 mAb Mouse Santa Cruz Biotech 1 in 1000 
Src: 3389 #327537 mAb Mouse R & D Systems Biot. 1 in 1000 
PKC alpha (H-7): sc-8393  Mouse Santa Cruz Biotech 1 in 5000 
PKC zeta (H-1):sc-17781  Mouse Santa Cruz Biotech 1 in 10,000 
PI3 Kinase p85α (6G10) #13666 mAb  Mouse R & D Systems Biot.  1 in 1000 
CXCR4 12G5  Mouse Santa Cruz Biotech 1 in 5000 
CCR5 HEK/1/85a/7a cell growth supernatant  Rat **   undiluted 
p-STAT3 (B-7): sc-8059 Mouse Santa Cruz Biotech 1 in 1000 
(*working dilution in 5% bovine serum albumin (BSA) in Tris Buffered Saline + Tween (TSBT) 
**Gift from J.A. McKeating, Reading. 
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Table 2.7: Secondary Antibodies 
Secondary Reagent Species Supplier Dilution* 
 
Horseradish peroxidase  
 
Mouse 
 
Sigma Aldrich 
 
1 in 20,000 
Horseradish peroxidase  Rabbit Sigma Aldrich 1 in 20,000 
Horseradish peroxidase Rat Sigma Aldrich 1 in 10,000 
Fluorescein isothiocyanate (FITC)  Mouse Sigma Aldrich  1 in 500 - 1000 
Fluorescein isothiocyanate (FITC)  Rabbit Santa Cruz Biotechnology 1 in 500 - 1000 
Fluorescein isothiocyanate (FITC)  Rat Santa Cruz Biotechnology 1 in 500 - 1000 
(*working dilution in 5% BSA in TSBT) 
 
 
2.1.5: Small Interfering Ribonucleic Acids (siRNA) 
 
Table 2.8: siRNAs (All used at 50 nM in RNAase-free water) 
siRNA Supplier / Reference Target sequence 5’-3’ 
   
 QIAGEN  
PKCα                           Hs_PRKCA_5   AACCATCCGCTCCACACTAAA 
PKCδ                           Hs_PRKCD_11 CAGCAGCAAGTGCAACATCAA 
PKCε                            Hs_PRKCE_6 CACGGAAACACCCGTACCTTA 
PKCζ                            Hs_PRKCZ_6 GACCAAATTTACGCCATGAAA 
Scr-Xerogon Allstars Neg 
Modlf.s: 3’Rh 
Cat1027291,B/Noas173445 
(Nonsense sequences) 
Rhodamine (20 nmol) 
S177811 
   
On-TARGETplus Human - 
Individual 
Dharmacon  
Pi3K    J-003020-16-0005  PIK3R1(5296) GACGAGAGACCAAUACUUG 
SRC                   SRC (6714) GGGAGAACCUCUAGGCACA 
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Table 2.9: SMARTpool siRNAs (All used at 50 nM in RNAase-free water) 
On-TARGETplus Human - SMARTpool Dharmacon Target sequences 
   
  Dynamin-2 Pool sequences 
Dynamin-2       DMN2(1785)-05 GGCCCUACGUAGCAAACUA 
 DMN2(1785)-06 GAGAUCAGGUGGACACUCU 
 DMN2(1785)-07 CCGAAUCAAUCGCAUCUUC 
 DMN2(1785)-08 GAGCGAAUCGUCACCACUU 
   
  Cofilin-1 Pool sequences 
Cofilin-1      CFL1(1072)-05 CCUCUAUGAUGCAACCUAU 
 CFL1(1072)-06 CAUGGAAGCAGGACCAGUA 
 CFL1(1072)-07 UAAAUGGAAUGUUGUGGAG 
 CFL1(1072)-08 ACUCUGUGCUUGUCUGUUU 
   
 
 
 
2.1.6: Imaging Stains and Activation Kits 
Table 2.10: Imaging Stains 
Cell stains Synonym Supplier Experimental conc. 
Alexa Fluor™ 488 Phalloidin  
 
Phalloidin 
 
Sigma Aldrich 
 
1:200 
4′,6-Diamidino-2-phenylindole 
dihydrochloride 
DAPI Sigma Aldrich 1:5000 
    
 
Table 2.11: Activation Kits 
Kit Reference Supplier 
   
CatchPoint cyclic-AMP Fluorescent Assay Kit  #R8089 Molecular Devices 
Rac1 Activation Assay Biochem KitTM  
PhosphoSTAT3 (Tyr705) InstantOne ELISATM 
#BK035-S 
#85-86102-11 
Cytoskeleton, Inc 
eBioscience 
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2.2: Cell-lines 
Table 2.12: Cell-lines 
Cell-line Source Supplier 
   
THP-1 Homo sapiens blood monocyte cell line originating from the 
peripheral blood of a one year old male donor suffering acute 
monocytic leukaemia 
ATCC* 
   
Jurkat Homo sapiens blood T-lymphocyte cell line originating from the 
peripheral blood of a male donor suffering acute T-cell 
leukaemia 
ATCC* 
   
MCF7  Homo sapiens epithelial breast cell line originating from the 
pleural effusions of a 69 yr old female suffering metastatic 
breast adenocarcinoma (Michigan Cancer Foundation-7) 
ATCC* 
   
PC3 Homo sapiens prostate cell line originating from metastatic 
growth in bone producing grade IV adenocarcinoma  in 62 yr 
old male 
ATCC* 
   
CHO.CCR5  Chinese Hamster Ovary cell line transfected with pcDNA3 
encoding chemokine receptor CCR5 and resistance gene to 
antibiotic G418 maintained by culturing cells in presence of 
200μg/mL G418  
J. McKeating 
Reading[495] 
   
*original source American Type Culture Collection (ATCC) - cell line identities were presumed to 
be as supplied. 
 
2.3: Cell culture 
Table 2.13: Cell Culture Mediums 
Medium Contents  
  
RPMI 
Complete 
500 mL Roswell Park Memorial Institute 1640 medium + 50 mL Heat 
inactivated FCS + 5 mL L-glutamine 200 mM + 5 mL MEM Non-essential 
Amino Acid Solution (100 X) 
DMEM 
Complete 
500 mL Dulbecco’s Modified Eagle’s Medium-high glucose + 50 mL Heat 
inactivated FCS + 5mL L-glutamine 200 mM + 5 mL MEM Non-essential 
Amino Acid Solution (100 X) 
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2.3.1: FCS Heat Inactivation 
FCS was thawed, warmed to 55°C in a water bath, maintained at 55°C ± 2°C for 30 ± 2 minutes 
then cooled, then aseptically aliquoted and frozen for future use. 
2.3.2: Propagating Cell Cultures 
Adherent cells were cultured in DMEM complete and split at 80% confluency. Suspension cells 
were maintained in RPMI complete at approximately 80 x 104 cells/mL  
2.3.3: Cell Counting and Viability  
0.1 mL of 0.4% Tryptan Blue in PBS was added to 0.1 mL of cell suspension, incubated for 15 
minutes, and the mixture used to load Neubauer haemocytometer. Blue cells were non-viable. 
Cells were counted using light microscopy, at X400. Viability was calculated as % viable = [1-(blue 
cells/total cells)] x 100. Cells were only used if viability was above 95%. 
2.3.4: Freezing and thawing cells 
Freezing: 5 x 106 cells in logarithmic growth phase were aseptically centrifuged (900 rpm/5 
minutes), the supernatant was discard, then cell pellet re-suspend in 1 mL freezing mixture 
(sterile FCS+10% sterile DMSO), transferred to 2 cryogenic tubes (Fisher), wrapped in several 
layers of tissue to slow freezing rate and immediately place at -70°C for ≥ 24 hours, once fully 
frozen tubes were transferred to liquid nitrogen storage (-195°C). 
Thawing: A cryogenic tube was warmed rapidly to 37°C, once contents were freely moving they 
were aseptically tipped into 5 mL simple medium (37°C), shaken gently, centrifuged (900 rpm, 5 
minutes), the supernatant discard, and pellet re-suspended in 5 mL warmed complete medium 
maintain at 37°C 5 % CO2. 
2.3.5: Harvesting Adherent Cells  
Concentrated EDTA solution (0.5 M) was prepared by weighing 37.224 g EDTA, adding to 100mL 
of Millipore filtered distilled water, then placing on a magnetic stirrer in plastic beaker, 6-10 
pellets of sodium hydroxide added, and stirred until all solids were in solution. The pH was 
adjusted if necessary with HCl 5 M to give pH 7-8, solution was transferred to a 200 mL glass 
bottle and autoclaved, 121°C, 15 minutes. 2mL of this sterile 0.5 M EDTA was then added 
aseptically to 200 mL of sterile PBS to prepare working ~5 mM EDTA. Adherent cells were 
detached by pouring off medium, adding 4 mL of 5 mM EDTA/PBS, incubating (37°C, 5% CO2, 10 
minutes), the flask tapped until cells detached, cells were then centrifuged and washed with PBS 
(37°C) to remove EDTA. 
Harvesting using Trypsin/0.05% EDTA (Gibco-invitrogen): Medium was tipped out from 75 cm2 
flasks, and attached cells rinsed with PBS, before adding 2.5 mL Trypsin/0.05% EDTA solution, 
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flasks were then left for 10 seconds, before 1.5 mL of Trypsin/0.05% EDTA was removed leaving 1 
mL on cells, flasks were then briefly incubated (2 minutes, 37°C, 5% CO2), and flask tapped until 
cells detached. Cells were used without further rinsing as the new medium dilutes remaining 
trypsin/EDTA enough so it does not impede attachment or growth. 
2.3.6: Phorbol 12-myristate 13-acetate differentiation of THP-1 to macrophages 
THP-1 were centrifuged, re-suspended at 20 x 104 cells/mL in fresh RPMI complete, and 25-50 
ng/mL Phorbol 12-myristate 13-acetate (PMA, TPA) added, e.g. 1.5 μL per 30 - 60 mL cell 
suspension. For cell staining 5 mL of cell suspension was added to each well of 6 well plate 
containing glass coverslips previously sterilised in ethanol 70%, plates were left 72 hours for cells 
to adhere and grow on coverslips. 
2.4: Chemotaxis 
The wells in a Neuro Probe ChemoTx® System micro-chemotaxis plate (ChemoTx# 101-5 with 5 
μm pores) were blocked with 30 µL blocking buffer (1% BSA in RPMI without additives) for at least 
30 minutes at room temperature. Chemokine solutions were prepared at working 
concentration/s, 1 nM unless otherwise stated, in working buffer (0.1% BSA in RPMI without 
additives). Jurkat or THP-1 cells were spun at 900 rpm and re-suspended in working buffer to give 
25 x 104 cells per well. Inhibitors at the required concentrations were added and cells incubated 
(37°C 30 minutes). Blocking buffer was removed from the plate and replaced with 31 µL of the 
relevant chemokine solution or working buffer for the control. The membrane was attached and 
20 µL of cell suspension was added to the top surface. The plate was placed in a humidified 
chamber which was then incubated for 4 hours at 37°C, 5% CO2. Next the remaining cell solution 
on membrane was carefully removed, the membrane detached, and the cells that had migrated 
through the pores into in each well counted using a haemocytometer. Each data point was 
performed in duplicate, and the whole experiment repeated on three or more occasions.    
 
2.5: Wound-healing assays 
MCF7 cells were removed from flasks using EDTA 0.5 mM/PBS, centrifuged, (transfected if 
required), seeded onto 12 well plates, incubated (37°C, 5% CO2) for 24 hours. A scratch was 
introduced to the monolayer with 200 µL pipette tips (time point 0), medium and loose cells 
removed, monolayer washed once in DMEM, then 500 μL DMEM without additives was added 
along with inhibitors or vehicle control and plates incubated (37°C, 5% CO2 30 minutes). 
Chemokines (at 10 nM unless otherwise stated) were added to the cells and pictures were taken 
(time point 0). Plates were incubated (37°C, 5% CO2 24 hours) then imaging repeated (time point 
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24 hours), using an inverted Leica microscope 10 times magnification. Images were analysed and 
the width of the wound was measured for control and with inhibitor treatment (with and without 
chemokine) at 0 hours and 24 hours. Ratios were calculated (width of the wound after 24 hours 
divided by the width of the wound at 0 hours) and the effects of inhibitor and chemokine 
analysed. The nearer the result is to 1 the more effective the inhibitor in preventing migration. 
2.6: Cytotoxicity Assays 
2.6.1: CellTitre 96® Aqueous One Solution Cell Proliferation Assay  
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assays were performed using Promega’s CellTiter 96® Aqueous Non-Radioactive Cell Proliferation 
Assay and 96 well plates. Suspension cells were spun down, and re-suspended in RPMI complete 
at 1 x 106 cells/mL, 100 uL of cell solution was placed in each well. (For adherent cells these were 
seeded into the plate and incubated (37°C, 5% CO2) in complete medium overnight to form a 
monolayer, medium was then pipetted out and 100 μL of complete medium per well added). 
Then for both adherent and suspension cells inhibitors were added at the required 
concentrations. Each condition/inhibitor was duplicated. Plates were incubated for 4 hours at 
37°C before 20 μL of the MTS solution was added per well and the plate incubated for 2-5 hours 
at 37°C. The MTS is reduced by live cells to a red/brown soluble formazan that absorbs at 490 nM. 
Once sufficiently coloured the plate was read in a BMG Labtech Fluostar OPTIMA fluorometer at 
490 nm.  
2.6.2: Manual Toxicity Assay 
Inhibitors that are chromophores that absorb light at 490 nm can give erroneous results with any 
absorbance tests. The inhibitor β-ARK-1 was a good example. At 190 μM β-ARK-1 no toxicity is 
detected by MTS assays, yet β-ARK-1 IC50, depending on cell type, was nearer 10 μM. Manual 
toxicity assay were undertaken as above (2.6.1) except MTS was not used instead cells are 
counted manually after required incubation time with inhibitors. 20 μL of cell suspension was 
added to 20 μL of Trypan blue 0.4% filtered solution, mixed, incubated (37°C, 5% CO2, 15 
minutes), then loaded into a haemocytometer and any live cells counted manually. Dead cells 
stained completely blue, live cells stayed clear.  
2.7: Fluorescent Phallotoxin (Phalloidin) F-actin Stain  
Twelve well plates were prepared aseptically, each well with one glass cover slip dipped in 70% 
ethanol. Adherent cells were detached using 0.5mM EDTA/PBS, and sparsely seeded into wells, 
500 μL complete medium was added to each well and plate incubated overnight to allow cell 
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attachment and growth on glass coverslips. Complete medium was then removed aseptically and 
500μL of medium without additives placed in each well. Inhibitors were added in duplicates and 
plate incubated (37°C, 5% CO2, 30 minutes). Chemokines were then added to one of each 
duplicate and plate incubated for a further hour. Solutions were then removed, coverslips gently 
washed with cold PBS, and 100 μL 4% paraformaldehyde added, and plate left at room 
temperature for 10-15 minutes. Paraformaldehyde was then removed, coverslips gently washed 
with cold PBS and 100 μL of 0.1% Triton X-100 added for 3-5 minutes. Triton X-100 was then 
removed, coverslips washed with cold PBS, and 50μL per well of Phalloidin DaylightTM488 
Conjugated (1 μL per 100 μL cold PBS) added. Plate was covered to exclude light and kept at room 
temperature for 20 minutes. Phalloidin solution was pipetted off, coverslips were washed once 
with cold PBS, then if required DAPI staining was undertaken next (see methodology below). 
Finally coverslips were lifted from wells and mounted face down on a labelled glass slide/s using a 
spot of DPX mounting medium or PBS/glycerol 50/50 mix and nail varnish to seal edges of 
coverslip onto glass slide.  
2.8: 4’,6-diamidino-2-phenylindole (DAPI) stain 
This can be used after actin or receptor staining, where cells were fixed with paraformaldehyde 
and permeabilised with 0.1% Triton X-100. 1 μL of DAPI was diluted in 1 mL PBS (300 nM) and 50 
μL placed on coverslip in well, plate incubated at room temperature for 5 minutes in dark, DAPI 
solution removed and wells rinsed three times cold PBS, coverslips were mounted on glass slides 
as above. 
2.9: Receptor Immunofluorescence staining 
For suspension cells, cells were centrifuged, washed 1 x cold PBS, re-suspended at 5 x 106 cells/mL 
in cold 0.5% BSA in PBS, and primary antibody (1:1000) in 0.5% BSA in PBS added or control (0.5% 
BSA in PBS). Cells were incubated (4°C, 1 hour) washed twice in cold 0.5% BSA in PBS, before re-
suspended in fluorescein isothiocyanate (FITC) labelled immunoglobulin secondary antibodies 
(1:100 in 0.5% BSA in PBS) for 1 h at 4°C. Cells were then washed twice (0.5% BSA in PBS) and a 
droplet placed onto a labelled glass slide and a coverslip added before imaging using an inverted 
Leica DMII fluorescence microscope magnification 500X – 1000X UV excitation 435 nM emission 
480 nM. For adherent cells, cells were seeded, as in Phalloidin actin stain above, onto glass 
coverslips in 12 well plates, incubated overnight (37°C,5%CO2) on coverslips, washed with 0.5% 
BSA/PBS, then stains and washes were added to wells as described above, and coverslips 
mounted as in Phalloidin actin stain.  
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2.10: Immunofluorescence staining of cellular proteins 
Twelve well plates were prepared aseptically, each well with one glass cover slip dipped in 70% 
ethanol. Adherent cells were detached using 0.5 mM EDTA/PBS, and sparsely seeded into wells, 
500 μL complete medium was added to each well and plate incubated overnight to allow cell 
attachment and growth on glass coverslips. Solutions were then removed, coverslips gently 
washed with cold PBS, and 100 μL 4% paraformaldehyde added, and plate left at room 
temperature for 10-15 minutes. Paraformaldehyde was then removed, coverslips gently washed 
with cold PBS and 100 μL of 0.1% Triton X-100 added for 3-5 minutes. Triton X-100 was removed, 
coverslips washed 3x with cold PBS. Cells were incubated in 1% BSA in PBS + 1% Tween 20 (PBST) 
for 30 minutes (blocks non-specific binding). Then incubated in desired antibody (1:1000) in 1% 
PBST in humidified chamber 1 hour RT, before antibody was removed, washed 3x with cold PBS 
for 5 minutes,  secondary antibody (1:1000) in 1% BSA in PBST added, and plate kept 1 hour RT (in 
dark). Secondary antibody was then pipetted off, coverslips washed with cold PBS (3x 5 minutes), 
then mounted with drop of DPX, and stored at 4°C in dark, imaged using an inverted Leica DMII 
fluorescence microscope magnification 500X – 1000X UV excitation 435 nM emission 480 nM.   
2.11: Transfection of cells 
2.11.1: siRNA Transfection 
2.11.1.1: siRNA transfection using AMAXA Nucleofector 
siRNA was prepared by adding 200 uL of RNAse free siRNA suspension buffer (Qiagen Sciences) to 
5 nmol of siRNA to produce 25 μM (approximate) stock, tube was centrifuged briefly and placed 
on the orbital shaker (30 minutes, RT). 2 μL of 25 μM siRNA stock was added to 198 μL RNAse free 
suspension buffer to produce approximate 250 nM stock. Solution concentration was confirmed 
using Nanodrop readings on the RNA/DNA tab. The average of three RNA readings was used and 
concentration calculated using formula 13.4 ng/μL = 1 μM - formula uses average siRNA mol. wt. = 
13,400 g/mol (Dharmacon, UK). 
Adherent cells were removed from flasks using 0.5mM ETDA/PBS or suspension cells were 
harvested. Cells were then counted, centrifuged and re-suspended in electroporation buffer (EPB) 
containing Hepes 20 mM 4.766 g, NaCl 137 mM 8.0063 g, KCl 5 mM 372.8 mg, Dextrose (D-
glucose) 6 mM 1.081 g, Na2HPO4 0.7 mM 99.372 mg, H2O to 1000 mL. The pH was adjusted to 7.5 
using KOH to raise pH or HCl to lower pH, before filter sterilising through a 0.22 μm Millipore 
filter. 3 x 106 cells were used per 200 μL per cuvette (Gene Pulser Cuvette 0.4 cm electrode gap). 
siRNA was added to cuvette to produce final concentration of 50 nM. Cuvette was treated in 
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Lonza Amaxa Nucleofector II according to manufacturer’s instructions on programme U001, then 
contents immediately aseptically transferred to pre-warmed complete medium. Suspension cells 
were grown for 24 hours before chemotaxis or preparation of proteins for western blotting. 
Adherent cells were seeded directly after AMAXA treatment into 12 well plates prepared for 
scratch assay. Controls were nonsense siRNA (Scr) also at 50 nM and AMAXA only treatment of 
cells in absence of siRNA.  
2.11.1.2: Chemical siRNA transfection 
Adherent cells were also transfected with siRNAs using Lipofectamine RNAi (ThermoFisher 
Scientific) according to manufacturer’s instruction. Controls were nonsense siRNA (Scr) also at 50 
nM, and transfection agent only treatment in absence of siRNA. 
2.11.2: Plasmid transfection using AMAXA 
Cells were counted, centrifuged and re-suspended at (per cuvette) 3 x 106 cells in 200 μL 
electroporation buffer, plus 12.5 μL tRNA and 2 μg plasmid DNA, with only tRNA as one control. 
Other controls were 2 μg mutant arrestin plasmid or eGFP plasmid. Each cuvette was then placed 
in turn into the AMAXA and treated on programme U001. Next 250 μL warm RPMI was 
immediately added to each cuvette, then entire contents transferred to 5 mL warmed complete 
medium. Plates or flasks were incubated for 24 hours (37°C, 5% CO2) before use in experiments. 
Adherent cells were transfected in the same way after detaching from plastic using 0.5 mM 
EDTA/PBS or were transfected following Lipofectamine DNA (ThermoFisher Scientific) following 
manufacturer’s instructions. 
2.11.3: Fugene or Lipofectamine plasmid transfection for adherent cells 
Previously seeded cells growing on cover slips in a 12 well plate were used, or cells directly seeded 
onto the plate (for scratch assays). Old medium was removed, replaced with 500 μL of medium 
without supplements, and plate replaced into an incubator to allow 5% CO2 to acidify medium pH 
(important for transfection success). Next one Eppendorf with 100 mL simple medium for each 
transfection, plus one as a Fugene or Lipofectamine control was prepared. Then either 3 μL of 
Fugene or 5 μL of Lipofectamine was added rapidly, and the Eppendorfs left standing under 
laminar flow (RT) for 10 minutes, before 1 μg of plasmid DNA per Eppendorf was added and again 
left for 5 minutes under laminar flow (RT). Then the contents of each Eppendorf were added to 
one well of a 12 well plate along with 200 μL simple medium. Plate was incubated (37°C, 5% CO2, 
4-8 hours) then 500 μL of complete medium added to each well. A check for fluorescence (UV 
excitation 435 nM emission 480 nM) was carried out at 24 hours. 
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2.12: Plasmid technology 
2.12.1: DH5α Escherichia Coli transformation 
2 ng of relevant plasmid was added to 50 μL of freshly thawed DH5α E. coli on ice, tube flicked 
gently 4-5 times to mix, incubated (4°C, 30 minutes), heat shocked (42°C, 30 seconds), placed on 
ice (4°C, 2 minutes), tube incubated (37°C, 40 minutes), tube flicked gently every 5 minutes. Agar 
petri plates were prepare using agar containing the relevant antibiotic (10 μg/mL kanamycin for 
arrestin plasmids), plates were inoculated using sterilised spreader, incubated overnight (37°C), 
colony collected and transferred to bacterial fermentation (2.12.2). 
2.12.2: Bacterial fermentation for plasmid DNA harvesting  
One litre of Luria Broth (LB), was prepared and sterilised (by autoclaving), 10mg/mL of antibiotic 
relevant to resistant gene in plasmid (Kanamycin used for arrestin plasmids) added aseptically 
once broth cool. 
100 mL conical flask/s were sterilised, using foil to cover tops, then to each 20 mL LB/ kanamycin 
broth added, plus 20 μL DH5α E. coli carrying plasmid to each flask, flasks were placed on shaker 
to oxygenate at 37 °C for 12-24 hours until contents became cloudy, (aliquots of this cloudy 
culture were frozen for later use). 10 mL of the first culture was then transferred to sterile LB 
broth + Kanamycin 10 μg/mL (150 mL) in a 250 mL sterile foil covered conical flask, then shaken 
overnight at 37 °C. Content of flask were then centrifuged to pellet bacteria in 50 mL tube/s (4000 
rpm 5 minutes), supernatant discarded and pellet then processed or stored at -20°C, for later 
purification (2.12.3). 
2.12.3: Plasmid Purification (Qiagen Plasmid Midi Kit method) 
Qiagen Midi Kit protocol was followed using buffers provided briefly: 4 mL Buffer P1 was added to 
each 50 mL tube to lyse bacteria, pipetted up and down to create a suspension then the lysis mix 
transferred into the next 50 mL tube containing a bacteria pellet, process was repeated for up to 
four pellets. 4 mL of Buffer P2 (contains NaOH and SDS) to 4 mL of re-suspended cells in P1 was 
gently added. Tube lid put on and tube inverted two or three times, before waiting 3 minutes. 
Then 4 mL buffer P3 (contains Acetic Acid) which neutralises and precipitates proteins was added 
and tube shaken vigorously 2-3 times, then centrifuged (4000 rpm 5 minutes). A Qiagen Plasmid 
Midi Kit column was suspended over a new 50mL centrifuge tube, and equilibrated by adding 5 
mL of QBT Buffer. Once QBT had run through the column centrifuged tube was carefully lifted 
from centrifuge, it contained a white pellet of protein below and above a clear solution. Tube was 
poured carefully into equilibrated column so that the clear solution went into the columns the 
white pellet and surface should stay in centrifuge tube. Clear solution was allowed to run through 
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column and the eluate discarded, as plasmid DNA had bound solid phase in column. Once all 
supernatant from bacteria proteins had run through column was filled with QC wash buffer, and 
again eluate discarded. Column was then suspended over a new 50 mL tube, and 5 mL QF elution 
buffer added to elute DNA off column, eluate was collected then column discarded.  
3.5 mL isopropanol was added to 5 mL eluted DNA solution in centrifuge tube (5 mL x 0.7 = 3.5 
mL) tube capped and tipped 3 or 4 times, then centrifuged (4°C, 4000 rpm, 1 hour). Supernatant 
was then poured off, 1 mL 70% ethanol added to pellet without mixing, and tube centrifuged (4°C, 
4000 rpm 15 minutes), before ethanol was tipped off and tube inverted onto tissue to drain (RT, 1 
hour). DNA pellet was then re-suspend in sterile distilled H2O (200-500 μL), nano-dropped for DNA 
concentration and then diluted if necessary in water down to 1 μg/μL, before freezing (-20°C). 
Alternatively pellet was re-suspend in TrisEDTA buffer and solution stored at 4°C.  
2.12.4: Confirming DNA on Agarose Gel 
The DNA digest mixture was set up as follows: 2 μL of plasmid DNA, 1 μL of 10x HIND3 buffer, 1 μL 
enzyme HIND3 restriction enzyme (in glycerol), 6 μL water, mixture was incubated (1 hour, 37°C). 
Agarose Gel was prepared and run as follows: 50 x TAE buffer was mixed containing: Tris Base 
24.218g, Sodium acetate 2.05g (water free), EDTA 1.86 g, Acetic acid 5 mL, Water to 100 mL. The 
agarose gel was made by heating 0.1 g Agarose with TAE to 100 mL, solution was cooled, 2 μL 
non-toxic DNA dye added, before gel was poured into mould to set. Loading buffer was added to 
each sample, then sample/s, and a DNA ladder to check plasmid size, loaded into gel wells. 
 
2.13: Peptide synthesis 
Two 15 mer peptides were synthesized on a Multisyntech Syro I automated peptide synthesiser 
using standard Nα-Fmoc-based solid-phase peptide synthesis, an active peptide called W56 with 
the sequence VDGKPVNLGLWDTAG and an inactive peptide called F56 with the sequence 
VDGKPVNLGLFDTAG. The synthesis was carried out on a NOVA PEG Rink amide polystyrene resin 
(substitution: 0.49 mmol/g) employing methodology similar to that described by Malkinson [496], 
varying only in that Fmoc de-protection was carried out with 40% piperidine (1 x 10 minutes) and 
20% piperidine (2 x 5 minutes). Next the peptides were cleaved from the resin by shaking the 
resin beads in 5 mL trifluroacetic acid (TFA), water and triisopropylsilane (TIPS) mixture i.e. 
TFA/H2O/TIPS (95:2.5:2.5% v/v) solution for 3 hours. The beads were then filtered from the 
solution and washed with neat TFA then combined with TFA/H2O/TIPS (95:2.5:2.5% v/v) which 
was then evaporated under vacuum. The crude peptide was then precipitated with cold diethyl 
ether before being filtered. The peptides were purified using reverse phase chromatography on a 
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Biotage Isolera Four (SNAP Cartridge KP-C18-HS 12 g) using two phases. Mobile phase A: 5% 
methanol in H2O + 0.05% TFA. Mobile phase B: 5% H2O in methanol + 0.05% TFA. The gradient 
employed was 0100%B over one hour. Next the fractions containing the peptides were 
evaporated under vacuum, and the peptides dissolved in purified water before being freeze dried.  
Peptide purity was examined using analytical HPLC (column ZORBAX Eclipse XBD-C18) Mobile 
phase A: H2O + 0.05% TFA. Mobile phase B: methanol + 0.05% TFA. Gradient 595%B over 20 
minutes; the peptides were found to be ≥ 90% pure. Finally the mass of the peptides was 
examined using MALDI mass spectrometry, the active W56 peptide gave readings of (M+Na, 
1562) and (M+K, 1578), and the control F56 peptide readings of (M+Na, 1523) and (M+K, 1539). 
2.14: SDS–PAGE and Western blot  
2.14.1 Total protein extraction for Western Blot 
Unless otherwise stated cells were exposed to treatment with inhibitors or controls (30 minutes, 
at 37°C, 5% CO2) then to chemokines at 5 nM or H2O control (15 minutes at 37°C, 5% CO2), before 
cells were harvested, washed (ice-cold PBS), re-suspended in minimum volume of ice-cold PBS, 
before an equal volume of Mammalian Protein Extraction Buffer (GE Healthcare), with 5 mM 
Dithiothreitol (DTT) was added. Solutions were then rapidly mixed (using Gilson), and Eppendorfs 
kept on ice for 40 minutes, vibrated every 5 minutes to mix, then centrifuged (10 minutes, 13,000 
rpm, 4°C), then the clear supernatant was pipetted into fresh Eppendorfs, which were kept on ice. 
Supernatant protein concentrations was analysed at 280 nm absorbance (Nanodrop Spectrometer 
ThermoFisher Scientific). The average of 3 readings were recorded as protein content, proteins 
were used immediately or flash frozen and store at -20°C. The volumes of protein extracts 
required to give equal protein content (μg) in all lanes were calculated, mixed 50:50 with 2xSB 
buffer + 5 mM DTT, boiled 5 minutes, spun briefly to return condensation to solution, and loaded 
onto a 10% Acrylamide gel.   
2.14.2: Gel preparation for Western Blot 
Using BioRAD system, glass plates were cleaned with 70% ethanol, fixed into holder, and 10% gels 
prepared (ideal separation for ~30-90 kDa proteins), then upper gel added with 10 well combs. 
Bottom gel (10%) contained: 6 mL H2O, 3.7 ml Bottom gel stock (hydroxymethyl aminomethane  
aka Tris 90.75g, 20% SDS 10ml, pH to 8.8 water to 500ml), 5ml Bis-acrylamide (30% acrylamide), 
130 μL 10% ammonium persulfate (APS), 13 μL TEMED. Solution was mixed, rapidly pipetted 
between prepared plates, and immediately overlaid with water and left until set.  
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Upper gel contained: 600 μL  Upper gel stock (Tris 12.11g, SDS 20% 4mL, pH to 6.8 water to 200 
mL), 4.25 mL H20, 1 mL Bis-acrylamide, 75 μL APS 10%, 7.5 μL TEMED, Solution was mixed, 
pipetted into gap above bottom gel, comb inserted immediately, then left to set. 
BioRAD electrode chamber was set up with gel plates and running buffer (Laemnibuffer) 
containing: Tris 17.5g, Glycine 72g, 5g sodium dodecyl sulfate (SDS), H2O to 5 Litres. Combs were 
removed, 5 μL of pre-stained protein ladder (Thermo Scientific #26612), 20-120 kDa, loaded in 
well 1, and then prepared protein samples in wells 2-10 as needed. BioRAD was operated at 25 
amps until proteins had advanced close to base of gels. 
2.14.3: Protein transfer to membrane 
Using PVC gloves Whatman Protran pore 0.45 μm nitrocellulose membrane was cut to size, 
labelled, soaked (30 minutes H2O), gel was extracted from glass plates and sandwiched with 
membrane between ten blotting paper layers, laid on semidry blotter and soaked with 
transfer/blotting buffer containing: 14.4 g Glycine, 3 g Tris, 200 ml Methanol, 2.5 mL 20% SDS, 
water to 1 L. BioRAD semi-dry blotter was assembled and run at 10 volts for 2 hours. Membranes 
were then extracted, washed TBST, and blocked in 5% BSA/TBST, or 5% dried skimmed milk/TBST 
for one hour RT in 50 mL centrifuge tubes. TBST contained: 2.4 g Tris Base, 8.8 g NaCl, 1 mL Tween 
20, H2O to 1000 mL (pH 7.6).  
2.14.4: Primary antibody labelling 
Blocking solution was poured off, 5mL primary antibody diluted (usually 1:1000) in 5% BSA/TBST 
added, and tube was rolled at RT for 2 hours or 4°C for 12 hours.  Then the primary antibody 
solution was removed the membrane washed with TBST (3 x 5 minutes), drained, rolled with 5 mL 
species specific horseradish peroxidase diluted in 5% BSA/TBST, or 5% dried skimmed milk/TBST 
(usually 1:20,000, 1 hour). Horseradish peroxidase solution was then drained off, membrane 
washed TBST (3 x 5 minutes), membrane blotted then covered with Pierce® ECL Western Blotting 
Substrate mix, (RT, 3 minutes) blotted, placed between two pieces of clear acetate and imaged in 
camera (G-BOX SynGene Imager using Gene Snap Software). 
2.14.5: Loading confirmation 
Membranes were stripped by either rolling with Millipore Stripping Solution (Millipore, Temecula 
California) for 20 minutes, followed by 3 washes (TBST) then re-blocked 5% BSA/TBST or 5% 
Milk/TBST (1 hour) or using Stripping buffer (7.5 g Glycine, 0.5 g SDS, 5 mL Tween 20, water to 500 
mL pH to 2.2 with concentrated HCl). Membrane was placed in stripping tray, covered with 
stripping buffer, shaken (10 minutes), step repeated with fresh stripping solution, membrane 
washed twice with PBS by shaking in tray (2 x 10 minutes), washed twice with TBST (2 x 5 
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minutes), membrane placed in tube and blocked with 5% BSA/TBST or 5% Milk/TBST for 1 hour 
then treated with loading control e.g. Beta-actin. 
 
2.15: Immunoprecipitation of CCR5 receptor 
1 x 107 THP-1 cells were centrifuged, washed 2 x cold PBS, and 1 mL of lysis buffer (150 mM NaCl, 
20 mM Tris, 20 mM EDTA, with 0.5 mL polyoxyethylene 10 oleoyl ether (Brij 97), plus 1 protease 
inhibitor tablet per 50 mL) added. Cells were pipetted up and down to lyse, left suspended in lysis 
buffer (40-60 minutes 4°C) with gently mixing. Centrifuged 17,000g in Eppendorfs (4°C, 25 
minutes) to produce a white pellet of nuclear proteins, pellet was discarded and the supernatant 
put into two Eppendorfs (labelled CCR5 and control). 500 μL (5 μg) Rat HEK/1/85a/7a CCR5 
antibody was added to 500 μL supernatant for active, and 5 μg control (Rat IgG isotype) protein to 
control. Eppindorfs were left on ice (4°C, 1 hour). Next G-sepharose was prepared (using G-
sepharose for rat antibodies as A-sepharose will not bind rat). G-sepharose was centrifuged 
(13,000 rpm, 2 minutes), supernatant pipetted off. G-sepharose pellet washed in cold PBS twice. 
200 µL G-sepharose diluted with 200 µL cold PBS making a slurry. 25 µL G-sepharose slurry was 
added to 25 µL supernatant for active and for control mixtures, then Eppendorfs put on turning 
device overnight for 14 hours (4°C), or left in fridge overnight and turned for 1 hour (RT) in 
morning. Eppendorfs were wrapped in Parafilm to stop evaporation. Eppendorfs were centrifuged 
(13,000 rpm 2 minutes). Pellet washed 4 X with 1 mL ice cold lysis buffer (without pipetting up 
and down, mix re-suspended itself (care with pellet, just to take off most of supernatant). After 
last wash tube was centrifuged (13,000 rpm, 3 minutes), supernatant discarded with care. Pellet 
was re-suspended in 20 µL sample buffer, boiled for 5 minutes, centrifuged, and supernatant 
loaded onto Western gel as above. Gel was transferred to nitrocellulose membrane as above. 
Membrane was blocked with 5% Milk/PBS for 1 hour, rolled with 1 mL HEK/1/85a/7a CCR5 
antibody in 25 mL 5% milk/PBS for 1 hour, washed (3 x 5 minutes) cold PBS. Rolled with Rat 
Horseradish Peroxidase 5 µL in 25 mL 5% milk/PBS for 1 hour washed (3 x 5 minutes) cold PBS, 
then visualised using Pierce® ECL solution following manufacturer’s instructions. 
 
2.16: Analysis of intracellular calcium ion flux 
Cells were harvested, centrifuged, washed in calcium flux buffer (NaCl 137 mM, KCl 5 mM, MgCl2 
2 mM, CaCl2 1.5 mM, HEPES 10 mM, D-Glucose 25 mM pH to 7.4) and re-suspended in calcium 
flux buffer. Fura2 (2 μM) was mixed with cells and cell solution aliquoted into 200 μL portions in 
Eppendorfs, inhibitors or controls were added, Eppendorfs were incubated (30 minutes, 37°C, 
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5%CO2). Then using calcium flux buffer, cells were washed twice before being re-suspended at 
2x106 cells/mL. 100 μL aliquots from each 200 μL sample were pipetted into two wells in a black 
96 well plate producing duplicates. Fluorescence was measured in response to a 20 μL injection of 
a 100 nM chemokine solution giving a final concentration of approximately 16.7 nM (unless 
otherwise stated), added either 15 or 30 seconds after incubation. Calcium mobilisation was 
measured by a BMG Labtech Fluostar OPTIMA fluorimeter, or calcium mobilisation and Area 
Under Curve (AUC) of mobilisation trace by a Flexstation III ROM V3.0.22 (Molecular Devices Ltd, 
Wokingham,UK) using SoftMax Pro, Excel and GraphPad Prism.  Fura2-AM binds free intracellular 
calcium; it absorbs and is excited by wavelengths 340 nm and 380 nm and emits at 510 nm, and 
the 340/380 ratio allows the measurement of intracellular calcium concentrations. Using ratios 
eliminates any effects of uneven dye loading or leakage, and photo-bleaching. Results are 
displayed as either as a 340/380 ratio trace or as bar charts (n≥3) showing changes in fluorescence 
ratio i.e. peak fluorescence with chemokine minus basal fluorescence before chemokine addition, 
mean ± SEM, or as Area Under Curve (AUC), mean ± SEM. 
2.17: Internalisation assay and flow cytometry analysis 
Cells were harvested, allowing 50 x 104 cells per sample, cells were suspended at 5 x 105 cells/mL 
in 0.1% BSA/RPMI with inhibitors or vehicle control at either 37°C or 4°C for 30 minutes, then 
were treated with CXCL12 (15 nM) or control (H2O) at either 37°C or 4°C for 15 minutes. Cells 
were then washed with ice-cold 0.5% BSA/PBS, and re-suspended in 0.5% BSA/PBS containing anti 
hCXCR4 clone 12G5 antibody from R&D Systems (1:2000) or control (0.5% BSA/PBS) for 1 hour at 
4°C. (NB. An alternative and better control would have been isotype control antibody.) Cells were 
then washed 3 times with ice-cold 0.5% BSA/PBS, then re-suspended in 0.5% BSA/PBS containing 
1:500 mouse fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG antibody for 1 hour at 
4°C. Stained cells were centrifuged, washed, and re-suspended in 300 μL 0.5% BSA/PBS, gated to 
exclude dead cells using FSC versus SSC and quantified using a FACS Calibur, and data analysed 
using CellQuest software version 3.1 (Becton Dickinson, San Jose, CA). 
2.18: Cyclic Adenosine Monophosphate (cAMP) Assay  
Cyclic Adenosine Monophosphate (cAMP) assays were performed following Molecular Devices kit 
instructions and using CatchPoint buffers and protocols for cAMP analysis. Cells were harvested, 
allowing 8 x 104 cells per well, cells were re-suspended at 2 x 106 cells/mL in 0.1% BSA/RPMI, 
aliquoted into Eppendorfs and treated with inhibitor or vehicle control for 15 minutes (37°C, 5%, 
CO2). Cells were centrifuged, washed once in Krebs-Ringer bicarbonate buffer KRBG (D-Glucose 
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1.8 g, MgCl2.6H2O 0.1 g, KCl 0.34 g NaCl 7.0 g, Na2HPO4 0.1 g, NaH2PO4.2H2O 0.234 g, H2O to 1 
Litre, pH to 7.4), sterilised with 0.22 μm Millipore filter, pelleted and then re-suspended in 
stimulation buffer (0.75 mM 3-Isobutyl-1-methylxanthine (IBMX) in KRBG) at 2 x 106 cells/mL and 
incubated for 10 minutes RT. Cells were pipetted gently to re-suspend and 40 μL added to desired 
wells of a 96 well round-bottomed plate. 2 mL of 60 μM Forskolin in PBS was prepared, and 20 μL 
(or 20 μL PBS for control) pipetted onto cells in wells, plate was gently agitated to mix and 
incubated (37°C, 5% CO2, 15 minutes). Chemokines to produce 10 nM (6 μL of 100 nM CXCL12, 6 
μL of 1μM CCL3 or 6 μL H2O for controls), were then added for set periods (20 minutes, 10 
minutes, 5 minutes and 1 minute), wells were gently agitated. Next 20 μL lysis buffer was added 
to all wells and plates incubated for 10 minutes on a shaker to lyse cells. Samples were then 
transferred to a CatchPoint cAMP 96 well assay plate, and the cAMP protocol was followed 
exactly using CatchPoint buffers to produce both a standard curve, and analyse the samples. 
Results were read at excitation 530 nm, emission 585 nm, cut off 570 nm, gain 20%, using 
Flexstation III ROM v3.0.22. 
2.19: Rac1 Activation Assay 
Cells were serum starved for 24 hours, treated at 37°C with inhibitors for 30 minutes then with 10 
nM CXCL12 for 15 minutes. Cells were then washed with ice cold PBS, then lysed on ice using 
Cytoskeleton Rac1 Activation Assay Biochem Kit supplied Cell Lysis Buffer (50 mM Tris pH 7.5, 10 
mM MgCl2, 0.5 M NaCl, 2% Igepal) plus 1x protease inhibitor cocktail (100x contains 62μg/mL 
Leupeptin, 62 μg/mL Pepstatin A 14 mg/mL Benzamidine, 12 mg/mL  tosyl arginine methyl ester). 
Cells were harvested with a cell scraper and cells transferred to ice cold pre-labelled Eppendorfs, 
centrifuged (13,000 rpm 1 min), then the clarified lysate was collected, transferred to ice cold 
labelled tubes and flash frozen using dry ice and ethanol mix. 20 μL was retained of each sample 
for protein quantification using Nanodrop analysis. 800 μg protein in 800 μL lysis buffer per 
sample was used in Rac1 Activation pull down assay along with 10 μg of PAD-PBD beads following 
Cytoskeleton protocol. Briefly protein samples were rolled with beads (4°C, 60 minutes), 
centrifuged (3000 g, 4°C, 1 minute), 90% supernatant removed. Beads washed with 500 μL wash 
buffer for 30 seconds, centrifuged (3000g, 4°C, 3 minutes), supernatant removed without 
disturbing beads, 15 μL of 2X Laemmli sample buffer (125 mM Tris pH 6.8, 20% glycerol, 4% SDS, 
0.005% bromophenol blue, 5 % β-mercaptoethanol) added. Samples were boiled 2 minutes, then 
beads and samples were loaded together into gel lanes (beads stayed in well and only the 
proteins moved down gel). His-Rac1 control protein was run with samples. On a second gel 10 μg 
of protein per sample was run for analysing total Rac. The samples were separated on 10% gels 
63 
 
and electrophoretically transferred to a nitro-cellulose membrane as described in detail above. 
The membranes were blocked with 5% non-fat powdered milk in TBST (30 minutes, RT), then 
incubated at 4°C overnight with 1:500 anti-Rac1 antibody (ARC03) in TBST, (no blocker) then 
rinsed (50 mL TBST, 1 minute) and then incubated with 1:10,000 goat anti-mouse HRP conjugate 
in TBST (1 hour, RT) (with no blocking agent), then membrane washed with TBST (5x10 minutes). 
The blots were developed using Pierce® ECL western blotting substrate (ThermoFisher Scientific) 
as per manufacturer’s instructions. 
2.20: Enzyme linked immunosorbance assay (ELISA)  
Using InstantOneTM STAT3 phosphotyrosine 705 ELISA eBiosciences, UK according to protocol 
THP-1 cells were harvested, centrifuged and re-suspended at 1x106 cells/200 μL in simple DMEM 
per Eppendorf, treated with inhibitor or control (1% DMSO), incubated (37°C, 5% CO2, 30 
minutes), then CXCL12 was added to the relevant samples to produce a final concentration of 5 
nM and incubated (37°C, 5% CO2, 0, 1, 5 or 10 minutes). Cells were washed once with cold PBS, 
centrifuged and supernatant removed from pellet.  50 μL of supplied 1X lysis buffer was added 
per pellet, mixed and shaken (RT, 10 minutes, 140 rpm). Then 50 μL of lysate was added to each 
well of ELISA plate with 50 μL of kit antibody cocktail. Plate was shaken (RT, 60 minutes 140 rpm). 
Samples were then washed with kit buffer (3 x 200 μL) and 100 μL pre-equilibrated detection 
reagent added to all wells and plate incubated (RT, 30 minutes, covered). 100 μL of the supplied 
stop reagent was added to all wells and the plate was read at 450 nM using BMG Fluostar OPTIMA 
fluorimeter. 
2.21: Analysis of data 
Chemotaxis, Calcium and MTS data were analysed using one-way ANOVA followed by Bonferroni 
post hoc tests, or when only two samples were being compared by Students t-Test. Throughout a 
p value greater or equal to 0.05 was considered significant and represented on graphs and figures 
as one star (i.e. * = p≤0.05), two stars was considered very significant (** = p≤0.01), and three 
stars highly significant (*** = p≤0.001). Data represent the mean  standard error of mean, of at 
least three independent experiments. GraphPad Prism 4 (GraphPad Software Inc Ca, USA) was 
used for all statistical tests. 
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Chapter 3: Exploring the intricacies of dynamin function in malignant cell migration  
 
3.1: Introduction 
For a receptor to internalise an endocytic vesicle needs to form from the cell membrane. This 
requires the recruitment of several cytosolic proteins including the ~98 kDa GTPase dynamin. 
Dynamin is purported to aid the scission of vesicles from the membrane by forming helical 
oligomers around the necks of budding vesicles, before GTP hydrolysis creates conformational 
change in the dynamin polymer producing vesicle/membrane fission. However this is not 
dynamin’s only role in cellular function [163, 164], dynamins are also involved in cytokinesis, 
organelle division, pathogen resistance and transport vesicle budding [165]. Dynamin other 
important cellular functions including roles in signalling and the endocytosis of receptors [164, 
497].  
There are many dynamin splice variants and 3 key isoforms, Dynamin-1, -2 and -3. Dynamin-2 is 
ubiquitous [166-168]. The closely related Dynamin-like proteins (DLP) include Dynamin-related-
protein one (Drp-1), mitofusin (Mfn), and Optic Atrophy protein 1 (OPA1) involved in the 
mitochondrial fission and fusion essential for cell division [170, 498]. The dynamin protein 
contains five regions including a Pleckstrin homology (PH) and GTPase domains. Dynamin 
monomers form dimers which can then oligomerise to produce constricting rings round 
endosomal vesicles containing receptors which cause vesicle scission [165, 497]. Dynamin-1, -2 
and -3 have differing abilities to curve membranes to produce endosome fission [177-179]. The 
pathways and fates of endocytic vesicles can qualitatively and quantitatively control downstream 
signalling and cellular responses that mediate cancer prognosis and metastasis. Endosome cargo 
such as specific GPCRs can influence sorting decisions between recycling to cell surface and 
ubiquitination and degradation [193-195]. Endosomes can also contain signalling platforms such 
as GPCR/β-arrestin complexes that can trigger signalling favouring malignancy [196, 198, 199]. 
Endocytosis can be clathrin-dependent or independent; dynamin plays a role in both [189]. 
Dynamin may rate-limit the former and, along with EndophilinA and F-actin, facilitate vesicle 
scission in the later, along with signalling through Pi3K, Rho and Rac [221-224]. Aberrant function 
of dynamin and DLPs such as Drp-1 are implicated in metastasis [226]. Dynamin-2 interactions 
with oncogenes expressed in many cancers can activate CXCL12 signalling through Akt, JAK and 
Rac1 favourable to metastasis [229-234]. Drp-1 drives mitosis in many cancers. Drp-1, OPA-1 and 
Mfn modulate mitochondrial fission and fusion in cell division.  Drp-1 inhibition can increase 
malignant cell apoptosis and decrease cell proliferation [235, 236]. Thus dynamin plays 
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importance roles both in homeostasis and malignancies. What is less well understood is dynamins 
role in metastasis supported by chemokines. This work explored the role of dynamin in malignant 
cell migration through chemotaxis assays in THP-1 monocytes and Jurkat T-cells, along with 
wound-healing assays of chemokinesis in MCF7 breast cancer cells. 
Hypothesis: Dynamin supports chemotactic migration of cancer cells; therefore inhibition of 
dynamin may prevent metastasis. 
Aim: To expose the role of dynamin in CCL3 and CXCL12-chemotactic migration in cancer cell-lines 
THP-1 and Jurkat along with dynamins role in CCL3 and CXCL12 supported wound-healing in 
MCF7.  
Objectives:  
(i)     Establish the presence of CCR5 and CXCR4 in cell-lines. 
(ii)    Establish that dynamin is expressed in THP-1, Jurkat and MCF7. 
(iii)   Explore the effects of siRNA knockdown of dynamin in THP-1, Jurkat and MCF7. 
(iv)  Observe the effects of a range of small molecule inhibitors of dynamin on chemotaxis in 
Jurkat and THP-1 looking for any chemokine and/or dynamin domain-specific effects.  
 
3.2: Results 
Please note controls are common between graphs where experiments were conducted 
simultaneously; results for each inhibitor have been displayed separately for ease of description 
of results, this applies to: figures 3.8 and 3.15; 3.16 and 3.19; 3.23 and 3.24. 
 
3.2.1: The expression of CXCR4 and CCR5 in cell-lines 
First the expression of CXCR4 in THP1, Jurkat and MCF7 was examined by flow cytometry, levels 
appeared highest in Jurkat, figure 3.1. 
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A                      THP-1 B                 Jurkat C                 MCF7 
    
 
CXCR4 
  
CXCR4 
 
CXCR4 
   
 
Figure 3.1: CXCR4 expression in (A) THP-1, (B) Jurkat and (C) MCF7. Flow cytometry analysis of 
20,000 events following incubation with 12G5 (10 μg/mL, 60 mins, 4°C) then FITC (1 in 500, 60 
mins, 4°C), n=1.  
CXCR4 and CCR5 receptors were then visualised on MCF7 and THP-1 cells by 
immunofluorescence, figure 3.2.  
A       MCF7, CCR5 B     MCF7, CXCR4 C     MCF7, CXCR4 D      THP-1. CCR5 
    
Figure 3.2: Anti-CCR5 (HEK/1/85a/7a) antibody (1hr, 4°C) followed by FITC (1 hr, 4°C) confirm 
expression of CCR5 on (A) MCF7 and (D) THP-1. Anti-CXCR4 (12G5) (1hr, 4°C) followed by FITC 
(1hr, 4°C) confirms expression of CXCR4 on (B) MCF7 and (C) THP-1. Imaged UV inverted 
microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
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CXCR4 expression in
fucin / FITC treated unfixed cells
09.02.16
TH
P
-1
 C
X
C
R
4
TH
P
-1
 n
eg
Ju
rk
at
 C
X
C
R
4
Ju
rk
at
 n
eg
M
C
F7
 C
X
C
R
4
M
C
F7
 n
eg
0
50
100
150
M
e
a
n
 F
L
1
-H
67 
 
The presence of CCR5 in THP-1 was demonstrated using Immunoprecipitation as expression is 
relatively low, and in CHO.CCR5 by immunofluorescence and Western blot, figure 3.3. 
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Figure 3.3: Anti-CCR5 (HEK/1/85a/7a) antibody reveals presence of CCR5 in (A) THP-1 using IP (C) 
CHO.CCR5 using western blot. (B) CHO.CCR5 using immunofluorescence, HEK/1/85a/7a (1hr, 4°C) 
followed by FITC (1hr, 4°C) Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 
500x Ex 490 nm, Em 520 nm). 
CCL3 may illicit responses through binding CCR1 or CCR5. Inhibition of CCR1 using J113863, or 
CCR5 using Maraviroc both significantly inhibit chemotaxis of THP-1 to CCL3, suggesting both 
receptors were expressed by THP-1, and relevant to CCL3-induced chemotaxis, figure 3.4.  
THP-1 
 
Figure 3.4: Chemotaxis of THP-1 to 1 nM CCL3 following pre-treatment with CCR1 inhibitor 
J113863 or CCR5 inhibitor Maraviroc or control (DMSO). Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001 
3.2.2: Exploring the role of dynamin in cell-lines 
Next the presence and location of dynamin in cell-lines was established using 
immunofluorescence. The effects of dynamin siRNA knockdown, and various small molecule 
inhibitors of dynamin, such as Dynasore (a small molecule inhibitor of both dynamin, and at lower 
concentrations, Drp-1 [499]) were explored, using CCL3 and CXCL12-induced chemotaxis in THP-1, 
CXCL12 chemotaxis in Jurkat, and wound-healing in MCF7.  
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3.2.3: Immunofluorescence established dynamin’s presence  
Although dynamin plays roles at the membrane and in the cytoplasm, figure 1.4, dynamin-2 
appeared more concentrated in nucleus than membranes of THP-1 and MCF7, figure 3.5, possibly 
because both are cancer cell-lines.  
  
 
 
 
(A) MCF7 (B) THP-1 macrophages  (C) Controls, FITC only. 
Figure 3.5: Dynamin-2 immunofluorescent staining. (A) THP-1, pre-treatment 25 nM PMA or (B) 
MCF7, grown on glass for 24 hours, fixed (4% paraformaldehyde), incubated with anti-dynamin-2 
then probed with FITC. Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 
500x Ex 490 nm, Em 520 nm). 
Immunofluorescent staining on adherent MCF7 and THP-1 after differentiation to macrophages 
demonstrated that Dynamin-2 was present in both, figure 3.5. Jurkat, a suspension cell-line were 
not successfully differentiated, however dynamins presence in Jurkat was clearly demonstrated 
by Western Blot, figure 3.6 below.  
3.2.4: Dynamin-2 siRNA knockdown inhibits wound-healing but not chemotaxis 
Dynamin-2 knockdown with siRNA in THP-1 and Jurkat cells had no significant inhibitory effect on 
chemotaxis to CCL3 and CXCL12 respectively, figure 3.6. 
 
 
 
 
 
 
 
 
MCF7 Negative Control 
FITC only 
THP-1 Negative Control 
FITC only 
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Figure 3.6: Dynamin-2 siRNA knockdown. Cells transfected with 50 nM Human Dynamin-2 or 50 
nM nonsense siRNA (Scr) control, chemotaxis assays and Western Blots undertaken 24 hours after 
transfection. (A) THP-1 chemotaxis to 1 nM CCL3 (B) Western Blot of THP-1, loading confirmed 
with β-actin (C) Jurkat chemotaxis to 1 nM CXCL12 (D) Western Blot of Jurkat, loading confirmed 
with β-actin. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
ns=p>0.05.   
 
Dynamin-2 siRNA almost complete knockdown did not significantly affect chemotaxis of THP-1 to 
CCL3 or Jurkat chemotaxis to CXCL12. Knockdown was very effective in THP-1 but less so in Jurkat 
where dynamin knockdown may have been partial in all cells or complete in a proportion of Jurkat 
hence a more effective knockdown in Jurkat may have produced a very different result. 
However effective Dynamin-2 knockdown did significantly inhibited wound-healing in MCF7 cells, 
possibly indicating a differential use of Dynamin-2 in adherent and suspension cell-lines, figure 
3.7. 
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Figure 3.7: MCF7 wound-healing assays following transfection with 50 nM Dynamin-2 siRNA or 
nonsense siRNA (Scr) control. Analysis 24 hours after (A and C) 10 nM CCL3, or (B and C) 10 nM 
CXCL12. (D) Western blot dynamin-2 expression 24 hours after siRNA knockdown, β-actin loading 
control. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001. 
In both MCF7 and THP-1 Western Blots indicated Dynamin-2 siRNA knockdown was complete. 
CCL3 chemotaxis in THP-1 was not significantly inhibited however in MCF7 CCL3 (and CXCL12) 
wound-healing was dramatically reduced. The assays differ in that cell movement in wound-
healing is non-directional whereas in chemotaxis it is; suggesting either that there may be a 
differential use of dynamin-2 in these cell lines or that dynamin-2 is important for other factors 
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involved in wound-healing. Such factors may involve haptokinetic (random) migration, or 
haptotaxis migration along a substrate [500], In vivo substrate may be the extracellular matrix, to 
which chemokine gradient may be bound. In vitro the plastic substrate of a wound-healing assay 
may absorb chemokine, but gradients are absent, hence chemotaxis which involves a cell 
extending a leading edge towards and then moving up a diffusing chemokine gradient does not 
occur, but chemokinesis random migration prompted by a chemokine can. 
To further analyse the effects of dynamin in chemotaxis a range of small molecule inhibitors were 
employed in THP-1 and Jurkat chemotaxis assays. Inhibitors were chosen with structural 
similarities such as MitMAB with OcTMAB, and Dynasore with Dyngo4a, along with inhibitors with 
unique structures, such as RTIL-13, table 3.1. This range of inhibitors will block either dynamin 
recruitment at the plasma membrane (MiTMAB, OcTMAB or RTIL-13) or inhibit dynamins 
functions once at the membrane (Dynasore, Dyngo4a) [501]. With these tools it was hoped to 
fully probe the functions of dynamin in chemotaxis to CCL3 and CXCL12. 
 
3.2.5: Dynamin and Drp-1 inhibitors 
Dynamin inhibitors are anti-mitotic and so potential anti-cancer drugs. The dynamin inhibitors 
used here include (i) the first dynamin inhibitor synthesised, Dynasore, a cell-permeable 
reversible non-competitive inhibitor of the dynamin GTPase and at lower concentrations Drp-1 
[499]. (ii) A Dynasore analogue with purportedly greater specificity and potency and less 
cytotoxicity, Dyngo4a [502]. (iii) The long-chain ammonium salt inhibitors MiTMAB and OcTMAB 
which target the PH domain of dynamin [503]. (iv) Room Temperature Ionic Liquid 13 (RTIL-13) 
which targets both dynamins PH and GTPase domains. (v) RhodadynC10 a Rhodanine N-ethyl 
analogue with a potency at least as good as other in-cell dynamin inhibitors [504], which targets 
dynamin’s GTPase domain and Transferin-A, and (vi) Pyrimidyn7, one of the most potent dynamin 
inhibitors available which inhibits dynamin-1 interactions with both GTP and phospholipid [505, 
506]. Table 3.1 illustrates the site/s of action of dynamin inhibitors used in this investigation. 
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Table 3.1: Small molecule inhibitors of dynamin, their structures, target region/s and reported 
IC50‘s [499, 502-506]. 
Dynamin 
region 
BSE G-domain BSE 
 
Stalk PH 
 
Stalk BSE PRD 
 
 
Inhibitor 
Targeting 
region  
 Dynasore 
IC50 = 15 μM 
Dyngo 4a 
IC50 = 2.6 μM 
RhodadynC10 
IC50 = 30.3 μM 
RTIL-13 
IC50 = 2.3 - 9.3 μM 
Pyrimidyn-7
TM
 
IC50 = 1.8 µM 
  MiTMAB 
IC50 = 3.15 µM 
OcTMAB 
IC50 = 4.4 μM 
 
 
RTIL-13 
IC50 = 2.3 - 9.3 μM 
Pyrimidyn-7
TM
 
IC50 = 1.8 µM 
   
 
 
 
 
 
 
 
Dynasore Dyngo 4a RTIL-13™ RhodadynC10™ 
  
 
MitMAB OctMAB Pyrimidyn-7™ 
 
 
3.2.6: Dynasore 
The non-competitive inhibitor Dynasore dose-dependently blocks the GTPase activity in dynamin-
1 and dynamin-2 at the membrane and Drp-1 [507]. Actin filament remodelling enables cell 
motility and metastatic invasion of tissues. Dynasore inhibits actin dynamic remodelling and 
malignant cell invasion [508]. Dynasore has reported relatively low potency and specificity, 
compared to Dyngo4a,  [501] hence Dynasore has been used at 100 μM in cell assays by others 
[509] however MTS assays illustrated at 80 μM Dynasore caused cytotoxicity in THP-1 cells but 
not in Jurkat. At 60 μM or below this toxicity was lost, figure 3.8. 
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Jurkat THP-1 MCF7 
  
A 
 
B 
 
C 
Figure 3.8: Cytotoxicity assays for Dynasore. MTS assays were over 7 hours in (A) Jurkat and (B) 
THP-1 and over 24 hours in (C) MCF7 cells. Basal absorbance occurs in presence of medium after 
MTS treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, **=p<0.01, ns=p>0.05. 
Dynasore contains a chromophore explaining the increased absorbance seen at 80 μM in Jurkat, 
figure 3.8A, this is likely to have also have affected MTS results in THP-1 and MCF7, possibly 
disguising Dynasore toxicity at lower concentrations. Dynasore was also found to cause 
cytoskeletal damage, adherent cells were seen to develop membrane ruffles, neural-like 
projections and have a tendency to detach from surfaces, leading to less cell density on the slides, 
figure 3.9B (control and treated slides were seeded at the same density). This is expected as 
dynamin mechanistically interacts with myosin and actin. Others have observed these effects with 
Dynasore at 80 μM [510], figure 3.9. 
 
(A) CHO control (DMSO) (B) CHO + Dynasore (C) MCF7 
control(DMSO) 
(D) MCF7 + Dynasore 
    
Figure 3.9: Filament actin stain following Dynasore. Alexa-488 Phalloidin (green) and DAPI nuclear 
stains (blue) of CHO.CCR5 and MCF7 following pre-treatment with 80 μM Dynasore (1 hr). Imaged 
UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
 
The effect of Dynasore on CXCL12 and CCL3-induced chemotaxis in Jurkat and THP-1 cells was 
explored using different inhibitor concentrations. At 80 μM, figure 3.10, probably due to toxicity 
cytotoxicity suggested by the MTS assays, figure 3.8B, Dynasore produced significant inhibition of 
chemotaxis in THP-1 (p<0.001), as well as non-significantly reducing basal migration, figure 3.10C. 
Hence using Dynasore at 80 μM in THP-1 does not inform on dynamin function in THP-1 
chemotaxis. 
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Jurkat THP-1 THP-1 
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Figure 3.10: Chemotaxis assays following pre-treatment with 80 μM Dynasore or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, ns=p>0.05. 
 
Due to indicated toxicity chemotaxis assays were repeated with Dynasore at concentrations of 60 
μM, results mirrored those at 80 μM, figure 3.11A, Jurkat inhibition was absent but in THP-1 
inhibition was still highly significant, figure 3.11B and 3.11C.  
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Figure 3.11: Chemotaxis assays following pre-treatment with 60 μM Dynasore or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001. 
 
Surprisingly at 40 μM Dynasore had no effect on CXCL12-chemotaxis in Jurkat or THP-1, but still 
caused highly significant inhibition to CCL3-induced chemotaxis in THP-1, figure 3.12.  
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Figure 3.12: Chemotaxis assays following pre-treatment with 40 μM Dynasore or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, ns=p>0.05. 
 
Dynasore is also reported to dynamin-independently disrupt lipid rafts and membrane cholesterol 
homeostasis [511].  Dynasore application at 80 μM has been shown to inhibit dynamin-dependent 
endocytic pathways rapidly stopping coated vesicle formation causing the accumulation of partly 
formed pits and arresting the pinching off of vesicles [512], suggesting dynamin is essential in 
coated vesicle formation and endocytic vesicle scission. However, Dynasore and another dynamin, 
G-domain inhibitor Dyngo-4a, have been shown to produce off-target effects. In cells where 
dynamin isoforms 1, 2, and 3 were knocked out, Dynasore at 80 μM and Dyngo-4a at 30 μM both 
still inhibited membrane ruffles, cell attachment and spreading, as well as inhibiting F-actin and 
lamellipodia formation [513]. Dynasore at 75 μM is also reported to increase calcium levels at the 
membrane [514]. The effects of Dynasore on CCL3 and CXCL12-induced calcium release were 
explored; the results did not mimic those from the chemotaxis, figure 3.13. 
 
                                                      MCF7                       CHO.CCR5 
A  B 
 
Figure 3.13: Intracellular calcium responses to 80 μM Dynasore. (A) Representative traces 
following stimulation of MCF7 with 10 nM CXCL12 following pre-treatment with Dynasore or 
DMSO control. (B) Representative trace following stimulation of CHO.CCR5 with 10 nM CCL3 
following pre-treatment with Dynasore or DMSO control, n=1.  
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Dynasore at 80 μM eliminated release of intracellular calcium in response to CXCL12 in MCF7, and 
reduced calcium release in response to CCL3 in CHO.CCR5, figure 3.13, again indicating cell-
specific responses to dynamin inhibition or Dynasore toxicity.  
3.2.7: Dyngo4a 
Dyngo4a is a Dynasore analogue, table 3.1, with reportedly 40-fold improved potency over 
Dynasore and more specificity as explained above [501]. It has reported IC50 values of 380 nM and 
2.6 μM at dynamin-1 and -2 respectively compared to Dynasore IC50 of 15 μM. Both Dyngo4a and 
Dynasore target the GTPase activity of dynamin-1 and dynamin-2 [515]. Membrane-permeable 
Dyngo4a, like Dynasore, inhibits dynamin by binding to an allosteric site within the GTPase 
domain of both dynamin-1 and -2 [516], and both inhibitors block dynamin function after 
membrane recruitment [501]. However here Dyngo4a was only found to inhibit chemotaxis to 
CXCL12 and CCL3 at concentrations of 80 μM, figure 3.14, but not to have any significant effects 
on chemotaxis at lower concentrations (data not shown). Suggesting Dyngo4a’s reported 
increased potency over Dynasore is not applicable to chemotaxis of THP-1 or Jurkat. MTS assays 
showed that Dyngo4a’s observed effects were not due to toxicity, figure 3.15. 
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Figure 3.14: Chemotaxis assays following pre-treatment with 80 μM Dyngo4a or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001.  
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Jurkat THP-1 
A  B  
Figure 3.15: Cytotoxicity assays for Dyngo4a. MTS assays were over 7 hours in (A) Jurkat and (B) 
THP-1. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, n≥3 independent experiments, one-way ANOVA with post-hoc Bonferroni 
revealed no significant differences. 
The results of the chemotaxis and cytotoxicity assays for Dyngo4a indicate its reported 40-fold 
increased potency over Dynasore with respect to dynamin either does not apply in THP-1 or 
Jurkat or that Dyngo4a does indeed target dynamin more effectively than Dynasore, blocking both 
endocytosis and clathrin-mediated endocytosis [501], with less off target toxicity than Dynasore.  
Suggesting the above Dynasore results could be due more to off target toxicity than dynamin 
inhibition, as the chemokine specific response produced by 40 μM Dynasore was not repeated by 
Dyngo4a. 
3.2.8: MiTMAB and OcTMAB 
Next the effects of MiTMAB and OcTMAB, inhibitors of dynamins PH domain were explored. 
MiTMAB and OcTMAB are water-soluble, cell-permeable and block cytokinesis without any other 
effects on mitosis and also induce apoptosis in cancer cells [517]. Their toxicity in cancer cells is 
higher than in healthy cells. Classical anti-mitotics such as taxanes and vinca alkaloids target 
microtubules, but tubulin is important for function of healthy and non-dividing cells [518]. Other 
anti-mitotics target kinases and kinesin spindle proteins expressed in dividing cells, and so also 
target the mitotic spindle early in cell division [519]. Targeting dynamin does not target the 
mitotic spindle; blocking dynamin prevents the necessary dynamin activation of phosphatase 
calcineurin to produce cytokinesis. Hence MiTMAB and OcTMAB block the abscission phase of 
cytokinesis producing polyploidy without affecting any other stage of mitosis and they are 
selective for cancer cells [520, 521]. Apoptotic death may not follow cytokinesis failure, 
senescence and reversible mitotic arrest may occur [522]. In cancer cells responses to MiTMAB 
and OcTMAB negatively correlate with levels of Bcl-2 and Mcl-1, another Bcl-2 protein family 
member. MiTMAB/OcTMAB-induced apoptosis is caspase-dependent. If cell-lines express Bcl-2, 
an anti-apoptotic protein, they are resistant to MiTMAB and OctMAB [517]. 
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MiTMAB and OcTMAB inhibit the recruitment of dynamin to membranes [523]. MiTMAB inhibits 
dynamin-1 and -2 with an IC50 of 3.1 μM and 8.4 μM respectively competing with the lipid-binding 
pleckstrin homology but not the GTPase. IC50 for inhibiting dynamin-1 and -2 receptor-mediated 
endocytosis is 19.9 μM and 2.2 μM respectively [503, 520]. 
3.2.8.1: MitMAB 
MitMAB targets the dynamin-phospholipid interactions, may interact with phospholipase-Cδ PH 
domain, and has been shown to block calcium influx [524], hence may inhibit endocytosis through 
an effect on calcium channels [525]. Cytosolic calcium changes support a shift from early to late 
endocytosis [526, 527]. MitMAB has also been shown to inhibit nicotinic acetylcholine receptors 
[523]. In cancer cells MitMAB can block dynamin-2, as it inhibits cytokinesis and cell proliferation 
but not any other cell-cycle stage [520].  MTS assays indicated cytotoxicity at 10 μM in THP-1 and 
Jurkat, figure 3.16. MiTMAB at 10 μM had no effect on calcium release (data not shown). 
Jurkat THP-1 
A  B  
Figure 3.16: Cytotoxicity assays for 10 μM MiTMAB. MTS assays over 7 hours in (A) Jurkat and (B) 
THP-1. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
**=p<0.01, ***=p<0.001. 
 
Figure 3.17: Chemotaxis assays following pre-treatment with 10 μM MiTMAB or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3, 
***=p<0.001, ns=p>0.05. 
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MitMAB at 10 μM very significantly inhibited chemotaxis to CXCL12 in both Jurkat and THP-1 but 
not CCL3-induced chemotaxis in THP-1, figure 3.19. Therefore further investigations probed 
differences in effects between CCL3 and CXCL12 chemotaxis in THP-1 as such differences in 
response were not found in the literature. 
Dynasore and MitMAB have been shown to produce temporally distinct effects. Dynasore but not 
MitMAB block dynamin-1 GTPase activity, and so may block the early stages of endocytosis when 
receptor stimulus is still present, whereas MitMAB, a competitive inhibitor, may block dynamin 
binding to phospholipid membranes later in the endocytosis process [523]. Suggesting the 
endocytosis kinetic differences in CXCR4/CXCL12 and CCL3/CCR5 could explain results, see 
discussion. 
 
3.2.8.2: OcTMAB 
OcTMAB, like MiTMAB, is an inhibitor of dynamin-1 and -2, IC50 is approximately 1.9 μM, and 4.4 
μM respectively, about half that of MiTMAB. OcTMAB IC50 for inhibiting receptor-mediated 
endocytosis is approximately 6.7 μM OcTMAB also completes for phospholipids for the lipid 
binding pleckstrin homology of dynamins IC50 ~16 μM all values depend on cell type [501]. 
OcTMAB modestly inhibited chemotaxis to CXCL12 in Jurkat and THP-1, but not to CCL3 in THP-1, 
figure 3.18.  OcTMAB at 5 μM had no effect on calcium release (data not shown) and displayed no 
toxicity in MTS assays, figure 3.19. 
A                  Jurkat B                    THP-1 C                    THP-1 
   
 
Figure 3.18: Chemotaxis assays following pre-treatment with 5 μM OcTMAB or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***= p<0.001, **=p<0.01, ns =p>0.05. 
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Jurkat THP-1 
A  B  
Figure 3.19: Cytotoxicity assays for OctMAB. MTS assays over 7 hours in (A) Jurkat and (B) THP-1. 
Basal absorbance occurs in presence of medium after MTS treatment in the absence of cells. 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns=p>0.05. 
Thus MiTMAB and OcTMAB, both reported as inhibitors of dynamins PH domain, at the 
concentrations employed selectively inhibited CXCL12 but not CCL3 chemotaxis. Next the effects 
of Rhodadyn-C10 , purportedly an inhibitor of Dynamins GTPase domain [504] were explored. 
 
3.2.9: Rhodadyn-C10™ 
Rhodadyn-C10 is the N-ethyl analogue of a rhodanine scaffold. It is cell-permeable and inhibits 
dynamin-1 and -2 GTPase activity IC50 values are reported as 6.4 μM and 30.3 μM at dynamin-1 
and dynamin-2 respectively. Rhodadyn-C10 also blocks clathrin-mediated endocytosis of 
transferrin and receptor-mediated endocytosis with an IC50 of 7.0 μM [504]. Rhodadyn-C10 at 20 
μM did significantly inhibit CXCL12 chemotaxis of Jurkat, and to a much lesser extent CCL3 
chemotaxis in THP-1 but MTS assays indicated significant toxicity over seven hours in both cell 
lines, figure 3.20. At concentrations of 20 μM Rhodadyn-C10 had no effect on calcium release and 
at concentrations below 20 μM Rhodadyn-C10 had no effect on chemotaxis. 
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Jurkat THP-1 
A  B  
 
  
Jurkat THP-1 
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Figure 3.20: Chemotaxis assays following pre-treatment with 20 μM Rhodadyn-C10 or control 
(DMSO). (A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) 
Cytotoxicity (MTS) assay for Rhodadyn-C10 over 7 hours in Jurkat and (D) THP-1. Basal absorbance 
occurs in presence of medium after MTS treatment in the absence of cells. Means ± SEM, one-
way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, 
*=p<0.05. 
 
Results with Rhodadyn-C10 did not support the theory that the G-domain is more applicable to 
CCL3- than CXCL12-chemotaxis, however its cytotoxicity limited its usefulness. Next the effects of 
two dynamin inhibitors credited with inhibiting both dynamins G- and PH- domains, RTIL-13 and 
Pyrimidyn-7TM were examined.  
 
3.2.10: RTIL-13 
Room Temperature Ionic Liquids (RTILs) are salts with high melting points (>150°C) used as 
replacements for volatile organic solvents in chemical synthesis as they produce faster, cleaner 
reactions, however predicting any individual RTIL’s properties is difficult. RTIL-13 (4-(N,N-
dimethyl-N-octadecyl-N-ethyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione bromide) was 
developed as a tool to solubilise the PH domain of dynamin for protein experiments, and was 
found to inhibit dynamin GTPase with an IC50 of 2.3 μM. Hence RTIL-13 targets both dynamin’s 
lipid binding PH domain and its GTPase domain [528].  Abcam claim RTIL-13 also inhibits receptor-
mediated endocytosis (IC50 9.3 μM) and synaptic vesicle endocytosis (IC50 7.1 μM). RTIL-13 at 
concentrations between 5 and 20 μM inhibited chemotaxis of Jurkat and THP-1. Levels of 
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inhibition steadily increased from significant (p<0.05) at 5 μM (data not shown) to very highly 
significant (p<0.001) at 20 μM, figure 3.21A and B, and was not cell type or chemokine specific. 
However even at 20 μM RTIL-13 did not have any impact on calcium release, figure 3.21C.  
 
Jurkat THP-1 THP-1 
A  B  C  
Figure 3.21: Chemotaxis assays following pre-treatment with 20 μM RTIL-13 or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) Fura2 Ca2+ assay 
in THP-1 following 20 μM RTIL-13 or control (DMSO). Data expressed as fluorescence ratio change 
(∆340/∆380 nm), i.e. peak fluorescence following 10 nM CCL3 addition minus basal fluorescence 
(prior to chemokine). (A) & (B) one-way ANOVA (C) t-test, Means ± SEM, n≥3 independent 
experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
 
In THP-1 chemotaxis to CCL3 RTIL-13 at 20μM significantly (p<0.05) inhibited basal migration in 
the absence of chemokine, figure 3.21B, as this could be caused by cytotoxicity MTS assays using 
a range of RTIL-13 concentrations were under taken in both THP-1 and Jurkat, figure 3.23. 
                A                 CHO.CCR5                 B                 CHO.CCR5 
  
RTIL-13 20 μM Control (DMSO) 
Figure 3.22: Actin filament staining following RTIL-13. Alexa-488 Phalloidin (green) and DAPI 
nuclear stains (blue) of CHO.CCR5 following pre-treatment with (A) 20 μM RTIL-13 or (B) Control 
(1 hr). Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 
520 nm). 
RTIL-13 at 20 μM slightly lessened Phalloidin staining but did not distort or eliminate actin 
filaments, figure 3.22. 
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Jurkat THP-1 
A  B  
Figure 3.23: Cytotoxicity assays for RTIL-13. MTS assays were over 7 hours in (A) Jurkat and (B) 
THP-1. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01, *=p<0.05, ns=p>0.05. 
MTS assays indicated RTIL-13 caused significant cytotoxicity at 10 μM and above in Jurkat and at 5 
μM and above in THP-1.  
Thus although 20 μM RTIL-13 significantly reduced cell migration figure 3.21A and B, cytotoxicity 
assays, figure 3.23, and the significant inhibition of basal migration, figure 3.21B, indicated this 
may have been due to toxicity. Also Phalloidin stains in CHO.CCR5 following treatment with 20 μM 
RTIL-13 illustrated that loss of actin filaments may have also contributed to reduced cell 
migration. Hence it is hard to isolate and effectively evaluate RTIL-13’s effects on dynamin using 
chemotaxis assays.  
3.2.11: Pyrimidyn-7TM 
Pyrimidyn-7 inhibits the binding of dynamin to phospholipid, by binding membrane 
phosphatidylserine. Phosphatidylserine binds the PH domain of dynamin and aids its GTPase 
activity by enhancing co-operative helix oligomerization [175, 176, 529]. Pyrimidyn-7 shares 
structural similarities with ammonium salt inhibitors of dynamin, such as MiTMAB and some 
RTILs, and so has amphiphilic properties that inhibit dynamin-binding phospholipids. Also 
Pyrimidyn-7 is a nucleotide analogue and so mimics GTP and targets the GTPase domain of 
dynamin competing with GTP for binding. Pyrimidyn-7 targets dynamin-1 (IC50, 1.1 μM) and 
dynamin-2 (IC50, 1.8 μM) with nearly equal potency, competitively inhibiting both basal and 
phosphatidylserine-stimulated activity [506].  
Pyrimidyn-7 has been shown to reversibly inhibit vesicle endocytosis and clathrin-mediated 
endocytosis possibly because dynamin inhibition can inhibit endocytosis. Pyrimidyn-7 at 30-40 μM 
can reversibly block clathrin-mediated endocytosis in cell lines. This is reversible after washout, 
and endocytosis activity is restored within an hour. At 30 μM Pyrimidyn-7 is reported to abolish 
dynamin-PH binding and dynamin localisation to the membrane, and hence blocks clathrin-
mediated endocytosis. At low concentrations (10 μM) pyrimidyn-7 inhibits cell proliferation, 
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increasing DNA fragmentation and causing apoptosis in cancer cells. At concentrations of 1.3 to 
3.2 μM pyrimidyn-7 inhibited growth of many different cancer cell-lines, suggesting potential 
therapeutic anticancer effects [506]. MTS assays confirmed Pyrimidyn-7 at 10 μM inhibited 
metabolism in both THP-1 and Jurkat cells, figure 3.24. 
Jurkat THP-1 
A  B  
Figure 3.24: Cytotoxicity assays for Pyrimidyn-7TM. MTS assays were over 7 hours in (A) Jurkat and 
(B) THP-1. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments,      
***=p<0.001, ns=p>0.05. 
Cytotoxicity assays of Pyrimidyn-7TM indicated inhibition of cell metabolism in Jurkat at 5 μM and 
above, and in THP-1 at 10 μM, figure 3.24. At 10 μM Pyrimidine-7 was found to inhibit CXCL12- 
but not CCL3-induced chemotaxis in THP-1 and CXCL12-induced chemotaxis in Jurkat, figure 3.25, 
again suggesting that unlike with CXCR4/CXCL12 chemotaxis, for CCR5/CCL3-induced signalling 
dynamin-involved receptor endocytosis may not be essential. 
Jurkat THP-1 THP-1 
A 
 
B 
 
C 
 
Figure 3.25: Chemotaxis assays following pre-treatment with 10 μM Pyrimidyn-7 or control 
(DMSO). (A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-
1 chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, **=p<0.01, ns=p>0.05. 
 
3.2.12: Dynamin inhibitors can interrupt cytokinesis  
Treatment with MitMab and OctMAB appears to interrupt cell cycle progression, increasing the 
proportion of cells in late G2 to M stage with effectively 4N content of DNA. This may be due to 
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interruption of the cell cycle progression or due to failure of cytokinesis [520]. Inhibition of 
dynamin-2’s role in cytokinesis, where it may stabilise the actin filaments in the contractile ring, 
[530] is one explanation. Here THP-1 cells differentiated to macrophages were transfected with 
eGFP plasmids then treated with Dynasore 40 μM; many of these cells showed defective 
cytokinesis, figure 3.26. Similar effects were seen with THP-1 treated RTIL-13 20 μM or Dynasore 
40 μM then stained with CCR5 antibody, figure 3.27. Cytokinesis requires membrane ingression 
then abscission. Actin and myosin both form filaments in line with the mitotic spindle; dynamin 
stabilises the actin filaments and hence plays a role in abscission [531]. 
 
 
 
A Control (DMSO)    B Dynasore 40 μM 
 
Figure 3.26: THP-1 transfected with eGFP (pEGFP.C2) plasmids. Cell treatment 40 μM Dynasore or 
control (DMSO) for 12 hours, fixed (4% paraformaldehyde). Imaged UV inverted microscopy (Leica 
DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
    
A Control (DMSO) B  RTIL-13 20 μM C Dynasore 40 μM 
 
Figure 3.27: CCR5 receptor immunofluorescent staining following Dynamin inhibitors. (A) THP-1, 
pre-treatment 25 nM PMA grown on glass for 24 hours, treated 20 μM RTIL-13 or 40 μM 
Dynasore or DMSO (6 hrs), fixed (4% paraformaldehyde), incubated with CCR5 antibody 
(HEK/1/85a/7a) (1 hr) then probed with rat FITC. Imaged UV inverted microscopy (Leica DMII 
Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
3.3: Discussion 
The above results may suggest that in CCL3 but not CXCL12-induced chemotaxis in THP-1 the 
dynamin G-domain has important for chemotaxis. The results in the Jurkat provide some support 
for this conclusion although it cannot be confirmed as Jurkat do not migrate to CCL3. This 
suggests that receptors CCR5 and/or CCR1, the likely targets of CCL3 [532], but not CXCR4, the 
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likely target of CXCL12, require an active dynamin G-domain for endocytosis. Others have found 
dynamin important in CC (CCR2) chemokine-induced endocytosis [533]. 
3.3.1: Dynasore may be inhibiting Drp-1 as well as dynamin 
Dynasore at low concentrations (1-10 μM) inhibits mitochondrial Drp-1 as well as dynamin-1 and -
2, hence at 40 μM it will produce significant inhibition of Drp-1. It is possible CCL3-induced 
chemotaxis in THP-1 is more sensitive to inhibition of Drp-1 than Jurkat chemotaxis to CXCL12.  
Increased Drp-1 expression confers resistance to chemotherapy, e.g. in T-cell lymphoblastic 
leukaemia [534], Drp-1 can also increase disease virulence [252] by producing mitochondrial 
fragmentation which itself can accelerate mitosis and prevent homeostatic intra-mitochondrial 
calcium fluxes which can mediate apoptosis [242]. By inhibiting Drp-1 for example with 1, 3 and 
10 μM Dynasore [535] proliferation can be inhibited and apoptosis supported. Whereas Dynasore 
at 80 μM has been shown to prevent receptor endocytosis [252, 536]. 
Drp-1 upregulation is found in many cancers [240] and Drp-1 mutations can support hypoxia-
induced migration in vitro in malignant glioblastoma cells [537]. MAPK/ERK pathway signalling 
leads to phosphorylation of Drp-1 on Ser616 [538] which can be suppressed by ERK inhibition. 
MAPK/ERK signalling is reportedly very active in Jurkat, and MAPK/ERK signalling also supports the 
phosphorylation of Drp-1 Ser616, and so activation of Drp-1 which modifies mitochondrial 
metabolism [534]. 
3.3.2: CCR5 and CXCR4 endocytosis kinetics 
There are important differences in the endocytosis kinetics and routes of the CCR5 and CXCR4 
receptors which offers an alternative explanation of the different responses of CXCL12- and CCL3- 
induced chemotaxis to some dynamin inhibitors such as Dynasore. CXCL12-bound CXCR4 
receptors start to internalise within two minutes and bound receptor internalisation is complete 
within 20 minutes. A likely target of CCL3 are CCR5 receptors; these have an extended 
conformation fatty acid saturated C-tail facilitating insertion into membrane lipid rafts, which 
slows internalisation by about 10-fold compared to CXCR4 in T-cells. CCR5 internalises very slowly, 
it can take up to 40 minutes to get underway and two hours to complete. The longer transit time 
of the CCR5 may allow ligand release, receptor re-sensitisation, re-stimulation and further 
signalling. Also CXCR4-internalisation can be clathrin-dependent, and CCR5-clathrin-independent, 
as CCR5 may internalise via caveolae or glycolipid rafts [539]. These factors could explain the 
discordant effects of dynamin inhibition on CCL3 and CXCL12-induced chemotaxis, if the CCR5 
longer residency time on the membrane makes the receptor more sensitive to dynamin inhibitors 
such as Dynasore, figure 3.28 
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Figure 3.28A: Caveolae invaginations can 
recruit signalling receptors which may 
translocate between lipid rafts within and 
without caveolae while continuing to 
signal; they may or may not undergo 
endocytosis [540]. CCR5 may signal via this 
mechanism [539] 
 Figure 3.28B: Clathrin-mediated endocytosis 
is initiated when the ligand binds the 
receptor, clathrin is recurited for coating pit, 
F-actin and dynamin promote membrane 
curvature and dynamin neck scission 
endocytosis follows [541]. CXCR4 may be 
internalised by this method [539] 
 
Dynamin along with many other players such as Bin-Amphiphysin-RVS (BAR) proteins are key in 
both clathrin-coated pit formation and in vesicle neck strain and scission [542].  However there 
are many endocytic accessory proteins (EAPs) involved in clathrin and/or caveolin-mediated 
endocytosis. These can vary with cell type [543] and may be modified in cells with mutated DNA 
such as cancer cell-lines. EAPs include Adaptor proteins with basic motifs that bind negative PIP2 
or phosphatidylserine [544] and so trigger clathrin-coated pit initiation. Knockdown of one of 
these Adaptor Protein Complexes, AP2, inhibits clathrin-coated pit formation and to some extent 
receptor-internalisation [545]. This appears to be because stoichiometrically two AP2 complexes 
associate with PIP2 and a clathrin triskelion to initiate clathrin-coated pit formation [546]. 
Therefore if any of the dynamin small molecule inhibitors used in this investigation have off-target 
effects on adaptor proteins that play a role in one but not both cell-lines employed this could also 
explain discordant effects of the inhibitor on one but not both Jurkat and THP-1 chemotaxis. 
 
3.4: Conclusions  
Western Blot confirmed dynamin-2 was present in Jurkat, THP-1 and MCF7, Immunofluorescence 
confirmed in THP-1 and MCF7 the highest dynamin-2 concentrations were in the nucleus.  
Knockdown of Dynamin-2 very significantly inhibited wound-healing supported by CCL3 or CXCL12 
in MCF7, suggesting an important role for dynamin in chemokinesis. However even complete 
dynamin-2 knockdown had no significant effect on CCL3 chemotaxis in THP-1. Dynamin siRNA 
investigations in Jurkat were somewhat inconclusive due to incomplete knockdown.  
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Receptor
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Dynamin was concluded to be important in cell division as inhibition, with RTIL-13 or Dynasore, 
interrupted cytokinesis producing conjoined cells. 
Drawing conclusions from the results with Rhodadyn-C10, RTIL-13 and Pyrimidyn-7 are hampered 
by these inhibitors toxicity at concentrations needed to inhibit chemotaxis. Pyrimidyn-7 inhibits 
both the GTPase and PH domains of dynamin [506]. At 10 μM Pyrimidyn-7 inhibited CXCL12 but 
not CCL3 chemotaxis, although it also inhibited cell metabolism in both THP-1 and Jurkat. 
Pyrimidyn-7’s differing effects on CXCL12 and CCL3 chemotaxis may be due to CXCR4/CXCL12 but 
not CCR5/CCL3-induced signalling requiring rapid receptor endocytosis to produce signalling 
leading to chemotaxis. 
 
Dynasore targets dynamins GTPase domain [512], at 40 μM it selectively inhibited CCL3 but not 
CXCL12 chemotaxis. As discussed this may be due to differing endocytosis kinetics and/or 
mechanisms of CXCR4 and CCR5, or due to the G-domain being important for CXCL12 but not 
CCL3 chemotaxis. However as Dynasore at much lower concentrations inhibits Drp-1 [499] 
therefore the effects of Dynasore at 40 μM on CCL3 assays could be partly due to inhibiting Drp-1 
modulated motility. This conclusion is supported by dynamin-2 siRNA knockdown not significantly 
inhibiting chemotaxis in THP-1. Dyngo4a, which also purportedly inhibits dynamin GTPase 
domain, inhibited equally both CCL3 and CXCL12 chemotaxis so also did not confirm differential 
results from Dynasore. These contrasting effects of Dynasore and Dyngo4a were seen at inhibitor 
concentrations that did not cause toxicity. MiTMAB was seen to inhibit CXCL12 chemotaxis in 
THP-1 and Jurkat but not CCL3 chemotaxis in THP-1, suggesting the PH domain may be more 
important for CXCL12 than CCL3 chemotaxis. 
 
Overall results demonstrate that dynamin is clearly present in these cell-lines and plays an 
important role in both CCL3 and CXCL12 chemokinesis in MCF7. Results in THP-1 and Jurkat 
suggest differential use of dynamin domains in CCL3 and CXCL12 stimulated chemotaxis. With the 
PH domain being more important for CXCL12-chemotaxis and the GTPase domain for CCL3-
chemotaxis, figure 3.29. However factors such as the role of Drp-1 and the very different 
endocytosis kinetics between CCR5 in and CXCR4 receptors may have influenced these results.  
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Figure 3.29: Different dynamin domains are involved in CCL3- compared to CXCL12-chemotaxis. In 
some cell types dynamin can support chemotaxis to both CCL3 and CXCL12, however dynamins PH 
domain may be more important for chemotaxis to CXCL12 and dynamins GTPase domain for 
chemotaxis to CCL3 [547].   
 
 
Dynamins diverse roles are only part of the chemokine signalling story leading to chemokinesis 
and chemotaxis supporting spread of cancer cells to secondary sites. Other key players in 
metastasis include PKC, Src, ROCK and the Raf/MEK/ERK signalling cascade; investigations into 
these proteins are reported in chapter 4.   
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Chapter 4: PKC and other key signalling proteins in cell migration towards CXCL12 and 
CCL3 in leukemic cells compared to breast cancer cells 
 
4.1: Introduction 
Key signalling in metastasis includes through the Ras/Raf/MEK/ERK pathway, Src and PKC. PKC is 
an important chemokine signalling transducer in health and disease [548, 549]. There are many 
PKC isoforms, activation of which can trigger their cellular translocation. PKC activation and 
structure is isoform dependent [261]. Abnormal PKC expression is observed in many pathologies, 
in malignancies PKC plays a complex role, isoforms may act as oncoproteins or tumour 
suppressors [306, 307]. PKC isoforms are involved with other kinases in GPCR phosphorylation 
[275, 277]. Including of CXCR4 following CXCL12 binding [279], as this can be prevented by PKCα 
inhibition [280]. PKC also modulates signalling through GSK3 a key protein in many signalling 
pathways including those involving Pi3K, Akt, PKA and Wnt [550-552].  
Src plays a key role in cell proliferation and metastasis [553]. Src levels can modulate cell adhesion 
and cell migration interacting with many cellular proteins [554]. Deregulation of Src is key to 
survival of many malignant cells [555]. Proliferative and pro-migratory signalling also occurs via 
the Ras/Raf/MEK/ERK pathway [556, 557]. Raf kinases activating MEK1 and MEK2 which 
subsequently activate ERK1 and ERK2 although there is also purportedly cross-talk between all 
these signalling proteins, figure 4.1 [558, 559]. 
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Figure 4.1: PKC and other key signalling proteins involved in chemotaxis and metastasis. 
 
Hypothesis: Signalling through PKC, Src, ROCK and the Ras/Raf/MEK/ERK pathway can initiate 
metastasis, therefore inhibition of these proteins may prevent migration supported by 
chemokines CCL3 and CXCL12. 
Aim: To explore the role of PKC isoforms, Src, ROCK, Raf, MEK and ERK in CCL3 and CXCL12-
chemotactic migration in cancer cell-lines THP-1 and Jurkat along with PKCs role in CCL3 and 
CXCL12 supported wound-healing in MCF7. 
Objectives:  
(i)     Using small molecule inhibitors siRNA knockdown explore the role of PKC isoforms in CXCL12 
and CCL3 chemotactic migration of THP-1 and Jurkat along with CXCL12 and CCL3-supported 
wound-healing in MCF7.  
(ii)     Explore the effects of PKC small molecule inhibitors on cAMP production in THP-1 and Jurkat 
(iii)    Investigate the effects of PKC inhibition on calcium dynamics in THP-1 and Jurkat.  
(iv)  Use small molecule inhibition of β-catenin to look for effects on chemotaxis to CCL3 and 
CXCL12 in THP-1 and Jurkat. 
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(v)  Apply small molecule inhibition and siRNA knockdown to explore the role of Src in CXCL12 and 
CCL3 chemotactic migration of THP-1 and Jurkat along with CXCL12 and CCL3-supported wound-
healing in MCF7. 
(vi) Use small molecule inhibitors of Raf, MEK, ERK or ROCK to see if these proteins supported 
chemotaxis of THP-1 or Jurkat to CCL3 or CXCL12. 
4.2: Results  
Please note controls are common between graphs where experiments were conducted 
simultaneously; results for each inhibitor or siRNA have been displayed separately for ease of 
description of results, this applies to: figures 4.2A and 4.4A; 4.2B, 4.7A and 4.7B; 4.3A, 4.4B, 4.6E, 
4.12A, 4.17B, and 4.23B; 4.3B, 4.4C, 4.6F, 4.11A, 4.24C and 4.29C; 4.18 and 5.15; 4.8A and 4.8B; 
4.6D and 4.12B; 4.30A, 4.31A, 4.33B, 4.34B.  
There are several key proteins implicated in metastasis and in chemokine signalling. These include 
PKC, Src, MEK, ERK, and Pi3K. Here the effect of pharmacological blockage of these signalling 
proteins on CXCL12- and CCL3- supported cell migration was explored using three different cell-
lines, THP-1, Jurkat and MCF7.  
Firstly the role of PKC in CXCL12-induced signalling was explored in three cell lines Jurkat, THP-1, 
and MCF7. Tools employed were small molecule inhibitors, Rottlerin, Staurosporine, CID755673, 
GF109203X (for structures see appendix 4), along with PKC siRNA knockdown of PKCα, δ, and ε. 
Responses to PKC manipulation were analysed by chemotaxis-, cAMP- and calcium-assays. 
4.2.1: Rottlerin and PKCδ  
Rottlerin has been used in many studies as a selective PKCδ inhibitor, but it is not specific, it 
uncouples mitochondria so reduces ATP levels which may hinder PKCδ tyrosine phosphorylation. 
Rottlerin also is reported to block other kinases and inhibit sodium-dependent glutamate 
transport and accelerate the transporter degradation, it may also activate calcium and potassium 
channels hence Rottlerin can produce effects on cells where PKCδ is deleted [560, 561].  
The effects of Rottlerin and siRNA PKCδ inhibition on CXCL12-induced chemotaxis in Jurkat was 
explored, along with siRNA PKCδ inhibition of CXCL12-induced MCF7 wound-healing. siRNA 
controls were transfected with nonsense siRNA (Scr), figure 4.2.  
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Figure 4.2: Chemotaxis of Jurkat to 1 nM CXCL12 following pre-treatment with (A) Rottlerin 2 μM 
or control (Ethanol) or (B) following transfection with 50 nM PKCδ siRNA or nonsense siRNA 
(Scram) control. (C & D) MCF7 wound-healing assays supported by 10 nM CCL3 or 10 nM CXCL12 
following transfection with 50 nM PKCδ siRNA or nonsense siRNA control. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns=p>0.05, **=p<0.01, ***=p<0.001. 
 
Chemotaxis of Jurkat to CXCL12 was not inhibited by Rottlerin 2 μM but was very significantly 
inhibited (p<0.001) by siRNA knockdown of PKCδ. MCF7 wound-healing confirmed that siRNA 
PKCδ knockdown has no significant effect on CCL3-induced wound-healing but significantly 
(p<0.01) inhibits CXCL12-induced wound-healing, figure 4.2A-D. Unfortunately no antibody was 
available to confirm the extent of PKCδ knockdown. 
Others have shown a relationship between PKCδ and cAMP [562] so the effect of Rottlerin on 
CXCL12 modulation of cAMP production and also calcium release in Jurkat was explored, figure 
4.3.  
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Jurkat Jurkat 
A   B  
Figure 4.3: Effects of Rottlerin 4 um on cAMP and calcium responses to CXCL12 10 nM. (A) cAMP 
production in Jurkat following Rottlerin or control measured before or after 20 minutes CXCL12 
stimulation. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
*=p<0.05. (B) Fura2 Ca2+ assay in Jurkat following Rottlerin or control (Ethanol). Data expressed as 
fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following CXCL12 addition 
minus basal fluorescence (prior to chemokine), n=1. 
Jurkat pre-treatment with Rottlerin 4 μM blunted cAMP production but had no significant effect 
calcium responses in response to CXCL12 stimulation. 
Rottlerin at 2 μM was found to have no significant inhibitory effects on chemotaxis, or at 4 μM on 
calcium responses, although it blunted cellular cAMP reduction following CXCL12 stimulation. 
However PKCδ siRNA knock-down did inhibit Jurkat chemotaxis, suggesting that if there are any 
Jurkat responses to Rottlerin they are complex. It is possible Rottlerin’s off target effects masked 
any inhibitory effects. Rottlerin was found to reduce the establishment of cell-cell contacts due to 
E-cadherin and β-catenin internalization [563], and may therefore reduce the cell clumping often 
observed in Jurkat. Additionally ethanol, the inhibitors solvent, could dehydrate cells, and either 
effect, less clumping or cell shrinkage, could aid passage through the pores of the Transwell® 
chemotaxis assay plates and skew results. Additionally Rottlerin at 4 μM is reported to cause 
apoptosis body formation, this may be via death receptor 5 up-regulation [564]. Apoptosis-body 
formation causes the cells to shrink as contents are lost, this could also explain reported increases 
in chemotaxis assays through the 5 μm pores [565]. MCF7 scratch assays indicated PKCδ is more 
relevant to CXCL12 rather than CCL3-induced wound-healing, figure 4.2C.  
4.2.2: Staurosporine, GF109203X and PKC isoform knockdown 
Staurosporine is a natural product, an alkaloid isolated from Streptomyces staurosporeus, that has 
anti-proliferative actions on many cancer cell-lines as it arrests the cell cycle at G2/M. 
Staurosporine is also an non-selective inhibitor of PKC with and IC50 ~3 nM, and for cAMP-
dependent protein kinase ~8 nM. Jurkat caspase-3 induced-apoptosis, and the release of 
microparticles (apoptotic bodies), is reported within 2 hours of treatment with staurosporine 
[566, 567].  Staurosporine 10 nM treatment of Jurkat caused little inhibition of chemotaxis, no 
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effects on calcium production, but did blunt cAMP reduction in Jurkat but not THP-1, all response 
to CXCL12, figure 4.4, also in wound-healing assays caused apoptosis of MCF7 over 24 hours of 
incubation (data not shown). 
                A                               Jurkat           B                           Jurkat 
  
                  C                           THP-1           D                              Jurkat 
 
 
Figure 4.4:  Effects of Staurosporine 10 nM on chemotaxis, cAMP and calcium responses to 
CXCL12 in Jurkat. (A) Chemotaxis to 1 nM CXCL12. (B and C) cAMP production following 
Staurosporine or control measured before or after 20 minutes CXCL12 10 nM stimulation. Means 
± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, *** = 
p<0.001,*=p<0.05. (D) Fura2 Ca2+ assay following Staurosporine or control. Data expressed as 
fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following CXCL12 addition 
minus basal fluorescence (prior to chemokine). n=1. 
 
GF109203X is a pan PKC inhibitor, reported to inhibit PKCs with an IC50 values of ~ 0.008 μM 
(PKCα), 0.21 μM (PKCδ), 0.132 μM (PKCε) and 5.8 μM (PKCζ) respectively, it caused significant 
toxicity in MCF7 and THP-1, figure 4.5 
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MCF7 THP-1 
A  B  
Figure 4.5: Cytotoxicity assays for GF109203X. MTS assays were over 24 hours in (A) MCF7 and 
over 7 hours in (B) THP-1. Basal absorbance occurs in presence of medium after MTS treatment in 
the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, **=p<0.01, *=p<0.05. 
 
 
GF109203X inhibited metabolism at 5 and 10 μM in MCF7 over 24 hours and at 2.5 and 5 μM in 
THP-1 over 7 hours. The effects of GF109203X at 5 μM which should inhibit all PKC isoenzymes 
was explored in Jurkat and THP-1 cells using chemotaxis, cAMP and calcium assays, figure 4.6, the 
small effects observed on chemotaxis and cAMP assays in THP-1 may be explained by toxicity 
rather than any direct effects on PKC’s within cells.  
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Jurkat THP-1 THP-1 
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THP-1 Jurkat  Jurkat 
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F 
  
Figure 4.6: Chemotaxis, cAMP and calcium assays following pre-treatment with GF109203X at 5 
μM or control (DMSO). (A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM 
CXCL12. (C) THP-1 chemotaxis to 1 nM CCL3. (D) cAMP production in THP-1 and (E) Jurkat both 
measured before or after 20 minutes CXCL12 10 nM stimulation measured before or after 20 
minutes CXCL12 10 nM stimulation. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments. (F) Fura2 Ca2+ assay in Jurkat, n=1, data expressed as fluorescence ratio 
change (∆340/∆380 nm) i.e. peak fluorescence following 10 nM CXCL12 addition minus basal 
fluorescence (prior to chemokine), *=p<0.05, ns=p>0.05. 
 
GF109203X at 5 μM did not prevent Jurkat or THP-1 chemotaxis to CXCL12, but slightly inhibited 
chemotaxis of THP-1 to CCL3. Also GF109203X significantly modify cAMP in response to 20 
minutes CXCL12 10 nM in THP-1 and Jurkat. An increase in calcium responses to CXCL12 10 nM in 
Jurkat was also observed.  
The only dramatic effect of GF109203X appeared to be on calcium responses. GF109203X at 5 μM 
can be shown to strongly inhibit CXCL12-induced wound-healing in MCF7 cells [565] however this 
could be due to its cytotoxicity. Although at 5 μM GF109203X would be expected to inhibit PKCα, 
ε and ζ. PKC LOF mutations may remove the breaks on GPCR signalling possibly suggesting in 
certain circumstances PKC inhibitors could increase chemotactic responses. PKCα but not PKCε 
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was observed to suppresses signalling via Pi3K, PKCα may inhibit the catalytic subunit of Pi3K 
[568], and inactivate proto-oncogene Akt, this may be prevented by GF109302X [569]. This 
provides a possible mechanism for GF109302X to increase calcium responses, as observed above; 
however the very strong orange colouring of GF109302X may also impact on fluorescent assay 
accuracy.  Therefore next the effects of PKCα, and PKCε siRNA knockdown on MCF7 scratch assays 
and Jurkat chemotaxis were explored, figures 4.7 and 4.8. 
 
Jurkat Jurkat 
A  B  
Figure 4.7: PKCα and PKCε siRNA knockdown in Jurkat. Cells transfected with 50 nM Human PKCα, 
PKCε or nonsense siRNA (Scr) control. Chemotaxis assays undertaken 24 hours after transfection 
to CXCL12 1nM, (A) after PKCα knockdown, (B) after PKCε knockdown. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001. 
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MCF7 MCF7 
        A 
 
       B 
 
 
 
 
 
Figure 4.8: PKCα and PKCε siRNA knockdown in MCF7. Wound-healing assays 24 hours after 
transfection supported by (A & C) CCL3 10 nM, or (B & D) CXCL12 10 nM, following transfection 
with 50 nM human PKCα, PKCε or 50 nM nonsense siRNA (Scr) control. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, **=p<0.01, ns=p>0.05. 
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The success of the PKCα siRNA knock-down was confirmed by western blotting. Knockdown was 
more complete in MCF7 than Jurkat, figure 4.9, overall suggesting that Jurkat chemotaxis to 
CXCL12 is highly sensitive to PKCα knockdown. 
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Figure 4.9: siRNA PKCα knockdown was confirmed by Western Blot 24 hours post-transfection, for 
(A) Jurkat and (B) MCF7, loading confirmed with β-actin. 
The chemotaxis assays suggested that in Jurkat CXCL12-induced chemotaxis may be more 
sensitive to PKCα and PKCδ inhibition than PKCε, further experiments are required to confirm this, 
but one influence on results may be the low expression of novel and atypical PKCs in Jurkat [570]. 
MCF7 CXCL12- and CCL3-induced wound-healing was inhibited by PKCα but not by PKCε, whereas 
PKCδ knockdown specifically inhibited CXCL12 but not CCL3 migration, figure 4.2 above. PKCζ 
knockdown was also explored in Jurkat and MCF7, see chapter 8 section 8.2.13. 
4.2.3: PKD (PKCμ) activity is important for CCL3- but not CXCL12-induced chemotaxis in THP-1 
cells, and for CXCL12-induced chemotaxis in Jurkat 
Protein Kinase D (aka PKCμ) is a calmodulin-dependent kinase so also a target of DAG. There are 3 
PKD isoforms PKD1, PKD2 and PKD3. PKD is controlled by PKC-dependent mechanisms. PKC 
isoforms activate PKD by serine phosphorylation of PKD’s activation loop. The PKD pathway is 
involved through NFκB in cell survival and proliferation, and transport of proteins from Golgi to 
plasma membrane and cell migration [571, 572]. Transmembrane glycoprotein E-cadherin, critical 
for cell-cell adhesions, can be phosphorylated by PKD1 when they co-localise. In cancer such 
phosphorylation reduces cellular motility.  E-cadherin’s cytoplasmic tail is anchored to actin via 
catenins, including β-catenin [573]. When a cell migrates a lamellipodium pushes out at the 
leading edge, attaches to substrate, and pulls the cell forward, if anchorage is not achieved the 
lamellipodium flows back into the cell forming a membrane ruffle, any particles adhering to the 
top or bottom surfaces also move back, this is retrograde flow. Inhibiting PKD inhibits retrograde 
membrane transport and actin-dependent membrane ruffles hence cytoskeleton dynamics.  PKD 
is reported to be involved in directional lamellipodia formation. In the absence of PKD Rac1 can 
restore lamellipodia formation but there is still loss of directional migration [574].  
The effects of the PKD inhibitor CID755673 and β-catenin inhibitor FH535 were explored in Jurkat 
and THP-1. In MCF7 wound-healing assays 5 μM CID755673 over 24 hours caused cell death (data 
101 
 
not shown) reflecting the significant inhibition of metabolism shown in MTS assay over 24 hour, 
figure 4.15A. CID755673 did not significantly inhibit metabolism in THP-1, figure 4.15B, but very 
significantly inhibited Jurkat chemotaxis and calcium flux and produced chemokine specific 
responses on THP-1 migration, figures 4.10 and 4.11. 
A                  MCF7 B                  THP-1 C                      Jurkat 
  
 
 
Figure 4.10: Cytotoxicity assays for CID755673.  MTS assays were over 24 hours in (A) MCF7 and 
over 7 hours in (B) THP-1. Basal absorbance occurs in presence of medium after MTS treatment in 
the absence of cells. (C) Chemotaxis of Jurkat to 1 nM CXCL12. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, *=p<0.05, ***=p<0.001, ns=p>0.05. 
 
CID755673 at 5 μM caused significant inhibition of CXCL12-induced calcium flux in Jurkat but only 
inhibited CCL3-induced, not CXCL12-induced, chemotaxis in THP-1, figure 4.11. 
 
Jurkat THP-1 
 
 
 
A B  
Figure 4.11: Calcium and chemotaxis responses to CID755673 5 μM. (A) Fura2 Ca2+ assay in Jurkat. 
Data expressed as fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 
nM CXCL12 addition minus basal fluorescence (prior to chemokine). Means ± SEM, Student t-test, 
n≥3 independent experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
4.2.4: PKD inhibition modulates cAMP levels 
PKD inhibition modulated cAMP levels in both THP-1 and Jurkat producing cell type specific 
effects, figure 4.12. 
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Jurkat THP-1 
A   B   
Figure 4.12: cAMP production in (A) Jurkat and (B) THP-1 following 5 μM CID75673 or control 
measured before or after 20 minutes CXCL12 10 nM stimulation. Means ± SEM, one-way ANOVA 
n≥3 independent experiments *=p<0.05. 
CID755673 at 5 μM blunted cAMP responses to CXCL12, non-significantly decreased basal and 
post CXCL12 levels in Jurkat and non-significantly increasing them in THP-1. Possibly supporting 
the conclusions from the chemotaxis assays that PKD inhibition may produce modest cell-type 
and chemokine specific effects. 
In contrast β-catenin inhibition reduced Jurkat and THP-1 chemotaxis to CXCL12 as well as THP-1 
chemotaxis towards CCL3. MTS assays indicated this was not due to inhibitor toxicity, figure 4.13. 
Jurkat THP-1 THP-1 
A  B  
 
C  
 
Jurkat THP-1 
D  E  
Figure 4.13: Chemotaxis following pre-treatment with FH535 1 μM or control (DMSO). (A) 
Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. (D & E) Cytotoxicity assays for FH535. MTS assays were over 7 hours in 
(D) Jurkat and (E) THP-1. Basal absorbance occurs in presence of medium after MTS treatment in 
the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, **=p<0.01, ns=p>0.05. 
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4.2.5: PKC inhibitors – effects on cellular calcium dynamics appear isoform specific 
As displayed above Staurosporine and Rottlerin did not change calcium release compared to 
control, GF109203X increased both peak fluorescence and total calcium release whereas PKD 
inhibitor CID755673 highly significantly reduced both calcium release and chemokine induced 
peak fluorescence, these results, shown separately above, are summarised in figure 4.14.  
Jurkat Jurkat 
A   B  
Figure 4.14: Fura2 Ca2+ assay in Jurkat following treatment with PKC inhibitor or control. Data 
expressed as (A) fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 
nM CXCL12 additions minus basal fluorescence (prior to chemokine); (B) Area under curve (AUC). 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01. 
Overall results suggest PKD is important in Jurkat for calcium, cAMP and chemotactic responses to 
CXCL12. Inhibiting PKCμ (PKD) in Jurkat reduces calcium responses, but inhibiting PKC with 
Rottlerin and Staurosporine have no significant effect the effects. GF109203X inhibits PKCα, ε and 
ζ; may increase calcium flux or its effects may be due to fluorescent assay interference as the 
inhibitor has a strong fluorescent orange colouring. Overall results suggest PKC signalling in MCF7, 
THP-1 and Jurkat is isoform, chemokine and cell-type specific.   
4.2.6: Src and Ras/Raf/MEK/ERK signalling appear important for CCL3 and CXCL12 induced 
migration in THP-1 and MCF7 and for CXCL12-induced migration in Jurkat 
c-Src protein tyrosine kinases (Src) are a family of non-receptor tyrosine kinases which have roles 
in cell signalling, adhesion, proliferation and migration. Src functions in agonist-induced receptor 
desensitization [553]. Both raised and lowered Src activity can alter cell migration. Over 
expression of Src can modulated cell dynamics and adhesion to other tissues. Src supports 
migration by aiding both cell adhesion to integrins and also disruption of cell-cell focal contacts, 
so has the potential to help leukocytes move through the extracellular matrix. Cofilin is involved in 
cellular dynamics and Focal Adhesion Kinase (FAK) in cell adhesion. Upregulation of Src does not 
alter the levels of FAK but increases its phosphorylation state, whereas Src upregulation decreases 
phosphorylation of cofilin, increasing F-actin dynamics, triggering cellular activity such as filopodia 
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formation. Filopodia are thin projections that can extend out from a migrating cell’s leading edge, 
they are produced by actin bundles in the cytoplasm [554]. Inhibition of Src with 4-[(2,4-Dichloro-
5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 piperazinyl) propoxy]-quinolinecarbo nitrile 
(bosutinib) a Src tyrosine kinases inhibitor significantly inhibited chemotaxis to CXCL12 and CCL3 
by THP-1 and to CXCL12 by Jurkat. Bosutinib did not inhibit cell metabolism at concentrations 
used, figures 4.15 and 4.16. Bosutinib also inhibits wound-healing in MCF7 [565]. 
Jurkat THP-1 THP-1 
A   B   C    
Figure 4.15: (A) Chemotaxis of Jurkat to CXCL12 1nM following pre-treatment with 1.25 μM 
Bosutinib or control (DMSO). (B) Chemotaxis of THP-1 following pre-treatment with 0.5 μM 
Bosutinib to CXCL12 1 nM or (C) CCL3 1 nM. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, 
n≥3 independent experiments, ***=p<0.001, **=p<0.01, *=p<0.05.  
 
MTS assays over 7 hours in Jurkat and THP-1 indicated in these cell lines that concentrations of 
Bosutinib at 5 μM and above were toxic, however no toxicity was observed even at 10 μM in 
MCF7 over 24 hours, figure 4.16. 
 
A                       Jurkat B                       THP-1 C                  MCF7 
 
 
 
 
 
 
 
Figure 4.16: Cytotoxicity assays for Bosutinib. MTS assays were over 7 hours in (A) Jurkat and (B) 
THP-1 and over 24 hours in (C) MCF7 cells. Basal absorbance occurs in presence of medium after 
MTS treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
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Bosutinib had no effect on calcium assays in THP-1, figure 4.17A but in cAMP assays in Jurkat at 5 
μM Bosutinib reduce basal levels of cAMP but had no significant effect on levels following 20 
minutes of CXCL12 stimulation, figure 4.17B. Actin fibre visualisation following treatment of 
CHO.CCR5 cells with 5 μM Bosutinib indicated inhibition of migration see in above assays may be 
due to disruption of F-actin formation, figure 4.17C. Bosutinib is reported to damage cell 
morphology [575] in cell-lines.  
 
A                       THP-1 B                     Jurkat C                 CHO.CCR5 
 
 
 
Figure 4.17: Calcium and cAMP assays with Bosutinib. (A) Fura2 Ca2+ assay in THP-1 following 10 
μM Bosutinib or control (DMSO). Data expressed as fluorescence ratio change (∆340/∆380 nm) 
i.e. peak fluorescence following 10 nM CCL3 addition minus basal fluorescence (prior to 
chemokine). Means ± SEM, Student t-test. (B) cAMP production in Jurkat following  5 μM 
Bosutinib measured before or after 20 minutes CXCL12 stimulation. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns=p>0.05,*=p<0.05. (C) Alexa-488 
Phalloidin actin-stain of CHO.CCR5 following pre-treatment with 5 μM Bosutinib (1 hr). Imaged UV 
inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
It can be seen that Bosutinib even at low concentrations significantly inhibits basal migration in 
THP-1, figure 4.15B & C, and appears to modify filament actin formations in CHO.CCR5. Bosutinib 
did not significantly modify calcium signalling but reduced cAMP levels, figure 4.17. However in 
addition to inhibiting Src Bosutinib also inhibits Src-family kinases Lyn and HCK, and is also 
reported to reduce signalling via Pi3K/Akt/mTOR, JAK/STAT3 and MAPK/ERK pathways [575]. The 
above results show Bosutinib can inhibit cell migration in presence and absence of chemokines 
CCL3 and CXCL12, but to explore if this was due to Src inhibition alone siRNA knockdown was 
undertaken. 
 
4.2.7: Src siRNA knockdown also inhibits cell migration 
Src knockdown, using Src siRNA at 50 nM confirmed the importance of Src signalling in MCF7 and 
THP-1 migration to CCL3 and CXCL12 and Jurkat chemotaxis to CXCL12, figures 4.18 and 4.19. 
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A                    Jurkat B                       THP-1 C                       THP-1 
   
 
Figure 4.18: Src siRNA knockdown. Cells transfected with 50 nM Human Src or 50 nM nonsense 
siRNA (Scr) control, chemotaxis assays undertaken 24 hours after transfection. (A) Jurkat 
chemotaxis to 1 nM CXCL12 (B) THP-1 chemotaxis to 1 nM CXCL12 (C) THP-1 chemotaxis to 1 nM 
CCL3 (D). Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001.  
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               A                    MCF7 B                     MCF7 
  
 
  
 
Figure 4.19: Src siRNA knockdown in MCF7. Wound-healing assays undertaken 24 hours after 
transfected with 50 nM Human Src or 50 nM nonsense siRNA (Scr) control. (A and C) Wound-
healing supported by 10 nM CXCL12, or (B and D) 10 nM CCL3. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001. 
siRNA knockdown of Src was confirmed by western blot, figure 4.20. 
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Figure 4.20: Anti-Src Western Blot following transfection with 50 nM Human Src or 50 nM 
nonsense siRNA (Scr) control (A) MCF7 and (B) Jurkat. Loading confirmed with β-actin. 
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siRNA knockdown of Src inhibited MCF7 wound-healing supported by CXCL12 or CCL3 and 
chemotaxis of THP-1 to both CCL3 and CXCL12 and Jurkat to CXCL12, figures 4.18-4.20.  The above 
data confirms other studies that suggest Src signalling is critically important in chemokine-induced 
migration in both leukemic and breast cancer malignancies. For example Src deregulation is 
important in the cell proliferation, adhesion, invasion, migration and survival of breast 
malignancies; and in oncogenic resistance by protecting cells from chemotherapy-induced 
apoptosis [555]. CXCR4 expression correlates with breast cancer aggressiveness and poor 
prognosis [576]. Also CXCL12 signalling through CXCR4 links to the BCR/ABL fusion oncoprotein 
which causes and maintains chronic myelogenous leukaemia (CML). BCR/ABL phosphorylates so 
activates and dysregulates normal bone marrow progenitor and stem cells causing immature 
dysfunctional cells to populated the blood and spleen, the phenotype of CML. CXCL12/CXCR4 
signalling via Src facilitates BCR/ABL oncoprotein to control CXCL12 signalling through both Pi3K 
and Ras/MAPK pathways [577, 578].  
4.2.8: Signalling through the Ras/Raf/MEK/ERK pathway lacks chemokine or cell specificity  
The effects of p38 MAPK inhibition and ERK inhibition on CCL3 and CXCL12-induced chemotaxis in 
leukemic cells was explored using the following small molecule inhibitors, SB203580, which 
inhibits p38-MAPK stimulation of MAPK APK2 and total SAPK/JNK activity. L779450 which inhibits 
Raf kinase, and PD98059 which inhibits ERK1/2 and SL327 which inhibits MEK1/2. MAPK/ERK 
signalling involves the activation by GRKs of small G-protein Ras followed by a Raf, MEK and ERK 
protein kinases phosphorylation cascade. Malignancies involve uncontrolled growth; this is often 
due to aberrant MAPK/ERK signalling.  
There are three homologues of Raf; B-Raf, A-Raf and Raf 1 also known as C-Raf. In humans, all are 
kinase components of the Ras/Raf/MEK/ERK signalling pathway. Raf kinases activate MEK1 and 
MEK2 also known as type 1 and 2 MAP kinase kinases and Mitogen Extracellular signal regulated 
kinase (MAPKK). MEK threonine and tyrosine kinases subsequently phosphorylate ERK1 and ERK2 
thus signals are transferred from cell membrane to cellular effectors regulating cell motility, 
proliferation and apoptosis [556, 557, 579]. Of the three Raf proteins B-Raf may be the most 
potent due to its high affinity for MEK1 [580], however there may be cross-talk between Raf 
homologues [558] and feedback from ERK1 and ERK2 may inhibit Raf-1 phosphorylation so 
activation [556] while downregulating MEK2 and upregulating MEK1 [559], figure 4.21.  
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Figure 4.21: Inhibitors and feedback affecting 
the mitogenic Ras/Raf/MEK/ERK and ROCK 
signalling pathways [556-558, 579, 580].  
 
 
Others have used the Raf-1 inhibitor 2-Chloro-5-[2-phenyl-4-(4-pyridinyl)-1H-imidazol-5-yl]phenol 
(L779450) (for structure see appendix 4), at 10 μM for 24 hours to explore the relationship 
between Raf-1 inhibition and apoptosis regulation, L779540 was found to have a pro-apoptosis 
affect, and this was attributed to its ability to inhibit Raf-1 [579]. MTS assay here found L779540 
at the concentrations used here had no effect on cell metabolism over seven hours but caused 
significant toxicity over twenty-four hours, figure 4.23, hence L779450, which inhibits Raf-1 by 
competing for ATP at the protein kinase catalytic site, was only used to explore the effect of Raf-1 
inhibition on chemotaxis in Jurkat cells to CXCL12 and THP-1 cells to CXCL12 and CCL3. Inhibition 
of Raf 1 with 1 μM L779450 significantly reduced CXCL12- and CCL3-induced chemotaxis in THP-1 
and CXCL12-induced chemotaxis in Jurkat, figures 4.22. 
 
THP-1 THP-1 Jurkat 
A  B  C  
Figure 4.22: Chemotaxis assays following pre-treatment with L779450 or control. (A) Chemotaxis 
of THP-1 to 1 nM CXCL12, (B) THP-1 chemotaxis to 1 nM CCL3. (C) Jurkat chemotaxis to 1 nM 
CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, *=p<0.05. 
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Cytotoxicity assay of in THP-1 showed at 1 μM L779450 did not inhibit THP-1 metabolism but in 
MCF7 over 24 hours caused highly significant inhibition of metabolism. Also 5 μM L779450 in 
Jurkat had no effect on basal cAMP levels or 20 minutes response to CXCL12, figure 4.23. 
 
THP-1 MCF7 Jurkat 
A
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C 
 
Figure 4.23: Cytotoxicity assays for L779450. MTS assays were over 7 hours in (A) THP-1 and over 
24 hours in (B) MCF7 cells. Basal absorbance occurs in presence of medium after MTS treatment 
in the absence of cells. (C) cAMP production in Jurkat following  5 μM L779450 or control 
measured before or after 20 minutes 10 nM CXCL12 stimulation. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, *=p<0.05. 
 
 
L779450 also modestly inhibited calcium responses of Jurkat to CXCL12 and THP-1 to CCL3, figure 
4.24. 
THP-1 Jurkat Jurkat 
A
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Figure 4.24: Fura2 Ca2+ assays following L779450 or control (DMSO). In (A) THP-1 trace, (% 
simulation over basal) n=1 (B) Jurkat, Data expressed as fluorescence ratio change (∆340/∆380) 
nm i.e. peak fluorescence following 10 nM CCL3 or 10 nM CXCL12 addition minus basal 
fluorescence (prior to chemokine), n=1. (C) Jurkat 10 nM CXCL12, Area under curve (AUC), Means 
± SEM, Student t-test, n≥3 independent experiments, **=p<0.01. 
 
CXCL12 can induce chemotaxis but can also in some circumstances induce proliferation, for 
example in leukemic cells in stromal cultures. Such proliferation can be prevented by CXCR4 
antagonists such as AMD3100 [581]. CXCL12 appears not to have proliferative effects on normal 
leukocytes in stromal cultures [582]. This suggests CXCL12 is working in synergy with other factors 
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present in malignancies, possibly other cytokines such as IL-3 and IL-7 present in the stromal 
support. Pre-treatment of leukemic cells with ERK1/ERK2 inhibitor PD98059 or p38 MAPK 
inhibitor SB203580 was found to inhibit proliferation triggered by CXCL12 in the presence of 
stromal tissue [583]. Here the effects of PD98059 and SB203580, (for structures see appendix 4), 
on CXCL12 and CCL3-induced chemotaxis in Jurkat and THP-1 were explored after MTS assays 
established concentrations that did not inhibit metabolism, figures 4.25-4.28. 
 
THP-1 Jurkat 
A  B  
Figure 4.25: Cytotoxicity assays for 10 μM SB203580. MTS assays were over 7 hours in (A) THP-1 
and (B) Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the 
absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ns=p>0.05. 
 
 
At 5 μM SB203580 had little impact on chemotaxis (data not shown) but at 10 μM inhibited 
CXCL12-induced chemotaxis in both Jurkat and THP-1 and THP-1 to CCL3, figure 4.26. 
 
A                      Jurkat B                     THP-1 C                   THP-1 
   
Figure 4.26: Chemotaxis assays following pre-treatment with 10 μM SB203580 or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001. 
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        A                           THP-1          B                                Jurkat 
  
Figure 4.27: Cytotoxicity assays for PD98059. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
ns=p>0.05. 
 
PD98059 at 25 μM significantly inhibited both Jurkat chemotaxis to CXCL12 and THP-1 chemotaxis 
to CCL3. At 25 μM PD98059 blunted cAMP responses to CXCL12 in Jurkat, possibly by reducing 
basal levels, figure 4.28.   
 
   A                   Jurkat B                THP-1     C               Jurkat 
   
Figure 4.28: Chemotaxis assays following pre-treatment with 25 μM PD98059 or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) cAMP 
production in Jurkat following 25 μM PD98059 or control measured before or after 20 minutes 10 
nM CXCL12 stimulation. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, *=p<0.05. 
 
PD98059 at 25μM was found to have no effect on calcium signalling in response to CXCL12 or 
CCL3, figure 4.29. 
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THP-1 Jurkat Jurkat 
A  
 
B  C  
Figure 4.29: Fura2 Ca2+ assay following 25 μM PD98059 or control (DMSO). (A) THP-1 responses to 
10 nM CCL3 (B & C) Jurkat responses to 10 nM CXCL12. (A & B) Data expressed as fluorescence 
ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 nM CCL3 or 10 nM CXCL12 
addition minus basal fluorescence (prior to chemokine) (C) Area under curve. Means ± SEM, 
Student t-test, n≥3 independent experiments, (B, trace n=1), ns=p>0.05. 
 
Results show targeting signalling through ERK1/ERK2 with PD98059 or p38 MAPK with SB203580 
can specifically inhibit chemotaxis in Jurkat and THP-1 to these chemokines, and that the 
reduction in chemotaxis is not due to toxic effects of the inhibitors on cell metabolism. 
 
4.2.9: Inhibiting pairs of signalling proteins provides further evidence of signalling through Src 
and Ras/Raf/MEK/ERK pathways triggered by CXCL12 and CCL3. 
 
The Ras/Raf/MEK/ERK pathway is often dysregulated in malignancies. This can be due to BRAF or 
NRAS mutations [584]. BRAF and NRAS can be targeted therapeutically but often resistance 
develops [585, 586]. A situation where targeting downstream Raf, MEK or ERK signalling may be 
helpful. However MEK inhibition may induce unhelpful Pi3K signalling [587]. Metastatic cells can 
invade or escape tissues by stimulating matrix metalloproteases (MMP’s) digestion of the 
extracellular matrix (ECM), this can be activated by MEK/ERK signalling. To migrate cancer cells 
attach to the extracellular matrix and then need to change shape, which requires Rho/ROCK-
mediated actin dynamics [588]. Cell movement requires integrin-mediated ECM adhesion which is 
itself regulated by SRC kinases, and can be inhibited by Src inhibitors [589]. Src kinases are 
implicated in both cell invasion and cell migration, and aberrant Src signalling is implicated in 
many cancers [590]. Inhibition of pairs of proteins involved in Src/Ras/Raf/MEK/ERK CXCL12 and 
CCL3 signalling was explored to look for synergistic inhibition of chemotaxis that may be 
applicable to preventing metastatic spread, figures 4.30-4.34. 
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A                    THP-1 B                 THP-1 C                 Jurkat  
   
Figure 4.30: Chemotaxis assays following pre-treatment with 0.5 μM L779450 and/or 12.5 μM 
PD98059 or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM 
CXCL12. (C) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, *=p<0.05, ns=p>0.05. 
 
Combined low dose Raf (0.5 μM L779450) and ERK (12.5 μM PD98059) inhibition produces slightly 
greater inhibition of chemotaxis than L779450 or PD98059 at the same concentrations alone in 
THP-1 to CCL3 or CXCL12 but not in Jurkat to CXCL12, figure 4.30. For chemical structures of 
inhibitors used in this section please see appendix 4.  
 
Similarly in THP-1 combined low dose Raf (0.5 μM L779450) and MEK (0.5 μM SL327) inhibition 
produced only slightly greater inhibition (p<0.05) than Raf or MEK inhibition alone in CCL3 and a 
slightly increased response (p<0.01) in CXCL12-induced chemotaxis, figure 4.31. 
 
                   A                     THP-1                    B                     THP-1 
    
Figure 4.31: Chemotaxis assays following pre-treatment with 0.5 μM L779450 and/or 0.5 μM 
SL327 or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM 
CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
**=p<0.01, *=p<0.05, ns=p>0.05. 
 
 
Raf and ROCK simultaneous inhibition produced more chemokine and cell-type specific responses. 
Combined Raf (0.5 μM L779450) and ROCK (0.5 μM Y27632) inhibition produced very significantly 
(p<0.001) increased inhibition of chemotaxis compared to Raf or ROCK inhibition alone in CXCL12-
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induced chemotaxis in THP-1 but less inhibition (p<0.01) in CCL3-induced chemotaxis in THP-1 or 
CXCL12-induced chemotaxis in Jurkat (p<0.05), figure 4.32. 
A                      THP-1 B                      THP-1 C                      Jurkat 
   
Figure 4.32: Chemotaxis assays following pre-treatment with 0.5 μM L779450 and/or 0.5 μM 
Y27632 or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 
nM CCL3. (C) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, *=p<0.05, **=p<0.01, ***=p<0.001, ns=p>0.05. 
 
Raf inhibition with 0.5 μM L779450 and Pi3K inhibition with 5 μM LY294002 was found to be 
additive compared to Pi3K inhibition alone in CXCL12 but not CCL3-induced chemotaxis in THP-1, 
Pi3K itself producing a chemokine specific effect, i.e. no significant inhibition of CCL3-induced 
chemotaxis, figure 4.33. 
                     A                THP-1                  B                       THP-1 
  
Figure 4.33: Chemotaxis assays following pre-treatment with 0.5 μM L779450 and/or 5 μM 
LY294002 or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 
nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01, ns=p>0.05. 
Similarly 0.5 μM L779450 and Pi3K inhibition with 0.5 μM AS605240 in THP-1 produced similar 
additive and chemokine specific effects as L779450 with LY294002, no greater inhibition than Pi3K 
inhibition alone in CXCL12-induced chemotaxis and no significant inhibition of CCL3-induced 
chemotaxis, figure 4.34. 
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                   A                       THP-1                B                         THP-1 
  
Figure 4.34: Chemotaxis assays following pre-treatment with 0.5 μM L779450 and/or 0.5 μM 
AS605240 or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 
nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
**=p<0.01, *=p<0.05, ns=p>0.05. 
Whereas Src inhibition and Raf inhibition produced no greater effect than Src inhibition alone, 
figure 4.35.  
Jurkat  
 
 
Figure 4.35: Chemotaxis assays following pre-treatment with 
0.5 μM Bosutinib and/or 0.5 μM L779450 or control (DMSO). 
Chemotaxis of THP-1 to 1 nM CXCL12. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
**=p<0.01, ns=p>0.05. 
 
4.3: Discussion 
Here Rottlerin at 2-4 μM failed to inhibit cell migration, calcium flux, or cAMP reduction in 
response to CXCL12 in Jurkat cells, figures 4.2-4.3. At the higher concentration ethanoic solutions 
of Rottlerin may increase migration in Jurkat towards CXCL12 [565], this may be as Rottlerin has 
been shown to induce malignancy in human and rat fibroblasts and can block apoptosis in cells 
suffering DNA damage [591]. Rottlerin therefore may inhibit cell death in malignant cell-lines such 
as Jurkat. The Rottlerin used in these experiments was active as was shown to inhibit MCF7 
wound-healing (published experiments undertaken by Dr Anja Mueller [565]). Here very different 
effects were found with siRNA knockdown of PKCδ compared to Rottlerin treatment, chemotaxis 
was significantly reduced by PKCδ, figure 4.2. This was somewhat surprising as PKCδ can act as a 
tumour suppressor as over expression can stall the cell cycle at G2/M, and its inhibition is 
reported to support malignancies [592]. PKCδ and PKCε can have opposite effects. PKCδ can be 
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pro-apoptotic and inhibit cell proliferation, and can reduce mitochondrial activity inducing 
apoptosis, whereas in ischaemia PKCε can prevent mitochondrial damage and cell death [593]. 
Similarly PKCε supports NIH3T3 fibroblast cell-line proliferation whereas PKCδ may support 
myeloid and epithelial cell differentiation [594, 595]. PKCδ may be activated by Caspase-mediated 
proteolytic mechanisms aiding apoptosis in UV or carcinogen damaged keratinocytes preventing 
skin cancers [596]. Also PKCδ inhibition can support neoplastic transformation. Ras activating 
mutations, acting via Transforming Growth Factor alpha (TGFα) can have opposing effects 
reducing PKCδ activation via phosphorylation and expression but not inhibiting PKCα, PKCε or 
PKCζ [597]. 
4.3.1: Roles of PKCα in malignancies 
PKCα is ubiquitously expressed, it promotes cell growth, migration and inhibits apoptosis [598], 
but PKCα can support both pro- and anti-tumorigenic signalling. PKC effects can show cell-type 
specificity, but also produce opposite effects in similar cells. For example PKCα upregulated 
ERK1/2 signalling supporting PAR2-induced cell proliferation, migration and survival in a 
metastatic colon cell-line [599]. Conversely PKCα can phosphorylate β-catenin marking it for 
proteosome degradation, reducing Wnt/β-catenin signalling and the cyclin D1 and c-Myc 
expression which supports proliferation of colon cancers [600]. Also inhibition of PKCα has been 
shown to inhibit the mesenchymal-amoeboid transition of cells including MDA-MB-231 breast 
cancer cells, reducing amoeboid invasiveness, hence PKCα may support breast cancer metastasis 
[601]. This may explain why here knockdown of PKCα reduced CCL3- and CXCL12-induced wound-
healing in MCF7 breast cancer cell-line, figure 4.8. 
PKC expression levels in cancers can vary as every cancer is genetically different, but also as PKC-
regulated signalling pathways can be modulated by the oncogenes expressed in any particular 
cancer or cell-line [602].  For example PKCα deletion increased lung mutations where K-Ras was 
activated [603] and PKCα inhibitor GÖ6976 decreased migration of colon cancer cells SW480 
[604] whereas in MDA-MD-231 breast cancer cells PKCα activation inhibited cell motility [605]. 
This may be why assays comparing small molecule inhibitors with siRNA knockdown, and result in 
different cell-lines can lead to opposite conclusions. Also small molecule inhibitors are rarely 
specific for example GÖ6976 is marketed as a specific PKCα inhibitor but also hits PKCβ [606] 
JAK2, FLT3 [607], and PKCμ (PKD) [608].  
4.3.2: PKCε upregulation may support cell survival, invasion and motility 
PKCε upregulation is seen in some cancers [609], it has been found to increase the rate of cell 
replication in some cell-lines [610], and the malignant transformation potential of other 
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carcinogens albeit in mice [611]. PKCε over expression also inhibits apoptosis in leukaemic [612] 
and breast cancer cells [613]. PKCε inhibits programmed cell death triggered both through the 
extrinsic pathway, through ligand activation of receptors [614], and the intrinsic pathway 
involving mitochondrial release of apoptotic factors in cellular stress. These direct Activating 
Transcription Factor 2 (ATF2) to mitochondria increasing membrane permeability and cytochrome 
C release which activates caspases triggering apoptosis [615]. PKCε can phosphorylate ATF2 
causing its translocation to the nucleus, therefore overexpression of PKCε can inhibit 
mitochondrial triggered apoptosis. This has been observed in MCF7 [613]. TNF can produce 
extrinsic triggered apoptosis, overexpression of PKCε inhibits this process [616]. Inhibiting PKCε 
inhibits apoptotic effects of TNF in lymphomas cells [617]. So PKCε can promote cell proliferation 
and inhibit apoptosis [262]. Certainly here siRNA knockdown of PKCε appeared to have less effect 
than knockdown of PKCα, figures 4.7-4.8 however the extent of PKCε knockdown was not 
established. 
PKB (Akt) regulates cell survival, proliferation [618] and metastasis. In MDA-MB-231 breast cancer 
cells which overexpress PKCε silencing PKCε decreased proliferation, invasion and motility and 
metastasis (in mice) [619] similar results were seen in HNSCC cells where PKCε supported RhoA 
and RhoC signalling [620]. Here PKCε knockdown appeared have greater effects in Jurkat than 
MCF7, figures 4.7-4.8, but again the extent of knockdown was not analysed as no PKCε antibody 
was available in the laboratory. 
Non-selective PKC inhibitor staurosporine had no effect on Jurkat CXCL12-stimulated chemotaxis, 
cAMP or calcium assays, figures 4.4 and 4.14. Staurosporine’s effects on Jurkat have been studied 
by others. CXCR4 undergoes slow CXCL12-independent internalisation and recycling. PKC can 
trigger endocytosis signalling, but CXCR4 trafficking can vary by cell type [279]. Pre-treatment of 
Jurkat with 10 nM Staurosporine was shown to restore CXCR4 expression reduced by phorbol 
ester (PMA) treatment, leading researchers to conclude that CXCR4 internalisation in Jurkat is via 
PKC [570]. CXCR4 internalisation has previously been shown to be mediated by PKC, however 
CXCL12 and phorbol ester may induced CXCR4 internalisation involving differing pathways, 
whereas phorbol esters require PKC, PKC usage via CXCL12 induced CXCR4 internalisation was not 
inhibited by Staurosporine [279, 621]. Therefore the slight inhibition of chemotaxis observed 
here, figure 4.4, may be due more to Staurosporine off target effects than PKC inhibition. 
Pan PKC inhibitor GF109203X in Jurkat had no effect on CXCL12-induced cAMP production or 
chemotaxis but dramatically increased calcium flux whereas in THP-1 GF109203X reduced CCL3- 
but not CXCL12-induced chemotaxis, figures 4.5-4.6 and 4.14. 
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In Jurkat the siRNA and small inhibitor approaches to inactivating PKC were not complementary, 
suggesting in Jurkat siRNA knockdown may produce either more effective or specific silencing of 
PKC than Rottlerin, staurosporine or GF109203X.  
CID755673, which targets PKCμ (PKD), inhibited CCL3- but not CXCL12-induced chemotaxis in THP-
1 and strongly inhibited CXCL12-induced calcium flux and chemotaxis in Jurkat. PKCμ inhibition 
also produced opposite but both non-significant effects on cAMP levels before and after CXCL12 
stimulation in Jurkat and THP-1, suggesting that PKCμ usage may be cell type specific, figures 
4.10-4.12 and 4.14.   
4.3.3: PKC signalling through GSK3, Slingshot and cofilin  
Glycogen synthase kinase 3 (GSK3) is a key protein in many signalling pathways including those of 
Wnt and Pi3K [550]. It exists as two isoforms GSK3α, and GSKβ. GSK3 is tonically active in resting 
cells. GSK3 can be activated by phosphorylation on its T-loop, and inactivated by phosphorylation 
in various locations including GSK3’s N- and C- terminals in response to PKC, p38MAPK, Erk, PKCα, 
Akt and PKA signalling  [551, 552], figure 4.36. 
 
 
 
 
 
Figure 4.36: Many proteins 
activate or inactivate GSK3, 
including PKC [552, 622]. 
  
Here Raf inhibition with L779450 reduced Jurkat CXCL12-induced chemotaxis but did not 
significantly alter cAMP levels, figure 4.23. Whereas the PKC inhibitors mainly blunted cAMP 
responses to CXCL12, figures 4.3-4.4, 4.6 and 4.12. Raf-inhibition also reduced calcium peak 
fluorescence and total calcium release in response to CXCL12 stimulus in Jurkat and to CCL3 
stimulus in THP-1. Raf inhibition in THP-1 decreased both CCL3- and CXCL12-induced chemotaxis, 
figures 4.22-4.24, Also ERK1/2 inhibitor PD98059 prevented chemotaxis in Jurkat to CXCL12 and 
THP-1 to CCL3 and blunted cAMP responses, but had no significant effect on chemokine 
stimulated calcium-responses, figures 4.27-4.29. These results suggest the Raf/MEK/ERK signalling 
pathway may be critically important for CCL3- and CXCL12-induced migration in these leukemic 
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cell-lines. The cAMP responses suggest cross-talk, possibly through GSK3, figure 4.36, and/or 
other intermediaries may influence chemotaxis. Similarly p38 MAPK inhibitor SB203580 strongly 
inhibits chemotaxis of Jurkat to CXCL12 and THP-1 to CCL3, figure 4.25-4.26. 
 
Combining Raf and Pi3K inhibition produced additive effects on CXCL12 but not CCL3-induced 
chemotaxis, figures 4.33-4.34, suggesting biased signalling, Pi3K being more important for CXCL12 
but not CCL3-triggered chemotaxis, this is covered further in chapter 5, section 5.2.6 of this thesis. 
 
Combining Src with Raf inhibition, using Bosutinib with L779450, produced no greater inhibition 
than Src alone, suggesting Src operates near the receptor, high in the signalling pathway, figure 
4.35. Whereas Raf with MEK (SL327), Raf with ERK 1/2 (PD98059), and Raf with ROCK (Y27632) 
inhibition all produced additive inhibitory effects on effect chemotaxis to CXCL12 and CCL3, 
figures 4.30-4.32. Again this indicated the importance of Raf/MEK/ERK signalling for chemotaxis in 
these cell-lines, but also suggesting cross-talk with ROCK, occurs from the Raf/Ras/MEK/ERK 
cascade. 
 
Inhibition of ROCK in adherent cells can inhibit detachment apoptosis which is linked to Rho/ROCK 
pathway phosphorylation (activation) of cytoskeletal components and actin-myosin contraction 
which disrupts the E-cadherin mediated cell-cell adhesion balance with actin-myosin contraction 
[623]. By suppressing ROCK PPARγ is upregulated and PPARγ inhibits GSK3B which allows more β-
catenin to move to membrane supporting E-cadherin cell-cell adhesion. Selective PPARγ agonists 
such as pioglitazone are reported to add to the effects of ROCK inhibitor Y27632 [624].  
E-cadherin by recruiting β-catenin inhibits β-catenin nuclear translocation where it will aid the 
transcription of genes such as c-myc and cyclin D1 facilitating cell proliferation [624, 625], figure 
4.37. β-catenin inhibition with FH535, figure 4.13, was found to significantly reduce CXCL12-
induced chemotaxis in Jurkat and CXCL12 and CCL3-induced chemotaxis in THP-1.  
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Figure 4.37: Effects of ROCK inhibition on β-catenin 
signalling [552, 623, 625]. 
GSK3 inhibition reportedly does not stop CXCL12 phosphorylation of serines in CXCR4 C-terminal 
[280] however GSK3 can inactivate Slingshot (SSH) [34]. Slingshot dephosphorylates (activates) 
cofilin, a key protein in cell migration, figure 4.38, discussed further here in chapters 5-8. 
 
 
 
 
 
Figure 4.38: PKC signalling 
through GSK3, Slingshot and 
cofilin [34, 280]. 
 
4.4: Conclusions 
The above data suggest Src and PKC are key signalling proteins in CXCL12- and CCL3-induced 
migration of both the leukaemic and breast cancer cell-lines employed here. Src knockdown with 
siRNA and small molecule inhibitor Bosutinib produced similar responses. PKC isoenzyme specific 
responses were apparent with PKCα, PKCδ and PKCμ (PKD) being key for CXCL12 signalling, off 
target effects were possible issues with some small molecule inhibitors of PKC. Overall PKC 
involvement in CCL3 and CXCL12-induced migration was found to be isoform and cell type 
specific. Signalling through β-catenin, Src and the Raf/MEK/ERK pathway was not found to be 
chemokine specific, all of the pathway proteins were important for CCL3- and CXCL12-induced 
chemotaxis in THP-1 and Jurkat. This conclusion was supported by the additive effects found 
between inhibition of Raf plus ERK, Raf plus MEK, and Raf plus ROCK. Inhibition of Raf plus Pi3K 
GSK3B
RhoA
ROCK
PIP5K
PPARγ
β-catenin
E-cad
h
e
rin
Y27632
cytoskeleton
+
cofilincofilin Slingshot
P
GSK3
α
γ
P
chemokine
β
Cofilin active – migration
GSK3 
inactivated 
by PKCα
cofilincofilin Slingshot
P
GSK3
Phosphocofilin – inactive
GSK3 
active
siRNA knockdown
122 
 
produced inhibition of CXCL12- but not CCL3-induced chemotaxis, suggesting CXCL12/CCL3 biased 
signalling through Pi3K and supporting the use of combination therapies to inhibit more than one 
mitogenic signalling pathway in metastatic cancers. 
The data presented provides evidence for chemokine and cell-type favoured signalling pathways 
but also obvious cross talk, as where one signalling pathway or component is inhibited other 
signalling routes appear to ensure chemotactic attraction continues albeit to a reduced extent. 
Thus signalling pathways originating from any specific receptor, such as CXCR4 or CCR5, cannot be 
generalised between chemokines or between cell types; this may frustrate pharmacologists but 
may provide oncologists opportunities to develop targeted therapeutic molecules. 
There are many other proteins purportedly involved in cell migration leading to metastasis, 
important ones include β-arrestins along with cofilin, a cytoskeleton-associated protein that 
controls actin dynamics. β-arrestins can dephosphorylate and so activate cofilin and spatially 
regulate cofilin activity [626] therefore in chapter 5 the CXCL12 and CCL3 signalling involving these 
proteins was explored.  
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Chapter 5: CXCL12 and CCL3 chemokine-induced migration in leukaemic and breast 
cancer cells can involve cofilin phosphorylation, Pi3K and β-arrestins 
 
 
5.1: Introduction 
Cell dynamics leading to metastasis involves a myriad of signalling and mechanical proteins and 
the hijacking of homeostatic chemotactic cell migration. Chemotaxis requires a directional leading 
edge; a small protein called cofilin is key to this process. Cofilin forms co-filaments with actin 
facilitating both EMT and metastasis [627]. Cofilin has three isomers cofilin-1 (non-muscle), 
cofilin-2 (muscle) and destrin (aka ADF) [628, 629]. Throughout this thesis reference to cofilin 
refers to cofilin-1. Cofilin expression is upregulated in many cell lines and cofilin activity is 
controlled by phosphorylation and ATP.  De-phosphorylation by phosphatases such as PP2 and 
Slingshot, itself directed by proteins such as Pi3K, activates cofilin [375, 376]. This allows cofilin to 
bind actin, causing filament fragmentation and so producing a source of actin filament-initiation 
barbed ends and actin monomers to build new filaments [373]. Cofilin is inactivated by LIMK 
phosphorylation mediated by Rho GTPases Rac, Rho and Cdc42 [630, 631]. Metastasis and 
malignant cell invasion of healthy tissue have been associated with reduced LIM kinase (LIMK) 
expression and associated lower levels of phosphorylated cofilin [632]. Cell location of 
phosphorylated cofilin is influenced by 14-3-3 regulatory proteins sequestering Slingshot and also 
cell membrane PIP2 sequestering cofilin. PIP2 itself can be modulated by PLCγ [381, 384], figure 
5.1.  
  
Figure 5.1: Summary of actin remodelling and the involvement of cofilin [375, 376, 386, 630]. 
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Hypothesis: Cofilin supports chemokinesis in cancer cells, and is mediated by key signalling 
pathways involved in metastasis. 
Aim: To explore the role of β-arrestin and cofilin in CCL3 and CXCL12 chemokinesis; observe the 
effects, on chemotaxis and cofilin phosphorylation, of inhibition of signalling transducers Gβγ and 
GRKs, and key signalling proteins in metastasis Raf, MEK, Pi3K, ROCK and Src.  
Objectives:  
(i)     Establish that cofilin is expressed in cell-lines 
(ii)    Explore the effects of siRNA knockdown of cofilin 
(iii)   To investigate the effect of chemokines alone and in combinations on chemotactic migration 
and cofilin phosphorylation  
(iv)  Explore the effects on chemotaxis and cofilin phosphorylation of Pi3K inhibition and Pi3K 
siRNA knockdown, and also of Gβγ, GRK, FAK, ROCK, and MEK small molecule inhibition.  
(v)  Explore the effects of over-expression of β-arrestins on chemokinesis in MCF7, and 
chemotactic migration in THP-1 and Jurkat.    
 
5.2: Results  
Please note controls are common between graphs where experiments were conducted 
simultaneously; results for each inhibitor or siRNA have been displayed separately for ease of 
description of results, this applies to: figures 5.15 and 4.18; 5.21D and 5.27.  
 
 
5.2.1: Cofilin modulates leading edge dynamics 
Cofilin is highly expressed in human T-cells; it regulates their movement especially through 3D 
environments [633]. Therefore Jurkat were first explored as a tool for examining cofilin 
phosphorylation in response to CXCL12 stimulus. However westerns extracting cytoplasmic but 
not nuclear cofilin, showed consistent high expression of both phosphorylated cofilin and cofilin, 
in the presence or absence of CXCL12, figure 5.2. Hence Jurkat did not offer a sensitive readout 
tool.  
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Figure 5.2: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in Jurkat in presence and absence of CXCL12 (5 nM, 15 mins before lysis). 
Arrestin-2 loading control. 
 
 
5.2.2: Cofilin knockdown reduces migration to CCL3 and CXCL12 
 
Cofilin expression in THP-1 and MCF7 was then explored with western blot or 
immunofluorescence assays. MCF7 were also modified using cofilin siRNA, with knockdown 
confirmed using western blot, and the effect of this on wound-healing triggered by CCL3 and 
CXCL12 explored, figure 5.3. 
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                            MCF7                                                MCF7 
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Figure 5.3: Cofilin siRNA knockdown reduced CXCL12 and CCL3 chemokinesis. MCF7 wound-
healing assays 24 hours after transfection with 50 nM Cofilin siRNA or nonsense siRNA (Scr) 
control. Analysis 24 hours after (A and E) 10 nM CCL3, (B and F) 10 nM CXCL12. Means ± SEM, 
one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001. (C) Western 
Blot MCF7 total-cofilin expression 24 hours after siRNA knockdown, β-actin loading control. (D) 
Immunofluorescent shows THP-1 cofilin expression. THP-1 incubated with anti-cofilin then probed 
with FITC. Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, 
Em 520 nm). 
Complete cofilin knockdown in MCF7 was found to be lethal, whereas partial knockdown 
producing low expression of cofilin (19 kDa) and cofilin breakdown products with lower molecular 
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weights, figure 5.3C, very significantly (p<0.001) inhibited wound-healing in MCF7. Complete 
cofilin knockdown in THP-1 and Jurkat also proved lethal to cells. 
 
5.2.3: Cofilin phosphorylation can be triggered by a range of chemokines 
Westerns revealed cofilin phosphorylation state could be manipulated by several CC and CXC 
chemokines in THP-1 to a much greater extent than by CXCL12 in Jurkat, figure 5.4.  
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Figure 5.4: Western Blot with phosphocofilin (Ser3) antibody reveals cofilin phosphorylation levels 
in THP-1 in presence and absence of various chemokines (5 nM, 15 mins before lysis), Arrestin-2 
loading control. 
 
In THP-1 various chemokines were found to dramatically alter the phosphorylation state of cofilin, 
figure 5.4. Results showed that cofilin is present in the phosphorylated and un-phosphorylated 
forms in unstimulated THP-1 cells at variable levels, so the phosphorylation state of the control, 
which must be prepared at the same time, was considered alongside results. Basal 
phosphorylation state may be partly due to the phosphatase activity of Slingshot whose 
concentration has been shown to vary between different subcellular compartments, and 
observed to change during the cell division cycle in cultured cells; levels increasing as mitosis 
proceeds, with maximum levels during telophase and cytokinesis when Slingshot is required to 
dephosphorylate and reactivate cofilin [634-636].   
 
5.2.4: Chemotactic responses to chemokines are concentration dependent 
Many chemokines can be shown to induce chemotaxis in THP-1 cells, figure 5.5A, although Jurkat 
only significantly respond to CXCL12. A Gaussian distribution response to CXCL12 chemokine dose 
was observed for both cell types; this is also the case for THP-1 chemotaxis to CCL3, figures 5.5 
and 5.6. 
 
 
128 
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Figure 5.5: (A) THP-1 chemotactic response to various chemokines. (B) THP-1 Chemotactic dose-
responses to CXCL12 and (C) to CCL3. Means ± SEM, one-way ANOVA comparing to no 
chemokine, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, 
*=p<0.05, ns=p>0.05. 
 
Results in THP-1 suggested that if a chemokine produced cofilin phosphorylation it may also be 
chemotactic. 
Jurkat Jurkat 
A  B  
Figure 5.6: Jurkat chemotactic dose-responses to CXCL12 (A) low dose and (B) higher dose. Means 
± SEM, one-way ANOVA comparing to no chemokine, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
 
5.2.5: Additive responses between chemokines may suggest dimerization 
Chemotaxis responses in THP-1 were additive if both CCL3 and CXCL12 were used in tandem. Such 
co-operation appeared not always to be the case between CC- and CXC- chemokines; for example 
in THP-1 with CCL2 and CXCL11, or CCL2 and CXCL9, there was no significant additive effect. 
CXCL11 produced chemotaxis in THP-1 but little response in Jurkat, however in THP-1 and Jurkat 
CXCL11 significantly reduced chemotaxis to CXCL12. CXCL11 purportedly can bind CXCR7 and 
CXCR3, therefore these results may suggest that stimulation of CXCR7 by CXCL12 contributes to 
CXCR4-induced chemotaxis, figure 5.7. Other concentration combinations of these chemokines 
may produce different responses. 
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A                      THP-1 B                       THP-1 C                          THP-1 
   
                  D                     THP-1                  E                   Jurkat 
  
Figure 5.7: (A) THP-1 chemotaxis to CCL3 and/or CXCL12 (B) THP-1 chemotaxis to CCL2 and/or 
CXCL11. (C) THP-1 chemotaxis to CCL2 and/or CXCL9  (D) THP-1 chemotaxis to CXCL11 and/or 
CXCL12 (E) Jurkat chemotaxis to CXCL11 and/or CXCL12 Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
 
The antibody 12G5 binds CXCR4 inhibiting chemotaxis to CXCL12 in both Jurkat and THP-1. Pre-
treatment with 12G5 antibody also inhibited chemotaxis to CXCL11 and CCL3 in THP-1 possibly 
indicating that CXCR4 supports chemotaxis to both these chemokines in this cell type. In Jurkat 
pre-treatment with 12G5 reversed some of the negative effects of adding CXCL11 to CXCL12 as a 
chemoattractant, suggesting the Jurkat expressed CXCR4 and CXCR7, but not CXCR3. In Jurkat and 
THP-1 pre-treatment with CXCL11 reduced chemotaxis to CXCL12 and combined CXCL12 and 
CXCL11, pointing to these cells expressing CXCR4, CXCR3 and/or CXCR7, figure 5.8.  
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THP-1 Jurkat 
A  B  
 
Figure 5.8: (A) THP-1 Chemotaxis to CCL3 1 nM, CXCL11 5nM and CXCL12 0.5 nM after CXCL11 
25nM or 12G5 12.5ng/μL pre-treatment (37°C, 30 mins). (B) Jurkat chemotaxis to CXCL11 5 nM or 
CXCL12 0.5 nM after CXCL11 25 nM or 12G5 12.5 ng/μL pre-treatment (37°C, 30 mins). Means ± 
SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, 
**=p<0.01, *= p<0.05, ns=p>0.05. 
 
These results suggest co-operation or dimerization of chemokine receptors or indeed chemokines 
may contribute to chemotaxis in both THP-1 and Jurkat. Co-operative effects of chemokines on 
calcium flux were also investigated in MCF7 and THP-1 cells. Both cell types respond well to CCL3 
and CXCL12, MCF7 have been shown to highly express CXCR4 and CXCR7 but not CXCR3 [637]. 
CXCR7 and CXCR3 respond to CXCL11.  
 
CXCL11 pre-treatment of MCF7 cells before calcium flux induced by CXCL12 indicated pre-
stimulation of CXCR7 inhibited calcium oscillations, figure 5.9. Overall these results suggest that 
CXCL11 supports dimerization or co-internalisation of CXCR7 and CXCR4 receptors in MCF7, THP-1 
and Jurkat.  
MCF7 MCF7 
B  A  
Figure 5.9: Fura2 Ca2+ assay in MCF7 following pre-treatment with CXCL11 10 nM or control (H20). 
Data expressed as fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 
nM CCL3 addition minus basal fluorescence (prior to chemokine). (A) trace n=1, (B) Means ± SEM, 
Student t-test, n≥3 independent experiments, ** = p<0.01. 
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CXCL12 but not CCL3 signalling is purportedly triggered through Gβγ subunits [638] to Pi3K this 
signalling can aid malignant cell invasiveness and metastasis  The small molecule inhibitor Gallein 
can prevent βγ subunit interactions with Pi3K [639]. Here Gallein was shown to specifically inhibit 
CXCL12 but not CCL3 chemotaxis in THP-1, however in the presence of both chemokines Gallein’s 
inhibitory effects on chemotaxis increased, this was not due to cytotoxicity, figure 5.10. 
THP-1 Jurkat 
           A 
 
 
        B  
 
THP-1 
C   
 
 
Figure 5.10: The effects of Gallein 10 μM. (A) Cytotoxicity assays over 7 hours in THP-1. (B) 
Chemotaxis of Jurkat to 1 nM CXCL12. (C) THP-1 chemotaxis to 1 nM CXCL12, 1 nM CCL3 or both. 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05.  
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Figure 5.11: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with Gallein  10 μM (37°C, 30 mins) in 
presence and absence of CCL2, CCL3 or CXCL12 (5 nM, 15 mins before lysis). Arrestin-2 loading 
control. 
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Gallein caused phosphorylation of cofilin before stimulation with chemokines but reduced cofilin 
phosphorylation seen previously in the presence of CCL2 and CCL3, figure 5.4, possibly suggesting 
βγ is involved in CCL2, CCL3 and CXCL12 signalling. Hence next the effect of Pi3K inhibition on 
cofilin phosphorylation and cell migration was examined. 
 
There are many Pi3K subtypes [640] including dimer 1A which can act as a lipid and protein 
kinase, it contains catalytic subunit p110 and regulatory subunit p85. Binding of p110 to Ras 
causes Pi3K activation producing second messenger PIP3 at the membrane. PIP3 binds Akt and the 
kinase PDK1 which itself binds and activates Akt and Rac. Akt can then activate and inhibit various 
downstream proteins including Caspase-9 and NFκB regulating for example apoptosis, 
proliferation, and migration [641]. Rac activity may be essential for lamellipodia formation [642]. 
By influencing Slingshot and thus cofilin phosphorylation Pi3K may mediate actin filament 
formation and membrane protrusion [643]. 
 
 
5.2.6: Pi3K inhibition and chemokine-induced migration 
Previous studies have indicated that inhibiting Pi3K signalling may block cofilin dephosphorylation 
[644, 645]. Chemotaxis investigations using inhibitors LY294002 which reversibly inhibits Pi3Kα, 
Pi3Kδ and Pi3Kβ with IC50’s of 0.5 μM, 0.57 μM and 0.97 μM, respectively, along with AS605240 a 
potent and selective inhibitor of Pi3Kγ with an IC50 of 8 nM and a 30-fold selectivity over Pi3Kδ 
and Pi3Kβ and 7.5-fold selectivity over Pi3Kα indicate that the Pi3K pathway may be involved in 
migration towards CXCL12 in Jurkat and THP-1, and that Pi3K may have little or no involvement in 
CCL3-induced chemotaxis in THP-1, figures 5.12 and 5.13. The inhibitors did not inhibit cell 
metabolism, figure 5.14. 
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THP-1, AS605240 1 μM, THP-1, AS605240 0.5 μM,  
A  B  
 
 
 
 
THP-1, LY294002 5 μM THP-1, LY294002 5 μM 
C  D  
 
Figure 5.12: Chemotaxis assays of THP-1 following pre-treatment with LY294002 or AS605240 or 
control (DMSO) (A) to 1 nM CCL3 (B) to 1 nM CXCL12 (C) to 1 nM CCL3 (D) to 1 nM CXCL12. Means 
± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, 
**=p<0.01, *= p<0.05, ns=p>0.05. Note: 5.12B data also displayed in figure 4.34; 5.12C & D data 
also in figure 4.33. 
Jurkat, LY294002 10 μM Jurkat, AS605240 
     A 
 
 
 
                            B 
 
Figure 5.13: Chemotaxis assays of Jurkat to CXCL12 1 nM following pre-treatment with (A) 10 μM 
LY294002 or (B) 1 or 5 μM AS605240 or control (DMSO). Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
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THP-1 THP-1 
A  B  
Figure 5.14: Cytotoxicity assays over 7 hours in THP-1 for (A) AS605240 1 μM and (B) LY294002 10 
μM. Basal absorbance occurs in presence of medium after MTS treatment in the absence of cells. 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns=p>0.05. 
 
 
5.2.7: Pi3K siRNA knockdown also inhibits chemokine-induced migration in MCF7 and THP-1 
These effects of Pi3K inhibition with small molecule inhibitors AS605240 and LY294002 on cell 
migration were confirmed using siRNA knockdown of Pi3K in THP-1, Jurkat and MCF7 cells, figures 
5.15 and 5.15. 
THP-1 THP-1 Jurkat 
A 
 
 
B 
 
 
C 
 
 
 
Figure 5.15: Pi3K siRNA knockdown. Cells transfected with 50 nM Human Pi3K or 50 nM nonsense 
siRNA (Sc) control, chemotaxis assays undertaken 24 hours after transfection. (A) THP-1 
chemotaxis to 1 nM CCL3 (B) THP-1 chemotaxis to 1 nM CXCL12 (C) Jurkat chemotaxis to 1 nM 
CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3, ***=p<0.001.  
 
 
 
 
 
MTS THP-1 Assay of AS605240
6 hours n=3 21.11.14
B
as
al
C
on
tr
ol M
A
S6
05
24
0 
1 
0
1
2
ns
A
b
s
o
rb
a
n
c
e
 a
t 
4
9
5
 n
M
MTS THP1 Assay of LY294002
6 hours n=3 21.11.14
B
as
al
C
on
tr
ol M
LY
29
40
02
 1
0 
0
1
2
ns
A
b
s
o
rb
a
n
c
e
 a
t 
4
9
5
 n
M
THP-1 Pi3K siRNA
 n=3 08.02.16
C
on
tr
ol
 +
 C
C
L3
S
c 
+ 
C
C
L3
P
i3
K
 +
 C
C
L3
C
on
tr
ol
 +
 n
o 
ch
em
ok
in
e
S
c 
+ 
no
 c
he
m
ok
in
e
P
i3
K
 +
 n
o 
ch
em
ok
in
e
0
50
100
150 ***
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
m
L
-1
THP-1 Pi3K siRNA CXCL12nM
 n=3 08.02.16
C
on
tr
ol
 +
 C
X
C
L1
2
S
c 
+ 
C
X
C
L1
2
P
i3
K
 +
 C
X
C
L1
2
C
on
tr
ol
 +
 n
o 
ch
em
ok
in
e
S
c 
+ 
no
 c
he
m
ok
in
e
P
i3
K
 +
 n
o 
ch
em
ok
in
e
0
25
50
75
100
125 ***
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
m
L
-1
Jurkat  Pi3K siRNA CXCL12nM
 n=3 05.01.16
C
on
tr
ol
 +
 C
X
C
L1
2
S
c 
+ 
C
X
C
L1
2
P
i3
K
 +
 C
X
C
L1
2
C
on
tr
ol
 +
 n
o 
ch
em
ok
in
e
S
c 
+ 
no
 c
he
m
ok
in
e
P
i3
K
 +
 n
o 
ch
em
ok
in
e
0
50
100
150
200
250
300
350
400
450
***
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
m
L
-1
135 
 
MCF7 MCF7 
A  B  
 
 
 
Figure 5.16: MCF7 Pi3K siRNA knockdown. Wound-healing assays following transfection with 50 
nM Pi3K siRNA or nonsense siRNA (Scr) control. Analysis 24 hours after (A and C) 10 nM CXCL12, 
or (B and C) 10 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3, *=p<0.05, 
***=p<0.001. 
 
Pi3K knockdown highly significantly inhibited chemotaxis assays in THP-1 and Jurkat, figure 5.15, 
along with wound-healing in MCF7 induced by CXCL12, and to a lesser extent CCL3, figure 5.16. 
siRNA knockdown was confirmed with western blots figure 5.17, Pi3K knockdown was less 
effective in Jurkat than THP-1 or MCF7, possibly explaining the greater effect of Pi3K knockdown 
on chemotaxis in THP-1 than Jurkat, figure 5.15. 
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Figure 5.17: Pi3K siRNA knockdown. Cells transfected with 50 nM Human Pi3K or nonsense siRNA 
control. Western Blot 24 hours post-transfection using anti-Pi3K(p85α) antibody, loading 
confirmed with β-actin in (A) Jurkat, (B) MCF7 and (C) THP-1. 
 
As above results indicate cofilin’s phosphorylation state correlates with a cell’s ability to migrate 
towards a chemokine, and chemotaxis to CCL3 and CXCL12 involves Pi3K. Possibly due to Pi3K 
signalling influencing phosphatase slingshot’s modification of cofilin’s phosphorylation state 
[645]. The ability of Pi3K inhibition to directly modulate cofilin phosphorylation was investigated.  
 
5.2.8: Cofilin phosphorylation is modified by Pi3K inhibition 
Cofilin phosphorylation was explored in THP-1 in the presence and absence of Pi3K inhibitors 
LY294002 (LY) 20 μM and AS605240 (AS) 5 μM. Cells were treated with inhibitors followed by 
CXCL12 or CCL3 at different concentrations, figure 5.18. 
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Figure 5.18: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with AS605240 (AS) 5 μM or LY294002 
(LY) 20 μM (37°C, 30 mins) in presence and absence of CXCL12, or CCL3 (0.5, 1 or 5 nM, 15 mins 
before lysis). β-actin loading control. 
 
In THP-1 at higher levels of chemokines (5 nM) AS605240 continued to increase phosphorylation 
responses in presence and absence of chemokine whereas LY294002 decreased them. However in 
Jurkat the cofilin phosphorylation showed little response to Pi3K inhibition or CXCL12 stimulation, 
figure 5.19, this may be due to differences between untransformed T-lymphocytes and Jurkat (a 
T-cell lymphoma cell line) with respect to Ras signalling. In Jurkat Ras fails to activate Pi3K [646] 
whereas in untransformed T-lymphocytes it can [647].  
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Figure 5.19: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in Jurkat following pre-treatment with AS605240 (AS) 5 μM or LY294002 
(LY) 20 μM (37°C, 30 mins) in presence and absence of CXCL12 (5 nM, 15 mins before lysis). β-
actin loading control. 
As explained cofilin is able to modify the assembly and reorganisation of actin filaments, so the 
effects of the Pi3K inhibitors on actin fibres in CHO.CCR5 cells were examined using Phalloidin, 
figure 5.20. 
(A) Control (B) AS605240 (C) LY294002  
   
   
Figure 5.20: Filament actin stains following Pi3K inhibition. Alexa-488 Phalloidin (green) and DAPI 
nuclear stains (blue) of CHO.CCR5 following pre-treatment with (A) DMSO control (B) 5 μM 
AS605240 or (C) 10 μM LY294002 (1 hr, 37°C). Imaged UV inverted microscopy (Leica DMII 
Fluorescence microscope 500x Ex 490 nm, Em 520 nm).  
 
AS605240 or LY294002 show no adverse effects on actin filament structure, therefore these 
inhibitors effects on chemotaxis are unlikely to be due to destruction of the cell’s actin 
cytoskeleton. 
 
Modification of GRK, Src, ROCK, Raf and MEK signalling, using small molecule inhibitors, also 
influences chemotaxis of THP-1 and Jurkat to CCL3 and/or CXCL12, so the influence of these 
inhibitors on cofilin phosphorylation was examined. GRK activity is linked to the actions of β-
arrestin, hence the effects of transfection of cells, with plasmids to increase or decrease β-arrestin 
levels, on cell migration were also explored. 
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5.2.9: G-protein coupled receptor kinases (GRKs) 
GRKs are a family of protein kinases that can support malignancies; they modulate survival, 
proliferation and invasion of cancers [648]. Activated chemokine receptors couple to G-proteins, 
enabling the exchange of GDP for GTP on the Gα subunit, which causes the Gα and the Gβ/Gγ 
dimers to dissociate and interact with downstream effectors such as adenylyl cyclase. This 
activation of the chemokine receptor causes the translocation of GRKs from the cytosol to the 
plasma membrane, and GRKs then phosphorylates serine/threonine residues on the receptor. 
This phosphorylation recruits β-arrestins (a non-visual arrestin) to the receptor. β-arrestins cause 
receptor desensitisation, that is uncoupling the chemokine receptor from the Gα and Gβ/Gγ G-
proteins [649]. However, β-arrestins can also act as scaffolding proteins and mediate signalling 
and receptor internalisation [650], hence GRKs influence the balance of β-arrestin and G-protein 
signalling [651].  
5.2.9.1: βARK 
The original GRK identified was the enzyme which phosphorylates rhodopsin, now called GRK1. 
Next, β-adrenergic receptor kinase (βARK), an enzyme that could phosphorylate and desensitizes 
an agonist bound GPCR was discovered, βARK is now called GRK2 [649]. There are at least six GRK 
isoforms, and some isoforms are involved in malignant cell migration and apoptosis [652]. Here 
the effects of a specific βARK inhibitor, Methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate (β-ARK-1) 
were explored, figure 5.21. 
 
THP-1, β-ARK-1 2 μM Jurkat β-ARK-1 1 μM β-ARK-1 2 μM Control 
   
 
A B C D 
 
Figure 5.21: Chemotaxis assays following pre-treatment with β-ARK-1 or control (DMSO). (A) 
Chemotaxis of THP-1 to 1 nM CCL3. (B) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01. (C and D) 
Filament actin stains. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of CHO.CCR5 
following pre-treatment with 2 μM β-ARK-1 (1 hr, 37°C). Imaged UV inverted microscopy (Leica 
DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm).  
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β-ARK-1 highly significantly inhibited chemotaxis of THP-1 to CCL3 and Jurkat to CXCL12 and had 
little effect on actin polymerization in CHO.CCR5, figure 5.21. The IC50 of β-ARK-1 is reported as 
126 µM [653], however this figure was derived from a βARK activation assay not a MTS or MTT 
toxicity assay. MTS assay results were deceptive with this highly coloured chromophore 
compound as they indicated inhibition of metabolism at low concentrations (~6 μM) but not at 
high concentrations (190 μM), figure 5.22A. Therefore manual toxicity assays were undertaken, 
over 24 and 48 hours showed above ~3 μM produced inhibition of proliferation and at higher 
concentrations β-ARK-1 produced cell death in Jurkat whereas in THP-1 cells toxicity was relatively 
consistent across all β-ARK-1 concentrations, figure 5.22B-E 
                                                              A                Jurkat, MTS 
 
 
B 
Jurkat, Toxicity after 24 hours exposure 
                 
             C 
Jurkat, Toxicity after 48 hours exposure 
  
 
THP-1, Toxicity after 24 hours exposure THP-1, Toxicity after 48 hours exposure 
D  E  
 
Figure 5.22: Cytotoxicity assays for β-ARK-1. (A) MTS assays were over 24 hours in Jurkat Basal 
absorbance occurs in presence of medium after MTS treatment in the absence of cells. Means ± 
SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, **=p<0.01. (B-E) 
Manual cytotoxicity assays, tryptan blue staining allowed live cell counts after 24 or 48 hours of β-
ARK-1 exposure (B and C n=2, D and E n=1). 
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Chemotaxis and toxicity assays indicate Jurkat are more sensitive to β-ARK-1 inhibition of GRK2 
than THP-1. This may relate to Pi3K being constitutively active in Jurkat [654] and important for 
Jurkat chemotaxis [565], as Pi3K signalling can trigger nuclear location of Mdm2, which then 
impedes Mdm2 E3-ubiquitin ligase-mediated GRK2 degradation [655].  
5.2.9.2: Ipyrimidine 
Ipyrimidine (4-Amino-5-ethoxymethyl-2-methylpyrimidine) is a relatively new small molecule 
inhibitor stated to target GRKs, but which GRK/s are not specified, and to-date there have been 
no publications detailing use of this inhibitor. Exploration of Ipyrimidine’s effects showed it to 
significantly inhibit chemotaxis in THP-1 and Jurkat, figure 5.23.  
THP-1 THP-1 Jurkat 
A  B  C  
Figure 5.23: Chemotaxis assays following pre-treatment with 5μM Ipyrimidine or control (DMSO). 
(A) Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) Jurkat 
chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, **=p<0.01. 
 
MTS assays using concentration up to 10 μM Ipyrimidine showed no evidence of significant cell 
toxicity in THP-1 over 7 hours, but over 24 hours in MCF7 cells very significant inhibition of cell 
metabolism was observed even at 5 μM, figure 5.24. The possibility that Ipyrimidine has off-target 
effects still needs exploring as another pyrimidine structure, 4-amine-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyrimidine, reportedly inhibits Src kinase activity [553], and both structures 
may be able to bind similar protein sites, as both contain a central pyrimidine, with an 
electronegative group on one side and aliphatic group on other, figure 5.25. Although as Src 
purportedly phosphorylates and activates GRK [553] the end result may be the same. 
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A                          THP-1 B                    MCF7 
 
 
Figure 5.24: Cytotoxicity assays for Ipyrimidine. MTS assays were over 7 hours in (A) THP-1 and 
over 24 hours in (B) MCF7 cells. Basal absorbance occurs in presence of medium after MTS 
treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
 
A  B  
Figure 5.25: The structures of (A) 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine 
and (B) 4-Amino-5-ethoxymethyl-2-methylpyrimidine (Ipyrimidine). 
Western blots revealed that in THP-1 Ipyrimidine increased basal cofilin phosphorylation, and 
modestly reduced CXCL12-induced, but had little effect on CCL3-induced cofilin phosphorylation, 
figure 5.26. 
 
 
 
 
Figure 5.26: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with 10 μM Ipyrimidine (IPY) (37°C, 30 
mins) in presence and absence of CXCL12 or CCL3 (5 nM, 15 mins before lysis). β-actin loading 
control. 
Ipyrimidine inhibition of GRKs may partly block the chemokine stimulation triggering cofilin 
phosphorylation. Phalloidin actin stains in CHO.CCR5 cells indicated Ipyrimidine treatment at 10 
μM may reduce actin filament polymerisation, figure 5.27, possibly through modification of cofilin 
phosphorylation which would also explain the inhibition of chemotaxis, figure 5.23. 
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A            Control B         Ipyrimidine 
  
Figure 5.27: Filament actin stain. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with (A) DMSO (B) 10 μM Ipyrimidine (1 hr, 37°C). Imaged UV 
inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
5.2.10: β-arrestins 
Downstream of CXCR4 β-arrestin mediates receptor trafficking and GRK signalling. β-arrestin may 
also play a role in CXCR7 activation of ERK 1/2 resulting in increasing cancer cell adhesion and 
proliferation [113, 656, 657]. GPCR overstimulation may cause cytotoxicity; β-arrestin can act to 
desensitize receptors preventing G-protein-receptor association over the short term, and over a 
longer term receptors can be internalised and degraded [658].  
β-arrestins may sequester RhoGEFs and RhoA in the cytosol producing compartment-specific 
regulation inhibiting spatial and temporal activities critical for cell migration [659]. Β-arrestin-1 
aka Arrestin-2, and β-arrestin-2 aka Arrestin-3, are implicated in cancer and cell migration. Both 
arrestins are expressed in haematopoietic cells, and may modulate the Wnt/β-catenin signalling 
pathway in stem cell maintenance of leukaemia [660]. Arrestin-2 in conjunction with Gαq/II 
influences RhoA-triggered stress-fibre formation and so actin remodelling [661], and also some 
cancer derived cell-lines show raised Arrestin-2 expression [662]. Arrestin-2 may regulate Rho 
GTPases through  RhoGAPs [663] and RhoGEFs [664]. Active Rac reportedly increases cofilin 
phosphorylation, and depletion of Arrestin-2 is reported to cause reduced directional migration 
and cofilin phosphorylation in transfected HEK cells [665]. In leukocytes β-arrestins scaffold cofilin 
with phosphatases at membrane protrusions controlling location of actin filament severing [626]. 
 
5.2.10.1: Immunofluorescence demonstrates the presence of β-arrestins in cell-lines 
The presence of arrestins in cell-lines was demonstrated using immunofluorescent staining and 
UV microscopy, figure 5.28. Jurkat and undifferentiated THP-1 also express Arrestin-2, figures 5.2 
and 5.11. 
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Figure 5.28: Arrestin immunofluorescent staining. (A) THP-1, pre-treatment 25 nM PMA or (B) 
MCF7, grown on glass for 24 hours, fixed (4% paraformaldehyde), incubated with anti-arrestin-2 
then probed with FITC. Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 
500x Ex 490 nm, Em 520 nm).  
  
5.2.10.2: β-arrestin transfection in CHO.CCR5 
The immunofluorescent staining showed the cell-lines expressed arrestin-2. Plasmids, carrying 
GFP-tagged Arrestin-2, Arrestin-3 or mutant Arrestin-2, were transfected into cells. These caused 
over- or in the case of the mutant dominant negative expression of arrestin, and so allowed the 
influence chemokines on the arrestin subtypes to be visualised and explored. The mutant 
arrestin-2 (β-arrestin-1-V53D) has a valine substituted for an aspartic acid. It is understood to 
interact normally with GPCR but then fail to facilitate sequestration to endocytic pathways so the 
mutant inhibits normal β-arrestin binding, uncoupling the receptor, and mediating receptor 
desensitisation, sequestration and subsequent recycling and re-sensitisation [494]. The effect of 
CCL3 on arrestin-transfected CHO.CCR5 was explored first, figure 5.29.  
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Figure 5.29: CHO.CCR5 were transfected with (A and B) Arrestin-2 eGFP or (C and D) mutant 
Arrestin-2 eGFP plasmids, grown on glass coverslips (24 hrs, 37°C, 5% CO2), (B and D) treated with 
CCL3 (10 nM, 15 mins, 37°C), fixed (4% paraformaldehyde) then imaged UV inverted microscopy 
(Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
Arrestin-2 eGFP plasmids clearly respond to CCL3 whereas mutant Arrestin-2 eGFP plasmids 
accumulate in the CHO’s nucleus, and transfects’ appearance is not altered in response to CCL3 
treatment. 
 
5.2.10.3: β-arrestin transfections in MCF7, THP-1 and Jurkat 
Similar responses, redistribution into aggregates are seen in MCF7 cells transfected with the 
Arrestin-2 eGFP plasmids then treated with CXCL12 or CCL3 (arrowed), figure 5.30, whereas after 
transfection with Arrestin-3 eGFP plasmids dense areas were apparent both before and after 
chemokine addition (arrowed), figure 5.31. 
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Figure 5.30: MCF7 were transfected with (A) eGFP control plasmids or (B, C and D) Arrestin-2 
eGFP plasmids, grown on glass coverslips (24 hrs, 37°C, 5% CO2), (C and D) treated with CCL3 or 
CXCL12 (10 nM, 15 mins, 37°C), fixed (4% paraformaldehyde), then imaged UV inverted 
microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
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Figure 5.31: MCF7 were transfected with (A and B) Arrestin-3 eGFP plasmids grown on glass 
coverslips (24 hrs, 37°C, 5% CO2), (B) treated with CXCL12 (10 nM, 15 mins, 37°C), fixed (4% 
paraformaldehyde) then imaged UV inverted microscopy (Leica DMII Fluorescence microscope 
500x Ex 490 nm, Em 520 nm). 
In Jurkat which express CXCR4, chemotaxis of cells transfected with mutant or active Arrestin-2 
eGFP plasmids suggests overexpression of Arrestin-2 may very modestly positively modify 
migration towards CXCL12 compared to eGFP control plasmids, figure 5.33A. In THP-1 
transfections with Arrestin-3 plasmids produced an increased migration towards both CCL3 and 
CXCL12, whereas Arrestin-2 plasmids only increased migration towards CXCL12, however both are 
compared to mutant Arrestin-2 plasmid transfection which may reduce migration, figures 5.33B 
and C. In MCF7 cells transfection with Arrestin-2 again modestly significantly increases 
chemokinesis in the presence of CCL3. Whereas Arrestin-3 and mutant Arrestin-2 plasmid 
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transfection did not increase wound-healing in response to CCL3 or CXCL12. What is not known is 
if eGFP plasmids used as control aid or impede wound-healing, figure 5.34. Overall response to 
overexpression of β-arrestins by plasmid transfection demonstrated both cell type and chemokine 
specific responses. Before chemotaxis experiments transfection efficiency was checked in Jurkat 
and THP-1 cells using UV imaging, figure 5.32. 
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Figure 5.32: Transfection efficiency was established using UV inverted microscopy (Leica DMII 
Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
 
A                      Jurkat B                     THP-1 C                    THP-1 
    
Figure 5.33: Chemotaxis assays 24 hours after transfection with arrestin-eGFP plasmids. (A) 
Chemotaxis of Jurkat cells transfected with Arrestin-2 eGFP or Arrestin-3 eGFP plasmids to 
CXCL12. (B) THP-1 cells transfected with Arrestin-2 or -3 eGFP plasmids to CCL3 and (C) to CXCL12. 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01. 
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Figure 5.34: MCF7 wound-healing assays (A) supported by 10 nM CCL3 or CXCL12 undertaken 24 
hours after transfection with eGFP (control), Mutant Arrestin eGFP, Arrestin-2 eGFP or Arrestin-3 
eGFP plasmids. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3, *=p<0.05. (B and C) 
wound-healing images UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 
nm, Em 520 nm).  
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5.2.11: Focal adhesion kinases play a role in chemokine chemotaxis  
The family of Focal adhesion kinases including FAK and Proline rich tyrosine kinase-2 (PYK2), a 
homologous kinase of FAK, play an important role in malignant cell chemotaxis and in cell cycle 
progression. FAK is often upregulated in human malignancies, and potent, reversible, ATP-
competitive FAK and PYK2 inhibitor PF562271 has undergone phase II trials in human pancreatic, 
head and neck, and prostate cancers, all solid tumours. Solid tumours usually consist of healthy 
stromal cells (cancer-associated fibroblasts) and cancer cells. Metastasis of the cancer cells, which 
can include malignant leukocytes, is to some extent controlled by adhesions between the healthy 
stromal cells [666]. T-cells also express both PYK2 and FAK which are involved in responses to 
chemokines [667]. When PYK2 and FAK are absent cells’ adhesion interaction with Intercellular 
Adhesion Molecule 1 (ICAM1) is defective and T-cell responses fall as T-cells’ activation by antigen 
presenting cells is disrupted. PF562271 is reported to inhibit T-cell proliferation [668]. MTS assays 
found some inhibition of metabolism in THP-1 but not Jurkat cells from PF562271, negative 
effects on actin filament with concentration of actin filament to cells periphery were also 
apparent, figure 5.35. 
A                   THP-1 B                    Jurkat C         Control D      PF562271 
 
 
 
 
  
Figure 5.35: Cytotoxicity assays for PF562271. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
*=p<0.05, ns=p>0.05. (C and D) Filament actin stains of CHO.CCR5 following PF562271 25 nM or 
control (1 hr, 37°C). Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue). Imaged UV 
inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
FAK phosphorylation on Tyr397 creates a Src binding site, the Src/FAK complex can then 
phosphorylate focal adhesion components that influence cell adhesion dynamics, initiate 
signalling cascades and contribute to scaffolding [668]. Here the effects of FAK inhibitor-2 (aka PF-
573228) and PF562271 which both inhibit FAK Tyr397 phosphorylation and so activation, were 
explored in THP-1 and Jurkat chemotaxis assays. PF562271 also inhibits ATP phosphorylation of 
PYK2 directly possibly explaining its increased potency, although PF562271 and PF-573228 are 
sulphonamides and have structural similarities, figures 5.36-5.38. 
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FAK inhibitor 2                                                                 
3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl) 
phenyl]methyl]amino]-5-(trifluoromethyl)-2-
pyrimidinyl]amino]-2(1H)-quinolinone 
PF562271  
N-methyl-N(3-((2-(2-oxo-2,3-dihydro-1H-indol-
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yl)amino)methyl)pyridine-2-yl)  
 
Figure 5.36 Structures of FAK Inhibitor-2 (PF-573228) and PF562271. 
 
Jurkat THP-1 THP-1 
   
Figure 5.37: Chemotaxis assays following pre-treatment with 10 μM FAK inhibitor-2 or control 
(DMSO). (A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-
1 chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, ns=p>0.05. 
Jurkat THP-1 THP-1 
A  B  C  
Figure 5.38: Chemotaxis assays following pre-treatment with 25 nM PF562271 or control (DMSO). 
(A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, ns=p>0.05.  
 
Both FAK inhibitors produced significant inhibition of CXCL12-induced chemotaxis in Jurkat and 
had no effect on CCL3-induced migration in THP-1, however PF562271 also inhibited CXCL12-
induced chemotaxis in THP-1 whereas FAK inhibitor 2 did not. PF562271 also slightly increased 
overall CXCL12-induced but not CCL3-triggered calcium flux, figures 5.39. 
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Figure 5.39: Fura2 Ca2+ assay in (A and B) Jurkat and (C) THP-1 following 25 nM PF562271 or 
control (DMSO). Data expressed as fluorescence ratio change (∆340/∆380 nm) i.e. peak 
fluorescence following (A and B) 10 nM CXCL12 and (C) 10 nM CCL3 addition minus basal 
fluorescence (prior to chemokine). (A and C) Means ± SEM, Student t-test, n≥3 independent 
experiments, **=p<0.01, ns=p>0.05. 
Inhibiting FAK allows PYK2 to increase Rho GTPase activation and macrophage motility, and cell 
survival via PYK2 regulation of p53 gene. Hence FAK-selective inhibitors may increase tyrosine 
phosphorylation by PYK2 [669], and inhibition of both proteins may be advantageous to hamper 
metastasis. FAK inhibition with PF562271 was found to inactivate (phosphorylate) cofilin in 
presence and absence of CXCL12 or CCL3, figure 5.40. 
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Figure 5.40: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with 25 nM PF562271 (37°C, 30 mins) in 
presence and absence of CXCL12 or CCL3 (5 nM, 15 mins before lysis). β-actin loading control. 
 
These results show in THP-1 and Jurkat that FAK/PYK2 inhibition inhibits chemotaxis, but 
specifically to CXCL12 not CCL3, and that in THP-1 FAK/PYK2 inhibition causes cofilin 
phosphorylation in the presence and absence of CXCL12 or CCL3.  
5.2.12: Rho Proteins 
Rho proteins are small GTPases of the Ras superfamily, including Rho A, B, C, D and E. Rho 
regulates actin stress fibres in cell-cell and cell-extracellular matrix environments. Cytoplasmic 
Rho switches between the active GTP-bound and inactive GDP-bound forms. Guanine nucleotide 
exchange factors (GEFs) activate Rho GTPase activating proteins, promoting GTP hydrolysis to 
GDP. Rho can also be maintained in its inactive form by nucleotide dissociation inhibitors. Rho 
targets Rho activated coiled-coil kinases (ROCKs). ROCK1 is a serine-threonine isomer, whose C-
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terminus and N-terminal kinase sandwich an alpha-helical coiled-coil domain that binds Rho. 
When Rho binds ROCK it activates ROCK which in turn then phosphorylates and so activates its 
substrates, one of which is LIMK. Rho is activated by many mediators including cytokines, and 
ROCK can also be activated by arachidonic acid [670-672], discussed in chapter seven.  
5.2.12.1: Rho activated coiled-coil kinase (ROCK) 
ROCK is found in a cell’s uropodium and lamellipodium. ROCK aids contractions of the uropodia 
and ROCK inhibition impedes migration by removing the myosin light chain contractions 
stimulated by RhoA [673, 674]. ROCK co-locates with the microtubule organising centres in the 
uropodia. Depolymerizing microtubules e.g. with Nocodazole, upregulates RhoA activity and 
interferes with cell polarity. Antimitotic Nocodazole, which disrupts microtubules by binding to β-
tubulin and activates the JNK signalling pathway, was found to significantly inhibit chemotaxis of 
both THP-1 and Jurkat to CXCL12, but not THP-1 to CCL3, figure 5.41.  
Jurkat THP-1 THP-1 
A  B        C  
 
Figure 5.41: Chemotaxis assays following pre-treatment with 7.5 μM Nocodazole or control. (A) 
Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
Inhibitors of ROCK such as Y27632 are reported to inhibit uropodia retraction in monocytes [675]. 
Cofilin controls actin depolarisation; Rac and Rho activate ROCK and PAK kinases that 
phosphorylate LIMK which then phosphorylates and inactivates cofilin [676]. Reportedly ROCK can 
activate LIMK 2, by phosphorylating a LIMK2 ‘activation segment’ on residue threonine-505. 
LIMK2 can then phosphorylate cofilin. LIMK 1 activation may follow signalling through Rac1 and 
Pac1, so LIMK1 and 2 are modulated by different kinases regulated by Rho GTPases [677, 678].  
However, in malignant cells ROCK may be mutated. Shortened constitutively active ROCK may be 
able to activate both LIMK1 and LIMK2 whereas full-length un-mutated ROCK specifically 
phosphorylates LIMK2 but not LIMK1. This phosphorylation of LIMK2 by ROCK has been shown to 
be inhibited in COS-7 cells by 10 μM Y27632 [678], reportedly a highly selective inhibitor of ROCK.  
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Inhibition of ROCK activation, using Y27632 at 10 μM for 1 hour, inhibited cofilin phosphorylation 
in THP-1 cells both before and after treatment with CCL3, figures 5.42. 
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Figure 5.42:  Western blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with 10 μM Y27632 (37°C, 30 mins) in 
presence and absence of CCL3 (5 nM, 15 mins before lysis). Arrestin-2 loading control. 
Thus in THP-1 ROCK activity appears needed for cofilin to exist in a phosphorylated state. Y27632 
at concentrations between 1 and 5 μM dose dependently inhibited chemotaxis in Jurkat cells, and 
at 2.5 μM inhibited chemotaxis in THP-1. The observed effects on chemotaxis were not due to 
toxicity, figures 5.43 and 5.44. Previous reports state that ROCK1 inhibition of NIH313 cells over 
16 hours did not cause cofilin dephosphorylation [644], however results may be cell-type or time 
specific. ROCK phosphorylates LIMK, which phosphorylates cofilin; therefore inhibition of ROCK 
with Y27632 would be expected to prevent chemokines triggering cofilin phosphorylation.  
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Figure 5.43: Chemotaxis assays following pre-treatment with Y27632 or control. (A and B) 
Chemotaxis of Jurkat to 1 nM CXCL12. (C) Cytotoxicity assay for Y27632. MTS assays were over 7 
hours in Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the 
absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, ns=p>0.05. 
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Figure 5.44: Chemotaxis assays following pre-treatment with Y27632 2.5 μM or control. (A) 
Chemotaxis of THP-1 to 1 nM CCL3. (B) Chemotaxis of THP-1 to 1 nM CXCL12 (C) Cytotoxicity 
assay for Y27632. MTS assays were over 7 hours in THP-1. Basal absorbance occurs in presence of 
medium after MTS treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001, ns=p>0.05. 
 
5.2.13: Mitogen extracellular signal regulated kinase (MAPKK) (MEK) and Src 
In untransformed T-lymphocytes both Pi3K and MEK are reportedly required to allow cofilin 
dephosphorylation [647]. This invited exploration to see if MEK was involved in CCL3 or CXCL12 
signalling that modifies the cofilin phosphorylation state in THP-1 cells. Incubation with MEK 
inhibitor α-[Amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl) benzeneacetonitrile 
(SL327) even at a low concentration, 2 μM, increased cofilin phosphorylation compared to 
control, more than 5 nM of CCL3 or CXCL12, figure 5.45. 
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Figure 5.45: A & B. Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals 
cofilin phosphorylation levels in THP-1 following pre-treatment with 2 μM SL327 (37°C, 30 mins) 
in presence and absence of CXCL12 or CCL3 (5 nM, 15 mins before lysis). β-actin or Arrestin-2 
loading controls. 
 
The results suggest MEK inhibition alone can influence cofilin phosphorylation in THP-1. MTS 
assays were used to check SL327 for toxicity in THP-1 and Jurkat, then the effects of MEK 
inhibition with SL327 on chemotaxis in THP-1 and Jurkat were explored, MTS assays found no 
evidence of SL327 inhibiting cell metabolism in THP-1 and Jurkat but inhibition of MEK very 
significantly inhibited chemotaxis to CXCL12 and CCL3, figures 5.46 and 5.47. 
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Figure 5.46: Cytotoxicity assays for SL327. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns 
=p>0.05. 
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Figure 5.47: Chemotaxis assays following pre-treatment with SL327 or control. (A) Chemotaxis of 
THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) Jurkat chemotaxis to 1 nM 
CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001. 
The above investigations show CXCL12, CCL3 and some other chemokines can increase cofilin 
phosphorylation in monocyte model THP-1, and also that phosphorylation levels can be modified 
by some small molecule inhibitors. CXCL12 triggered cofilin phosphorylation can be altered by 
Pi3K, ROCK and MEK inhibition. ROCK has been shown to phosphorylate and activate LIMK [633]. 
These results support the premise that Gi-induced activation of MEK, Pi3K and ROCK signalling 
pathways are involved in the control of cofilin activity. Results with Gallein, βγ G-protein inhibitor, 
and GRK inhibitor Ipyrimidine suggest these upstream pathway proteins are also involved. Src 
activation can cause loss of actin stress fibres, focal contacts and loss of cofilin phosphorylation 
these changes can support metastasis [679]. Inhibiting Src with Bosutinib 5 μM in THP-1 only 
slightly increased cofilin phosphorylation responses to CXCL12, figure 5.48. Whereas inhibiting 
MEK was found to consistently increase cofilin phosphorylation, possibly because cofilin 
dephosphorylation may require both active MEK and Pi3K. 
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Figure 5.48: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with 5 μM Bosutinib (37°C, 30 mins) in 
presence and absence of CXCL12 (5 nM, 15 mins before lysis). Arrestin-2 loading control. 
These responses appear cell type specific as in Jurkat cells baseline phosphocofilin levels are not 
significantly increased in the presence of CXCL12 except in the presence of some inhibitors, for 
example ROCK inhibitor Y27632 or PYK2/FAK inhibitor PF562271, where reduced baseline 
phosphorylation is increased by CXCL12, figure 5.49. 
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Figure 5.49: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in Jurkat following pre-treatment with Bosutinib 5 μM, Y27632 5 μM, or 
PF562291 25 nM (37°C, 30 mins) in presence and absence of CXCL12 (5 nM, 15 mins before lysis). 
β-actin loading control. 
 
5.3: Discussion 
This chapter examined if the signal transduction resulting in cofilin activation following CXCL12 
stimulation of CXCR4, or CCL3, variant 2-70 D26A [680], stimulation of CCR1 or CCR5 receptors 
involved βγ, Pi3K, GRK, MEK, Src or ROCK1 or β-arrestin, all proteins previously connected with 
leading edge signalling and/or chemotaxis. To achieve this β-arrestin plasmid transfection and the 
various small molecule inhibitors shown with targets in figure 5.50 were employed. 
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Figure 5.50: Major purported signalling pathways that modulate cofilin phosphorylation with 
inhibitors and protein targets. 
5.3.1: Cofilin phosphorylation and chemokinesis 
The above results indicate a relationship between cofilin Ser3 phosphorylation and chemokine 
stimulation of the cell-lines.  Cofilin Ser3 dephosphorylation has been shown to occur seconds 
after chemotactic receptor activation in leukocytes [372, 681] and in cytokine receptor 
stimulation re-phosphorylation can occur in 3-5 minutes [371]. Several investigations show active 
dephosphorylated cofilin translocates in leukocytes to their leading edge, supporting actin 
polymerization in lamellipodia. Cofilin inhibition using siRNA can inhibit formation of free actin 
barbed ends and monomers. In Jurkat actin dynamics at the leading edge appear heavily 
influenced by cofilin controlled by SSH and LIMK [370, 682, 683]. Here siRNA knockdown of cofilin 
was found to inhibit MCF7 chemokinesis supported by CCL3 and CXCL12, figure 5.3.  
Reduced Jurkat migration and lamellipodium formation has been shown to follow inhibition of 
LIMK cofilin phosphorylation and inhibition of SSH resulted in several lamellipodia formation and 
loss of directional migration; hence cofilin activity appears essential to maintain a single 
directional leading edge, i.e. to support chemotaxis. In leukocytes and mammary tumour cells 
investigations show cofilin is an essential team player along with ARP2/3 complex and Formins 
(Rho GTPase effector proteins supporting actin polymerization at barbed ends) to enable actin 
polymerization and facilitate chemotaxis [370, 372, 684]. Here a clear relationship between 
chemokine stimulation in THP-1 and cofilin phosphorylation was demonstrated, figure 5.4, and 
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the possibility that the degree of phosphorylation relates to the ability of a chemokine to induce 
chemotaxis in THP-1 was introduced, figure 5.5. 
 
5.3.2: Additive or inhibitory effects can occur when chemotactic chemokines are used in tandem 
Jurkat chemotaxis to CXCL12 increases steadily with concentrations from 0.1 nM to 1 nM but then 
plateaus, figure 5.6, whereas in THP-1 chemotaxis decreases at concentrations above and below 
1-2.5 nM, figure 5.5, both for CCL3 and CXCL12. CXCL12 has previously been shown to synergise 
with CCL3, increasing chemotaxis in dendritic cells possibly by augmenting CCL3-triggered Akt or 
ERK 1/2 phosphorylation [685]. Results here in THP-1 show CCL3 and CXCL12 produced additive 
effects on chemotaxis, figure 5.7. CXCL11 is an agonist for CXCR3, CCL11 also binds CXCR3 acting 
as an antagonist. CXCR3 may act as a decoy receptor for CCL11 mopping up excess chemokine. 
CCL11 is an agonist at CCR3, and CXCL11 acts as antagonist at CCR3. CCL11 and CXCL11 may share 
overlapping binding sites on CCR3 extracellular loops; this interplay may be essential for 
homeostasis fine tuning chemotactic responses [686]. The results here, figures 5.8-5.9, suggest 
CXCL11 acts as an antagonist at CXCR4 with respect to calcium release in MCF7 and chemotaxis in 
THP-1 and Jurkat. 
 
5.3.3: Pi3K, Phosphatidylinositol 3,4,5 triphosphate (PIP3), Gβγ signalling and GEFs 
Pi3K is a key signalling protein mediating cell metabolism, growth, apoptosis as well as influencing 
actin-induced polarisation and changes in cytoskeleton arrangement [643]. Pi3K phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) aka PIP2 producing phosphatidylinositol 3,4,5-
triphosphate (PI(3,4,5)P3) aka PIP3. Guanine nucleotide exchange factors (GEFs) are also involved; 
GEFs activate small GTPases by catalysing GTPase-GDP to GTPase-GTP, figure 5.51. 
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Figure 5.51: P13K and phosphatidylinositol-3,4,5-triphosphate signalling [638, 643, 646, 687, 688]. 
 
In immune cells the key controllers of levels of PIP3 include Pi3K and the phosphatases, 
Phosphatase and Tensin homolog (PTEN), which is a tumour suppressor, and SH2-containing 
inositol 5-phosphatase (SHIP1). PTEN is usually constantly active, but is often deleted or mutated 
in cancers [687], whereas SHIP1 is activated by cell stimulation. In malignant cells PTEN may 
suppress cell proliferation whereas SHIP1 may reduce cell migration and activation. PTEN can 
downregulate Pi3K, Akt activity and SHIP1, by degrading PIP3 producing PIP2. Genes coding 
Pi3K/Akt pathway proteins can be mutated in cancers, including in breast malignancies and 
lymphomas, producing constitutively active Pi3K, this appears to be the case with Jurkat [646, 
688]. Also Jurkat are reported deficient in SHIP1 and PTEN, but express the substrate for both 
these phosphatases, PIP3, in high levels [688].  Such differences in phosphatase expression levels 
may be one reason why Pi3K inhibition, with Pi3K small molecule inhibitors AS605240 and 
LY294002, produced very significant inhibition on CXCL12 chemotaxis in Jurkat but have a lesser 
effect in THP-1 especially on CCL3-induced chemotaxis, figures 5.12-5.13. This may be because 
CXCL12- but not CCL3-triggered signalling is through Gβγ [638]. This was demonstrated here using 
the small molecule inhibitor Gallein which interrupts the interaction of Gβγ with Pi3K, figure 5.10.  
Although small molecule inhibitors suggest signalling through Pi3K may be more relevant for 
CXCL12 than CCL3 stimulation of chemotaxis. Cofilin phosphorylation and siRNA knockdown in 
cell-lines suggested Pi3K is just as important in CCL3 chemokinesis, figures 5.15-5.19. Indeed in 
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THP-1 cofilin phosphorylation was slightly increased in the presence of Gallein, figure 5.11, 
possibly suggesting constitutively active signalling in THP-1 through βγ, but the expected 
chemokine induced increased cofilin phosphorylation from CCL3 and CCL2, seen in figure 5.4, was 
reduced by pre-treatment with Gallein supporting the findings of the siRNA knockdown.   
Cofilin phosphorylation was explored in THP-1 in the presence and absence of Pi3K inhibitors 
LY294002 and AS605240 and different concentrations of CXCL12 or CCL3. Phosphorylation of 
cofilin was increased with both inhibitors compared to control at low levels of chemokine (0.5 and 
1 nM), however low levels of chemokine alone were insufficient alone to cause cofilin 
phosphorylation to controls, figures 5.18A and 5.18B. Inhibition of Pi3K may reduce the 
concentration of chemokine necessary to cause cofilin phosphorylation as Pi3K/Akt signalling 
inhibits LIMK, which phosphorylates cofilin. Treatment with LY294002 or AS605240, followed by 
CCL3 or CXCL12 at 5 nM produced the usual phosphorylation in controls, which was increased 
further by AS605240 but reduced by LY294002 figure 5.18C. Hence like the siRNA knockdown 
these results suggest Pi3K signalling may be equally important in both CCL3 and CXCL12 signalling 
in THP-1 cells, but may also be Pi3K subtype specific. 
 
5.3.4: Cofilin links to mitogenic signalling networks 
The Ras-Raf-MEK-ERK signalling pathway can carry the signal from a chemokine stimulation of a 
GPCR to the cell’s nucleus. MEK is a tyrosine and threonine kinase also known as MAPKK. CXCL12 
stimulation of Gαi through CXCR4 is thought to trigger Ras signals to MEK. LIMK1 downstream of 
MEK is then inhibited and cofilin dephosphorylation (activation) occurs [689]. Here inhibition of 
MEK with SL327 strongly inhibited chemotaxis and produced cofilin phosphorylation in presence 
and absence of CCL3 and CXCL12, figures 5.45 and 5.47.  Inhibition of MEK may only inhibit 
leukocyte migration through three-dimensional (3D) not two-dimensional (2D) environments, 
possibly as on 2D surfaces leukocyte migration is based on the cells “walking” i.e. after extending 
a leading edge, the “back” of the cell then arches as the trailing edge or uropodia moves forward, 
resulting in movement similar to that seen in soft-bodied insect larva. Leukocytes migrate as 
single cells through many different tissues; their mode of motility has considerable plasticity 
depending on their extracellular environment, for example movement along 2D endothelial 
linings compared to through 3D interstitial spaces. Leukocytes can switch motility mode rapidly 
[690, 691]. Such 2D movement may not need actin tread-milling. Actin polymerization is needed 
for pseudopodia formation at the leading edge; actin’s barbed ends push the cell membrane 
forward and cell adhesion between linker proteins Shootin1 and LI-CAM, and also between F-actin 
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and N-Cadherin, allow grip between cell and surface [691]. If these contracting cycles are 
inhibited, but cofilin is not, cells have been shown to produce lamellipodia to migrate. The lower 
the level of G-actin the more cells may depend on cofilin to move, thus MEK and active cofilin 
appear important in 3D migration, and cells can adapt their migratory mode to suit their external 
environment [633]. Neuro Probe ChemoTx® plates as used here to explore chemotactic responses 
may represent a useful model of a 3D system as the cells need to squeeze through the 5 uM 
pores. This is a similar situation to T-cells protrusions pushing through interstitial meshes and in 
both cases movement is towards a chemokine attractant. 
 
5.3.5: GRKs and β-arrestin in chemokinesis 
GRK2 is a serine threonine kinase with three key domains, a Regulator of G-protein Signalling 
Homology (RH) domain, a Central Catalytic domain and a lipid-binding Pleckstrin Homology (PH). 
GRK2 can promote β-arrestin binding agonist-activated GPCRs halting the receptors’ activation of 
G-proteins [17, 692] but also interact with many cytosolic and nuclear oncogenic signalling 
proteins such as Mdm2, MEK, AKT and RhoA, [693], for example GRK2 has been shown to 
inactivate p38 MAPK [694]. GRK2’s N-terminal and PH domains interact with Gβ/Gγ subunits [695, 
696], and its C-terminal interacts with lipids or membrane proteins [652]. GRKs are also involved 
in G-protein independent signalling, such as GRK2/β-arrestin signalling producing ERK activation 
[697]. Inhibition of ERK inhibits chemotaxis [698] which may explain why inhibiting GRK2 inhibitor 
β-ARK-1 and Ipyrimidine both strongly inhibited CCL3 and CXCL12 chemotaxis, figures 5.21 and 
5.23.  
Different chemokines binding the same chemokine receptor can activate different GRKs 
promoting biased signalling, through either G-proteins or GRK/β-arrestin [699], as different 
chemokines produce specific conformational changes that selectively recruit specific GRK 
subtype/s [700]. Different GRKs then phosphorylate differing serine/threonine residues on the 
GPCR. The phosphorylation pattern selects the response, either receptor desensitisation or 
signalling [701]. GRKs also interact directly with non-GPCR proteins [702] including cytosolic and 
nuclear proteins involved with cell migration [703]; for example GRK2 interacts with MEK to 
negatively regulate ERK activated by CCL2 [704]. ERK triggered phosphorylation of GRK2 allows 
GRK2 location in mitochondria [705] and interaction with mitochondrial chaperone HSP90 [706] 
where it mediates the effects of cellular Ca2+ fluxes on mitochondria [707]. GRK2 also 
phosphorylates tubulin [708] and is itself phosphorylated by CDK-2 and can affect cell cycle 
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progression [709]. This may explain the cytotoxicity issues observed with both GRK inhibitors, 
figures 5.22 and 5.24.  
 
5.3.6: β-arrestin mediation of signalling leading to chemotaxis and chemokinesis 
Agonist phosphorylation of GPCRs by GRKs reportedly triggers arrestin binding which sterically 
discourages G-protein interactions with GPCR, and thus uncouples G-proteins from the GPCR and 
terminates signalling [710]. Arrestin-2 and Arrestin-3 may facilitate GPCR internalisation through 
clathrin-mediated endocytosis, a pathway that can lead to receptors recycling back to the 
membrane rather than degradation [711-713]. However arrestin is reported to associate with E3 
ubiquitin ligase which favours ubiquitination and degradation [714]; such association has been 
demonstrated for CXCR4 [715, 716]. Plasmid overexpression of Arrestin-2 and Arrestin-3 has been 
used by others to explore any preferences for receptors for arrestin-2 or -3 in this process, which 
purportedly involves β-arrestin binding to clathrin and AP2 proteins as well as other components 
of clathrin coated pits. Many early studies have shown β-arrestins can move with associated GPCR 
into early endosomes.  Arrestin also hinders phosphatase access to GPCRs phosphorylated C-
termini, and hence influences receptor re-sensitisation [493, 717].   
β-arrestins facilitate GPCR signalling via Src, ERK and p38 MAPK pathways [718]. MAPK signalling 
purportedly supports metastasis [719]. GPCRs can be classified as class A and B receptors, CCR5 is 
a class A and CXCR4 is a class B. Class A GPCRs preferentially associate with Arrestin-3 over 
Arrestin-2, whereas class B receptors show no preference [710, 720, 721]. Results here in THP-1 
and Jurkat support these factors; showing Arrestin-3 may be more relevant for CCL3-induced 
chemotaxis, likely to be mediated by CCR5 figure 5.33C, whereas both Arrestin-2 and -3 are 
relevant for CXCL12-induced chemotaxis likely to be mediated by CXCR4, figures 5.33A and 5.33B. 
However in MCF7 cells only Arrestin-2 appears to support CXCL12 wound-healing, transfection 
with Arrestin-3 or Arrestin-mutant plasmids may even impeded migration, figure 5.34, suggesting 
cell-type specificity. For CCR5-arrestin interactions to occur certain phosphorylation sites must be 
available [722].  CCR5 may only loosely bind β-arrestins whereas CXCR4 may bind more tightly 
[720]. This may modulate receptor fate [723], potentially giving CCR5 a better chance of recycling 
and CXCR4 of degradation. However over-expression of Arrestin-2 may be a negative biomarker in 
lung carcinoma [724]. 
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5.3.7: ROCK and MEK are key mediators of cofilin phosphorylation 
Ras proteins are a family of small GTPases. Signalling from Ras proteins is involved in cell 
differentiation, survival and growth, hence over-expression of Ras is common in cancer; the three 
Ras proteins in mammals N-Ras, H-Ras and K-Ras are all powerful oncogenes.  Ras can signal to 
Raf, and to Pi3K. Src can also signal to Raf and Pi3K which can also be stimulated by G protein-
coupled receptor kinase (GRK). MEK can in turn inhibit Rho activated kinase (ROCK), all these 
signalling cascades may be involve with cofilin phosphorylation [725]. ROCK inhibitor Y27632 was 
found to inhibit both chemotaxis and chemokine induced cofilin phosphorylation, figures 5.42-
5.43. Hence when MEK is inhibited cofilin is phosphorylated, figure 5.45, and when ROCK is 
inhibited cofilin phosphorylation is prevented, figure 5.42, suggesting both ROCK and MEK are key 
in chemokine induced cofilin phosphorylation. Further complexity is added to the picture by many 
other signalling pathways including those influencing the activity of LIMK1 and LIMK2. 
 
5.3.8: FAK inhibition may support haematological malignancies 
FAK inhibition produced cofilin phosphorylation and inhibited chemotaxis. Others have noted that 
FAK inhibition can inhibit chemotaxis but support invadopodia formation in melanoma [726]. 
Invadopodia are actin-based protrusions that would require cofilin phosphorylation and f-actin 
formation. Hence although FAK/PYK2 inhibition with PF562271 was found to inhibit CXCL12-
induced directional migration, figure 5.38, it produces cofilin phosphorylation, figure 5.40, 
suggesting it potentially could support tissue invasion by haematological cancers in a similar way 
to that observed for melanoma. 
 
5.4: Conclusions  
Although Jurkat were only found to migrate to CXCL12; CCL2, CCL3, CCL4, CCL5, CCL23, CXCL9, 
CXCL11 and CXCL12 were shown to induce chemotaxis in THP-1. A Gaussian distribution 
chemokine concentration response curve was seen with THP-1 to CCL3 and CXCL12, and Jurkat to 
CXCL12. In THP-1 CCL3 with CXCL12 were found together to produce additive chemotactic 
responses whereas CCL2 with CXCL11 did not; suggesting that chemokine chemotactic responses 
may be modulated by chemokine co-operation or antagonism. Western blot and 
immunofluorescence confirmed cofilin expression in THP-1, MCF7 and Jurkat. Chemokines CCL3, 
CCL2 and CXCL12 were shown to increase cofilin phosphorylation in THP-1, and siRNA cofilin 
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knockdown confirmed cofilin is important in MCF7 chemokinesis. Results in THP-1 support the 
conclusion that if a chemokine produces cofilin phosphorylation it may also be chemotactic. Also 
that cofilin phosphorylation can indicate the presence of a chemokines cognate receptor within a 
cell-line. 
 
Immunofluorescence and Western Blots demonstrated Arrestin-2’s presence in THP-1 
macrophages Jurkat and MCF7. Arrestin-2 over-expression, compared to eGFP control, increased 
migration of Jurkat. Arrestin-2 and Arrestin-3 plasmids were seen to locate to cell cytoplasm, and 
possibly associate with organelles; whereas Mutant-arrestin plasmids may target cell nuclei, 
possibly causing cytotoxicity. Chemokine addition produced plasmid aggregation possibly 
indicating Arrestin-2 and 3 plasmids associate with receptors on endocytosis. In THP-1 Arrestin-3, 
but not Arrestin-2, plasmid transfection increased chemotaxis to CCL3, and both Arrestin-2 and 
Arrestin-3 plasmids increased chemotaxis to CXCL12. However this was compared to dominant 
negative mutant plasmids which may themselves reduce migration. eGFP plasmid controls would 
have been better. In Jurkat Arrestin-2 plasmid transfection, compared to eGFP plasmid controls, 
modestly increased chemotaxis to CXCL12. In MCF7 only Arrestin-2, not Arrestin-3, plasmid 
transfection increased chemokinesis in presence of CCL3. Overall arrestin results suggest cell and 
chemokine biases in Arrestin-2 and Arrestin-3 activity.  
 
GRK inhibition inhibited chemotaxis to both CXCL12 and CCL3. GRK2 inhibitor, β-ARK-1, is a 
chromophore that is toxic to Jurkat and THP-1 at higher concentrations over longer timescales, 
whereas GRK inhibitor Ipyrimidine lacks toxicity, but still inhibits chemotaxis to CCL3 and CXCL12 
and cofilin phosphorylation, suggesting GRKs play a role in cofilin supported chemokinesis. 
 
siRNA knockdown and small molecule inhibition confirmed the importance of Pi3K to CXCL12 
migration in all cell-lines and to a lesser extent CCL3-induced chemokinesis in MCF7 and 
chemotaxis in THP-1. Indeed Pi3K inhibition in THP-1 and Jurkat may increase cofilin 
phosphorylation in presence and absence of CXCL12 or CCL3. FAK/PYK2 inhibition repressed 
chemotaxis to CXCL12 but not CCL3 in THP-1, and inhibited Jurkat chemotaxis to CXCL12. It also 
caused cofilin phosphorylation in THP-1 that was unaffected by CCL3 or CXCL12, and modulated 
CXCL12 but not CCL3 calcium flux. Overall suggesting FAK/PYK2 play a key role in CXCL12 signalling 
and cofilin activity.  
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ROCK co-locates with microtubule organising centres; Nocodazole, which depolymerizes 
microtubules, inhibits chemotaxis to CXCL12 but not CCL3; whereas ROCK inhibitor Y27632 
strongly inhibits chemotaxis to both chemokines as well as preventing cofilin phosphorylation in 
THP-1. MEK1/2 inhibitor SL327 has the opposite effect increasing cofilin phosphorylation, but still 
significantly inhibiting chemotaxis to CXCL12 and CCL3. Overall results suggested differential 
chemokine signalling through key cellular proteins such as Gβγ, Pi3K, FAK, MEK, Src and ROCK may 
modulate cofilin phosphorylation to influence chemotaxis. 
 
Having established above that phosphocofilin levels can be a useful readout tool in CXCL12 and 
CCL3 signalling, and that phosphocofilin levels can be modified by inhibiting proteins known to 
mediate CXCR4/CXCL12 pathways; next in chapter 6 cofilin phosphorylation along with 
chemotaxis assays were used to help to elucidate the somewhat controversial role of JAK2 and 
STAT3 proteins in CXCL12/CXCR4 signalling. 
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Chapter 6: JAK2 and STAT3 play role in chemokine-induced chemotaxis and cofilin 
phosphorylation 
 
6.1: Introduction 
CXCL12 binding CXCR4 can trigger Gαi signalling. This may involve signalling proteins termed 
‘JAKs’ phosphorylating firstly the CXCR4 receptors tyrosines and then JAKs phosphorylating 
‘STATs’ which are transcription factors which dimerize before translocating into the nucleus [323, 
727, 728]. JAK2 gene mutations are common in malignancies [324, 328]; JAK2 mutations can 
enhance oncogenic responses to CXCR4/CXCL12 signalling aiding cancer progression and 
metastasis; by, for example, facilitating Pi3K signalling supporting chemotaxis [328]. Here the 
effects of JAK2 and STAT3 inhibition, with small molecule inhibitors, on chemokine induced 
chemotaxis were examined along with STAT3 phosphorylation in the context of cofilin activation. 
Active Rho GTPases, including Rac1 may be important for STAT3 transcriptional activity [729-731]. 
Phosphorylation by LIMK inactivates cofilin. LIMK may also negatively regulate STAT3, through 
mediation of Myc expression [732], overall suggesting chemokine triggered phosphorylation of 
cofilin may correlate with STAT3 phosphorylation. This piece of research elucidates the effects of 
JAK2 and STAT3 inhibition on cofilin and STAT3 phosphorylation induced by chemokines and the 
effects of JAK2 and STAT3 inhibition on cAMP production mediated by Forskolin, figure 6.1. 
  
Figure 6.1: The effects of JAK signalling, through Rho GTPases, and Forskolin on cofilin 
phosphorylation. 
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Hypothesis: JAK2 and STAT3 signalling supports metastasis including through mediation of cofilin 
phosphorylation. 
Aim: To discover if JAK2 and STAT3 inhibition affects MCF7 chemokinesis or THP-1 chemotaxis to 
CCL2 or CXCL12, then explore if any effects observed relate to phosphocofilin or cAMP levels in 
cells. 
Objectives: 
(i)     Check small molecule inhibitors of JAK2 and STAT3 for cytotoxicity 
(ii)    Explore the effects of JAK2 and STAT3 inhibition on THP-1 chemotaxis to CXCL12 and CCL2. 
(iii)   Discover if inhibition of JAK2 or STAT3 modulates MCF7 chemokinesis supported by CCL2 or 
CXCL12 
(iv)   Investigate if JAK2 or STAT3 inhibition affects calcium dynamics in cell-lines 
(v)    Use Forskolin to explore the effects of increased cAMP levels in MCF7 chemokinesis and THP-
1 chemotaxis and cofilin phosphorylation 
(vi)   Examine the effects of JAK2 and STAT3 inhibition on cellular cAMP levels 
(vii)  Examine the effects of JAK2 and STAT3 inhibition on cofilin and STAT3 phosphorylation in 
THP-1 
 
6.2: Results   
Here the roles of JAK2 and STAT3 in chemokine induced chemotaxis or wound-healing, along with 
calcium responses in THP-1 or MCF7 are explored along with the involvement of JAK2 and STAT3 
in the temporally complex cofilin phosphorylation dynamics following CXCL12 stimulation; also 
possible links between cofilin and STAT3 phosphorylation are examined. Next the roles of 
Forskolin and PKA inhibitor H89HCl individually on chemokine-induced chemotaxis and wound-
healing are covered before using Forskolin as a tool in cAMP assays exploring the effects of JAK2 
and STAT3 mediation of cAMP responses to CCL2.  
Small molecule inhibitors employed here include JAK2 inhibitor II, Hexabromocyclohexane (HBC), 
which binds a pocket adjacent to JAK2’s activation loop preventing JAK2 autophosphorylation 
[733]; STAT3 inhibitor III, WP1066, an AG490 tyrphostin analog that inhibits the STAT3 pathway, 
and STAT3 inhibitor VIII, 5,15-Diphenylporphyrin (5,15-DPP), which inhibits STAT3 dimerization via 
STAT3 SH2 domain and prevents STAT3 nuclear translocation. Blocking STAT3 phosphorylation 
consequently inhibits STAT3 c-myc promotor binding, reducing cellular c-myc protein levels [734], 
figure 6.2. 
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Figure 6.2: JAK2/STAT3 signalling from 
CXCR4, and targets of inhibitors used. 
6.2.1: JAK2 and STAT3 inhibitors were examined for effects on cell metabolism and actin 
polymerisation 
MTS assays were used to establish inhibitor effects on cell metabolism in MCF7 and THP-1, figure 
6.3. 
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Figure 6.3: Cytotoxicity assays in THP-1 over 7 hours using a range of concentrations of (A) HBC, 
(B) 5,15 DPP and (C) WP1066 and in MCF7 over 26 hours using (D) HBC, (E) 5,15 DPP and (F) 
WP1066. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
ns=p>0.05. 
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No evidence of toxicity was seen from any of the inhibitors in THP-1 cells over 7 hours. In MCF7 
significant inhibition of metabolism occurred with WP1066, but at the concentration of 2 μM used 
in all assays here no toxicity was apparent.  
Next the effects of the JAK2 and STAT3 inhibitors on actin polymerisation, essential for cell 
migration was examined in MCF7 cells, figure 6.4. Some loss of filament actin and fine actin 
surface protrusions were apparent with STAT3 inhibitor 5,15-DPP. 
A          Control B       HBC 10 μM 
  
C    WP1066 2 μM D   5,15-DPP 10 μM 
  
Figure 6.4: Filament actin stains following JAK2 or STAT3 inhibition. Alexa-488 Phalloidin (green) 
and DAPI nuclear stains (blue) of MCF7, previously transfected with DsRed Mitochondrial 
Plasmids, following pre-treatment with (A) DMSO control (B)  10 μM μM HBC (1 hr, 37°C), (C) 2 
μM WP1066 (D) 10 μM 5,15-DPP. Imaged UV inverted microscopy (Leica DMII Fluorescence 
microscope 500x Ex 490 nm, Em 520 nm). 
 
6.2.2. JAK2 and STAT3 role in chemotactic cell migration and chemokinesis. 
The effects of HBC, WP1066 and 5,15-DPP on THP-1 cell migration using chemotaxis assays, figure 
6.5, and then MCF7 wound-healing, figure 6.6, was examined. 
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                    A                     THP-1                  B                      THP-1 
 
 
Figure 6.5: Chemotaxis assays following pre-treatment with WP1066 2 μM, HBC 10 μM or 5,15-
DPP 10 μM or control (DMSO). (A) Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 
1 nM CCL2. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001. 
 
                A                         MCF7             B                           MCF7 
  
 
Figure 6.6: MCF7 wound-healing assays following pre-treatment with 2 μM WP1066, 10 μM HBC, 
10 μM 5,15-DPP or DMSO control. Analysis 24 hours after (A) 10 nM CCL2, or (B) 10 nM CXCL12, 
(C-E) wound-healing images, see overleaf. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, 
n≥3, ***=p<0.001. 
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Figure 6.6C-E: Wound-healing images from 6.6A and B above.  
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CXCL12 10 nM - + + - -
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WP1066 2 μM, HBC 10 μM and 5,15-DPP 10 μM all very significantly reduced THP-1 migration to 
CXCL12 and CCL2 and MCF7 wound-healing induced by CXCL12. However Jurkat chemotaxis to 
CXCL12 was found not to be influenced by these three inhibitors, figure 6.7, suggesting JAK and 
STAT3 involvement in chemotaxis has cell type specificity. 
Jurkat 
 
Figure 6.7: Chemotaxis assays following pre-treatment with HBC 10 μM, WP1066 2 μM, 5,15-DPP 
10 μM or control (DMSO). (A) Chemotaxis of Jurkat to 1 nM CXCL12. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ns=p>0.05. 
6.2.3: The roles of JAK2 and STAT3 in calcium dynamics 
The effects on calcium release in THP-1, MCF7 and Jurkat of JAK2 II, STAT3 III  and STAT3 VIII 
inhibition was examined using calcium flux stimulated by CXCL12, figures 6.8 and 6.9. 
A              THP-1 B             MCF7 C             Jurkat 
  
 
 
Figure 6.8: Fura2 Ca2+ assay in THP-1 following HBC 10 μM, WP1066 2 μM, 5,15-DPP 10 μM or 
control (DMSO). Data expressed as fluorescence ratio change (∆340/∆380 nm) i.e. peak 
fluorescence following 10 nM CXCL12 addition minus basal fluorescence (prior to chemokine), 
traces n=1. 
 
JAK2 and STAT3 inhibition had little effect on THP-1 cells but appeared to stimulate CXCL12-
induced calcium release in MCF7 and Jurkat. Total calcium release was significantly greater in 
Jurkat, figure 6.9, thus as with chemotaxis, the effect of the inhibitors on calcium dynamics was 
found to be cell-type specific.  
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                          Jurkat 
 
Figure 6.9: In Jurkat both STAT3 inhibitors highly significant (p<0.001) increased total calcium 
responses (AUC) but JAK2 inhibition had no significant effect.  
6.2.4: cAMP and JAK STAT signalling  
Raised cAMP levels can either directly or via cross-talk inhibit cell proliferation in immune cells 
[735], possibly through inhibition of proliferative JAK/STAT signalling [736], although other 
pathways such as MEK and ERK may be involved [737]. Rodriquez et al. (2013) found PKA 
promoted JAK3 serine phosphorylation negatively regulating its catalytic activity and that 3-
isobytyl-1-methylxanthine (IBMX) had the same effect. IBMX is a broad spectrum 
phosphodiesterase inhibitor that prevents the breakdown of cAMP and cGMP [738]. Hence the 
effects on chemotaxis of manipulating cellular cAMP levels were assessed, followed by looking at 
JAK2 and STAT3 inhibition wrt intercellular cAMP levels. 
6.2.4.1: cAMP modulator Forskolin and PKA inhibitor H89HCL inhibit chemotaxis and chemokinesis 
Forskolin, a direct reversible activator of cAMP, is a diterpene derivative originally from the Coleus 
forskohlii plant and a useful tool for exploring the role of cAMP in cellular signalling. Forskolin 
induces a conformational change in the adenylyl cyclase ATP binding site, located close to the Gαs 
subunit binding site, and results in more efficient cAMP synthesis [739]. Forskolin and 
phosphodiesterase inhibitors such as IBMX can elevate intracellular cAMP levels [740]. Forskolin 
increases intracellular cAMP levels several fold above baseline, this can interfere with expression 
of cell cycle regulatory genes [741, 742], so potentially inhibits cell proliferation and produces cell 
type specific responses. In the following investigations Forskolin and the PKA inhibitor H89 HCl 
were employed to explore the effects of modulation of cAMP and PKA levels on chemotaxis and 
wound-healing in THP-1 and MCF7 respectively. PKA was of interest as cAMP negative regulation 
can occur through PKA [743, 744], and PKA may phosphorylate JAK2 [745].  
No significant effects on cell proliferation, as measured by MTS assay, were seen with H89 HCl or 
Forskolin in THP-1 or MCF7 cells, figures 6.10 and 6.11. 
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THP-1 MCF7 
A      B  
Figure 6.10: Cytotoxicity assays for Forskolin. MTS assays were over 7 hours in (A) THP-1 and over 
24 hours in (B) MCF7 cells. Basal absorbance occurs in presence of medium after MTS treatment 
in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ns=p>0.05. 
                              THP-1                              MCF7 
            A  B  
Figure 6.11: Cytotoxicity assays for H89 HCl. MTS assays were over 7 hours in (A) THP-1 and over 
24 hours in (B) MCF7 cells. Basal absorbance occurs in presence of medium after MTS treatment 
in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ns=p>0.05. 
 
As Forskolin and H89 HCL did not cause toxicity their effects on chemotaxis alone and in 
combination in THP-1, and individually in MCF7 wound-healing were explored, figures 6.12-6.15. 
A                    THP-1   B                    THP-1 C                   Jurkat 
   
Figures 6.12: Chemotaxis assays following pre-treatment with 1 μM H89 HCl or control. (A) 
Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) Jurkat chemotaxis 
to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001. 
 
At 1 μM H89 HCl significantly inhibits chemotaxis THP-1 and Jurkat, so experiments were repeated 
with lower concentrations of H89 HCL alone and in combination with Forskolin, figure 6.13. At 0.5 
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μM H89 HCl alone did not significantly inhibit THP-1 chemotaxis and instead of opposing worked 
synergistically with Forskolin to potentiate inhibition of chemotaxis to CCL3 and CXCL12 in THP-1. 
(C) Forskolin 50 μM very significantly inhibits Jurkat chemotaxis to CXCL12. 
A                THP-1                                       B                THP-1 C                 Jurkat 
  
 
Figure 6.13: Chemotaxis assays following pre-treatment with 0.5 μM H89 HCl and Forskolin 50 μM 
alone or combined. (A) Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM CXCL12. 
(C) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
  
These results show H89 HCl inhibition of chemotaxis is dose dependent, possibly due to off target 
effects of the inhibitor, as H89 HCl should inhibit Forskolin-induced protein phosphorylation. One 
possible off target effect of H89 HCl, which has an IC50 of 135 nM for PKA, is ROCKII (IC50 ~ 270 
nM) [606]. 
In MCF7 Forskolin significantly reduced wound-healing stimulated by CXCL12, whereas H89 HCl 
had no significant inhibitory effects. Both inhibitors have a small inhibitory effect on CCL3-
stimulated chemokinesis, figures 6.14 and 6.15. 
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                  A                        MCF7                        B                      MCF7 
  
 
 
 
Figure 6.14: MCF7 wound-healing assays following pre-treatment with 50 μM Forskolin or DMSO 
control. Analysis 24 hours after (A and C) 10 nM CXCL12, or (B and C) 10 nM CCL3. Means ± SEM, 
one-way ANOVA, post-hoc Bonferroni, n≥3, *=p<0.05, ***=p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF7 Scratch Assay
Forskolin 50 M compared to untreated
CXCL12 10 nM n=3 17.02.16
C
on
tr
ol
C
on
tr
ol
 +
 C
X
C
L1
2
Fo
rs
ko
lin
 +
 C
X
C
L1
2
Fo
rs
ko
lin
, n
o 
ch
em
ok
in
e
0.00
0.25
0.50
0.75
1.00
***
w
o
u
n
d
w
id
th
 2
4
h
r/
0
h
r
MCF7 Scratch Assay
Forskolin 50 M compared to untreated
CCL3 10 nM n=3 17.02.16
C
on
tr
ol
C
on
tr
ol
 +
 C
C
L3
Fo
rs
ko
lin
 +
 C
C
L3
Fo
rs
ko
lin
, n
o 
ch
em
ok
in
e
0.00
0.25
0.50
0.75
1.00
*
w
o
u
n
d
w
id
th
 2
4
h
r/
0
h
r
0 hours
24 hours
CXCL12 10 nM - + - + -
CCL3 10 nM - - + - +
Forskolin 50 μM - - - + +
C 
177 
 
                      A                   MCF7                    B                       MCF7 
  
 
 
Figure 6.15: MCF7 wound-healing assays following pre-treatment with 2 μM H89 HCL or control. 
Analysis 24 hours after (A and C) 10 nM CXCL12, or (B and C) 10 nM CCL3. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3, *=p<0.05, ns=p>0.05. 
   
6.2.4.2: JAK2 and STAT3 inhibition did not statistically significantly increase cAMP levels 
Having seen some effects on chemotaxis and chemokinesis that may be due to altered cAMP 
levels next the effect of JAK2 and STAT3 inhibition on cAMP production in response to CCL2 and 
CXCL12 was examined. THP-1 cells were treated with Jak2 inhibitor HBC, STAT3 III inhibitor 
WP1066 or STAT3 VIII inhibitor 5,15-DPP in presence of phosphodiesterase inhibitor IBMX 
(0.75mM) and Forskolin (20 μM) with or without 10 nM CCL2 stimulation for periods varying from 
1 to 20 minutes. Similarly THP-1 cells were treated with the same inhibitors, IBMX and Forskolin 
concentrations then CXCL12 10 nM for 20 minutes, figure 6.16. 
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                                                           A                                    THP-1 
 
                                              THP-1 
B  C  
Figure 6.16: cAMP production in THP-1 following 10 μM HBC, 2 μM WP1066, 10 μM 5,15-DPP or 
control (DMSO), (A) cAMP levels before or after 1, 5, 10 or 20 minutes CCL2 stimulation (cells pre-
treated with IBMX 0.75 mM & Forskolin 20 μM). (B) 20 minute CCL2 data only, (C) cAMP levels 
before or after 20 minutes CXCL12 stimulation. Numbers are ratio of cAMP levels after chemokine 
treatment compared to levels in inhibitor treated control. Means ± SEM, one-way ANOVA, post-
hoc Bonferroni, n≥3 independent experiments, *=p<0.05, ns=p>0.05. 
  
JAK2 or STAT3 inhibition may reduce the steady fall in cAMP levels seen with controls following 
stimulation by CCL2, the most prominent effects were recorded 20 minutes after stimulation but 
this did not reach significance. However the ratios of cAMP level with inhibitor treatment 
compared to cAMP levels after inhibitor and 20’ of CCL2 treatment illustrate that inhibition with 
HBC, WP1066 or 5,15 DPP all reduced the usual response to CCL2 compared to untreated control 
cells by nearly two fold. However with CXCL12 stimulation only JAK2 inhibitor HBC produced any 
significant loss in cAMP responses, figure 6.16B.  
6.2.4.3: cAMP levels may modulate actin filaments 
Most cell signalling is governed by reversible phosphorylation often via kinases. There are 
hundreds of protein kinases each phosphorylating many proteins, and any individual protein 
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activated or inactivated by phosphorylation may be phosphorylated by several different kinases. 
Although H89 HCl is marketed as a selective inhibitor of PKA, H89 HCl has been shown to inhibit at 
least eight other kinases including ROCKII where H89 HCl was recorded as having an IC50 of 0.27 
μM in Sf9 cell transfects [606]. The effects of H89 HCl seen here may well therefore be off-target 
effects. ROCK inhibitor Y27632, also inhibited CXCL12 induced migration in THP-1 (see Chapter 5, 
figure 5.44). ROCK is known to be involved in leading edge dynamics [746] possibly upstream of 
cAMP, hence the effects on actin fibres in the presence of Forskolin, H89 HCL and Y27632 and 
CCL3 or CXCL12 were explored. 
First the direct effect of Forskolin and H89 HCl on actin was examined using CHO.CCR5, figure 
6.17.  
  
 
 
 
(A & B) Forskolin 50 μM + CCL3 (C) Control + CCL3 (D & E) H89HCl 1 μM + CCL3 
 
Figure 6.17: Filament actin stains. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with Forskolin, DMSO control, or H89 HCl (1 hr, 37°C) followed 
by CCL3 5 nM (15 mins, 37°C). Imaged UV inverted microscopy (Leica DMII Fluorescence 
microscope 500x Ex 490 nm, Em 520 nm).  
 
In CHO.CCR5 Forskolin produces considerable actin derangement of actin stress fibre responses to 
CCL3 treatment both at the cell boundary and intracellularly, H89HCl also caused actin clumping. 
cAMP addition itself has been observed in CHO cells to produce similar effects and loss of 
membrane architecture [747]. Phalloidin and DAPI stain in MCF7 pre-treated with Forskolin and 
H89HCl along with ROCK inhibitor Y27632 supported above findings in CHO.CCR5, figure 6.18.  
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Control Control + 
CCL3 
Control + 
CXCL12 
Forskolin  
50 μM 
Forskolin + 
CCL3 
Forskolin+ 
CXCL12 
      
H89 HCl 2 μM H89 HCl + 
CCL3 
H89HCL + 
CXCL12 
Y27632  
10 μM 
Y27632 +  
CCL3 
Y27632 + 
CXCL12 
      
Figure 6.18: Filament actin stains. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
MCF7 following pre-treatment with (A-C) DMSO control, (D-F) Forskolin, (G-I) H89 HCl, or (J-L) 
Y27632 (1 hr, 37°C) followed by CCL3 or CXCL12 (5 nM, 15 mins, 37°C). Imaged UV inverted 
microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
The distinctive fine filaments and protrusions produced by chemokine stimulation in controls are 
mostly lost in the presence of Forskolin. MCF7 treated with Forskolin produced concentrated 
clumps of f-actin in the cytoplasm often near the cell boundary, which are modified by CCL3 or 
CXCL12 stimulation of cells. In H89 HCl treated MCF7 some actin bundles are apparent. ROCK 
inhibition with Y27632 again modifies the fine actin filament formation and as with Forskolin and 
H89 HCl treatment produced actin clumping but also encouraged the formation of long processes 
on the MCF7 in presence and absence of chemokines. 
PC3 are a prostate cancer cell-line, used here to compare cytoskeletal responses to pre-treatment 
with Y27632, again ROCK inhibition produced elongation of cells, figure 6.19. 
Control  Y27632  
 
 
Figure 6.19: Filament actin stains. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with (A) DMSO or (B) Y27632 10 μM (1 hr, 37°C). Imaged UV 
inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
A B C D E F 
G H I J K L 
A B 
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These results suggest the ROCK inhibitor does not destroy actin filament integrity but may modify 
ability of actin to branch and re-arrangement. Migration requires the maintenance of a polarized 
cell; chemokines may trigger Rho GTPase signalling so modulation of actin and/or microtubules in 
the cytoskeleton. ROCK activity elevates stress fibre Myosin-II and affects microtubule assembly 
dynamics [748]. Y27632 by inhibiting ROCK and thus Myosin-II produces loss of stress fibres, and 
actin filaments at the leading edge, causes the cell edges to appear smooth, figures 6.18J-L. ROCK 
inhibition upsets cell polarization in these epithelial cell-lines causing cells to develop one, figure 
6.19B, or multiple processes, this may explain how Y27632 inhibits cell migration.  
Forskolin and H89 HCl can be seen to disrupt the directional F-actin responses to chemokines, 
cAMP may be responsible. The inhibitory effects of cAMP on cell migration have also been 
observed in murine embryonic fibroblasts and murine breast tumour cells [749]. Overall Forskolin 
induced increases in cAMP were found to inhibit lamellipodia and membrane protrusion 
formation in MCF7, and inhibit cell migration towards CXCL12 and CCL3 in THP-1, Jurkat and 
MCF7, hence the effects of Forskolin on cofilin phosphorylation, a key player in leading edge 
dynamics was investigated next. 
 
6.2.5: Forskolin increases cofilin phosphorylation 
Forskolin is reported elsewhere to modulate profilin-1, which like cofilin is an actin-modulating 
protein, through PKA [750] and prevent agonist stimulated changes in cofilin phosphorylation 
[751]. Here the effects of THP-1 pre-treatment with Forskolin 50 μM on cofilin phosphorylation in 
response to chemokine stimulation was examined, figure 6.20. Forskolin was found to increased 
cofilin phosphorylation in the presence or absence of CCL3 or CXCL12.   
 
    
 
 
 
 
Figure 6.20: Total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin phosphorylation 
levels in THP-1 following pre-treatment with 50 μM Forskolin or DMSO control (37°C, 30 mins) in 
presence and absence of CXCL12 or CCL3 (5 nM, 15 mins before lysis). Arrestin-2 loading control. 
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6.2.6: Cofilin phosphorylation in the presence of JAK2 and STAT3 VIII inhibition 
The effect of JAK2 and STAT3 inhibition on cofilin phosphorylation at Ser3 in THP-1 cells was then 
examined using western blot. Cofilin phosphorylation in response to CXCL12 stimulation was 
recorded over a period of 30 minutes. In THP-1 cofilin phosphorylation was found to be modified 
by CXCL12 over time, this temporal response was further modified by JAK2 and STAT3 inhibition. 
STAT3 III inhibition eliminated the phosphorylation seen in controls whereas JAK2 II inhibition 
reduced phosphorylation to a brief early response, and STAT3 VIII inhibition concentrated early 
phosphorylation responses to 5 minutes after cell stimulation, figure 6.21. 
A Control (DMSO)  
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D WP1066 2 μM (STAT3 III inhibitor)  
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Figure 6.21: Western Blot with total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin 
phosphorylation levels in THP-1 following pre-treatment with (A) DMSO (control), (B) 10 μM HBC, 
(C) 10 μM 5,15-DPP or (D) 2 μM WP1066 (37°C, 30 mins) in presence and absence of CXCL12 (5 
nM, zero to 30 mins before lysis). β-actin loading control. 
 
6.2.6.1: CXCL12 induce cofilin phosphorylation and STAT3 phosphorylation 
The literature discussed above suggests there may be a relationship between the phosphorylation 
of STAT3 and cofilin phosphorylation, hence possible correlation was explored by comparing 
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cofilin and STAT3 phosphorylation in the presence and absence of JAK2 II and STAT3 VIII and 
STAT3 III inhibitors and CXCL12, using western blot. STAT3 phosphorylation was seen in response 
to CXCL12 treatment after 10 and 30 minutes in control cells and in presence of STAT3 inhibition 
with WP1066, this phosphorylation was completely lost in presence of 5,15-DPP, and HBC. Cofilin 
phosphorylation was not altered by WP1066 but was lost with HBC whereas 5,15-DPP produced 
cofilin phosphorylation after 10 minutes CXCL12, figure 6.22A, similar to control in figure 6.22B. 
 
(A) Treatment Control 
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CXCL12 (mins)        0  10  30   0 10 30  0 10 30 KDa 
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(B) Treatment  Control (DMSO) 
 
HBC 
 
 
 
KDa CXCL12 (mins)      0 10 30   0 10 30 
p-STAT3             
 
←91 
βeta-actin               
 
←43 
Phosphocofilin  
 
←19 
Figure 6.22: Western Blot with phospho-STAT3 (B-7) and phosphocofilin (Ser3) antibodies reveals 
STAT3 and cofilin phosphorylation levels in THP-1 following pre-treatment with (A) DMSO control 
or 2 μM WP1066 or 10 μM 5,15-DPP (37°C, 30 mins) in presence and absence of CXCL12 (5 nM, 
zero, 15 or 30 mins before lysis), (B) Control or 10 μM HBC (37°C, 30 mins) in presence and 
absence of CXCL12 (5 nM, zero, 15 or 30 mins before lysis). β-actin loading control. 
 
 
STAT3 and JAK2 phosphorylation was also examined using ELISA, figure 6.23. ELISA suggested that 
STAT3 phosphorylation initially rapidly decreases in THP-1 stimulated by CXCL12 and that 5,15-
DPP and HBC significantly reduced basal phosphorylated STAT3 levels and non-significantly to 
CXCL12 responses at 10 minutes, concurring with Western blot, figure 6.22. 
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THP-1 
 
 
Figure 6.23: ELISA analysis of STAT3 phosphorylation. THP-1 were treated with DMSO (control), 10 
μM 5,15-DPP or 10 μM HBC (37°C, 15 mins) then CXCL12 5 nM (37°C, 0, 1, 5 or 10 mins), n≥3. 
 
6.3: Discussion 
Research suggests that chemokine triggered receptor dimerization, precedes JAK and Gαi 
association and activation [752], but both JAK and Gαi activation can be prevented with JAK 
inhibitor AG490 [727]. JAK activation is required for Gαi association with GPCR upstream of PLC 
stimulated Ca2+ mobilization, which itself is independent of Pi3K [728]. CXCL12 binds CXCR4 
triggering receptor dimerization; however JAK2 may have to be activated by autophosphorylation 
prior to docking with the GPCRs’ dimers. This docking involves JAK2 kinase phosphorylation of 
receptor tyrosines, and then Gαi-independent JAK2 activation by transphosphorylation, followed 
by the recruitment and tyrosine phosphorylation of STATs including STAT3. Also Gαi activation of 
tyrosine phosphatases, including Shp1, may terminate CXCL12 stimulation of JAK/STAT signalling, 
but further tyrosine kinases may bind CXCR4 after JAK dissociation to extend CXCR4 signalling 
[323, 753]. Soriano et al. (2003) concluded that JAK/STAT activation was essential for CXCL12-
induced G-protein activation, specifically JAK for Gαi activation and phospholipase-β (PLC-β) for 
calcium flux [728].   
Mueller and Strange (2004) showed CCL3 triggered interaction of JAK2 with CCR5 in THP-1 cells, 
and using HEK.CCR5 transfects found CCR5 ligand CCL3 could transiently enhance JAK2 
phosphorylation and this was unaffected by PTX inhibition of Gαi or U73122 inhibition of 
phospholipase C. They also demonstrated Gαi, CCR5 and JAK2 protein association in inactive 
receptor complexes [754]. Mellado et al. (1998) examined the effects of MCP-1 (CCL2) in a 
monocytic cell line and concluded that CCL2 causes JAK2 to phosphorylate CCR2 tyrosine139 
triggering JAK2/STAT3 Gαi-independent receptor association upstream of Gαi signalling [727]. 
Mellado then explored the relationship of JAK2 and CCR5, concluding JAK and heterotrimeric G 
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protein activation is JAK activation dependent [755].  Rodriguez-Frade et al. (1999) concluded the 
same sequence of events with a RANTES/CCR5 model, and suggested chemokine receptor 
dimerization and then internalisation were common features of JAK/STAT signalling [756].  
The above research shows that JAK/STAT signalling is important for CXCL12 and CCL2 
chemokinesis in MCF7 and chemotaxis in THP-1, but not in Jurkat, figures 6.5-6.7. Interestingly 
Khabbazi et al. (2013) found no effect of JAK2 or STAT3 inhibition on CCL3 induced chemotaxis in 
THP-1 and that only STAT3 inhibitor III not STAT3 inhibitor VIII induced cell death [757].  Further 
experiments with the inhibitors used by Khabbazi et al. (2013) in THP-1 and MCF7 cells were 
undertaken using CCL2 and CXCL12 to further elucidate JAK/STAT signalling complexities. Direct 
inhibition of STAT3 may induce cytotoxicity in a range of cancer cells suggesting these cells 
depend on STAT3 activation to thrive. JAK/STAT signalling is upregulated in some cancers 
including those of haematopoietic cells, with JAK inhibition sometimes the chosen therapeutic 
option [324].  
 
6.3.1: JAK2, STAT3 and cofilin phosphorylation 
Cytokines may trigger reactive oxygen species (ROS) production by membrane NADPH oxidase 
complexes in some cell types. ROS may activate JAK/STAT pathway, Rac1 can regulate NADPH 
oxidase and active Rho GTPases and may be essential for STAT3 transcription activity [729-731, 
758]. More recent research also demonstrates a Rac1 pathway link to STAT3. Inhibition of Rac1 
using NSC23766 (an inhibitor discussed in depth in chapter 8) or JAK2 using AG490 both 
reportedly reduced phosphorylation of STAT3, this may be attributed to Rac1 inducing STAT3 
activation through IL-6 [759]. However Rac1 downregulates Myc via PAK2 phosphorylation, Myc is 
a multifunctional transcription factor, responsive to mitogenic signals, that activates expression of 
many genes [760]. Downregulation of Myc can be inhibited by ROCK inhibition using Y27632, and 
downregulation of Myc increases cofilin phosphorylation, hence ROCK inhibition with Y27632 
decreases cofilin phosphorylation and increases Myc. ROCK inhibition also reportedly upregulates 
STAT3 activity. Src and JAK2 kinases bind to and activate STAT3, this has been inhibited with JAK2 
and Src inhibitors, suggesting ROCK and LIMK negatively affect STAT3 via Src and JAK2 [732]. Here 
JAK2 and STAT3 inhibition was shown to disrupt cofilin phosphorylation in response to CXCL12 
stimulation of THP-1, figure 6.21, and have similar effects on STAT3 and cofilin phosphorylation 
following CXCL12 stimulation of THP-1, figure 6.22. 
Cofilin orchestrates actin monomer and filament dynamics, and so cell motility, in response to 
chemotactic chemokines [761]. However chemotactic responses, and cofilin phosphorylation, 
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may be modified by metabolic environment stresses such as raised glucose or lipids. This has been 
shown to be the case for THP-1 In the presence of normal glucose and lipid levels the addition of 
CCL2 produced a gradual increase in cofilin phosphorylation, although total cofilin levels were 
unaffected [384].  The cofilin phosphorylation responses shown here, to CXCL12 in THP-1, 
similarly increase but in a wave-like temporal fashion, figure 6.21A This phosphorylation can be 
disrupted by JAK2 or STAT3 inhibition supporting the hypothesis that both may be relevant to 
cofilin’s function in THP-1 cell migration to CXCL12. In a metabolic stress environment of raise 
cholesterol and glucose THP-1 are reported to become sensitised to CCL2; a decrease in filament 
to globular actin ratio occurs, along with enhanced actin turnover, and decreased cofilin 
phosphorylation, producing increased migration of THP-1 towards CCL2 [384]. Although it is 
possible that the inhibitors used here could cause cellular stress, this seems unlikely as they 
decrease migration towards CCL2 not increase it, figures 6.5-6.6.  
 
6.3.2: cAMP involvement with JAK2 and STAT3 signalling  
cAMP is a second messenger that can be produced in response to stimulation of receptors, 
including chemokine receptors, via membrane associated adenylyl cyclase’s. Human cells can 
contain one soluble and up to nine adenylyl cyclase isoforms. These are purportedly variably 
expressed in different tissues and cellular compartments [739]. Adenylyl cyclase enzymatically 
converts ATP to pyrophosphate and 3’5’ cAMP [762]. cAMP then undergoes bond hydrolysis by 
phosphodiesterase’s to 5’AMP [763]. cAMP transfers signals from receptors to intracellular 
downstream effectors. cAMP is a negative regulator in immune cells through the protein kinase A 
(PKA) pathway. Protein phosphorylation is a fundamental regulatory mechanism in signalling and 
enzymes catalysing protein phosphorylation, protein kinases, are key in signal transduction, PKA is 
one such protein kinase. PKA is a serine/threonine kinase containing a four subunits, two catalytic 
and two regulatory [743, 744].  
PKA has been shown to phosphorylate JAK2, this may occur via Src and Rac1, and STAT3 via Pi3K 
[745]. PKA inhibition itself, with H89 HCl, was shown to inhibit chemotaxis, figures 6.12-6.13, but 
little or no effect on chemokinesis, figure 6.15. cAMP may produce responses in four ways; (i) 
activation of exchange factors Epac1 and Epac2; (ii) cAMP gated ion channels;  (iii) cAMP-
mediated phosphodiesterase’s; and (iv) via catalytic PKA activation, which affects a range of 
cellular processes. In some cell types the balance between RAS/RAF/MEK/ERK and cAMP 
signalling maintains healthy homeostasis between cell differentiation and proliferation [735, 743, 
764].   
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Forskolin reportedly may negatively regulate JAK3 or PKA activity, PKA may directly phosphorylate 
and inactivate JAK3 [735].  JAK/STAT signalling can be negatively regulated by (i) suppressing 
cytokine signalling, (ii) protein kinase phosphatases and (iii) by protein inhibitors of activated 
STATs inhibiting JAK/STAT signalling directly [765]. Other signalling proteins and pathways such as 
MAPK, Pi3K and cAMP are also involved [766]. ATP is converted to 3’5’-cAMP and pyrophosphate 
by membrane enzyme adenylate cyclase [762]. Phosphodiesterases then hydrolyse the 
phosphodiester linkage producing 5’AMP [763]. cAMP acts through several mediators including 
the serine/threonine kinase PKA [744]. Forskolin and phosphodiesterase inhibitors such as IBMX 
increase levels of cAMP [767] and cAMP levels may affect JAK/STAT signalling [768] hence 
Forskolin activation of adenylate cyclase, cAMP and PKA may inhibit JAK/STAT signalling [735]. 
Forskolin can increase intracellular cAMP several fold above normal. This may antagonise 
expression of cell cycle regulatory and checkpoint genes [741, 769] so potentially inhibit cell 
proliferation, however this may not be applicable to cancer cell lines where cell cycle checkpoints 
may no longer be functional. Certainly Forskolin did not show any obvious toxicity in above 
assays, figure 6.10, but inhibited chemotaxis and chemokinesis, figures 6.13-6.14. 
Rodriguez et al. (2013) concluded JAK3 could be inhibited by a Forskolin-cAMP-PKA pathway 
through serine residues negatively regulating JAK3 catalytic activity. Also that treatment with non-
specific phosphodiesterase IBMX may trap cells in Go phase and prevent JAK3 catalysing the 
phosphorylation of STAT5 [735]. Calcium mobilisation purportedly activates adenylate cyclase 
that produces cAMP [770-772]. The results here indicate cross talk may occur between cAMP/PKA 
and JAK2/STAT3 signalling, suggesting that Forskolin’s negative effect on CXCL12 chemotaxis may 
be through interfering with JAK-mediated stability of CXCR4 receptor dimerization or that PKA 
could phosphorylate JAK serine residues and negatively regulate its catalytic functions.  
The inhibitory effects of Forskolin on chemotaxis and wound-healing, may be due to the increased 
cAMP levels. Others have noted in breast cancer cell line MDA-MD-231 that increasing cAMP 
inhibits wound-healing. Research shows this can be attributed to abrogated STAT3 and ERK1/2 
activation, along with inhibition of FAK phosphorylation. FAK is a tyrosine kinase scaffolding and 
phosphorylating protein that acts, along with integrins, in focal adhesion complexes [773]. FAK 
inhibition itself was shown to inhibit CXCL12-induced cell migration (chapter 5 figure 5.37 and 
5.38). FAK expression may be upregulated in malignant cells [774] such as MCF7. An invasive 
phenotype can be produced by Src-FAK-p130CAS complex formation. p130CAS is a docking protein 
regulating FAK signalling to Rac1. FAK may signal through p130CAS to Rac1, Rac1 activation inhibits 
Rho signalling. Inhibiting Rho kinase (ROCK) with Y27632 may allow FAK stimulation of Rac1 
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signalling to predominate [775]. Rho activation can cause bundling of actin filaments into stress 
fibres, whereas activation of Rac can cause formation of long slender filopodia and lamellipodia 
[776] as seen in figure 6.18. 
PP2A is a serine-threonine phosphatase that may be present in malignant cells in lower levels 
than normal cells, present at normal levels, or present in a hyper-phosphorylated state. Hyper-
phosphorylation makes PP2A inactive by preventing it forming the active phosphatase an 
heterotrimeric catalytic complex. PP2A in addition to catalysing cofilin dephosphorylation and 
activation can also act as a tumour suppressor reducing AKT and ERK phosphorylation and 
signalling. In addition to raising cellular cAMP levels Forskolin can dephosphorylate PP2A. If hyper-
phosphorylated PP2 is dephosphorylated, it is activated [777]. PP1 and PP2 purportedly 
dephosphorylate cofilin. However these results indicate that at the concentrations used (50 μM) 
Forskolin has effectively increased cofilin phosphorylation, suggesting that PP2A if present in THP-
1 cells it is not hyper-phosphorylated and may have been inactivated by the Forskolin treatment, 
figures 6.20 and 6.24.  
 
 
 
Figure 6.24: Forskolin may produce cofilin 
phosphorylation in THP-1 by inhibiting PP2 
[777]. 
Overall results point to a relationship between the phosphorylation of cofilin in response to 
CXCL12 and JAK2/STAT3 signalling. LIMKs are modulated by Rho GTPases, they receive signalling 
from RhoA and RhoC and are phosphorylated and activated by ROCK producing linear actin, 
whereas actin branching, and lamellipodia, are mediated by Rac GTPases via p21-activated 
kinases (PAK). Rac1 activates LIMKs, including LIMK1 and LIMK2. LIMK can reportedly negative 
regulates not only cofilin but also STAT3 and Myc [732, 778]. Downstream of ROCK, LIMK and 
Rac1 negatively regulate Myc, Rac1 through PAK2-mediated phosphorylation and LIMK via cofilin 
phosphorylation [779]. Rho GTPases can mediate Myc, and Myc down-regulation negatively 
correlates with cofilin phosphorylation. Also cofilin knockdown with siRNA can reduce Myc 
expression [732]. Hence ROCK, LIMK and cofilin can reduce Myc levels, and ROCK can increase 
phosphorylation of cofilin via downregulation of Myc. Src and JAK2 kinases bind and activate 
cofilincofilin
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STAT3; STAT3 also targets Myc [780, 781]. ROCK and LIMK can decrease levels of phosphorylated 
(active) STAT3 by decreasing Myc, but this decrease can be dependent on Src or JAK2 [732]. 
Overall this suggests the phosphorylation of cofilin may relate to or correlate with STAT3 
phosphorylation, figure 6.25. 
 
Figure 6.25: Signalling that may link STAT3, JAK2 and cofilin phosphorylation [732, 780, 781]. 
 
The involvement of JAK2 in chemokine signalling has produced diametrically opposed debate 
[782], and has indicated that JAK2 is not essential in CCL3-induced chemotaxis [757]. However 
JAK/STAT signalling may be cell type or chemokine specific. Research by others has also shown 
CXCL12 to induce JAK-STAT signalling, and that inhibition of JAK2 may block CXCL12-stimulated 
JAK2 tyrosine phosphorylation and prevent the binding of GTP to RhoA stimulated by CXCL12 
[783].  
 
The inhibitor HBC binds the kinase domain of JAK2 inhibiting tyrosine kinase auto-
phosphorylation. WP1066 inhibits the STAT3 pathway but also JAK2, although WP1066 inhibition 
of JAK2 may be less than that achieved by the specific JAK2 II inhibitor HBC.  HBC and WP1066 
causes a dramatic change in cofilin phosphorylation compared to control, figure 6.21, that is not 
seen with the STAT3 VIII inhibitor DPP, suggesting JAK2 may directly or indirectly influence LIMK 
activity to stimulate cofilin phosphorylation. This may be through Rho associated protein kinase, 
as inhibition of ROCK using Y27632 also inhibits cofilin phosphorylation, (chapter 5, figure 5.42). 
Rac1 may also activate STAT3, as inhibition of Rac1 using NSC23766, (an inhibitor discussed in 
chapter 8) and JAK2 with AG490 both reportedly reduced phosphorylation of STAT3; IL-6 
stimulating Rac1 to activate STAT3 [759]. JAK2 inhibitor HBC also eliminated STAT3 
phosphorylation, figure 6.22. 
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CXCL12/CXCR4 signalling and JAK2 and one of its downstream targets STAT3 signalling may cross-
talk in THP-1 monocytes. Others have also concluded cross-talk between JAK2 and the 
CXCR4/CXCL12 co-operate to increase chemotactic responses in malignant hematopoietic cells 
through Pi3K signalling, and that chemotaxis is reduced in JAK2 inhibition [328]. Here results in 
THP-1 and MCF7 cells support their findings and further demonstrate that STAT3 may be involved. 
Perez-Rivero et al. (2013) also implicated JAK2 signalling in CXCL12 chemotaxis in leukocytes (in 
mice) and linked this to F-actin polymerization [784]. Early work implicated JAK/STAT signalling in 
EMT, concluding Gαi association with GPCR is JAK activation dependent and that phospholipase C 
activity is downstream of JAKs [728]. Here results further elucidate the relationships between 
cofilin phosphorylation and JAK2/STAT3 signalling.  
6.4: Conclusions 
In THP-1 JAK2 and STAT3 inhibition can modify the usual temporal cofilin phosphorylation 
responses to CXCL12, this appeared not due to inhibitor cytotoxicity. JAK2 and STAT3 inhibition 
can in a cell- and chemokine-specific manner significantly reduce chemotaxis and chemokinesis. 
Increasing cAMP levels appear to inhibit both CXCL12 and CCL3 chemotaxis in THP-1 and 
chemokinesis in MCF7. Also JAK2 may support intracellular cAMP falls in responses to CXCL12 
signalling in THP-1. Overall results provide considerable evidence of JAK2 and STAT3 involvement 
in CXCL12 and CCL2 supported cell migration in both cell-lines.  
 
With CCL3-induced migration in THP-1 higher concentrations of H89 HCl were required to 
significantly inhibit migration, at this higher concentration H89 HCl may also be inhibiting ROCK11 
kinase as well as PKA. Both H89 HCl and ROCK inhibitor Y27632 were found to disrupt actin 
filament formation, with Y27632 especially producing elongated lamellipodia, possibly due to 
ROCK inhibition producing Rac over Rho signalling predominance. Forskolin also disrupted the fine 
actin filaments produced in response to chemokines, instead actin bundles were present. 
Forskolin also inhibited chemotaxis and chemokinesis, plus produced increased phosphorylation 
of cofilin, suggesting cAMP levels influence lamellipodia and membrane protrusion formation and 
so cell migration in THP-1 and MCF7.  
 
Some tenuous correlation was observed between early STAT3 phosphorylation and cofilin 
phosphorylation produced in response to CXCL12 in THP-1. Both were somewhat similarly 
modified by JAK2 or STAT3 inhibition, further work is needed to clarify if STAT3 and cofilin 
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phosphorylation are related, if both involve JAK2 or STAT3, and if this phosphorylation occurs in a 
cell- or chemokine-specific manner. 
 
Cofilin may mediate inflammatory factors through the JAK/STAT pathway [785] thus posing the 
question do anti-inflammatories such as COX inhibitors mediate cofilin phosphorylation, or indeed 
CXCL12 or CCL3 chemotaxis, answering these questions was the challenge addressed in chapter 7. 
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Chapter 7: Direct and indirect effects of NSAIDs in chemotactic metastasis  
 
7.1: Introduction 
The NSAIDs Ibuprofen, Naproxen and Celecoxib along with Paracetamol and Aspirin, are widely 
prescribed analgesics. NSAIDs inhibit cyclooxygenase enzymes COX1 or COX2 that catalyse the 
production of prostaglandins, including prostaglandin E2 (PGE2) [414]. Aspirin, Ibuprofen and 
Naproxen inhibit both COX enzymes whereas Paracetamol has diverse modes of action including 
COX2 inhibition [419-421]. Celecoxib is a specific COX2 inhibitor; the inflammation that 
accompanies cancer can induce COX2 activity [411]. PGE2 can suppress leucocyte activity causing 
immunosuppression [438]. PGE2 may stimulate cancer initiation, proliferation survival and 
metastatic spread [439]. NSAID therapy may reduce cancer incidence for example by inhibiting 
progression of dysplasia to cancer [786], which some chemokines support [787]. COX2-produced 
PGE2 expressed by tumours can inhibit apoptosis, promote proliferation and support metastasis 
[453, 464, 465]. NSAIDs’ off-target effects can also be therapeutic in malignancy. Celecoxib can 
cause cell cycle arrest [478] and activate apoptosis [480, 481]. NSAIDs can also modulate calcium 
ATPases and Ca2+ dynamics so favourably inhibiting EGFR, Pi3K-Akt and Raf-MEK-ERK signalling 
often corrupted in cancer [467-469, 487, 788-790]. Chapters 4 and 5 of this thesis show that 
CXCL12- and CCL3-induced chemotaxis also involves Pi3K-Akt and Raf-MEK-ERK signalling. This 
suggested NSAIDS may affect chemotaxis and even cofilin phosphorylation. This chapter reports 
investigations into the effects of various NSAIDs and Paracetamol on CCL3 and CXCL12-induced 
cell migration in THP-1, Jurkat and MCF7, and some preliminary work on NSAID mediation of 
cofilin phosphorylation in THP-1, figure 7.1. 
 
 
 
 
Figure 7.1: How NSAIDs interact with 
signalling pathways influencing cofilin 
phosphorylation [409, 458, 791-794]. 
 
 
 
PGE2
LIMK1/2
Oestrogen 
Biosynthesis
PIP3
NSAIDs
CofilinCofilin
P
CofilinCofilin
PPAK
Rac1
ROCK
RhoA PPARγ
ERK1/2
Pi3K/Akt
PTEN
PIP2
VEGF
COX1/2
EGFR
= activation
= inhibition
193 
 
Hypothesis:  NSAIDs can inhibit anti-apoptotic and proliferative signalling through Pi3K/Akt, EGFR 
and Raf/MEK/ERK pathways, and may inhibit LIMK phosphorylation of cofilin and metastasis. 
Aim: To investigate if NSAIDs affect CCL3 or CXCL12-stimulated THP-1 or Jurkat chemotaxis or 
MCF7 chemokinesis, and if effects can be related to cellular levels of cAMP or phosphorylated 
cofilin. 
Objectives: 
(i)    Select a range of NSAIDs and check for cytotoxicity 
(ii)   Examine NSAIDs for effects on CXCL12-chemotaxis in THP-1 and Jurkat and CCL3-chemotaxis 
in THP-1 
(iii)   Investigate if NSAIDs mediate CCL3 or CXCL12-supported chemokinesis in MCF7 
(iv)   Use Phalloidin stains to probe NSAIDs effects on actin filaments 
(v)    Explore the effects of NSAIDs on cellular cAMP levels following chemokine stimulation  
(vi)   Observe if NSAIDS effect cofilin phosphorylation following CCL3 or CXCL12 stimulation 
 
7.2: Results  
Here the effects of Ibuprofen, Naproxen and Celecoxib along Paracetamol and Aspirin on 
chemokine induced migration, cAMP release and calcium responses was explored in THP-1 and/or 
Jurkat and cofilin phosphorylation in THP-1. Concentrations of the drugs used are those reached 
by therapeutic doses [795, 796]. 
Please note controls are common between graphs where experiments were conducted 
simultaneously; results for each inhibitor have been displayed separately for ease of description 
of results, this applies to: figures 7.7B and 6.17C; 7.6B and C; 7.10B and C; 7.11A and 5.27A; 7.12B 
and C; 7.18C and 4.11A; 7.21A and 6.16A. 
 
7.2.1: Aspirin and Naproxen 
Aspirin, which has been attributed with cancer preventative properties [797], very significantly 
inhibited chemotaxis to CXCL12 in THP-1 (p< 0.001), and to a lesser extent in Jurkat (p<0.05). 
Whereas Aspirin had no significant effect on CCL3-induced chemotaxis in THP-1, figures 7.2. 
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THP-1 Jurkat THP-1 
A  B  C  
Figure 7.2: Chemotaxis assays following pre-treatment with Aspirin 555 μM or control. (A) 
Chemotaxis of THP-1 to 1 nM CXCL12. (B) Jurkat chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, *=p<0.05, ns=p>0.05. 
This effect on migration could not be explained by toxicity, as MTS assays showed aspirin at 555 
μM and even up to 1.11 mM did not inhibit cell metabolism in either cell line, figure 7.3. 
THP-1 Jurkat 
A  B  
Figure 7.3: Cytotoxicity assays for Aspirin. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **=p<0.01, ns=p>0.05. 
The effects of Naproxen were then examined on chemokine-induced chemotaxis in THP-1 and 
Jurkat cells and on wound-healing in MCF7 cells after first checking the drug for toxicity using MTS 
assays, figures 7.4-7.6.  
THP-1 Jurkat 
A  B  
Figure 7.4: Cytotoxicity assays for Naproxen. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, **= p<0.01, ns=p>0.05. 
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THP-1 THP-1 Jurkat 
A  B  C  
Figure 7.5: Chemotaxis assays following pre-treatment with Naproxen 217 μM or control. (A) 
Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) Jurkat chemotaxis 
to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, ns=p>0.05. 
 
MTS assays confirmed Naproxen treatment had no toxic effects on cell metabolism in THP-1, 
Jurkat or MCF7.  However Naproxen at 217 μM significantly inhibited Jurkat chemotaxis to 
CXCL12, figure 7.5, and MCF7 wound-healing induced by both CCL3 and CXCL12, figure 7.6. 
 
MCF7 MCF7 MCF7 
A  B  C  
 
 
Figure 7.6: (A) Cytotoxicity assay for Naproxen 217 μM over 24 hours in MCF7. Basal absorbance 
occurs in presence of medium after MTS treatment in the absence of cells. (B) MCF7 wound-
healing assays following transfection with Naproxen 217 μM or control, analysis 24 hours after 10 
nM CCL3, or (C) 10 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, ns=p>0.05. 
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The effects of Aspirin and Naproxen on actin fibres in CHO.CCR5 cells was also examined. Aspirin 
appeared to concentrate the F-actin fibres in the cells’ periphery and cause some distortion of cell 
morphology compared to control. Whereas Naproxen caused some loss of clearly defined F-actin 
filaments, reduced cell size and produced cell rounding, figure 7.7. 
  
 
  
(A) Aspirin 555 μM (B) Control (C) Naproxen 217 μM 
Figure 7.7: Filament actin stain. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with (A) Aspirin 555 μM, (B) Control and (C) Naproxen 217 μM 
(1 hr, 37°C). Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 
nm, Em 520 nm). 
7.2.2: Ibuprofen 
MTS assay showed ibuprofen very significantly inhibited cell metabolism of both Jurkat (IC50 = 
1.16 mM), and THP-1 (IC50 = 690 μM), although at the experimental concentration used (290 μM) 
no evidence of toxicity was apparent over 7 hours in THP-1 or Jurkat, figures 7.8. 
THP-1 Jurkat 
A  B  
Figure 7.8: Cytotoxicity assays for Ibuprofen. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, *=p<0.05, ns=p>0.05. 
Others have examined the IC50 of ibuprofen by other methods, for example Akrami et al. (2015), 
using an adenocarcinoma gastric cell line, found an IC50 of 630 μM by trypan blue staining and 456 
μM by neutral red uptake assays over 24 hours; these values fell to 549 μM and 408 μM 
respectively over 48 hours [798]. Ibuprofen is a racemic mix, in vivo the R-enantiomer is 
extensively converted to the S-enantiomer which is more pharmacologically active [799]. It is not 
clear if this conversion occurs in THP-1, Jurkat or MCF7 in vitro. However both enantiomers are 
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reported to COX2-independently down-regulate cyclin A and B and cause a G0/G1 phase block 
[800]. 
Ibuprofen’s reported therapeutic benefits in cancer may partly relate to its inhibition of cell 
migration [801], and so the effects of Ibuprofen on chemotaxis in Jurkat and THP-1 and wound-
healing in MCF7 were explored, figures 7.9. 
THP-1 THP-1 Jurkat 
A  B  C  
 
Figure 7.9: Chemotaxis assays following pre-treatment with Ibuprofen 290 μM or control (DMSO). 
(A) Chemotaxis of THP-1 to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CCL3. (C) Jurkat 
chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001. 
 
Monocytes are reported to express EP receptors, mainly EP2 and EP4, these may modulate 
monocyte responses via CCR5 to CCL3 and via CXCR4 to CXCL12 respectively as EP2 and EP4 
agonists are reported to increase chemotaxis to CCL3 and CXCL12 [802]; this may be why NSAIDs 
inhibit chemotaxis to these two chemokines in monocyte cell-line THP-1.  
Ibuprofen may exert its anti-tumour effects through inhibiting cell apoptosis or proliferation. 
Assays in MCF7 undertaken in the absence of serum to prevent proliferation demonstrated 
significant inhibition of migration-induced wound-healing produced by CXCL12 and CCL3 in cells 
exposed to ibuprofen 290 μM. MTS assays in MCF7 over 26 hours at 290 μM did show significant 
inhibition of cell metabolism, although wound-healing imaging revealed no evidence of cell death, 
figure 7.10. 
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MCF7 MCF7 MCF7 
A  B  C  
 
Figure 7.10: (A) Cytotoxicity assay for Ibuprofen 290 μM over 24 hours in MCF7. Basal absorbance 
occurs in presence of medium after MTS treatment in the absence of cells. (B) MCF7 wound-
healing assays following transfection with Ibuprofen 290 μM or DMSO control, analysis 24 hours 
after 10 nM CCL3, or (C) 10 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, ns=p>0.05. 
Chemotaxis employs actin dynamics, pre-treatment of monocytes with PGE2 is reported to aid 
conversion of globulin to filamentous actin when cells were stimulated with CCL3 or CXCL12 [802]. 
Here pre-treatment of CHO.CCR5 cells with ibuprofen caused loss of stress fibres, and actin fibre 
distortion in the presence of CCL3, figure 7.11.  
A          Control B     Control + CCL3 C    Ibuprofen 290 μM D   Ibuprofen + CCL3 
  
 
 
Figure 7.11: Filament actin stain. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with (A) DMSO control (1 hr, 37°C) (B) Control then CCL3 (10 
nM, 15 mins 37°C) (C) 290 μM Ibuprofen (1 hr, 37°C) (D) 290 μM Ibuprofen then then CCL3 (10 
nM, 15 mins 37°C). Imaged UV inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 
490 nm, Em 520 nm). 
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Ibuprofen, Naproxen and Aspirin all reportedly inhibit both COX1 and COX2 enzymes, so next 
celecoxib a specific COX2 inhibitor’s ability to influence chemotaxis and chemokinesis were 
investigated [414]. 
 
7.2.3: Celecoxib 
Celecoxib is a commonly prescribed COX2 inhibitor which has many on- and off-target cellular 
effects. Celecoxib can modulate the expression of many genes involved in cell metabolism, 
proliferation, energetics, and apoptosis [803]. Celecoxib at low concentrations (10 μM) is reported 
to work synergistically with calcitrol (vitamin D) to inhibit proliferation of MCF7 in vitro, both 
drugs were thought to be targeting COX2 [804]. Celecoxib is also reported to inhibit 3-
phosphoinositide-dependent kinase 1 (PDK-1), one of the proteins that phosphorylate Akt [805]. 
Celecoxib but not Rofecoxib, another COX2 inhibitor, can at nanomolar concentrations, cause 
inhibition of some carbonic anhydrase isoforms [806]. Carbonic anhydrases support pH and CO2 
homeostasis by catalysing the conversion of CO2 to the bicarbonate ion and hence mediate 
transport of CO2/HCO
-
3 between lungs and metabolising/respiring tissues. Many cellular processes 
are influenced including bone reabsorption and calcification, gluconeogenesis, lipogenesis and 
tumourigenicity [807].  Certain carbonic anhydrases such as tumour-associated isoform hCA 1X are 
implicated in cancer cell development and invasion [808]. 
 
MTS assays indicated Celecoxib at 50 μM very significantly inhibits MCF7 cell proliferation, this 
cytotoxicity could explain the inhibition of wound-healing induced by CCL3 or CXCL12 in MCF7, 
figure 7.12.  
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Figure 7.12: (A) Cytotoxicity assays for Celecoxib. MTS assays were over 24 hours in MCF7 cells. 
Basal absorbance occurs in presence of medium after MTS treatment in the absence of cells. (B) 
MCF7 wound-healing assays following 50 μM Celecoxib or DMSO control. Analysis 24 hours after 
10 nM CCL3, or (C) 10 nM CXCL12, (D) wound-healing images. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *=p<0.05, 
ns=p>0.05. 
 
MTS assays allowed calculation of Celecoxib’s IC50 in THP-1 (54 μM) and Jurkat (48 μM), figure 
7.13, yet even at 50 μM celecoxib did not inhibit chemotaxis of THP-1 to CXCL12 or CCL3 or Jurkat 
to CXCL12, figure 7.14. 
THP-1 Jurkat 
A  B  
Figure 7.13: Cytotoxicity assays for Celecoxib. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, ns=p>0.05. 
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THP-1 THP-1 Jurkat 
A  B  C  
Figure 7.14: Chemotaxis assays following pre-treatment with Celecoxib 50 μM or control (DMSO). 
(A) Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) Jurkat 
chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, **=p<0.01, *=p<0.05, ns=p>0.05. 
 
The effect of Celecoxib on actin fibres was examined in CHO.CCR5 and MCF7 cells. 30 minutes 
pre-treatment with Celecoxib followed by Phalloidin stain revealed cell shrinkage and lack of actin 
filament definition in both cell types, total disorganisation of f-actin formation after CCL3 (10 nM) 
treatment was more easily seen in CHO.CCR5, figure 7.15. 
 
    
(A) CHO.CCR5 
Control 
(B) CHO.CCR5 + 
Celecoxib 
(C) CHO.CCR5 + 
Celecoxib enlarged 
(D) MCF7 Control (E) MCF7 + 
Celecoxib 
Figure 7.15: Filament actin stain following Celecoxib. Alexa-488 Phalloidin (green) and DAPI 
nuclear stains (blue) of (A-C) CHO.CCR5 or (D-E) MCF7 following pre-treatment with 50 μM 
Celecoxib or control (DMSO) (30 mins, 37°C). Imaged UV inverted microscopy (Leica DMII 
Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
 
One of the most commonly used analgesics in the UK is paracetamol [809]. Paracetamol inhibits 
COX2 more than COX1, and may reduce COX2 activity by 80% in monocytes [422, 423] so its 
effects on chemotaxis in THP-1 and Jurkat were explored. 
7.2.4: Paracetamol 
Paracetamol is reported to have increased apoptosis, possibly through both the death receptor 
and mitochondrial pathways, and decreased caspase 9 expression in two colon-cancer cell lines 
[810]. However in Jurkat, THP-1 and MCF7 cell lines MTS assays indicated no significant effect on 
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cell metabolism, although at concentrations well above safe therapeutic levels THP-1 metabolism 
fell, figure 7.16. 
THP-1 Jurkat MCF7 
A
 
B 
 
C 
 
Figure 7.16: Cytotoxicity assays for Paracetamol. MTS assays were over 7 hours in (A) THP-1 and 
(B) Jurkat and over 24 hours in (C) MCF7. Basal absorbance occurs in presence of medium after 
MTS treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ns=p>0.05.   
 
Chemotaxis assays explored the effects of Paracetamol at 130 μM on chemotaxis with THP-1 to 
CCL3 and CXCL12 along with Jurkat assays to CXCL12. Paracetamol had no significant effect on 
chemotaxis in Jurkat or THP-1, figure 7.17, or wound-healing in MCF7 (data not shown). 
THP-1 THP-1 Jurkat 
A  B  C  
Figure 7.17: Chemotaxis assays following pre-treatment with Paracetamol 130 μM or control. (A) 
Chemotaxis of THP-1 to 1 nM CCL3. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) Jurkat chemotaxis 
to 1 nM CXCL12. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ns=p>0.05. 
  
7.2.5: Paracetamol, Aspirin and NSAID’s effects on cellular calcium dynamics  
Calcium acts as a second messenger. Calcium dynamics are central to the oncogenesis, 
deregulation, proliferation and resistance to apoptosis that defines malignancy, as cellular Ca2+ 
concentrations and fluctuations can modulate signalling pathways [811]. Expression of calcium 
v1.2 L-type calcium channels, Voltage Gated Calcium Channels (VGCC) in THP-1 is increased by 
their differentiation into macrophages [812], although THP-1 also operate via receptor and Store 
Operated Calcium Channels (SOCC) [813]. Whereas Jurkat also express Ca2+ permeable non-
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selective cation channels termed TRPs [814]. TRPV1 channels reportedly contribute to Ca2+ 
signalling triggered proliferation in MCF7 [815].  
Calcium levels in cell cytosol are approximately 10,000 times lower in resting conditions than 
levels in the ER and other Ca2+ stores. This gradient is created by Ca2+ pumps in the stores’ plasma 
membranes. Both VGCC on calcium store membranes and cell Receptor-Operated Calcium 
Channels (ROCC) can potentially respond to signalling causing cytosol calcium influx [816]. Ca2+ 
fluctuation can themselves trigger other calcium release channels controlled by inositol-1,4,5-
triphosphate and ryanodine receptors located on the ER membrane. This generates further Ca2+ 
movements [817, 818].  
Here the effects of Paracetamol treatment of THP-1, CHO.CCR5 and Jurkat on calcium dynamics 
induced by CCL3 and CXCL12 were explored, figure 7.18. 
CHO.CCR5 THP-1 Jurkat 
A 
 
B 
 
C 
 
   
Jurkat, CXCL12 CHO.CCR5, CCL3 
D  E  
 
Figure 7.18: Fura2 Ca2+ assay following 130 μM Paracetamol or control. Traces for (A) CHO.CCR5 
following 10 nM CCL3, (B) THP-1 following 10 nM CCL3 and (C) Jurkat following 10 nM CXCL12, all 
n=1. (D) Jurkat AUC following 10 nM CXCL12, (E) CHO.CCR5 following 10 nM CCL3. Means ± SEM, 
Student t-test, n≥3 independent experiments, **=p<0.01, *=p<0.05. Data: Fluorescence ratio 
change (∆340/∆380 nm) i.e. peak fluorescence following 10 nM chemokine additions minus basal 
fluorescence (prior to chemokine).  
Paracetamol at 130 μM was found to significantly decrease calcium responses to CCL3 in 
CHO.CCR5 cells, and conversely to significantly increase calcium release in response to CXCL12 in 
Jurkat. The effects observed with Paracetamol suggest cell type and chemokine specific 
responses. Others have observed a slight increase in calcium responses in Jurkat after treatment 
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with Paracetamol metabolite AM404 [819]. THP-1, like HEK cells [820], may express FAAH, or 
other enzymes that degrade Paracetamol’s active metabolites, so calcium flux was not affected. 
Next the effects of Ibuprofen and Celecoxib on chemokine-induced calcium flux were explored, 
figure 7.19. 
THP-1 MCF7 Jurkat 
A
 
B 
 
C  
 
 
Jurkat, CXCL12 MCF7 
D  E  
Figure 7.19: Fura2 Ca2+ assays following Ibuprofen, celecoxib or control (DMSO). Traces following 
Ibuprofen 290 μM pre-treatment (A) THP-1 response to 10 nM CCL3, (B) MCF7 response to 10 nM 
CCL3 (C) Jurkat response to 10 nM CXCL12, all n=1. (D) Jurkat, AUC following 10 nM CXCL12, 
Means ± SEM, Student t-test, n≥3 independent experiments, ns=p>0.05. (E) Celecoxib 50 μM pre-
treatment of MCF7 response to 10 nM CCL3, n=1. Data: Fluorescence ratio change (∆340/∆380 
nm) i.e. peak fluorescence following chemokine addition minus basal fluorescence (prior to 
chemokine). 
 
Rather than reduce calcium flux Ibuprofen significantly increased both the speed and peak levels 
reach in all three cell types, although the smaller increase seen in Jurkat was not statistically 
significant. Celecoxib also increased calcium flux. Some NSAIDs may mediate apoptosis in 
malignant cells partly through effects on intracellular calcium concentrations. Celecoxib inhibits 
both calcium uptake and Ca2+ ATPases (aka SERCAs). Calcium enters the endoplasmic reticulum 
(ER) through Ca2+ ATPases, and Celecoxib inhibits this calcium uptake causing calcium mobilisation 
and elevation [487]. Calcium levels can affect apoptosis. Celecoxib may trigger apoptosis via 
inhibiting signalling via ERK and Akt, both pathways support cell survival [821]. Ca2+ rise may 
activate calcium-dependent proteases, endonucleases and calcineurin, all of which can induce 
apoptosis. Raised Ca2+ levels facilitate Ca2+ infiltration of mitochondria, causing cytochrome C 
release, which activates caspases causing apoptosis [822, 823]. 
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In contrast Aspirin was found to have a small negative effect on CCL3 calcium dynamics in THP-1, 
but significantly increased calcium flux in Jurkat in response to CXCL12. Whereas Naproxen 
blunted peak calcium release but prolonged the time of release, hence overall did not significantly 
reduce the total AUC, figures 7.20.  
THP-1 Jurkat Jurkat, CXCL12 
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Jurkat Jurkat, CXCL12 
D  E  
Figure 7.20: Fura2 Ca2+ assays following Aspirin, Naproxen or control. Traces following Aspirin 555 
μM pre-treatment (A) THP-1 response to 10 nM CCL3, (B) Jurkat response to 10 nM CXCL12, both 
n=1, (C) Jurkat AUC response to 10 nM CXCL12. (D) Naproxen 217 μM pre-treatment of Jurkat 
trace response to 10 nM CXCL12, n=1, and (E)  Jurkat AUC following 10 nM CXCL12, Means ± SEM, 
Student t-test, n≥3 independent experiments, ns=p>0.05. Data: Fluorescence ratio change 
(∆340/∆380 nm) i.e. peak fluorescence following chemokine addition minus basal fluorescence 
(prior to chemokine). 
 
7.2.6: COX2-inhibition may modulate basal cAMP levels 
cAMP is a second messenger that can be produced in response to stimulation of receptors 
including chemokine receptors, via membrane associated adenylyl cyclases converting ATP to 
cAMP. cAMP is then degraded by phosphodiesterases. cAMP transfers signals from receptors to 
intracellular downstream effectors, and is a negative regulator in immune cells through the 
protein kinase A (PKA) pathway [743].  
Here the effects of Celecoxib, Ibuprofen and Paracetamol on cAMP levels before and after CCL2 
treatment were examined. THP-1 cells were treated with the drugs in the presence of 
phosphodiesterase inhibitor IBMX 0.75 mM with or without 10 nM CCL2 stimulation for periods 
varying from 1 to 20 minutes, figure 7.21.  
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A B 
Figure 7.21: THP-1 cAMP levels before and following treatment with CCL2 10 nM. (A) THP-1 in 
presence of IBMX 0.75 mM, were pre-treated with control (DMSO), Celecoxib 50 μM, Ibuprofen 
290 μM or Paracetamol 260 μM (30 mins, 37°C) before Forskolin 20 μM then CCL2 for timed 
periods (1, 5, 10 and 20 minutes). Cells were then lysed and cAMP levels recorded. (B) Analysis of 
data selected from (A). Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, **=p<0.01, *=p<0.05, ns =p>0.05. 
 
 
Paracetamol and Celecoxib reduced basal cAMP levels, but not the fall in cAMP levels over 1 to 20 
minutes in THP-1 subject to 10 nM CCL2 stimulation, figure 7.21B. Reduction in basal cAMP levels 
were statistically significantly with Celecoxib (p<0.01) and Paracetamol (p<0.05) but not with 
Ibuprofen (p>0.05), suggesting observed effects may relate more to COX2 than COX1 inhibition. 
Although cAMP levels at 20 minutes post CCL2 treatment were slightly higher than control in the 
presence of all three drugs, the increases did reach statistical significance.  
 
7.2.7: NSAIDs and Paracetamol modulated cofilin phosphorylation 
Cofilin phosphorylation in response to CCL3 and CXCL12 was examined in THP-1 cells pre-treated 
for 30 minutes with Celecoxib, Aspirin, Naproxen, Paracetamol or Ibuprofen, figure 7.22. 
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Figure 7.22: Total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin phosphorylation 
levels in THP-1 following pre-treatment with Celecoxib 25 μM, Aspirin 555 μM, Ibuprofen 290 μM 
or Paracetamol 130 μM (37°C, 30 mins) in presence and absence of (A) CCL3 or (B) CCL3 (5 nM, 15 
mins before lysis). (C) THP-1 pre-treatment with control (DMSO) (37°C, 30 mins) then CCL3 or 
CXCL12 (5 nM, 15 mins). (D) THP-1 pre-treated with Naproxen 217 μM (37°C, 30 mins) then CCL3 
(5 nM, 15 mins). Arrestin-2 loading controls. 
 
Cofilin phosphorylation usually follows treatment with CCL3 or CXCL12 in THP-1, as discussed in 
chapter five, see figure 5.4. Celecoxib, Naproxen, Aspirin and Paracetamol eliminated the 
expected phosphorylation from CCL3 or CXCL12 treatment whereas Ibuprofen consistently 
produced cofilin phosphorylation in presence and absence of CCL3 or CXCL12, figure 7.22. 
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7.3: Discussion 
Aspirin, Paracetamol and NSAIDs Ibuprofen, Naproxen and Celecoxib were found to have drug 
and/or cell-line specific effects on chemotaxis, chemokinesis, calcium flux, cAMP production and 
cofilin phosphorylation in response to chemokines.  
7.3.1: Ibuprofen may have PGE2-independent effects on cell viability and migration 
Ibuprofen was used here at 290 μM a concentration that did not cause cytotoxicity, well below 
the IC50s found of 690 μM in THP-1 and 1.16 mM in Jurkat, figure 7.8, and below IC50’s reported by 
others [798].  In other cancer cell-lines exposed to growth-supporting media and conditions 
ibuprofen is reported to have caused apoptosis and/or inhibited proliferation, including in human 
malignant colorectal, gastric adenocarcinoma, human cutaneous and prostate cancer cells [801, 
824, 825]. Ibuprofen may produce a concentration-dependent effect over 24-72 hours inhibiting 
cell proliferation, decreasing cell size and inducing cell rounding with loss of detachment but not 
direct cytotoxicity [801]. Akrami et al. (2014) found Ibuprofen at 500 μM upregulated apoptosis 
supporting proteins p53 and Bax, and down-regulated angiogenesis supporter VEGF-A along with 
stemness markers OCT3/4 and CDC44 [798]. Others concur that ibuprofen increases p53 and BAX 
expression [799].  
At 600 μM Ibuprofen is reported to upregulate MDM2, p53, p21 and caspase-3 along with 
caspase-6 to caspase-9, while down regulating cell cycle related proteins E2F2, CDC25A and PCNA. 
Detailed examination of the effects of ibuprofen on cell cycle genes showed, in a gastric cancer 
cell-line, that at 600 μM ibuprofen caused cells to move from S and G2/M phases to G0/G1 and 
cause G1 arrest [801]. Similar effects have been reported for another NSAID, Indomethacin [446]. 
Ibuprofen appeared to block cells in G1, by decreasing cyclins and cyclin-dependent kinase 
expression and increasing cell cycle inhibition by protein p21. Ibuprofen at 800 μM also increased 
Reactive Oxygen Species levels inducing p21/p53-dependent apoptosis [801]. 
Ibuprofen at 290 μM was found to inhibit chemotaxis and chemokinesis supported by CCL3 
and/or CXCL12 in THP-1, Jurkat and MCF7, figures 7.9-7.10. The mechanism may involve Akt. 
Ibuprofen is reported to inhibit Akt and hence Pi3K-Akt signalling [798]. The Akt pathway 
regulates cell survival, migration and angiogenesis, and Akt inhibition by NSAIDs may induce 
apoptosis in some cell types [826]. Akt is pivotal in cancer development. Akt activation requires 
direct interaction of Akt’s PH domain with PIP3, at the plasma membrane. Phosphorylation by 
kinases PDK1 and mTORC2 activate Akt which can inactivate cell cycle inhibitors p27 and p21 thus 
facilitating G1/S phase progression [618, 827]. Akt may also interact with Cyclin A2 which 
activates Cyclin-Dependent Kinase-2 (CDK2) [828]. 
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Ibuprofen was found to cause loss and distortion of actin filaments and stress fibres, figure 7.11. 
Others have examined the effects of NSAIDs in vitro on A549 lung cancer cell morphology. 
Indomethacin but not Aspirin (3 mM), or NSAIDs Diclofenac (300 μM) or Sulindac (300 μM) caused 
exposure time-dependent reversible loss of actin stress fibres along with cell elongation and 
shrinkage. PGE2 levels were equally reduced by around 70% by all four NSAIDs, but morphology 
was not restored in Indomethacin-treated cells by PGE2 supplementation. However, only 
Indomethacin was found to have reduced cellular levels of adhesion molecules, E-cadherin and 
collagen IV, by upregulating matrix metalloprotease 9 (MMP9), molecular scissors that support 
epithelial mesenchymal transition (EMT). Indomethacin’s effects on cell morphology were all 
reversible by treatment with PPARγ agonist troglitazoneb [829].   
Ibuprofen has been found to activate transcription factor PPARγ [830], which is expressed in a 
very wide range of cancers [831], neuronal, and adipocyte cells [830, 832]. PPARγ activation 
inhibits RhoA and Rac1 activation essential for cell migration [671], blocks P13K/Akt and Erk1/2 
signalling [833, 834], and stimulates transcription of PTEN tumour suppressor [835]. PTEN can 
dephosphorylate PIP3 and so inhibit the activation of Akt and also induce mitochondrial 
translocation of cofilin [792, 793, 836], although PTEN can be mutated in cancer [687]. Thus while 
Indomethacin could potentially aid epithelial-mesenchymal transition from primary tumour and 
mesenchymal-epithelial transition at a secondary (seeding) site [829], Ibuprofen by activating 
PPARγ would not. This may be one factor why the effects of different NSAIDs in cancer are 
inconsistent. 
Ibuprofen ability to inhibit cell migration, figures 7.9-7.10, invites further investigation as 
potentially may translate to Ibuprofen in vivo inhibiting chemokine-supported metastasis. Other 
potential therapeutic benefits of Ibuprofen on signalling in cancer include evidence that VEGF, a 
key mediator of angiogenesis in cancer which induces growth factor release from its target 
tissues, and fibroblast growth factor production, may be reduced by NSAID inhibition of COX1 and 
COX2 [837, 838]. For Ibuprofen these effects may be concentration dependent. Ibuprofen has 
been shown to reduce hypoxia-inducible factors HIF-1α and HIF-2α, along with HIF-regulated 
proteins Glut-1 and VEGF, in cells not expressing COX2 [839]. Some NSAIDs may inhibit hypoxia-
induced angiogenesis by increasing the expression of tumour suppressor VHL so reducing HIFα 
levels and consequently reducing VEGF secretion [840].  HIF support tumour survival, 
aggressiveness and angiogenesis [841].  Many tissues may produce VEGF including neutrophils, 
platelets and endothelium [842]. Ibuprofen may also reduce the production of fibroblast growth 
factor which supports PGE2 and PGI2 inflammation and angiogenesis [843].  
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Ibuprofen has been shown to inhibit ovarian and breast cancer growth and tumour PGE2 levels 
[844], possibly partly through an anti-oestrogenic effect [845]. Overall Ibuprofen is attributed with 
many off-target effects, figure 7.23, the drug may even partly reduce pain by inhibiting the 
excitatory neurotransmitter, Acid Sensing Ion Channel 1a which is involved in pain sensation and 
inflammation [846].  
 
 
 
 
 
 
Figure 7.23: Ibuprofen’s possible off target 
effect, and links to cofilin phosphorylation 
[830, 833]. 
 
7.3.2: NSAIDS effects on calcium fluctuations 
Receptor stimulation by physiological agonists such as chemokines can trigger Ca2+ oscillations 
[847], which then affect gene expression [848]. Chemokine-stimulated Ca2+ signalling can 
stimulate PIP2 hydrolysis to DAG and Inositol trisphosphate (InsP3) which then binds InsP3 
receptors, which are calcium release channels in the ER [849]. The calcium release that follows 
can stimulate calmodulin [850] which binds and activates calcineurin, a protein phosphatase, (and 
other targets) which themselves activate transcription factors including NFκB and Nuclear Factor 
of Activated T-cells (NFAT), and hence Ca2+ dynamics can regulate gene expression [811, 851, 
852]. This can produce proliferation, progression of cell cycle and mediate apoptosis [853]. 
Inhibiting T-type Ca2+ channels can reduce proliferation and support apoptosis in cancer cells 
[854]. Also targeting ORAL1, a plasma membrane pore structure, and STIM1, an ER calcium 
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sensor, (see annotated illustration chapter 8, figure 8.36) which both mediate store operated 
calcium re-entry following stimulation, may inhibit malignant cell growth [855].  
Here Aspirin, but not Naproxen, was observed to significantly increase overall CXCL12-stimulated 
Ca2+ responses in Jurkat but not to affect THP-1 Ca2+ oscillations following CCL3, figure 7.20. 
Conversely Celecoxib and Ibuprofen consistently increased peak calcium stimulation levels 
following CCL3 or CXCL12 in Jurkat MCF7 and THP-1, figure 7.19. Overall results suggest calcium 
responses are chemokine and cell-type specific. Aspirin and some NSAIDs may inhibit Ca2+ uptake 
by mitochondria which support Ca2+ oscillations by importing Ca2+ after influx effectively acting as 
Ca2+ buffers [856].  NSAIDs and Aspirin have for many years been reported as having inhibitory 
effects on malignant cell proliferation [857, 858], as has Phenacetin which is converted to 
Paracetamol in vivo [857]. Proposed mechanisms include modulation of calcium dynamics that 
support migration. This may be via modulation of focal adhesions; by inhibiting store-operated 
calcium influx focal adhesion turnover is stalled, inhibiting cell migration [859, 860].  
The crosstalk between the immune and nervous systems contributes to inflammation in cancer 
[861]. The transient receptor potential (TRP) proteins are a family of cation proteins implicated in 
pro-inflammatory immune cells including macrophages and T-cells [862]. Important TRPs include 
TRPV1 and TRPA1; both play key roles in neurogenic inflammation. Both are Ca2+ permeable non-
selective cation channels that can depolarise plasma membranes allowing Ca2+ influx. Activation 
of TRPV1 produces anti-tumour activity in many breast cancer types [863] and may be therapeutic 
in other cancers including bladder and endometrial [864, 865]. However Ca2+ influx through 
another TRP cation channel, Transient Receptor Potential Melanostatine-2 (TRPM2), is reported 
to contribute to Paracetamol toxic effects in overdose [866].  
Many inflammatory mediators, including prostaglandins and cytokines, act as TRP channel 
agonists, for example CCL3 has been shown to sensitize TRPs and activate TRPV2 Ca2+ channels 
[867] and TRPA1 agonists include a metabolite of PGD2 called 15-deoxy-δ(12,14)-PGJ2 [868]. The 
actions of agonists at TRPA1 and TRPV1 and channel activation are dependent on both agonist 
combinations and concentrations, plus intracellular Ca2+ concentrations [869, 870]. PGE2 can 
increase cytosolic free calcium in monocytes treated with 10 nM CCL3 or CXCL12 [802].  
Paracetamol also produced specific chemokine and cell-type calcium responses, figure 7.18. The 
mode of action of Paracetamol, discussed in chapter one section 1.9.2, includes increasing levels 
of anandamide, which can act as a T-type calcium channel blocker [871] and inhibits Cav3.2 
channels [872]. Paracetamol in vivo is metabolized to p-aminophenol in the liver then to N-(4-
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hydroxyphenyl)-5,8,11,14-eicosatetraenamide (AM404) by fatty acid amide hydrolase in the brain 
[421]. AM404 can activate TRPV1 channels. TRPV1 may interact with Cav3.2 channels found in the 
dorsal horn and dorsal root ganglion, two key pain pathway areas [820, 873]. Therefore in vitro 
investigations into Paracetamol’s effects on calcium responses may not accurately reflect in vivo 
reality. 
7.3.3: NSAIDs and basal cAMP levels 
The cAMP/PKA pathway must be tightly regulated to prevent excessive immunological activation. 
NSAIDs negatively regulate the cAMP/PKA pathway by inhibiting COX1 and COX2. Inhibition of 
these enzymes with NSAIDs blocks PGE2 synthesis, which subsequently, via EP3 receptors and Gi 
responses, downregulates cAMP levels in some immune cells including T-cells, see figure 7.24. 
This may enhance anti-tumour responses in cancer [874-877]. Although neither Ibuprofen, 
Paracetamol or Celecoxib had any significant effect on cAMP falls following CCL2 stimulation, 
figure 7.21, results suggest that COX2 inhibition with Paracetamol and Celecoxib may 
downregulate basal cAMP levels in THP-1 monocytes, this may deserve further investigation for 
anti-cancer effects. COX2 is expressed in adenoma and malignant tissues but colon cancer 
initiation appears connected with COX2 expression in macrophages within mildly dysplasic 
adenoma tissues [878]. Inhibition of COX2 appears therapeutic in preventing progression of 
dysplasia to cancer [786], possibly as COX2 expression in macrophages supports angiogenesis. 
Colon tumours have high macrophage density as CCL2 recruits circulating monocytes which 
differentiate to macrophages. In macrophages CCL2 stimulates both COX2 expression and, via a 
COX2/PGE2 autocrine/paracrine pathway, Vascular Endothelium Growth Factor (VEGF) release 
[787].  
 
7.3.4: The Prostaglandin Cascade, cAMP and Cofilin 
PGE2 is produced through COX metabolism of membrane arachidonic acid. PGE2 can produce 
effects through the E-series Prostanoid GPCRs [879] which through Gαs G-proteins increase cAMP 
activity stimulating PAK and Epac1/2 which acting via PTEN [791] inhibit macrophage phagocytosis 
[880]. PTEN can dephosphorylate PIP3 and inhibit Akt [791, 881]. The PGE2 triggered cAMP 
signalling through PKA and PTEN can activate cofilin-1 preventing effective actin polymerization 
[409] so NSAIDs may, through inhibition of PGE2 production, influence phosphorylation of cofilin 
and hence cell migration. Prostanoids can coordinate autocrine and paracrine signalling by 
binding GPCRs EP1-4 [882]. COX1 and COX2 are regulated by arachidonate and peroxide 
availability. The lower levels of substrate peroxide activate COX2 more than COX1 [883]. Tissue-
specific synthases then control the pathway from PGH2 onwards [459], figure 7.24. 
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Figure 7.24: Hydrolysis of the ester linkage in phospholipid by phospholipases C and A2 releases 
arachidonic acid which COX1 & COX2 along with peroxidases oxidise to PGH2. Specific 
prostaglandin synthases then produce products including prostanoid PGE2. PGE2 binds 
prostaglandin E2 receptors 1 – 4. Leukocytes carry EP2 and EP4 receptors, stimulation of which 
activate Adenylyl Cyclase (AC) and increases cAMP. EP4 signals via Gαi, Pi3K, β-arrestin, and β-
catenin [884-886]. 
 
Celecoxib, Aspirin, Naproxen and Paracetamol were all found to reduce cofilin phosphorylation, 
figure 7.22, an expected response from drugs which reduce PGE2 levels. However pre-treatment 
with Ibuprofen consistently caused cofilin phosphorylation in the presence and absence of CCL3 
or CXCL12. Ibuprofen can decrease RhoA activation and ROCK-1 expression [794, 887]. Ibuprofen 
enhances axonal sprouting and regeneration [888] possibly as activation of Rho contributes to 
lack of nerve regeneration [889]. So logically Ibuprofen should inhibit PGE2 and possibly directly 
RhoA-ROCK-LIMK-cofilin phosphorylation, but as the above blots show this was not found to be 
the case.  
Ibuprofen is also reported to mediate cytoskeletal Ca2+ binding protein Swiprosin-1 aka EFHD2 
[890], which is present in monocytes [891], and both buffers intracellular Ca2+ and regulates 
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cofilin’s access to filament actin [892]. Here Ibuprofen was shown to increase peak calcium flux 
levels in response to chemokines, figure 7.19. Raised Ca2+ may enhance Calcineurin’s activation of 
Slingshot, hence dephosphorylation of cofilin [893], conversely here Ibuprofen increased 
phosphocofilin levels, figure 7.22. Amplification of Swiprosin-1, which lies upstream of Cdc42, Rac 
and Rho, has been shown to increase the effects of CXCL12 on Jurkat. When inhibited Swiprosin-1 
may amplify Rho and PAK signalling stimulating cofilin phosphorylation through LIMK [894]. 
Ibuprofen mediation of Swiprosin-1 may contribute to Ibuprofen’s effects on cofilin 
phosphorylation, calcium flux, actin filaments, figure 7.11, and chemokinesis, figures 7.9-7.10. 
Also Ibuprofen is reported to inhibit MEK-ERK signalling [895]. The MEK small molecule inhibitor 
SL327 also consistently strongly induces cofilin phosphorylation (chapter 5, figure 5.45) possibly 
suggesting that Ibuprofen may have some anti-cancer effects through strongly inhibiting MEK 
signalling and chemotaxis. 
7.4: Conclusions 
Only Ibuprofen amongst the drugs investigated here inhibited chemotaxis or chemokinesis to 
both chemokines in all three cell-lines. Naproxen inhibited CXCL12 migration in Jurkat and THP-1 
but not CCL3-induced migration in THP-1 or chemokinesis in MCF7. Whereas Aspirin inhibited 
CXCL12 but not CCL3-chemotaxis and Celecoxib and Paracetamol had no effect on chemotaxis 
although Celecoxib did inhibit MCF7 chemokinesis. These results were not explain by cytotoxicity 
as for example Celecoxib appeared more cytotoxic, IC50 54 μM in THP-1 and 48 μM in Jurkat, than 
Ibuprofen, IC50 1.16 mM in Jurkat and 690 μM in THP-1. Thus Aspirin and NSAIDs but not 
Paracetamol appear able to inhibit chemotaxis and/or chemokinesis but they may do so in a 
chemokine and cell-type specific fashion. 
All the drugs tested here modulated calcium oscillations in a cell- or chemokine-specific manor. In 
THP-1, Paracetamol and Celecoxib but not Ibuprofen significantly reduced basal cAMP levels but 
not cAMP level reduction produced by CCL2 suggesting signalling involving calcium channels or 
cAMP may be involved in some of NSAIDs off-target effects.   
Aspirin, Naproxen, Ibuprofen and Celecoxib all adversely influenced actin filament formation. Also 
Celecoxib, Aspirin, Naproxen and Paracetamol eliminated, but Ibuprofen increased, THP-1 basal 
phosphorylation of cofilin, and that following treatment with CCL3 or CXCL12.  
The results suggest the effects of Ibuprofen, Naproxen, Celecoxib and Aspirin, on cancer initiation 
and progression should be assessed individually, as each produced contrasting responses to 
chemokines. Ibuprofen appears the most consistent and potent inhibitor of chemotaxis and 
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chemokinesis and Ibuprofens eliciting of cofilin phosphorylation suggest its reported 
antineoplastic effects may be PGE2-independent; possibly acting through inhibiting MEK signalling 
or modulation of cytoskeletal protein cytoskeletal Ca2+ buffering protein Swiprosin-1. 
 
Fascinatingly the R-enantiomer of Naproxen, which is marketed as a racemic mix, has been found 
to inhibit Rho GTPase Rac1 and act in a similar way to popular Rac1 inhibitor NSC23766 [896]. 
Also Rac1 overexpression in bowel cancer may be prevented by NSAIDS [897]. These factors 
raised the questions; what effects does Rac1 inhibition have on CXCL12- and CCL3-chemotaxis, 
and cofilin phosphorylation? Investigations exploring these questions are reported in chapter 8. 
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Chapter 8: Rac1 mediates chemotaxis to CXCL12 but not CCL3, in leukaemic and breast 
cancer cell-lines, and Rac1 GEF inhibitor NSC23766 may have off-target effects on 
CXCR4/CXCR7 axis 
 
8.1: Introduction 
The CXCR4/CXCL12 axis is complex, as CXCR4 variants and oligomerization along with CXCL12 
functioning in monomeric and dimeric forms adds to the challenge of understanding CXCL12-
induced chemotaxis in cancers [142, 145, 148]. The illumination of how CXCR4 ligands, such as 
CXCL12 and AMD3100, bind has taken extensive research over decades [147, 149]. CXCR4 ligands 
have the potential to mitigate metastasis [135]. Ras family Rho GTPases, co-ordinate actin 
polymerization, cell adhesion and cytoskeletal dynamics. They are molecular switches which can 
be activated by chemokines to trigger downstream signalling pathways [330, 336]. Rho GTPases 
are controlled by three sets of proteins Rho GDIs which can sequester and inactivate RhoGTPases 
[337]; Rho GAPs which facilitate switching ‘off’ Rho GTPases [341, 342]; and Rho GEFs which 
promote switching Rho GTPase ‘on’. There are many Rho GEFs, most are controlled by 
phosphorylation [330, 338, 343]. One important Rho GTPase, Rac1, is key in the formulation of 
lamellipodia and overall cell motility [334], figure 8.1. Rac1 is activated, i.e. bound GDP is replaced 
by GTP, by Rho GEFs including Tiam1 and TrioN. In some cell-lines Rac1 supports chemotaxis 
through signalling also involving Akt and PKC [344, 346-350]. Here the aim was to elucidate the 
role of Rac1 in CXCL12- and CCL3-induced chemotaxis and wound-healing using small molecule 
inhibitor NSC23766 which purportedly selectively inhibits Rac1 interactions with Rho GEFs Tiam1 
and TrioN [346], direct Rac1 inhibitor EHT1864, and Rac1-inhibiting peptide W56.  
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Figure 8.1: CXCL12-induced signalling can be modified by CXCR4 inhibition, for example with 
AMD3100 or ATI2341, and by Rac1 inhibition with W56 or NSC23766. 
Hypothesis: Rac1 signalling is important for chemokine-supported cell migration of both 
haematopoietic and epithelial cancers. 
Aim: To elucidate the role of Rac1 in THP-1 and Jurkat chemotaxis, MCF7 chemokinesis, cofilin 
phosphorylation, cAMP responses and calcium flux stimulated by chemokines CXCL12 and CCL3. 
Objectives: 
(i)    Explore the role of Rac1 in THP-1 and Jurkat chemotaxis and MCF7 wound-healing using small 
molecule inhibitor NSC23766, and Rac1-inhibiting peptide W56. 
(ii)    Examine the effect of CXCR4 small molecule inhibition on Rac1 activation. 
(iii)  Investigate if Rac1 inhibition interacts positively or negatively with CXCR4-binding antibody or 
small molecule inhibitors using chemotaxis assays and flow cytometry. 
(iv)  Explore the effect of Rac1 and CXCR4 inhibition on cAMP modulation by CXCL12. 
(v)   Elucidate the effect of PKCζ siRNA knockdown on Jurkat chemotaxis and MCF7 chemokinesis. 
(vi)  Explore the effects of Rac1 inhibition in THP-1 and Jurkat on calcium mobilisation triggered by 
chemokine stimulation.  
(vii) Examine if inhibition of Cdc42 or PLC affects chemotaxis, calcium flux or cAMP levels in THP-1 
and Jurkat.  
(viii) Investigate if Rac1 inhibition modulates actin filament formation or cofilin phosphorylation in 
response to CXCL12 in THP-1. 
(ix)  Discover if NSC23766 or W56 affect THP-1 chemotaxis to other CXC and CC chemokines.  
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8.2: Results 
Please note controls are common between graphs where experiments were conducted 
simultaneously; results for each inhibitor have been displayed separately for ease of description 
of results, this applies to: figures 8.6A and B; 8.25A and 4.24C; 8.30A and B. 
The tools used to achieve the chapter aims included small molecule inhibitors of Rac, NSC23766 
and EHT1864, along with a peptide that binds a region of the human Rac1 protein between its 
two Switch regions. Rac1 residues 45-60 appear critical for specific Rac1 guanine nucleotide 
exchange factors (GEF’s) recognition and activation, with Trp56 located in the Rac1 Switch II 
region being key for specificity between Rac1 and Cdc42 binding. These 15 residues, (see chapter 
one, figure 1.16), have been found to act as a very specific inhibitor preventing Rac1–GEF 
interactions [898]. Two 15 amino acid peptides were synthesised: active peptide W56 sequence 
VDGKPVNLGLWDTAG, and inactive control F56 sequence VDGKPVNLGLFDTAG where the key 
amino acid Trp56 was replaced by Phe56 to inactivate the peptide. 
8.2.1: NSC23766 inhibits chemotaxis to CXCL12 but not CCL3 
NSC23766 is a small molecule inhibitor that binds to the surface of Rac1 at the location where 
Rac1 specific GEFs Tiam1 and TrioN bind [899]. Hence NSC23766 inhibits TrioN and Tiam1 binding 
and activating Rac1. NSC23766 effects on Jurkat, THP-1 and MCF7 chemotaxis or chemokinesis in 
response to CCL3 and CXCL12 were examined, figure 8.2.  
 
THP-1 THP-1 Jurkat 
A  
 
 
B 
 
 
C 
Figure 8.2: Chemotaxis assays following pre-treatment with NSC23766 100 μM or control (A) 
Chemotaxis of THP-1 to 1 nM CXCL12, 1 nM CCL3 or 1 nM CCL3 + 1 nM CXCL12. (B) THP-1 
chemotaxis to 1 nM CCL3. (C) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *=p<0.05, 
ns=p>0.05. 
In THP-1 the effects of 100 μM NSC23766 on CXCL12 chemotaxis were dramatic, figure 8.2, yet on 
CCL3-induced chemotaxis 100 μM NSC23766 either had no inhibitory effects, or in some THP-1 
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CCL3 assays 100 μM NSC23766 was seen to statistically significantly increase chemotaxis. 
Combining chemokines CXCL12 1 nM and CCL3 1 nM increased migration further, but not in the 
presence of NSC23766, suggesting either a direct effect of NSC23766 on CXCR4 or that Rac1 
specifically supports CXCL12-induced chemotaxis. In Jurkat CXCL12 assays 100 μM NSC23766 
consistently highly significantly inhibited chemotaxis.  
AMD3100 inhibits CXCR4 so its effect on THP-1 chemotaxis to CXCL12 but also CCL3 was 
investigated. AMD3100 was found to produce a small (p<0.05) inhibitory effect on CCL3 
chemotaxis, while very significantly inhibiting chemotaxis to CXCL12 (p<0.001), figure 8.3, 
suggesting CXCR4 may play a role in CCL3/CCR5 or CCL3/CCR1 chemotaxis or that AMD3100 has 
some off target effects. 
 
Figure 8.3: Chemotaxis assay of THP-1 following pre-treatment with AMD3100 1 μM or control to 
1 nM CXCL12 or 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, *= p<0.05. 
Cell viability assays using NSC23766 at 100 μM in THP-1, Jurkat and MCF7 were conducted to 
confirm that the effects seen were not just from toxicity, figure 8.4. 
THP-1 Jurkat MCF7 
A
 
B
 
C
 
Figure 8.4: Cytotoxicity assays for NSC23766. MTS assays were over 7 hours in (A) THP-1 and (B) 
Jurkat and over 24 hours in (C) MCF7 cells. Basal absorbance occurs in presence of medium after 
MTS treatment in the absence of cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, ns =p>0.05.  
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MTS assays showed NSC23766 produced no significant inhibition to metabolism over 7 hours in 
THP-1 or Jurkat at concentrations up to 100 μM but produced toxicity above 100 μM, whereas in 
MCF7 over 24 hours toxicity was apparent over 50 μM. 
8.2.2: Rac1 inhibiting peptide W56 inhibits chemotaxis to CXCL12 but not CCL3 
The effects of Rac1 inhibiting peptide W56, and control peptide F56, on chemotaxis in THP-1 and 
Jurkat were examined, figure 8.5. 
Jurkat THP-1 
A 
 
B 
 
Figure 8.5: Chemotaxis assays following pre-treatment with Active Rac1 inhibiting peptide (W56) 
or Control peptide (F56) at 280 μM. (A) Chemotaxis of Jurkat to 1 nM CXCL12. (B) Chemotaxis of 
THP-1 to 1 nM CXCL12, 1 nM CCL3 or 1 nM CCL3 + 1 nM CXCL12. Means ± SEM, one-way ANOVA, 
post-hoc Bonferroni, n≥3 independent experiments, **=p<0.01, *= p<0.05, ns=p>0.05. 
 
Active peptide (W56) significantly inhibited chemotaxis to CXCL12 of Jurkat and THP-1 but not 
THP-1 to CCL3. Control peptide (F56) at 280 μM had no significant effect compared to untreated 
controls in either cell-line. MTS assays demonstrated W56 and F56 peptides had no effect on 
metabolism in THP-1, Jurkat or MCF7 (data not shown). 
 
8.2.3: NSC23766 and W56 inhibit CXCL12-induced but not CCL3-induced wound-healing in MCF7 
Assays examined the effects of 50 μM NSC23766, 280 μM W56 and 280 μM F56 on MCF7 wound-
healing induced by CCL3 and CXCL12, figure 8.6. 
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                 MCF7                        MCF7 
A  B  
 
 
Figure 8.6: MCF7 wound-healing following pre-treatment (30 mins, 37°C) with 50 μM NSC23766, 
280 μM W56, or 280 μM F56. Analysis 24 hours after (A) 10 nM CXCL12, or (B) 10 nM CCL3. (C and 
D) representative images. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, **= p<0.01. 
 
MCF7 chemokinesis in presence of CXCL12 but not CCL3 was significantly inhibited by both 
NSC23766 and W56, whereas control F56 had no effect. 
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8.2.4: NSC23766, AMD3100 and ATI2341 inhibit CXCL12-induced Rac1 activation in MCF7 
The above results suggested that in all three cell-lines Rac1 was important for CXCL12-induced 
migration and had little effect on CCL3-induced migration. However the dramatic effect on Jurkat 
migration to CXCL12 did stand out. Unfortunately Jurkat fail to migrate to other chemokines in 
any numbers so the effects of CXCL12 on Rac activation were explored using a Rac1 activation 
pull-down assay, and western blotting. Rac1 activation signal was clear in MCF7 but not detected 
in THP-1 or Jurkat; possibly this is not surprising as only 5-10% of Rac1 may be activated by 
extracellular stimulation [900]. In MCF7 NSC23766 and two CXCR4 inhibitors, AMD3100 and 
ATI2341, clearly inhibited Rac1 activation by CXCL12, figure 8.7.  
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Figure 8.7: Western Blot of Rac1 activation pull-down assay, MCF7 were serum starved for 24 
hours, treated with 25 μM NSC23766, 5 μM ATI2341 or 1 μM AMD3100 (30 mins, 37°C) then with 
10 nM CXCL12 (15 mins, 37°C), loading confirmed using total Rac. 
 
 
8.2.5: NSC23766 competes with CXCL12 for CXCR4 binding.  
These results suggested that the responses seen with NSC23766 treatment on CXCL12-induced 
chemotaxis in Jurkat and THP-1 may not be predominantly due to the effects of the inhibitor on 
Rac1 GEFs Tiam1 or TrioN. Published research suggests NSC23766 may have off target affinity for 
NMDA and mACh receptors [901, 902], so investigations into NSC23766’s effect on CXCR4 
signalling were undertaken. Firstly chemotaxis assays to CXCL12 at a range of concentrations were 
conducted with NSC23766 at lower than concentrations, 25 μM and 50 μM, than previously used 
in Jurkat chemotaxis. The results suggested CXCL12 and NSC23766 may be competing for CXCR4, 
and/or that NSC23766 by interacting with CXCR7, is modulating CXCL12’s effect on CXCR4, figure 
8.8.  
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                           Jurkat                           Jurkat 
A  B  
Figure 8.8: Chemotaxis assays of Jurkat treated with NSC23766 (A) 25 μM or (B) 50 μM to 
reducing concentrations of CXCL12, the ratio of treated to untreated cells migrating, at each 
concentration of CXCL12, are shown in green. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments. 
 
Figure 8.8 shows that the inhibitory effect of a set concentration of NSC23766 increased as the 
concentration of CXCL12 decreased. For example with CXCL12 at 1 nM and NSC23766 at 50 μM 
the ratio of inhibition was 60; and with CXCL12 at 0.5 nM, 70. This indicated a concentration 
response towards CXCL12, suggesting the inhibitor and the chemokine may be competing for 
CXCR4. The data from the above chemotaxis assays translates to the concentration response 
curves below, figure 8.9. 
Jurkat Jurkat 
A  B  
Figure 8.9: Data from figure 8.8 shown as concentration response curves towards CXCL12 
comparing control or NSC23766 treatment at (A) 25 μM or (B) 50 μM. Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments. 
 
The sigmoidal dose response curve indicates a reduction in CXCL12 potency in the presence of 
NSC23766. The CXCL12 EC50 calculates as 0.19 nM in absence of NSC23766 25 μM and as 2 nM in 
presence of 50 μM NSC23766, however the efficacy of CXCL12 remains the same. This suggests 
NSC23766 may have been acting as a competitive antagonist of CXCR4 in these migration assays. 
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8.2.6: NSC23766 competes with CXCR4 antibody 12G5 and CXCL12 
Next the effects of NSC23766 in competition with the CXCR4 antibody 12G5 were explored. 12G5 
was used at saturating concentrations 10 μg/mL, 12G5 EC50 is reportedly 1.9 ± 0.5 μg/mL [903], 
figure 8.10. 
Jurkat Jurkat 
A 
 
B 
  
 
 
 
 
Figure 8.10: (A) Jurkat cells were treated with 10 μg/mL 12G5 and/or with NSC23766 at various 
concentrations before CXCL12 1nM chemotaxis assays. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001, *= p<0.05, ns=p>0.05. (B) Data from (A) 
illustrating that with CXCL12 1 nM the combined inhibitory effects on chemotaxis of NSC23766 
and 12G5 reached a maximal at NSC23766 100 μM.  
Figure 8.10 illustrates that 12.5 μM NSC23766 does not add greatly to 12G5 inhibitory effects on 
chemotaxis but that 25 μM or 50 μM NSC23766 has an additive inhibitory effect to 12G5; and at 
100 μM NSC23766 the presence or absence of 12G5 makes no difference, inhibition is at a 
maximum, yet compared to the absence of CXCL12 some chemotaxis to CXCL12 still occurs. This 
suggests CXCR4 activity is not completely abrogated by either NSC23766 100 μM or 12G5, or the 
combination, hence neither is totally blocking CXCL12 stimulation. These results may suggest 
NSC23766 binds the same or similar sites to 12G5 and that these sites impact CXCL12 binding but 
do not completely abrogate the chemokine activating CXCR4. However results do not exclude the 
possibility that NSC23766 could be acting as an allosteric modulator, or is binding CXCR7 so 
modulating CXCR4/CXCR7 dimerization which could also partly but not completely inhibit 
chemotaxis to CXCL12. 
8.2.7: ATI2341, AMD3100 and NSC23766 are not chemotactic to Jurkat  
The small molecule CXCR4 inhibitors AMD3100 and ATI2341 were then employed to establish 
what response they would have in Jurkat and THP-1 chemotaxis assays to CXCL12. ATI2341 is an 
allosteric ligand, a pepducin. ATI2341 has a long palmitate lipidic tail to facilitate cell penetration 
Jurkats treated with Fucin then
NSC23766 dose response
to CXCL12 1 nM 12.08.16 n=3
C
on
tr
ol
, C
X
C
L1
2
Fu
ci
n 
+ 
C
X
C
L1
2
M
 +
 C
X
C
L1
2

N
S
C
 1
00
M
 +
 F
uc
in
 +
 C
X
C
L1
2

N
S
C
 1
00
M
 +
 C
X
C
L1
2

N
S
C
 5
0
M
 +
 F
uc
in
 +
 C
X
C
L1
2

N
S
C
 5
0
M
 +
 C
X
C
L1
2

N
S
C
 2
5
M
+ 
Fu
ci
n 
+ 
C
X
C
L1
2

N
S
C
 2
5
M
 +
 C
X
C
L1
2

N
S
C
 1
2.
5
M
 +
 F
uc
in
 +
 C
X
C
L1
2

N
S
C
 1
2.
5 C
on
tr
ol
, n
o 
ch
em
ok
in
e
0
100
200
300
400
500
600
ns
ns
*
***
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
m
L
-1
Jurkats CTX NSC23766 dose response
in presenceof Fucin & CXCL12 1nM n=3 5.8.16
0 25 50 75 100
0
100
200
300
400
500
600
Control + CXCL12
Fucin + CXCL12
NSC23766 concentration (M)
M
ig
ra
ti
n
g
 c
e
ll
s
 X
 1
0
4
m
L
-1
225 
 
and a peptidic moiety derived from a 16-amino acid stretch of CXCR4 ICL1, the location it is 
thought to bind, figure 8.11A. None of the inhibitors used here had any chemotactic effects in 
Jurkat, figure 8.11B. 
A B                                    Jurkat 
 
 
Figure 8.11: (A) Structure of ATI2341 C104H178N26O25S2 (Pal-Met-Gly-Tyr-Gln-Lys-Lys-Leu-Arg-Ser-
Met-Thr-Asp-Lys-Tyr-Arg-Leu), modification Met1 = N-terminal palmotoyl, Mol Wt: 2256.82. (B) 
Inhibitors NSC23766, AMD3100 or ATI2341 did not show any chemotactic properties towards 
Jurkat. Means ± SEM, n≥3 independent experiments. 
 
Allosteric ligands bind to spatially distinct sites away from the orthosteric site, but are capable of 
modifying the orthosteric site conformation.  Allosteric ligands can have higher receptor isoform 
selectivity and often have limited or subtle effects on normal spatiotemporal signalling, also their 
maximal effect may be determined by co-operation with endogenous ligand/s. If they affect 
orthosteric signalling an allosteric ligand can produce positive or negative modulation of 
orthosteric agonism. But equally allosteric ligands may themselves act as agonists or inverse 
agonists. An agonist can shift a receptor from an inactive conformation to an active one, an 
inverse agonist moves a receptor to an inactive state. An agonist’s efficacy is a measure of the 
shift to an active state [904].  
 
8.2.8: CXCR4 inhibition in presence of NSC23766 
MTS assays found no evidence of toxicity for AMD3100 or ATI2341 up to 10 μM, in MCF7, THP-1 
or Jurkat (data not shown). The effects of ATI2341 5 μM and various concentrations of AMD3100 
in combination and alone with 25 μM, 50 μM and 100 μM NSC23766 were first explored in Jurkat 
chemotaxis, figure 8.12. 
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           A                           Jurkat            B                        Jurkat 
  
                                                               C                         Jurkat 
 
Figure 8.12: Jurkat chemotaxis following pre-treatment with AMD3100, ATI2341 and various 
concentrations of NSC23766 in combination. (A) Chemotaxis to 1 nM CXCL12 following 25 μM 
NSC23766, 0.2 μM AMD3100 or 5 μM ATI2341 and in combination. (B) Chemotaxis to 1 nM 
CXCL12 following 50 μM NSC23766, 0.5 μM AMD3100 or 5 μM ATI2341 and in combination. (C) 
Chemotaxis to 1 nM CXCL12 following 100 μM NSC23766, 1 μM AMD3100 or 1 μM ATI2341 and in 
combination. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
 
At 25 μM NSC23766, both 0.2 μM AMD3100 and 5 μM ATI2341 added to inhibition of chemotaxis. 
At 50 μM NSC23766 and above inhibition of chemotaxis was increased by allosteric inhibition with 
5 μM ATI2341 but the combined inhibitory effect of NSC23766 and 0.5 μM AMD3100 was not any 
greater than 0.5 μM AMD3100 alone. At 100 μM NSC23766 neither AMD3100, nor ATI2341 added 
to inhibition, figure 8.12. These results support the above suggestion that in Jurkat NSC23766 may 
act as a competitive antagonist in CXCL12-induced chemotaxis.  
 
8.2.9: Flow cytometry demonstrated NSC23766 was displacing CXCR4 antibody 12G5 
Flow cytometry was used to explore the effects of NSC23766 with Rac1-inhibiting peptide W56, 
and then with ATI2341, AMD3100 CXCR4 inhibitors, on CXCR4 expression in presence and 
absence of CXCL12, figures 8.13-8.14. 
Jurkats CXCL12 1nM AMD3100 0.2 M,
ATI2341 5 M NSC23766 25 M n3 19.7.16
C
on
tr
ol
 +
 C
X
C
L1
2
A
TI
 +
 C
X
C
L1
2
A
M
D
 +
 C
X
C
L1
2
N
SC
 +
 C
X
C
L1
2
A
TI
 +
 N
S
C
 +
 C
X
C
L1
2
A
M
D
 +
 N
S
C
 +
 C
X
C
L1
2
C
on
tr
ol
, n
o 
ch
em
ok
in
e
N
SC
, n
o 
ch
em
ok
in
e
A
M
D
, n
o 
ch
em
ok
in
e
A
TI
, n
o 
ch
em
ok
in
e
0
50
100
150
200
250
300
350
400
450
******** ***
Control
ATI2341 5M
AMD3100 0.2M
NSC23766 25M
ns
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
 m
L
-1
Jurkats CXCL12 1nM AMD3100 0.5 M,
ATI2341 5 M NSC23766 50 M n3 08.7.16
C
on
tr
ol
 +
 C
XC
L1
2
A
TI
 +
 C
XC
L1
2
N
S
C
 +
 C
X
C
L1
2
A
M
D
 +
 C
X
C
L1
2
A
TI
 +
 N
SC
 +
 C
X
C
L1
2
A
M
D
 +
 N
S
C
 +
 C
X
C
L1
2
C
on
tr
ol
, n
o 
ch
em
ok
in
e
N
S
C
, n
o 
ch
em
ok
in
e
A
M
D
, n
o 
ch
em
ok
in
e
A
TI
, n
o 
ch
em
ok
in
e
0
50
100
150
200
250
300
350
400
450
ns
****** ***
Control
ATI2341 5M
NSC23766 50M
AMD3100 0.5M
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
 m
L
-1
Jurkats CXCL12 1nM AMD3100 1M,
ATI2341 1M NSC23766 100 M n3 30.6.16
C
on
tr
ol
 +
 C
XC
L1
2
A
TI
 +
 C
XC
L1
2
N
S
C
 +
 C
X
C
L1
2
A
M
D
 +
 C
X
C
L1
2
A
TI
 +
 N
SC
 +
 C
X
C
L1
2
A
M
D
 +
 N
S
C
 +
 C
X
C
L1
2
C
on
tr
ol
, n
o 
ch
em
ok
in
e
N
S
C
, n
o 
ch
em
ok
in
e
A
M
D
, n
o 
ch
em
ok
in
e
A
TI
, n
o 
ch
em
ok
in
e
0
100
200
300
400
500 ** ***
*
ns
ns
Control
ATI2341 1M
NSC23766 100M
AMD3100 1M
M
ig
ra
ti
n
g
 c
e
ll
s
 x
 1
0
4
 m
L
-1
227 
 
                                     Jurkat Jurkat 
A 
 
 
B 
 
Figure 8.13: (A) Flow cytometry measurement of CXCR4 expression in Jurkat treated with 
NSC23766 100 μM, F56 peptide 280 μM or W56 peptide 280 μM (30 mins, 37°C), followed by 
CXCL12 15 nM (15’, 37°C) then 12G5/mouse FITC staining (both 1 hr, 4°C). Means ± SEM, 20,000 
events, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, **= p<0.01, ***= 
p<0.001, ns =p>0.05.(B) Representative trace illustrating position of NSC23766 with and without 
CXCL12 15 nM trace compared to negative control (solid black) and control + CXCL12 15 nM. 
 
     Jurkat    Jurkat 
A                                     37°C 
 
B                                        4°C 
 
 
Figure 8.14: Flow cytometry measurement of CXCR4 expression in Jurkat treated with NSC23766 
100 μM, AMD3100 5 μM or ATI2341 5 μM (30 mins, 37°C) followed by CXCL12 15 nM for 15 
minutes at (A) 37°C and (B) 4°C, in both cases followed by 12G5/mouse FITC staining (both 1 hour, 
4°C). Post treatment is control with inhibitors added after 12G5/FITC at (A) 37°C, 30 minutes or 
(B) 4°C, 30 minutes. Means ± SEM, 20,000 events, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, *= p<0.05, **= p<0.01, ***= p<0.001, ns =p>0.05. 
 
The flow cytometry clearly shows CXCL12 causes internalisation of CXCR4 in Jurkat, this 
internalisation is prevented when the system is kept at 4°C, figure 8.14. The Rac peptide W56 did 
cause some loss of receptor from the cell surface compared to F56 control but this was marginal 
compared to the effect of NSC23766 100 μM, figure 8.13.  It can be seen that NSC23766 controls 
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the CXCR4 signal loss in presence and absence of CXCL12, and NSC23766 activity is not 
substantially affected by temperature, figure 8.14.  
 
8.2.10: Rac1 inhibitor ETH1864 does not modify 12G5 binding or CXCL12-triggered CXCR4 
internalisation  
To explore if the NSC23766 flow cytometry results could be due to Rac1 inhibition the experiment 
was repeated using 10 μM ETH1864 which binds and directly inhibits Rac1, Rac2 and Rac3, figure 
8.15. 
 
Jurkat 
 
EHT1864 
A  
 
  
 
                   B 
Figure 8.15: (A) Flow cytometry measurement of CXCR4 expression in Jurkat pre-treated with 
EHT1864 10 μM (30’, 37°C) followed by CXCL12 15 nM (15’, 37°C) followed by 12G5/mouse FITC 
staining (both 1 hr, 4°C). Means ± SEM, 20,000 events, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ns =p>0.05. (B) Structure of EHT1864. 
 
The EHT1864 had no effect on CXCR4 internalisation indicating that direct Rac inhibition did not 
explain results. 
 
8.2.11: Sucrose and sodium azide pre-treatment does not stop NSC23766 causing CXCR4 
internalisation 
Endocytosis is a process that requires energy so to further examine if NSC23766 was causing 
endocytosis the flow cytometry with AMD3100 and NSC23766 was repeated in the presence of 
sodium azide at 9 mM to deplete cellular ATP [905] and sucrose at 0.4 M which can inhibit 
endocytosis, figure 8.16.   
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Jurkat Jurkat 
A  B  
Figure 8.16: (A) Flow cytometry measurement of CXCR4 expression in Jurkat pre-treated with (A) 
sodium azide 9 mM (30’, 37°C)  or (B) Sucrose 0.4 M (30’, 37°C) then NSC23766 100 μM or 
AMD3100 5μM (30’, 37°C) followed by CXCL12 15 nM (15’, 37°C) followed by 12G5/mouse FITC 
staining (both 1 hr, 4°C). Means ± SEM, 20,000 events, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ns=p>0.05 
 
Flow cytometry showed that NSC23766 and AMD3100 continued to influence endocytosis in 
response to CXCL12 after pre-treatment of Jurkat with sodium azide or sucrose, figure 8.16. 
Sodium azide non-significantly increased CXCR4 expression, in control, in absence but not 
presence of CXCL12. AMD3100 and NSC23766 both reduced CXCR4 basal signal. In presence of 
sodium azide NSC23766 but not AMD3100 very significantly increased CXCR4 expression after 
CXCL12 stimulation. Sucrose very significantly increased CXCR4 basal signal before but not after 
CXCL12 stimulation, so in the absence of CXCL12 sucrose does hinder CXCR4 internalisation. 
AMD3100 and NSC23766 reduced CXCR4 basal signal similarly in the presence of sucrose before 
CXCL12 stimulation but neither significantly changed CXCR4 signal after CXCL12 treatment.  
 
8.2.12: NSC23766 may act as a biased antagonist with respect to cAMP signalling 
The CXCR4 receptor couples to heterotrimeric G-proteins, including Gαi; Gαi responses include 
reduction of cellular second messenger cAMP levels, figure 8.17. 
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Jurkat Jurkat 
   A 
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Figure 8.17: (A) Jurkat cAMP production following NSC23766 100 μM, AMD3100 5 μM, ATI2341 5 
μM, PKA inhibitor H89 HCl 2 μM or control (30 mins, 37°C) measured before or after 1, 5, 10 or 20 
minutes CXCL12 stimulation (10 nM, 37°C) (cells pre-treated with IBMX 0.75 mM & Forskolin 20 
μM). (B) Control and 20 minute data from A. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, 
n≥3 independent experiments, ***= p<0.001, ** = p<0.01, * = p<0.05, ns =p>0.05. 
 
Compared to control NSC23766 very significantly reduced basal cAMP levels and significantly 
reduce cAMP levels after CXCL12 stimulation. AMD3100, ATI2341 did not significantly change 
basal levels or those after CXCL12 treatment, and H89 HCl statistically significantly increased 
cAMP levels both before and after 20 minutes CXCL12 treatment, figure 8.17. 
 
8.2.13: cAMP levels may modulate PKCζ signalling  
The RhoGEF Tiam1 has been reported to sit in a feedback loop involving cAMP, Rac1, PKCζ and 
CXCR4. Increasing cAMP levels has been shown to increase the presence of membrane CXCR4, by 
both reducing CXCR4 endocytosis, prolonging CXCR4’s stay at the membrane, and increasing the 
speed of recycling CXCR4 back to the membrane from endosomes [906]. Increasing cAMP also 
antagonises CXCL12-induced receptor internalisation [907].  
 
 
The effects of siRNA inhibition of PKCζ on CXCL12 chemotaxis in Jurkat, along with CXCL12 and 
CCL3 wound-healing in MCF7 cells confirmed the involvement of PKCζ in the CXCL12 and CCL3 
signalling pathways, figure 8.18. 
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Jurkat                            MCF7 
A  B  
 
Figure 8.18: Transfection with 50 nM PKCζ siRNA or nonsense siRNA (Scr) control. (A) Jurkat 
chemotaxis to CXCL12 (B) MCF7 wound-healing, analysis 24 hours after 10 nM CCL3, or CXCL12 
Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
***=p<0.001, ns=p>0.05. (C) Wound-healing images. 
The success of the PKC zeta siRNA 50 nM (PRKCZ6) knockdown was confirmed by western 
blotting, knockdown was very successful in MCF7, figure 8.19. 
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Figure 8.19: Western Blot and PKCζ antibody reveals PKCζ expression in MCF7 24 hours after 
siRNA knockdown, β-actin loading control. 
 
8.2.14: Effects of NSC23766 on intracellular calcium 
Tiam1 does not have a calcium-calmodium binding site but can be phosphorylated, and so 
activated, by calcium-calmodulin-dependent protein kinase II [908].  Hence Rac activation may be 
influenced by intracellular calcium levels. This is thought to occur via disruption of Rac-Rho-GDI 
complex orchestrated by PKC and translocation of Rac to the membrane where it is activated by 
GEFs [909]. To help understand the relationship of intracellular calcium signalling and Rac-1 
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inhibition with NSC23766, THP-1 were pre-treated with NSC23766 and Fura2-AM then stimulated 
by CXCL12 10 nM or CCL3 100 nM, figure 8.20. 
THP-1 THP-1 
A  B  
 
 
THP-1 
 
 
THP-1 
C  D  
 
Figure 8.20: Fura2 Ca2+ assay in THP-1 following 100 μM NSC23766 or control. Data expressed as 
fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following CCL3 or CXCL12 
addition minus basal fluorescence (prior to chemokine). (A & B) THP-1 responses to CCL3 10 nM 
(C & D) responses to CXCL12 10 nM (B & D) Means ± SEM, Student t-test, n≥3 independent 
experiments, **=p<0.01. 
 
 
NSC23766 produced opposite effects on calcium signalling in THP-1 in response to CXCL12 and 
CCL3, figure 8.20, again suggesting it may be having a direct effect on CXCR4 or a modulator of 
CXCR4 and CCR5. It also dramatically reduced calcium signalling in response to CXCL12 in Jurkat, 
and dose dependently in MCF7, figure 8.21. 
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                A                              Jurkat                       B                      Jurkat 
  
 
                 C                           MCF7                      D                     MCF7 
 
 
Figure 8.21: Fura2 Ca2+ assay in Jurkat and MCF7 following NSC23766 or control. Data expressed 
as fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following CXCL12 10 nM 
addition minus basal fluorescence (prior to chemokine). (A & B) Jurkat (C & D) MCF7 (B & D) 
Means ± SEM, Student t-test, n≥3 independent experiments, **=p<0.01. 
NSC23766 produces very significant inhibition of calcium release in response to CXCL12 in both 
Jurkat and MCF7. As expected both chemokines produced a rapid but transient rise in calcium 
release. The biased effects of NSC23766 suggested either that Rac1 activation relates to CXCL12-
induced but not CCL3-induced calcium signalling, or that NSC23766 is having a direct or indirect 
effect on CXCR4. CXCL12 was found to trigger calcium release in Jurkat dose dependently up to 10 
nM , figure 8.22, and NSC23766 at 100 μM was found to inhibit this calcium release, but this 
inhibition was eroded as CXCL12 dose increased to 100 nM. NSC23766 and CXCL12 appeared to 
be competing for CXCR4.  
Jurkat 
 
Figure 8.22: Fura2 Ca2+ assay in Jurkat following 100 μM NSC23766 or control. Data expressed as 
AUC following CXCL12 addition when peak release is normalised to stimulation over basal 
(Δ340/Δ380). Means ± SEM, Student t-test, n≥3 independent experiments. 
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Further investigations compared the effects of NSC23766 and CXCR4 inhibitors AMD3100 and 
ATI2341 on calcium release in Jurkat, figure 8.23.  
Jurkat Jurkat Jurkat 
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C 
 
 
Figure 8.23: Fura2 Ca2+ assay in Jurkat treated with NSC23766 100 μM, ATI2341 5 μM or 
AMD3100 5 μM. (A) Fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 
10 nM CXCL12 addition minus basal fluorescence (prior to chemokine). (B) Means ± SEM, one-way 
ANOVA, post-hoc Bonferroni, n≥3 independent experiments, (C) Area under curve from B, 
***=p<0.001, **= p<0.01, *=p<0.05, ns=p>0.05. 
NSC23766 and AMD3100 caused very significant inhibition of calcium release in Jurkat, figure 
8.23, whereas ATI2341 has no significant effect on peak release but when the trace is analysed as 
area under curve it is apparent that ATI2341 causes a significant (p<0.05) increase in the overall 
calcium release. 
8.2.15: U73122 inhibits PLC signalling 
IP3 receptors can be influenced by many intracellular signals including phosphorylation by PKC and 
Rho kinases [910]. If the signalling effects above are due to NSC23766 inhibiting Rac1 then 
inhibiting U73122 should modestly mirror NSC23766 inhibition to CCL3 and CXCL12 chemotaxis 
and calcium flux and cAMP responses, figures 8.24-8.26. 
Jurkat THP-1 THP-1 
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Figure 8.24: Chemotaxis assays following pre-treatment with U73122 10 nM or control. (A) 
Chemotaxis of Jurkat to 1 nM CXCL12. (B) THP-1 chemotaxis to 1 nM CXCL12. (C) THP-1 
chemotaxis to 1 nM CCL3. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent 
experiments, ***=p<0.001, **=p<0.01, ns=p>0.05. 
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U73122 at very low concentration significantly inhibited chemotaxis to CXCL12 in both Jurkat and 
THP-1, but failed to statistically significantly inhibit chemotaxis to CCL3 in THP-1. 
 
Jurkat Jurkat Jurkat 
A
 
B 
 
C 
  
Figure 8.25: Fura2 Ca2+ assay in Jurkat following 10 nM U73122 or control. Data expressed as 
fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 nM CXCL12 
addition minus basal fluorescence (prior to chemokine). (A) Trace n=1, (B & C) Means ± SEM, 
Student t-test, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *=p<0.05, ns =p>0.05. 
 
U73122 10 nM also caused changes in calcium responses in Jurkat to CXCL12 which were 
apparent from the trace and AUC, figure 8.25. 
Jurkat Jurkat THP-1 
A 
  
B 
 
C 
 
Figure 8.26: (A) cAMP production in Jurkat following 10 nM U73122 or control measured before 
or after 20 minutes CXCL12 10 nM stimulation (cells pre-treated with IBMX 0.75 mM & Forskolin 
20 μM). (B & C) Cytotoxicity assays for U73122. MTS assays were over 7 hours in (B) Jurkat and (C) 
THP-1. Basal absorbance occurs in presence of medium after MTS treatment in the absence of 
cells. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, 
**=p<0.01, *=p<0.05, ns=p>0.05. 
 
cAMP production in Jurkat following CXCL12 10 nM simulation showed U73122 significantly 
increased levels reached in response to CXCL12. MTS assays confirmed observed effects were not 
due to U73122 toxicity. Although figures 8.25-8.27 above show there was some correlation 
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between Jurkat responses to NSC23766 and U73122 with respect to inhibition of CXCL12 and not 
CCL3 chemotaxis, the inhibitors had opposite effects on calcium release and cAMP levels in Jurkat. 
8.2.16: Inhibiting Cdc42 reduced migration towards CCL3 and CXCL12  
Rac 1 regulates actin polymerization through WAVE complex proteins. WAVE activates ARP2/3 
triggering actin polymerization [911]. Cdc42 working through WASP proteins also produces 
ARP2/3 actin nucleation [912]. Additionally Cdc42 contributes to polarized cell migration [746], 
and aids transmigration by causing filopodia extensions into the epithelium [911]. Cdc42 also 
supports cells’ polarity by inhibiting lamellipodium formation in uropodium [913]. Inhibition of 
Cdc42 with ZCL278 was found to inhibit both CCL3 and CXCL12 chemotaxis, figure 8.27. ZCL278 
and NSC23766 do appear to hinder F-actin polymerization, figure 8.28. 
THP-1 Jurkat 
 
 
Figure 8.27: Chemotaxis assays following pre-treatment with ZCL278 or control. (A) Chemotaxis of 
THP-1 to 1 nM CCL3 or CXCL12 or both. (B) Jurkat chemotaxis to 1 nM CXCL12. Means ± SEM, one-
way ANOVA, post-hoc Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, 
*=p<0.05. 
 
 
 
   
Control ZCL278 20 μM NSC23766 100 μM W56 280 μM F56 280 μM 
Figure 8.28: Filament actin stains. Alexa-488 Phalloidin (green) and DAPI nuclear stains (blue) of 
CHO.CCR5 following pre-treatment with ZCL278, W56, F56 or NSC23766 (1 hr, 37°C). Imaged UV 
inverted microscopy (Leica DMII Fluorescence microscope 500x Ex 490 nm, Em 520 nm). 
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8.2.17: W56 and NSC23766 both inhibit CXCL12- but not CCL3-induced cofilin phosphorylation 
Rac1 regulation of lamellipodia also involves cofilin, reviewed in chapter five, therefore the effects 
of Rac1 inhibitors W56 and NSC23766 on cofilin phosphorylation triggered by CXCL12 were 
explored, figure 8.29. 
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Figure 8.29: Total-cofilin and phosphocofilin (Ser3) antibodies reveals cofilin phosphorylation 
levels in THP-1 (A) Control treated with CXCL12 5 nM over 1, 5, 10, 15, 20, 25, or 30 minutes at 
37°C. (B) Treated with NSC23766 100 μM (30’, 37°C) then CXCL12 5 nM over 1, 5, 10, 15, 20, 25, 
or 30 minutes (37°C) (C) Control or treated with NSC23766 100 μM (30’, 37°C) then CXCL12 5 nM 
or CCL3 5 nM (15’, 37°C) (D) Control or treated with NSC23766 100 μM, W56 280 μM, or F56 280 
μM (all 30’, 37°C) then CXCL12 5 nM (15’, 37°C). β-actin loading control. 
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Cofilin phosphorylation in THP-1 was observed to occur in response to CXCL12 in two waves, 
figure 8.29, initially as a response detectable at 1 and 5 minutes, which is lost by 10 minutes and 
returns at 15 minutes onwards. Treatment with NSC23766 inhibited the early and eliminated the 
later phosphorylation.  
8.2.18: NSC23766 also inhibits chemotaxis of THP-1 to CXCL11 but not to CXCL9 or CCL2 
The effect of NSC23766 and W56 and F56 was explored on CXCL11, CXCL9 and CCL2 chemotaxis in 
THP-1 cells, figure 8.30. 
THP-1 THP-1 
A  B  
Figure 8.30: Chemotaxis assays following pre-treatment with 100μM NSC23766, 280μM F56 or 
W56, or control. (A) Chemotaxis of THP-1 to 1 nM CCL2 and/or 1 nM CXCL9. (B) THP-1 chemotaxis 
to 1 nM CCL2 and/or 1 nM CXCL11. Means ± SEM, one-way ANOVA, post-hoc Bonferroni, n≥3 
independent experiments, ***=p<0.001, ns=p>0.05. 
THP-1 migration towards CCL2 or CXCL9 was not reduced by either NSC2376, W56 or F56 whereas 
both NSC23766 and W56 reduced migration towards CXCL11, figure 8.30.  
8.2.19: CXCL14 modulates CXCR4/CXCL12 signalling in Jurkat 
CXCL14 is a non ELR CXC chemokine with similarities in structure to CXCL12. The N-terminus of a 
chemokine interacts with its receptor, in CXCL14 this NH2 tail is shorter than in CXCL12 or CXCL11 
[914], and contains a unique amino acid sequence which appears to be CXCL14’s ‘Achilles heel’ in 
cancer. The sequence allows CXCL14 to be targeted for ubiquitination and degraded by 
proteasomes, but this may occur only in malignant and immortalised cells. Destroying CXCL14 
may help cancer cells hide from the immune system [915]. High expression of CXCL14 is linked to 
improved overall and event free survival in some cancers [916]. This may explain why responses 
to CXCL14 dramatically differ in various primary and malignant cell-lines, for example in cells that 
express CXCL14, like monocytes and THP-1, CXCL14 is chemotactic, in vivo this may support 
CXCL14’s role in immune surveillance, however CXCL14 can also inhibit endothelial cell migration, 
proliferation and be angiostatic [917]. Jurkat do not express CXCL14 [918]. Although CXCL14 alone 
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in some cells expressing CXCR4 will not induce chemotaxis, calcium responses, or trigger Rac1 
signalling alone, it may potentiate or antagonise CXCL12 responses and affect cell-surface 
distribution of CXCR4 [919]. Hence the effects of CXCL14 on Jurkat chemotaxis and calcium 
responses to CXCL12 and CXCR4 internalisation in presence of NSC23766 and W56 were 
investigated, figures 8.31-8.33. 
            A                           Jurkat                B                        Jurkat 
  
Figure 8.31: CXCL14 inhibits Jurkat chemotaxis to CXCL12. (A) Chemotaxis to 1 nM CXCL12 
following pre-treatment with 2 nM to 600 nM of CXCL14 (30 mins, 37°C). (B) Chemotaxis to 0.5 
nM CXCL12 and 1 to 300 nM CXCL14, no pre-treatment. Means ± SEM, one-way ANOVA, post-hoc 
Bonferroni, n≥3 independent experiments, ***=p<0.001, **=p<0.01, *= p<0.05, ns=p>0.05. 
Figure 8.31 illustrates that even high concentrations of CXCL14, either as pre-treatment or mixed 
with CXCL12 as chemoattractant, inhibited but did not completely prevent chemotaxis of Jurkat to 
CXCL12. CXCL14 pre-treatment was found to dose-dependently inhibit chemotaxis to CXCL12 1 
nM by up to about ~45%, whereas in the presence of 0.5 nM CXCL12, CXCL14 at concentrations 
above 50 nM reduce chemotaxis by ~25%, suggesting concentration of these two chemokines is 
key. 
The effects of CXCL14 on calcium flux in Jurkat were also explored, figure 8.32. 
                A                               Jurkat                   B                        Jurkat 
 
 
Figure 8.32: Fura2 Ca2+ assay in Jurkat following pre-treatment with 100 nM CXCL14 or control. 
Data expressed as fluorescence ratio change (∆340/∆380 nm) i.e. peak fluorescence following 10 
nM CXCL12 addition minus basal fluorescence (prior to chemokine). (A) Trace (B) Means ± SEM, 
Student t-test, n≥3 independent experiments, **=p<0.01. 
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Figure 8.32 demonstrated that in Jurkat CXCL14 pre-treatment significantly increased both the 
speed and volume of calcium response to CXCL12. Finally flow cytometry experiments were 
undertaken to establish the effect of CXCL14 on CXCR4 internalization triggered by CXCL12 in 
presence and absence of NSC23766 and W56, figure 8.33.  
Jurkat 
 
Figure 8.33: Flow cytometry measurement of CXCR4 expression in Jurkat pre-treated with 
NSC23766 100 μM, W56 280 μM or control (30 mins 37°C) followed by CXCL12 15 nM or CXCL14 
100 nM (15 mins, 37°C) followed by 12G5/mouse FITC staining (both 1 hour, 4°C). Means ± SEM, 
20,000 events, one-way ANOVA, post-hoc Bonferroni, n=2 independent experiments, *=p<0.05, 
ns=p>0.05. 
 
NSC23766 but not W56 was found to significantly reduce the expression of CXCR4 in the presence 
of CXCL14 and in the presence of CXCL12 and CXCL14, figure 8.33, both chemokines reputedly 
bind and cause internalisation of CXCR4, NSC23766 at 100 μM potentiated their effects.  
 
8.3: Discussion 
Results indicate specific Rac1 signalling differences in CCL3- and CXCL12-induced cell migration 
and suggest a surprising role for NSC23766 as a allosteric modulator of CXCR4. 
8.3.1: Rac1 inhibitor produces chemokine specific responses  
Figures 8.2, 8.5 and 8.6 indicate Rac1 inhibition specifically inhibits migration to CXCL12 but not 
CCL3. In contrast Cdc42 inhibition equally inhibits both CCL3 and CXCL12 chemotaxis, figure 8.27. 
Serine palmitoyltransferase (SPT) is an enzyme consisting of two components, SPT long chain base 
subunit 1 (SPTLC1) and SPTLC2. SPTLC1 interacts with Par3, a scaffolding factor, which recruits 
proteins such as atypical PKC and Cdc42 into PAR complexes required for directional migration. 
SPTLC1 is expressed in THP-1 cells. Loss of Par3 in THP-1 is reported to inhibit their migration to 
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inflammatory chemokine CCL2 [920]. NSC23766 inhibits Tiam1 which promotes tight junction 
assembly through Rac activation and the Par complex. Inhibition of Tiam1 could conversely 
therefore promote migration through a transwell plate 5 μM pore, if clumping of cells was 
inhibiting them moving through the pores towards the chemokine. This may be what is apparent 
in figure 8.2(B). 
Atypical PKCζ is reported to phosphorylate Tiam1, stabilising its interaction with Par3. The Par 
complex is reportedly crucial for cell polarity and chemotaxis [347]. CCL3 may phosphorylate 
Tiam1, which may be dependent on PKC as well as Par3 for activity. Tiam1 phosphorylation may 
be required for Rac1 activation, although this can be a transient effect depending on cell type and 
balance between phosphatases and kinases. 14-3-3 regulatory proteins can bind Tiam-1 N-
terminal PEST sequences triggering Tiam1 degradation. Tiam1 needs to be bound to membrane 
Phosphatidylinositol 5-phosphate (PtdIns5P) to be active; PtdIns5P can potentiate Tiam1 activity. 
Tiam1 has a myristoylation motif at its N-terminal which favours plasma membrane binding. 
Binding of Tiam1 to PtdIns5P can restrict Rac1 activation, causing active Tiam1 and Rac1 to 
relocate to early endosomes and membrane ruffles. Whereas treatment with NSC23766 is 
reported to restore F-actin polymerization [921]. So the dramatic differences seen in NSC23766’s 
effects on CCL3 and CXCL12 in the THP-1 may be differences in Rac1 signalling between CCL3 and 
CXCL12. This theory was supported by the inhibitory actions of NSC23766 on CXCL12 chemotaxis 
in Jurkat, but results seen were also the first indication that the NSC23766 was having some off-
target effects on CXCR4.  
 
8.3.2: Rac GEF inhibitor NSC23766 
The investigations undertaken with Rac GEF inhibitor NSC23766 reported here revealed some 
surprising results, suggesting NSC23766 modulates CXCR4 signalling either directly or allosterically 
as well as producing Rac1 inhibition. NSC23766, figure 8.34, is a nitrogen rich molecule with many 
rotatable bonds, making it a flexible molecule that could potentially bind into several sites on 
many receptors including CXCR4.  
 
 
Figure 8.34: Structure of Rac1 GEF inhibitor 
NSC23766  
 
NSC23766 contains primary, secondary and tertiary amines, a methylpyrimidine ring, a base 
weakened by the inductive effect of the second nitrogen, and a substituted quinoline ring, 6-
methyl-4,6-quinolinediamine. NSC23766 has a methylated butyl amine tail which may, like CXCR4 
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inhibitor AMD11070, interact with Asp97 in TM2. NSC23766 also has a plentiful supply of amines 
in common with CXCR4/CXCL12 signalling inhibitors AMD3100, AMD11070 and AMD3465. Testing 
NSC23766 with CXCR4 Glu288 (TM7) and Asp97 mutants, along with several ECL2 residue 
mutants, could provide evidence of if, and where, NSC23766 binds CXCR4, which would explain its 
ability to so effectively block CXCL12 activation in Jurkat, and less dramatically THP-1. There are 
several orientation options for computer modelling of NSC23766 onto CXCR4. NSC23766 has basic 
nitrogens so can form ionic bonds, and electronegative nitrogens so can form H-bonds. For 
example further research could investigate if NSC23766 forms ionic interactions with negatively 
charged amino acids Asp97, Asp171 (TM4), Glu179, Asp181, Asp182 (ECL2), Asp262 (TM6) and 
Glu288, cationic π-interactions with Trp94 (TM2), or aromatic interactions with Tyr45 (TM1) or 
Trp94 (TM2), or if NSC23766 binding disrupts the essential Cys186 (ECL2) – Cys109 (ECL1) 
disulphide bond.  
Interestingly NSC23766 has been found to act as a competitive antagonist at muscarinic 
acetylcholine receptors (mAChRs) and at the NMDA receptor [901, 902]. NSC23766 was found to 
inhibit carbachol responses in human-derived HEK293 cells expressing M1, M2 and M3 mAChRs 
and act as a non-selective mAChR competitive antagonist. Computer modelling, which was not 
backed by mutant studies and so is speculative, suggested NSC23766 could theoretically bind M2 
and M3 AChRs orthosteric binding pocket on the receptor extracellular surface. The suggestion 
was that NSC23766’s diethylamine group’s positively charged tertiary amine nitrogen could have 
electrostatic interactions with Asp, Tyr, or Trp residues. This would position NSC23766’s butyl 
chain methyl group sitting in a hydrophobic pocket in M2 AChRs formed of Ala, Tyr, Phe and Trp 
residues; the methylpyrimidine position 3 nitrogen acting as hydrogen acceptor to a Tyr residue in 
M2 AChR and the methylquinolinediamine ring with hydrophobic interactions with Tyr, Trp and 
Thr residues [901].  NSC23766 binding on NMDA receptor was not computer modelled by Hou et 
al. (2014), but it would be interesting to examine the mAChRs, NMDA and CXCR4 receptors using 
computer modelling looking for similar pockets where NSC23766 could theoretically bind. 
8.3.3: NSC23766 competes with CXCL12 and 12G5 
Rac1 activation can be prevented by CXCR4 inhibitors but also by NSC23766, figure 8.7, suggesting 
NSC23766 may be interacting with CXCR4. NSC23766 also competes with CXCL12 and 12G5, 
figures 8.8-8.10. 12G5 CXCR4 binding has been extensive researched. CXCR4 antibodies are 
reported to predominantly target CXCR4’s extracellular domains, ECL1, ECL2, ECL3 and N-terminal 
region [903], see figure 1.5, chapter 1. Western blots with 12G5 failed to show any specific 
binding (data not shown) suggesting that 12G5 binding is conformational dependent, hence 
NSC23766 just changing CXCR4 conformation could explain FACS results, figures 8.13-8.14. The 
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failure of 12G5 to completely prevent chemotaxis may be attributed to CXCR4 conformational 
heterogeneity, as has been identified in both CD4+ and CD4- Jurkat cells, indicating that Jurkat may 
carry two or more CXCR4 conformations. Whereas CXCL12 may bind all conformations of CXCR4, 
12G5 may not, also receptor dimerization or position in lipid rafts may influence 12G5 binding 
[903]. Conformation of CXCR4 ECL2, which contains residues 176 to 202, has been found essential 
for 12G5 binding in Jurkat, with residues Asp176, Glu179 and Asp181 essential, and N-terminal 
residues 1-23 unimportant. G-protein phosphorylation or activation and N-linked glycosylation or 
sulfation appears not to affect 12G5 binding [903, 922]. ECL2 residue Cys186 which forms 
disulphide bonds with Cys109 (ECL1) are needed for CXCR4 tertiary structure, and if broken 
weaken 12G5 binding [923]. Cys186, Asp187 and Tyr190 mutations either disrupt the 
conformation of ECL2 or are directly involved in 12G5 binding [151, 153]. Asp171 on TM4 close to 
ECL2 also appears to influence 12G5 binding [924]. 12G5 binding reportedly requires two 
disulphide bonds to be intact, not for binding but for CXCR4 conformation, between Cys28 (N-
terminal) and Cys274 (ECL3), plus Cys186 (ECL2) and Cys109 (ECL1) [922]. Signoret et al. (1997) 
exquisitely demonstrated that CXCL12 only modestly completes for 12G5 binding in T-cells [279]. 
Another explanation for the observed results in figures 8.8-8.10 are that NSC23766 is modulating 
CXCR4/CXCR7 heterodimer or oligomer formation. Certainly neither NSC23766, ATI2341 nor 
AMD3100 produced chemotaxis in Jurkat, figure 8.11. 
8.3.4: CXCR7 receptor in cancer 
CXCR7, aka RDC-1, a receptor which binds CXCL11 and CXCL12, is deemed pro-tumorigenic in 
malignancy and is upregulated in many cancers and cell-lines. CXCR7 is a highly conserved 
receptor across mammalian species and is now accepted as a major player in CXCR4-CXCL12 
signalling. Interestingly the affinity of CXCR7 for CXCL12 exceeds that of CXCR4 [106, 656, 925]. 
Like CXCR4, CXCR7 is induced by hypoxia, and is associated with poor prognosis and metastasis in 
cancers [926 , 927 , 928]. CXCR7 may also aid angiogenesis [929]. 12G5 has been shown not to 
inhibit CXCL12-induced chemotaxis in a T-cell-line expressing CXCR7 but not CXCR4 [106], 
suggesting CXCR7 could be influencing results reported here.  
8.3.5: NSC23766 can displace CXCR4 antibody 12G5 
Various explanations for the chemotaxis and flow cytometry results with NSC23766, AMD3100 
and ATI2341 are plausible, figures 8.12 and 8.14. However NSC23766 is unlikely to be triggering 
internalisation as results at 37°C and 4°C are similar; 4°C should prevent active internalisation. 
NSC23766 may be causing a conformation change of the receptor acting through Rac1, and so 
cause a loss of 12G5 binding, as has been suggested by others [930], but then a greater effect of 
W56 would be expected and Rac direct inhibitor ETH1864 has no effect, figure 8.15. The effects of 
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NSC23766 are similar at 37°C and 4°C, this suggests NSC23766 is displacing 12G5 from the 
receptor; also treatment with NSC23766 after 12G5 and FITC staining causes greater effects than 
pre-treatment of cells. This may suggest that NSC23766 rapidly binds or allosterically modulates 
CXCR4, but its affinity weakens over the 2 hours of primary and secondary antibody staining, 
suggesting if it binds CXCR4 directly affinity is much lower than that of CXCL12 or 12G5.  
ATI2341 5 μM produces non-significant effects at 37°C or 4°C. AMD3100 5 μM however causes 
greater loss of CXCR4 in absence of CXCL12 than NSC23766, but does not hinder CXCL12 
internalisation like NSC23766 at 37°C, and AMD3100 does not cause any significant internalisation 
at 4°C, suggesting AMD3100 and NSC23766 have very different modes of action and that 
NSC23766 is not simply acting as a CXCR4 antagonist or a Rac1 GEF inhibitor. The promiscuity of 
NSC23766 has been previously reported. Examples include: acting as an antagonist at NMDA and 
Muscarinic acetylcholine receptors [901, 902]; acting to modulate p21-activated kinase (PAK)1 
and PAK2, and inhibiting activation and glycoprotein 1b signalling in Rac1(-/-) platelets [931]; and 
acting to inhibit the phosphorylation of NF-κB and cyclin D1 in prostate cancer cells and directly 
inhibiting the phosphorylation of Rac1, albeit at 200 μM [932]. NSC23766 and EHT1864, figures 
8.34 and 8.15B, can also both modulate glucose-stimulated insulin secretion [933].  
8.3.6: Endocytosis inhibitors do not prevent NSC23766 triggered CXCR4 internalisation 
Sucrose treatment significantly increased CXCR4 expression in control, 8.16B, but did not prevent 
the NSC23766, AMD3100 or CXCL12 causing CXCR4 signal loss. Hyperosmotic sucrose at 0.4 M 
reportedly non-selectively inhibits GPCR internalisation, causes strong ERK activation [934] and 
may induce phosphorylation of p38MAPK causing pathway activation [935, 936]. Cell surface 
receptors can be internalised via clathrin-dependent or clathrin-independent, lipid raft and 
calveolae-dependent endocytosis. With the former the clathrin-coated pit is pinched off by 
dynamin and other proteins to form clathrin-coated vesicles which then fuse with early 
endosomes and recycle back to the surface or via late endosomes are degraded in lysosomes. 
Alternatively lipid raft/calveolae-dependent endocytosis occurs [937]. Binding of CXCL12 to CXCR4 
is reported to cause ubiquitation of receptor followed by degradation in lysosomes [715, 938]. 
Sucrose at 0.4 M appears unable to prevent this process in presence of 15 nM CXCL12, but did 
very significantly (p<0.001) increase CXCR4 expression in absence of CXCL12.. 
Sodium azide failed to modify CXCR4 expression in Jurkat, figure 8.16A. Sodium Azide reportedly 
inhibits ATP hydrolysis by inhibiting oxidative phosphorylation in mitochondria, the major source 
of ATP production in eukaryotes. Mitochondria contribute to gluconeogenesis, heme synthesis 
and the urea cycle, and are the location of the tricarboxylic acid cycle, β-oxidation of fatty acids, 
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ketogenesis and oxidative phosphorylation. Oxidative phosphorylation involves electrons being 
passed down a chain of enzyme complexes in a series of redox reactions that release energy 
[939]. Sodium azide reportedly blocks cytochrome C oxidase (aka Complex IV) the last enzyme of 
respiratory electron transport chain; sodium azide binds between iron and copper ions in the 
cytochrome C oxidase’s oxygen reduction site [940]. Cytochrome C oxidase receives and then 
transfers electrons to oxygen to make water and transport protons into the mitochondria 
intermembrane space. ATP synthase (aka F-ATPase and Complex V) then uses the proton gradient 
between the intermembrane space and the matrix to drive ATP production from ADP and 
inorganic phosphate [941]. 
However this experiment was completed using Jurkat, a cancer T-cell line. Mitochondrial 
metabolism has been shown to provide the necessary reactive oxygen species for antigen-specific 
T-cell activation in non-transformed cells [942]. Jurkat are a rapidly proliferating cell line. 
Proliferating cells have vastly increased metabolic requirements to quiescent ones. When 
activated non-transformed (healthy) T-cells increase glucose metabolism, they take up large 
amounts of glucose from their environment while also producing lactate. That is, they are 
primarily glycolytic via aerobic glycolysis [943-945]. Hence glycolysis provides ATP and fuels the 
pentose phosphate pathway generating NADPH and nucleotides. Activated non-transformed T-
cells also increase glutamine metabolism to fuel the mitochondrial tricarboxylic acid cycle via 
glutaminolysis to α-ketoglutarate [946, 947]. Cancer cells can flourish in conditions that would 
cause apoptosis of non-transformed healthy cells, for example in conditions of low pH or oxygen 
tension [948], this is because they preferentially generate ATP by glycolysis followed by cytosolic 
lactic acid fermentation rather than oxidative phosphorylation; oxygen can actually inhibit this 
process, which is known as the Warburg effect [949]. Tumour cells run glycolysis, which does not 
use oxygen, at much higher rates than normal cells to acquire the necessary ATP for rapid 
proliferation. If they used mitochondrial production to generate the required levels of ATP they 
would also generate levels of reactive oxygen species (ROS), a normal by-product of oxidative 
phosphorylation that would be toxic to the cells. Normally oxygen and ATP would inhibit 
phosphofuctokinae-1, the enzyme controlling the rate of glycolysis. But the Warburg effect allows 
the tumour cell (i) to accelerate glycolysis in presence of oxygen and (ii) to convert the end 
product of glycolysis, pyruvate, to lactate even in the presence of normal levels of oxygen. Lactate 
production then allows the necessary regeneration of NAD+. Lactate itself may stimulate signalling 
that stimulates tumour growth [950].  
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Hence the FAC results obtained following sodium azide pre-treatment, figure 8.16A, suggest the 
Jurkat were predominantly generating energy via glycolysis, not oxidative phosphorylation, as 
may be expected with a fast replicating cancer cell-line.  
8.3.7: cAMP levels are reduced by NSC23766 but not by AMD3100  
AMD3100 can act as a competitive orthosteric unbiased antagonist of CXCR4, figure 8.3 shows 1 
μM can strongly inhibit chemotaxis to CXCL12. AMD3100 can inhibit CXCR4 endocytosis and both 
β-arrestin and Gαi signalling [951] but can over time promote CXCR4 upregulation of CXCR4 so 
drug resistance and even increased responses to CXCL12 [952]. Here surprisingly 5 μM AMD3100 
failed to significantly modify cAMP production in Jurkat, pre-treated with 20 μM Forskolin plus 
IBMX, and stimulated by 10 nM CXCL12, figure 8.17. Hitchinson et al. (2018) also investigated the 
effects of AMD3100 on Jurkat cAMP production triggered by CXCL12. They used 100 μM 
Forskolin, 30 nM CXCL12 and AMD3100 (strength not stated) and saw a small (p<0.05) loss of 
reduction of cAMP in AMD3100/CXCL12 treated cells compared to control [953]. Mechanisms for 
the discrepancies include that AMD3100 at low concentrations (0.1-1 μM) may act as a weak 
partial agonist [954], and/or that other receptors were playing a role. However the artificial 
nature of Forskolin activation of adenylyl cyclase and IBMX phosphodiesterase inhibition of cAMP 
breakdown, noted by others as obvious possible sources of error [955] may have obscured 
AMD3100 responses. 
NSC23766 produced a very significant (p<0.001) reduction in basal cAMP levels, figure 8.17. Basal 
levels of cAMP may relate to numbers of receptors on the cell surface [956].    CXCL12 binds 
CXCR4 but also CXCR7, Jurkat express CXCR7 at high levels as well as CXCR4 [957]. CXCL12 binding 
CXCR4 activates canonical Gαi signalling, reducing cAMP levels. CXCR7 activation does not. 
However CXCR7/CXCR4 heterodimer formation prioritises activation of β-arrestins over Gαi 
signalling [958], suggesting CXCR7 can regulate coupling of CXCR4 to Gαi and thus cAMP levels 
[928]. If NSC23766 prevents CXCR4/CXCR7 heterodimer formation, increasing CXCR4 monomers 
on the cell surface it could increase basal CXCR4 Gαi signalling, and cAMP levels would fall, this 
could explain results. If both CXCR4 and CXCR7 are expressed then Ca2+ mobilisation may be 
greater that if just CXCR4 are present, as CXCR7 may enable CXCR4-Gαi conformational 
rearrangements supporting both CXCL12-induced chemotaxis and calcium flux [958], possibly 
explaining figures 8.20-8.22. Interestingly NSC23766 more strongly inhibited Ca2+ flux than the 
CXCR4 inhibitors ATI2341 or AMD3100, figure 8.23. These results therefore do not preclude that 
NSC23766 is binding CXCR7 rather than CXCR4 or acting as a biased ligand. 
247 
 
8.3.8: Biased signalling 
Different ligands binding the same receptor can produce specific conformations that trigger 
initiation of only a specific subset of the receptor’s many possible signalling cascades. This is 
termed biased agonism or functional selectivity. Equally allosteric ligands can produce biased 
modulation of biased agonism [959, 960].  The underlying molecular basis for biased agonism is 
complex and not fully understood [961]. In vivo other biases may add to the complexities; 
circadian rhythms and pathology including cancer affect natural ligand/receptor stoichiometry 
and may for example change cell expression of G-protein γ subunits  [962, 963]. Therefore 
computer modelling analysis of binding sites based on assays in any one cell-line or transfected 
system are unlikely to be universally applicable, and could mislead future research. 
8.3.9: cAMP levels may modulate PKCζ signalling 
Unlike AMD3100 or ATI2341, NSC23766 reduced both basal and post-CXCL12 stimulation cAMP 
levels compared to control, figure 8.17. Increasing cAMP levels increases Ras GTPase Rap1-GTP, 
hence Rap-1 activation [964]. Inhibiting Rap-1 decreases CXCR4 expression at the membrane so 
Rap-1-GTP appears to be required for cAMP-induced CXCR4-increased membrane expression. PKA 
inhibitor H89 was found here to significantly increase cAMP production, figure 8.17. Others note 
H89 failed to prevent CXCR4 expression [906].  
PKCζ is involved in cAMP signalling, as increasing cAMP increases PKCζ phosphorylation and 
activation [965]. Rap1 affects signalling upstream of PKCζ translocation to the membrane [906]. 
Rap1 recruits Rac1 GEFs including Tiam1. Active Rac1 triggers translocation and activation of PKCζ. 
Blocking Rac1 by NSC23766 can inhibit cAMP-induced PKCζ phosphorylation, suggesting Rac1 is 
required for PKCζ activation by cAMP [964, 966]. Thus PKCζ has a role in cAMP-activated CXCR4 
expression. Inhibiting PKCζ activity inhibits CXCR4 expression at the membrane; upregulating PKCζ 
increases CXCR4 expression. Inhibiting Rac1 activation has the same effect as blocking PKCζ 
activity, suggesting Rac1 and PKCζ are in the same signalling pathway influencing CXCR4 
membrane expression, possibly by reducing CXCR4 endocytosis. Hence in the absence of CXCL12 
cAMP prolongs CXCR4’s stay at the membrane, and increasing cAMP levels increases CXCR4 
recycling back to the membrane [906]. PKCζ is activated by binding to the Par activity complex 
containing Par6, Par3 and Cdc42; Rac1 binds Par6 to activate PKCζ [967]. Therefore there appears 
to be a feedback loop between PKCζ activation by cAMP causing elevated CXCR4 expression which 
itself increases PKCζ activity, figure 8.35. 
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Figure 8.35: Schematic representation of cAMP, PKCζ, Rac1 and CXCR4 expression feedback loop 
[906, 964]. 
8.3.9.1: PKCζ knockdown inhibits CCL3 and CXCL12 MCF7 wound-healing and Jurkat chemotaxis to 
CXCL12  
The cAMP results, figure 8.17, suggest that NSC23766 is stimulating Gαi signalling from CXCR4, 
which is inhibiting adenylyl cyclase hence reducing cAMP levels. The addition of CXCL12 increases 
the Gαi signal, reducing cAMP levels further. If NSC23766 was purely inhibiting Tiam1 it would be 
expected to reduce Rac1 activation of PKCζ/Par3/Par6/Cdc42 complex and possibly reduce CXCR4 
membrane expression and Gαi inhibitory signalling, increasing cAMP levels. The signalling may be 
complicated by the reported constitutively active signalling of Pi3K in Jurkat cells [647, 968, 969], 
so any effect on Tiam1 by NSC23766, figure 8.35, may be mitigated, but direct effects of 
NSC23766 on CXCR4 would not.  
8.3.9.2: Both PKCζ over-expression and inactivation can support malignancies 
PKCζ knockdown was found to inhibit both CXCL12 supported chemotaxis in Jurkat and 
chemokinesis in MCF7, confirming the proteins role in promoting CXCR4 signalling in these cell-
lines, figures 8.18-8.19. PKCζ’s roles in cancers are complex. PKCζ down-regulation has been found 
to promote malignancy in pancreatic [970], lung [971], and prostate cancers [972]. However PKCζ 
deletion increases prostate cancer invasiveness if Phosphatase and Tensin Homolog (PTEN) is 
lacking [973]. Possibly as PKCζ silencing can also promote invasion and growth in some cell-lines 
as PKCζ may conversely act as a tumour suppressor in some breast cancers, PKCζ may through IL-6 
modulation counteracting adverse transformed Ras-signalling [971].  
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PKCζ can be inactive in colon cancers resulting in poor prognosis [974] but PKCζ loss in colon 
cancer can increase transcription of β-catenin in crypt stem cells leading to malignancy [975]. LOF 
of PKCζ is also found in some breast cancers, and PKCζ appears essential for stem cell 
homeostasis. These contradictory findings may be due to effects of PDPK1, an upstream regulator 
of all PKCs. Rapamycin (sirolimus), temsirolimus and everolimus inhibit mTOR signalling, which is 
involved in activation of all novel and conventional PKCs. PDPK1 and mTOR phosphorylate all PKCs 
on conserved sequences [976]. Inhibiting mTOR can inhibit breast cancer growth yet these drugs 
are also immunosuppressants inhibiting cytokine-responsive T-lymphocyte activation and 
proliferation, and so resistance develops [262].  
8.3.10: Intracellular calcium, PLC and Rac1 
Intracellular calcium can act as a second messenger in signalling cascades. Resting intracellular 
calcium concentrations are usually far lower than extracellular levels. This is achieved by pumping 
calcium from the cytosol into the extracellular space and into the endoplasmic reticulum (ER), also 
by proteins and organelles in the cytosol sequestering Ca2+. GPCR stimulation can indirectly trigger 
opening of ion channels allowing Ca2+ to flood into the cytosol from the ER and/or extracellular 
space, triggering signalling cascades [977].  
In T-cells phospholipase C (PLC) gamma can be activated by GPCR triggered Ca2+ signalling. PLC 
hydrolyses membrane phosphatidylinositol bisphosphate (PIP2) forming inositol 1,4,5 
triphosphate (IP3) and diacylglycerol (DAG). DAG can then recruit PKC to the cell membrane while 
IP3 binds IP3 receptors opening Ca
2+ channels on the ER. This activates STIM1, an ER Ca2+ sensor, 
and finally Orai1 channels, the main T-cell SOCC, open. The IP3 channels opening and releasing ER 
Ca2+ may trigger PKC activation, and intracellular Ca2+ may activate calcium-calmodulin kinase 
pathways which can trigger dephosphorylation and activation of transcription factors [977]. 
Intracellular calcium signalling is accepted as a cellular second messenger system that links to 
chemokine receptor activation, and to the activation of Rho GTPases [978].  
Relationships between Rac and calcium signalling are thought to be dependent on cell type, and 
signalling trigger. For example in neutrophils Rac activation triggered by chemokines can be 
independent of intracellular calcium [979], and T-cells carry several varieties of calcium channels 
at the cell and/or ER membrane [977].  
NSC23766 may be acting via inhibiting Tiam1, which activates Rac1 and so influences the PLC-IP3 
pathway explained above, or via direct inhibition of CXCL12/CXCR4 activation. NSC23766 was 
found to increase Ca2+ flux in THP-1 triggered by CCL3 but reduce response from CXCL12, figure 
8.20. In Jurkat and MCF7 NSC23766 done-dependently competed with CXCL12 inhibiting Ca2+ flux, 
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figures 8.21 and 8.22. These results suggest NSC23766 has a direct effect on CXCL12/CXCR4 but 
not CCL3 signalling. Indeed it more effectively inhibited Ca2+ production than either CXCR4 
inhibitor AMD3100 or ATI2341, figure 8.23.  
PLC inhibition was achieved using U73122, figures 8.24 and 8.25. U73122 inhibits PLC so can 
reduce IP3 production in neutrophils [980, 981], although U73122 has also been found to 
potentiate IP3-mediated Ca
2+ release [982], figure 8.36. Here it statistically increases Ca2+ 
production in Jurkat, figure 8.25. 
 
Figure 8.36: Involvement of Rac1, PLC, PKC and Slingshot (SSH1) in GPCR calcium signalling. SSH1 
can be activated by two routes, rapidly through calcineurin and more slowly through Rac1-Pi3K. 
SSH1 phosphatase phosphorylates cofilin [977, 983]. 
 
U73122 behaved similarly in THP-1 and Jurkat chemotaxis to NSC23766, reinforcing evidence for 
specificity of Rac1 signalling in CXCL12 but not CCL3 chemotaxis, figures 8.2 and 8.24, however 
U73122 produced opposite effects on cAMP responses both before and after CXCL12 compared 
to NSC23766, figures 8.26A and 8.17, suggesting NSC23766 off-targets effects.   
8.3.11: NSC23766 inhibits both early and late cofilin phosphorylation events in response to 
CXCL12 
The temporal early responses of cofilin phosphorylation observed, figure 8.29, may be 
attributable to Ca2+ dependent cofilin re-phosphorylation, and the later ones to Rho-kinase/LIMK 
signalling. Rac1 inhibition was shown above to inhibit CXCL12-induced calcium flux, figures 8.20-
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8.22, indicating Rac1 activation may be calcium-dependent. Cofilin phosphorylation in other cells 
has been reported as calcium dependent, mediated through PAKs; phosphatase Slingshot can be 
activated by calcineurin [893]. PKC may function upstream, and Pi3K downstream of Rac1, Pi3K 
can stimulate SSH1 activity, figure 8.36. PKC can phosphorylate Tiam1 activating Rac1, however 
both PKC-independent and dependent pathways may trigger cofilin phosphorylation [643, 984]. 
Early changes in cofilin phosphorylation may also be involved with cell secretion; cofilin 
inactivation may reduce the constraints of actin cytoskeleton on monocyte secretion as vesicle-
membrane fusions involves actin polymerization [985, 986]. 
8.3.12: Rac1 may be involved in CXCL11 but not CCL2 or CXCL9 chemotaxis 
CCL2 aka Monocyte chemoattractant protein-1 (MCP-1) has both chemotactic and activating 
properties [987]. Rac1 is important for membrane ruffles formation as well as lamellipodia. 
Ruffles are instrumental in the formation of the phagocytic cup employed when macrophages 
phagocytose apoptotic cells, a process known as efferocytosis. CCL2 is reported to enhance 
efferocytosis through a CCL2/Rac1/Pi3K pathway in acute inflammation, and NSC23766 at 50 μM 
can inhibit this in mouse macrophages [988]. Others have implicated Rac1 activation in CCL2 
chemotaxis in CHO cells [989]. However, here in THP-1 neither NSC23766 at 100 μM or W56 at 
280 μM significantly inhibited chemotaxis to CCL2. However both inhibitors significantly reduced 
chemotaxis induced by CXCL11 but not CXCL9, suggesting Rac1 activation is involved in CXCL11- 
triggered chemotaxis in THP-1, or NSC23766 may be having off target effects on CXCR7, which 
also binds CXCL11. CXCL11, aka I-TAC, and CXCL9 are both ligands for CXCR3, but CXCL11 binds 
with higher affinity [990]. The different ligands trigger different downstream pathways and 
receptor locations; CXCR9 activation involves serine/threonine residues on CXCR3 C-terminus 
whereas CXCL11 involves CXCR3 ICL3 [991]. CXCL11/CXCR3 signalling involves p70 kinase/mTOR 
STAT3 and STAT6 whereas CXCL9/CXCR3 signals via STAT1 and STAT5, an example of ligand-biased 
signalling [992].  
The receptor CXCR3 is known to have two isoforms termed CXCR3-A and CXCR3-B. In malignancy 
CXCL11 binding CXCR3-A or CXCR7 triggers proliferation, but CXCL11 binding CXCR3-B inhibits 
tumour growth [993]. Ligands for CXCR3, CXCR4 and CXCR7 can be expressed by malignant cells, 
although only CXCR4 is accepted as a cancer stem cell marker [994, 995]. What is more complex 
to analyse is the outcome of signalling cross-talk and reported dimerization of CXCR4 and CXCR7 
[958], which may involve G-proteins or biased signalling through β-arrestin [996, 997], or CXCL14 
[919]. CXCL12 can be secreted by cells as monomers or dimers, and can dimerize once secreted. 
Monomeric CXCL12 may preferentially activate CXCR4 signalling via Gαi and Akt whereas dimeric 
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CXCL12 signals via β-arrestin-2 recruitment to CXCR4. CXCR7 may only bind monomeric CXCL12 
[998].  
Although CXCR7 binds both CXCL11 and CXCL12 neither partnership produces classical 
heterotrimeric G-protein signalling [113], but they have been shown to stimulate signalling via the 
recruitment of β-arrestin, and produce ERK1/2 phosphorylation. The presence of CXCR7 on 
immune cells such as monocytes was initially reported using an antibody approach, then 
challenged due to suggested limitations of the antibody, before being confirmed by proteomic 
evidence [999-1001].  CXCR7 has been shown to dimerize with CXCR4, modulating CXCR4-CXCL12 
signalling [958], and to play a role in murine haematopoietic stem cell development and so may 
also do so in humans [1002]. CXCR7 may also act as a sponge for CXCL11 and CXCL12 maintaining 
the gradient essential for chemotaxis [41, 1003]. Figure 8.30B may provide evidence that CXCR3 is 
involved in THP-1 migration stimulated by CXCL11, or that CXCL11 binding CXCR7 in monocytes 
can stimulate migration, and that NSC23766 may be inhibiting the actions of CXCR7. 
8.3.13: NSC23766 may potentiate CXCL14 inhibition of Jurkat chemotaxis to CXCL12 
CXCL14 is found in and produced by healthy epithelial tissues and macrophages, its expression 
can be reduced by inflammation, and malignancy [916, 1004]. Although chemotactic to most 
types of white blood cells, T-cells are not attracted to CXCL14 [1005]. CXCL14 appears to be an 
indirect [1006] or direct ligand for CXCR4 [1005] but reportedly also interacts with other 
proteins/receptors [914]. Collins et al. (2017) found that CXCL14 can displace bound CXCL12, but 
CXCL12 is less efficient at displacing CXCL14 [919], this may explain why here in figure 8.31A pre-
treatment with CXCL14 had more of a dose-dependent effect than the same concentrations of 
CXCL14 combined with CXCL12 as chemoattractant, figure 8.31B. Research suggests 300 nM 
CXCL14 can potentiate chemotaxis to 0.1-1 nM CXCL12 in PMBC’s [919]. PMBC’s include NK-cells 
and monocytes which migrate to CXCL14, as well as pre-B and T-cells which may not. Conversely 
Collins et al. found CXCR4 inhibitor AMD3100 (10 μM) pre-treatment did not prevent monocyte 
migration to a high concentration (1 μM) CXCL14, and that CXCL14 did not activate CXCR4-
associated signalling events [919], suggesting CXCL14-induced chemotaxis in monocytes employs 
a receptor, protein or chemokine partner other than CXCR4.  
The effects of CXCL14 on metastasis may depend on the degree of mitochondrial dysfunction 
present in malignant cells. Dysfunction in mitochondrial respiration has been shown to promote 
CXCL14 expression. CXCL14 binding inositol 1,4,5-trisphosphate receptors on the endoplasmic 
reticulum producing elevation of intracellular Ca2+ may promote cell motility and invasion [1007]. 
Explaining how CXCL14 could perform a useful role in immune surveillance but also promote 
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metastases. Here CXCL14 100 nM pre-treatment significantly increased responses to 
CXCL12/CXCR4 coupling to Gαi, producing elevation of intracellular calcium in Jurkat, figure 8.32.  
Others saw similar Ca2+ responses to CXCL12/CXCL14 combinations, along with elevation of Rac-
GTP in murine CXCR4-transfected cells [919]. Here using flow cytometry and Jurkat, figure 8.33, 
Rac1 inhibition with W56 did not modulate CXCL14 responses, but NSC23766 significantly did, 
again suggesting NSC23766 can allosterically modulate CXCR4 or a receptor forming dimers with 
CXCR4.  Collins et al. (2017) concluded that synergism between CXCL12 and CXCL14 is dependent 
on CXCR4 dimer/oligomerization, CXCL14 binding one CXCR4 partner facilitating CXCL12 binding 
other. However their cells only expressed CXCR4, so could only form CXCR4 homodimers. THP-1 
and healthy monocytes express little CXCR7 [1008], whereas Jurkat highly express CXCR7 [957], so 
Jurkat may express more CXCR4/CXCR7 heterodimers or oligomers than CXCR4 homodimers or 
oligomers. CXCL14 binding the CXCR4 component of a CXCR4/CXCR7 dimer would block CXCL12 
binding, so inhibit migration, which is what figure 8.31 illustrates. Whereas in monocytes, CXCL14 
binding one component of a CXCR4 homodimer could then facilitate CXCL12 binding other CXCR4 
and thus expedite chemotaxis, in vitro concentration of the two chemokines and cell-line appears 
key.   
 
8.4: Conclusions 
THP-1 express CXCR4 but possibly little CXCR7 [1008], this may explain why NSC23766 had less 
effect on CXCL12 chemotaxis in THP-1 than in Jurkat where CXCR7 is highly expressed [957]. Here 
THP-1 were shown to also express CCR5, chapter 3, figure 3.3. Overall NSC23766 was shown to 
inhibit CXCL12-induced chemotaxis, chemokinesis and calcium mobilisation in Jurkat, THP-1 and 
MCF7, figures 8.2, 8.6, 8.20-8.23; also to significantly reduce basal cAMP levels in Jurkat, figure 
8.17. One explanation for these results is that NSC23766 may be allosterically inhibiting CXCR4 by 
binding and inactivating CXCR7. Contrastingly NSC23766 increased THP-1 chemotaxis and calcium 
mobilisation to CCL3, acting as a partial agonist, figures 8.2B and 8.20A. Possible mechanisms 
include acting on CXCR4 affecting CXCR4/CCR5 dimers or by acting on CXCR7. CXCR4-CCR5 
modulate T-cell functions but recent research suggesting CXCR7-targeting may block HIV entry 
into cells [1009]. This raises the question could CXCR7 also modulate CCL3/CCR5 induced 
chemotaxis?  
NSC23766 had significantly different effects to AMD3100 and ATI2341 on cAMP basal levels and 
those following CXCL12 suggesting it was not targeting CXCR4 but either preventing CXCR4/CXCR7 
dimerization or targeting CXCR7. CXCR7 is upregulated in cancer cells and present in Jurkat [957]. 
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NSC23766 targeting CXCR7 may explain not only cAMP results but also results from the 
chemotaxis, calcium, and internalisation assays. As CXCR7 has been shown to signal through Gαi 
in some cell types [110], so may do in others, and to produce hetero-oligomers with CXCR4 
[1010]. Such hetero-oligomers may, depending on conditions and cell type, increase or decrease 
Ca2+ flux following CXCL12 stimulation and alter ERK activation and chemotaxis. Mechanisms may 
include CXCR7 altering CXCR4-Gαi interactions and/or sequestering CXCL12; in vivo CXCR7 
sequestering appears to maintain CXCR4 sensitivity to CXCL12 supporting metastasis [958, 1011]. 
The CXCR7 ligand CCX771 has been found to more potentially inhibit CXCL12 migration than 
AMD3100 [1010], similarly here AMD3100, at the concentration used failed to inhibit cAMP 
responses as much as NSC23766. Others have seen little effect of AMD3100 on cAMP production 
boosted by Forskolin [953]. CXCR7/CXCR4 co-expression can decrease CXCL12 stimulated Gαi-
mediated cAMP reduction [928] therefore if NSC23766 either inactivates CXCR7 or prevents 
CXCR4/CXCR7 dimer or oligomer formation this would explain why NSC23766 was able to reduce 
basal cAMP levels and those in the presence of CXCL12, figure 8.17. NSC23766 also reduced 
CXCL12 chemotaxis, when CXCR7 is inhibited so would β-arrestin responses that have been shown 
here, chapter 5, figure 5.33 and by others [1012] to significantly increase chemotaxis to CXCL12. 
Overall Rac1 was found important for CXCL12 chemotaxis but less essential for chemotaxis to 
CCL3, figure 8.2 and results hint receptor oligomerisation involving CXCR7 may mediate 
chemotaxis to CCL3. 
CXCR7 purportedly sequesters CXCL12, so CXCR7 may function to modify chemokine 
concentrations during in vitro assays. Also inhibition of a signalling protein may modify the 
concentration of chemokine needed to produce chemotaxis, chemokinesis or calcium flux. Thus 
figure 8.22 may illustrate an inhibitor simply modifying the concentration of a chemokine needed 
to achieve calcium flux.  
The balance of CXCR4/CXCR4 homodimers or CXCR4/CXCR7 heterodimers may influence whether 
CXCL14 inhibits or expedites chemotaxis to CXCL12, the high expression of CXCR7 in Jurkat [957] 
may explain why CXCL14 inhibits their chemotaxis to CXCL12, figure 8.31. Also CXCL14 may be 
synergistic to CXCL12-induced Ca2+ responses by mediating by endoplasmic reticulum inositol 
1,4,5-trisphosphate receptors [1007], explaining figure 8.32. Flow cytometry in Jurkat 
demonstrated CXCL14 significantly increase CXCR4 signal loss produced by NSC23766, figure 8.33, 
this could be explained by CXCL14 binding CXCR4 and NSC23766 binding CXCR7 component of 
CXCR4/CXCR7 dimers.   
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9: General Conclusions 
These are some of the many interesting conclusions that can be drawn from the research 
reported in this thesis. 
THP-1 and MCF7 were found to express both CCR5 and CXCR4. THP-1 migrated towards many CC 
and CXC chemokines; Jurkat only to CXCL12. In both cases numbers of cells migrating to a range of 
chemokine concentrations produced Gaussian distributions, with modest concentrations of 
chemokines being the most chemotactic. Spaks (2017) reports that chemokine concentrations can 
correlate with both the numbers of immune cells infiltrating a tumour’s microenvironment and 
chemokine receptor expression [1013]. This thesis contributes towards a better understanding of 
the chemokine concentrations that attract immune and cancer cells, knowledge necessary to 
enable therapeutic manipulation of the chemotactic responses that support metastases.      
In THP-1, CCL3 plus CXCL12 produced additive chemotactic responses, whereas CCL2 plus CXCL11 
does not, suggesting CCR5 and CXCR4 may dimerize to support migration but CCR2 and CXCR3 do 
not. When different chemokines bind the same chemokine receptor the specific receptor 
conformation changes may direct the GRK subtype recruited, and which serine/threonine 
receptor residues it phosphorylates and so directing resultant biased signalling through G-
proteins or β-arrestins. GRK2 was identified as important to both CCL3- and CXCL12-induced 
migration; Arrestin-2 as more important for CXCL12-induced migration and Arrestin-3 for 
migration to CCL3, depending on cell type. Gahbauer et al. (2018) and many others report that 
biased agonism and receptor dimerization relate to the agonist molecular structure, as different 
agonists may stabilise different GPCR conformations and consequent cellular responses [1014, 
1015]. This thesis provides further evidence for links between GPCR class and β-arrestin isotype, 
but also cell-type specific factors. It also adds evidence for the involvement of receptor 
dimerization and co-operation in chemokine-induced chemotaxis and hence contributes to a 
better understanding of chemokine receptor interplay in malignancies.  
Dynamin is a key protein in endocytosis. Dynamin was visualised in the cytoplasm and nucleus; 
knockdown of Dynamin-2 and small molecule inhibitors demonstrated Dynamin’s significance in 
cytokinesis and cell migration. Different Dynamin domains were found important for migration to 
different chemokines, the GTPase domain for migration to CCL3 and the PH domain for migration 
to CXCL12. Bazzani et al. (2018) has established that both clathrin and caveolin-mediated 
endocytosis depends on Dynamin, and that blocking endocytosis with Dynamin inhibitors can 
prevent receptor endocytosis that would enhance malignant cell proliferation [1016]. Results here 
suggest cell type and chemokine specific control over which ligand/receptor pairs undergo 
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endocytosis may be achieved by using different Dynamin inhibitors, a novel option to explore 
further.  
PKC’s role in cell migration was found to be isoform, cell type and chemokine specific. Results 
with small molecule PKC inhibitors were deceptive, suggesting only PKCμ was important, but 
siRNA knockdown of PKC isoforms clarified the importance of PKCα and PKCδ, and to a lesser 
extent of PKCε and PKCζ. Each isoform’s importance was resolved along with chemokine and/or 
cell type specificities. Isakov (2017) reviewed how many tumours have altered PKC expression or 
mutation of PKC isoform/s [262]. Results here show how this links to chemokine signalling 
through two important chemokines implicated in cancers, CXCL12 and CCL3, information which 
may help open windows for therapeutic exploitation. 
Extensive use of small molecule inhibitors established that both CCL3 and CXCL12 signalling 
employs Src and the Raf/MEK/ERK pathway. Research by others has recognised Src’s importance 
in CXCL12-supported malignancy [555, 576]. Results in this thesis suggest it may also be important 
in responses of cancer cells to CCL3. Investigations also discovered synergism between inhibition 
of ROCK and Raf, and also between MEK and Raf. Pi3K and FAK appear key in CXCL12- but not 
CCL3-signal transduction leading to cell migration, whereas ROCK and MEK are important in both 
CCL3 and CXCL12-induced migration; all three proteins influence cofilin phosphorylation. This 
demonstrates that CXCL12- and CCL3-signalling uses diverse pathways to trigger chemotaxis, but 
also that signalling protein use by a specific receptor/chemokine pair can be very individual to the 
chemokine and cell-type. This lack of generalisation needs further investigations but suggests 
opportunities for the further development of synergistic chemotherapies. 
In MCF7 siRNA knockdown of actin binding protein Cofilin established its importance to cell 
migration. In THP-1 Cofilin phosphorylation showed positive correlation with the ability of a 
chemokine to induce migration.  Also this phosphorylation can be modified by inhibition of 
cytosolic signalling proteins, and so can confirm the relevance of any individual signalling protein 
to a signalling pathway triggered by a specific chemokine. This offers a novel readout method that 
can be used alongside other assays to clarify chemokine signalling pathway components.   
JAK2 and STAT3 were found to support CXCL12-induced wound-healing in MCF7 and chemotaxis 
to CCL2 and CXCL12 in THP-1 but not migration to CXCL12 in Jurkat. Inhibition of JAK2 and STAT3 
potentiated calcium flux in all three cell types and blunted cAMP falls in THP-1 in response to 
CCL2 stimulation. Forskolin, employed in cAMP assays, also independently inhibited cell migration 
and wound-healing to CXCL12 and produced cofilin phosphorylation. In THP-1 JAK2 and STAT3 
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inhibitors were found to alter the temporal cofilin phosphorylation pattern produced between 
one and thirty minutes after CXCL12 stimulation, this cofilin phosphorylation pattern correlated 
with STAT3 phosphorylation responses to CXCL12. Roussos et al. (2011) described the role of 
cofilin in the amoeboid migration mode of adherent breast cancer cells [1017], the results here 
show how temporal phosphorylation of cofilin operates in the chemotaxis of leukaemic cells to 
chemokines. This research also suggests Forskolin shows promise as an anti-metastatic adjunctive 
treatment in chemotherapy, and further elucidates JAK2 and STAT3 signalling in both leukaemic 
and breast cancer cell-lines.  
The NSAIDs ibuprofen, naproxen and celecoxib, along with Aspirin and Paracetamol, were found 
to have varying effects on cell migration, cAMP levels and calcium dynamics.  COX1 inhibitors 
Ibuprofen, Naproxen and Aspirin inhibited migration to CXCL12, whereas COX2 inhibitors 
Paracetamol and Celecoxib did not. Ibuprofen dramatically increased cofilin phosphorylation, 
whereas the other drugs all eliminated CXCL12-induced phosphorylation, possibly as Ibuprofen 
may have off-target inhibitory effects on Akt or MEK. Often in population and retrospective 
cohort studies the effects of NSAIDs and Aspirin on cancer initiation and progression is assessed 
by grouping the drugs into one study [1018-1020], this thesis shows why such a strategy may give 
unclear outcomes, as each can produce contrasting drug-specific effects on factors that may 
influence metastasis. 
Rac1 GEF inhibitor NSC23766 was found to compete with 12G5 for CXCR4. This was confirmed by 
flow cytometry, where NSC23766 displaced CXCR4 antibody 12G5. NSC23766 also dose-
dependently inhibited calcium flux triggered by CXCL12, and reduced cAMP levels in presence and 
absence of CXCL12, whereas CXCR4 ligands AMD3100 and ATI2341 did not. Rho GTPases include 
Cdc42 and Rac1. Results here show Cdc42 is involved in CXCL12- and CCL3-induced chemotaxis 
whereas Rac1 is involved in migration to CXCL12 but not CCL3, this was confirmed by use of a Rac-
inhibiting peptide. Inhibition of CXCR4, using NSC23766, AMD3100 and ATI2341 was shown to 
impede both cell-migration to CXCL12 and Rac1 activation. This may relate to Rac1 signalling 
through PKCζ, as knockdown of PKCζ also inhibited CXCL12-induced chemotaxis. Additionally Rac1 
inhibition by NSC23766 was found to inhibit THP-1 migration to CXCL11 but not CCL2, suggesting 
NSC23766’s target could be CXCR7, and/or its effect on CXCL12/CXCR4 may be through 
modulating CXCR4/CXCR7 dimerization. Cofilin phosphorylation in presence of CXCL12 was 
reduced by both NSC23766 and Rac1-inhibiting peptide W56, demonstrating that NSC23766 
inhibits Rac1 signalling and also has off-target effects as a CXCR4-biased antagonist. Chemotaxis 
and flow cytometry assays using CXCL14 with CXCL12 in Jurkat supported this conclusion.  
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10: Future Work 
Chapter 3: Future investigations could establish if CCL3/CCR1 and CCL3/CCR5 respond in similar 
ways to dynamin inhibitors, and if chemokine concentration influences responses to inhibitors. 
Chapter 4: GSK3α/β are proteins with oncogenic (through promoting β-catenin) and tumour 
suppressing abilities [1021]. Small molecule GSK3 inhibitors are available e.g. StemMACSTM 
CHIR99021. Establishing the role GSK3 plays in chemotaxis would facilitate further interpretation 
of the results above.  
Chapter 5: Cofilin phosphorylation dynamics in adherent cell-lines such as MCF7 and PC3 could be 
investigated hence establish if chemokine-responses reported above in THP-1 are general or cell-
type specific. 
Chapter 6: Like many transcription factors STAT3 can translocate to mitochondria where it may 
influence function of complexes in the electron transport chain to modulate ATP levels and 
energy dynamics [1022]. Mitochondrial STAT3 may also influence ROS production, cell growth and 
transformation [1023] all factors thought important in malignancy.  MCF7 were transfected with 
mito-DS Red plasmids then treated with JAK2/STAT3 inhibitors, figure 6.4; however transfection 
levels were not sufficient to analyse if there were any visual changes in mitochondria 
appearance/location from control in cells treated with JAK2 or STAT3 inhibitors. This would be 
interesting to establish. 
Chapter 7: The next steps could include using Western Blot analysis of the effects of a range of 
NSAIDs along with Aspirin and Paracetamol on phosphorylation, i.e. activation or inhibition, of 
signalling proteins which purportedly are implicated in malignancies such as Akt, MEK, ERK and 
JAK. 
 
Chapter 8: Next all papers which have used NSC23766 as a selective Rac1 inhibitor could be 
reviewed in the light of this and research by others [901, 902] showing NSC23766 has off target 
effects. Also chemotaxis assays using NSC23766 with CXCR7 inhibitor CCX771 combinations could 
be done to see if they produce similar or additive effects. Then Flow cytometry and chemotaxis 
assays could be undertaken to see if AMD3100 competes with NSC23766 for CXCR4 or just has 
additive effect, if so this provides additional evidence that NSC23766 is binding CXCR7, preventing 
CXCR4/CXCR7 dimerization or hitting another cellular target to modulate CXCR4 expression. 
Finally treatment with pertussis toxin informs if signalling is Gαi linked, so further investigations 
could explore if NSC23766 effects are modulated by pertussis toxin. 
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Chapter 7: Direct and indirect effects of NSAIDs in chemotactic metastasis 
7.1: How NSAIDs interact with signalling pathways influencing cofilin phosphorylation. 
7.2: Aspirin in CCL3- and CXCL12-chemotaxis. 
7.3: Aspirin cytotoxicity assays.  
7.4: Naproxen cytotoxicity assays. 
7.5: Naproxen in CCL3- and CXCL12-chemotaxis. 
7.6: Naproxen in CCL3- and CXCL12 wound-healing and cytotoxicity assays.  
7.7: Aspirin and Naproxen in Phalloidin actin stains. 
7.8: Ibuprofen cytotoxicity assays. 
7.9: Ibuprofen in CCL3- and CXCL12-chemotaxis. 
7.10: Ibuprofen in CCL3- and CXCL12 wound-healing and cytotoxicity assays. 
7.11: Ibuprofen in Phalloidin actin stains. 
7.12: Celecoxib in CCL3- and CXCL12 MCF7 wound-healing and cytotoxicity assays. 
7.13: Celecoxib THP-1 and Jurkat cytotoxicity assays. 
7.14: Celecoxib in CCL3- and CXCL12-chemotaxis. 
7.15: Celecoxib in Phalloidin actin stains. 
7.16: Paracetamol cytotoxicity assays. 
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7.17: Paracetamol in CCL3- and CXCL12-chemotaxis. 
7.18: Paracetamol in Fura2 calcium assays. 
7.19: Ibuprofen and Celecoxib in Fura2 calcium assays. 
7.20: Aspirin and Naproxen in Fura2 calcium assays. 
7.21: Celecoxib, Ibuprofen and Paracetamol in cAMP assays. 
7.22: Western blot, cofilin phosphorylation following Celecoxib, Aspirin, Ibuprofen, 
Paracetamol and Naproxen. 
7.23: Ibuprofen’s possible off target effect, and links to cofilin phosphorylation. 
7.24: Phospholipid hydrolysis pathway to the production of prostaglandins. 
Chapter 8: Rac1 mediates chemotaxis to CXCL12, but not CCL3, in leukaemic and breast cancer 
cell-lines, and Rac1 GEF inhibitor NSC23766 may have off-target effects on CXCR4/CXCR7 axis. 
8.1: CXCL12-induced signalling can be modified by CXCR4 inhibition. 
8.2: NSC23766 in CCL3- and CXCL12-chemotaxis. 
8.3: AMD3100 in CCL3- and CXCL12-chemotaxis. 
8.4: NSC23766 cytotoxicity assays. 
8.5: W56 and F56 in CCL3- and CXCL12-chemotaxis. 
8.6: NSC23766, W56 and F56 in CCL3- and CXCL12 wound-healing. 
8.7: Western Blot, Rac1 activation pull down assay following NSC23766, ATI2341 and 
AMD3100. 
8.8: NSC23766 dose-dependence in CXCL12-chemotaxis.  
8.9: NSC23766 concentration-response curve towards CXCL12 (using data from figure 
8.8). 
8.10: NSC23766 and 12G5 competition in CXCL12-chemotaxis. 
8.11: ATI2341 chemical structure and combination with NSC23766 or AMD3100 in 
CXCL12-chemotaxis. 
8.12: ATI2341, AMD3100 and/or NSC23766 concentration-dependent effect on CXCL12-
chemotaxis. 
8.13: Flow cytometry, CXCR4 expression following NSC23766, F56 or W56. 
8.14: Flow cytometry, CXCR4 expression following NSC23766, AMD3100 and ATI2341. 
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8.15: Flow cytometry, CXCR4 expression following EHT1864 and EHT1864 chemical 
structure. 
8.16: Flow cytometry, CXCR4 expression following Sodium Azide or Sucrose, then 
NSC23766 and AMD3100. 
8.17: NSC23766, AMD3100, ATI2341 and H89 in cAMP assays. 
8.18: PKCζ siRNA knockdown in CXCL12-chemotaxis and CCL3- and CXCL12 wound-healing 
assays. 
8.19: Western blot PKC zeta expression in MCF7 following PKCζ siRNA 50 nM. 
8.20: NSC23766 in THP-1 Fura2 calcium assays. 
8.21: NSC23766 in Jurkat and MCF7 Fura2 calcium assays. 
8.22: NSC23766 CXCL12-dose dependent Fura2 calcium assay. 
8.23: NSC23766, AMD3100 and ATI2341 in Fura2 calcium assays. 
8.24: U73122 in CCL3- and CXCL12-chemotaxis. 
8.25: U73122 in Fura2 calcium assays. 
8.26: U73122 in cAMP assay. 
8.27: ZCL278 in CCL3- and CXCL12-chemotaxis. 
8.28: NSC23766, ZCL278, W56 or F56 in Phalloidin actin stains.  
8.29: Western blot, cofilin phosphorylation following NSC23766, W56, and F56. 
8.30: NSC23766, W56 or F56 in CCL2-, CXCL9-, and CXCL11-chemotaxis. 
8.31: CXCL14 in CXCL12-chemotaxis. 
8.32: CXCL14 in Fura2 calcium assays. 
8.33: Flow cytometry, CXCR4 expression following NSC23766, W56 and CXCL14. 
8.34: NSC23766 chemical structure. 
8.35: Schematic representation of cAMP, PKCζ, Rac1 and CXCR4 expression feedback loop. 
8.36: Involvement of Rac1, PLC, PKC and SSH1 in GPCR calcium signalling. 
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Appendix 3 - List of Abbreviations 
Table A3 – Abbreviations 
Abbreviation Full name 
  
AA Arachidonic acid 
AC Adenylyl Cyclase 
ACKR3 Atypical chemokine receptor 3 aka CXCR7 
ACKRs Atypical chemokine receptors 
ADP Adenosine diphosphate 
Aip1 Actin-interacting protein 1 
AKAPs A-kinase-anchoring proteins 
Akt AKT serine/threonine kinase 1  aka AKT and Protein kinase B (PKB),  
ANOVA Analysis of Variance 
AP1, AP2 Adaptor Protein Complex -1, Adaptor Protein Complex-2 
APL Acute Promyelocytic Leukaemia 
APPL1 Adaptor protein, phosphotyrosine interacting with PH domain and 
leucine zipper 1 
ARP2/3 
Arf6 
Actin-related protein 2/3 
ADP-ribosylation factor 6    
ATF2 Activating Transcription Factor 2 
ATP Adenosine triphosphate 
AUC Area Under Curve 
BAR Bin-amphiphysin-Rvs proteins 
β-ARK Beta-adrenergic receptor kinase 
BCR-ABL BCR-ABL oncogene aka Philadelphia chromosome causing CML 
BRAF serine/threonine-protein kinase B-Raf  
BSE Bundle Signalling Element 
cAMP Cyclic adenosine 3′,5′-monophosphate 
CAP Adenylyl cyclase-associated protein 
CCL2 C-C Motif Chemokine Ligand 2 aka MCP-1 
CCL3 C-C Motif Chemokine Ligand 3  aka MIP-1α 
CCR1 C-C motif chemokine receptor 1 aka MIP-1α receptor  
CCR2 C-C chemokine receptor type 2 aka CD192 
CCR5 C-C chemokine receptor type 5 aka CD195 
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Abbreviation Full name 
  
CD4+ Cells expressing surface protein Cluster of Differentiation 4  
CD8+ Cells expressing surface protein Cluster of Differentiation 8 
CDC25A cell division cycle 25 homolog A aka M-phase inducer phosphatase 1 
Cdc42 Cell division control protein 42 
CDK1,  CDK2 Cyclin-dependent kinase-1, Cyclin-dependent kinase-2 
CHO.CCR5 Chinese Hamster Ovary Cells transfected with CCR5 receptor 
CLTA-4 Cytotoxic T-Lymphocyte Associated Antigen-1 
CML Chronic myelogenous Leukemia 
COX1 & COX2 Cyclooxygenase-1, cyclooxygenase-2 
c-Src Proto-oncogene tyrosine-protein kinase Src aka proto-oncogene c-Src 
CXCL10  C-X-C motif chemokine ligand 10 aka IP-10 
CXCL11 C-X-C motif chemokine ligand 11 aka ITAC 
CXCL12 C-X-C Motif Chemokine Ligand 12 aka Stromal Cell-Derived Factor 1 
CXCL9 C-X-C Motif Chemokine Ligand 9 aka MIG 
CXCR3 C-X-C Motif Chemokine Receptor  3 aka CD183 
CXCR4 C-X-C Motif Chemokine Receptor 4  
CXCR7 Atypical chemokine receptor 3 aka ACKR3 
DAG Diacylglycerol 
DBL family Diffuse B-cell lymphoma family of guanine nucleotide exchange 
factors 
DHR1 DOCK homology region 1 
DLP Dynamin-Like Proteins 
DMSO Dimethyl sulfoxide (solvent) 
Drp-1 Dynamin related protein 1 
DRY motif Asp-Arg-Tyr 
E2F2 E2F Transcription Factor 2 
EC50 Half maximal effective concentration, measures a drug's potency 
ECL  Extracellular loop 
ECM Extracellular matrix 
EEA1 Early Endosome Antigen 1 
EGFR Epidermal Growth Factor Receptor 
EMT Epithelial mesenchymal transition 
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Abbreviation Full name 
  
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinase 2 aka MAPK 
FAAH Fatty acid amide hydrolase 
FACS Fluorescence-activated cell sorting 
FAK Focal Adhesion Kinase 
FITC Fluorescein isothiocyanate 
FKHR Forkhead box O1 transcription factor 
FOX03 Forkhead box protein O3 transcription factor 
FOX04 Forkhead box protein O4 transcription factor 
GAPs GTPase Activating Proteins 
G-CSF Granulocyte-colony Stimulating Factor 
G-domain guanosine triphosphate-binding domain 
GDP guanosine diphosphate 
GED GTPase Effector Domain 
GEF Guanine nucleotide Exchange Factor 
GOF Gain of function 
GPCR 
Grb2 
G-protein coupled receptor 
Growth factor receptor-bound protein-2 
GRK G-protein receptor Kinase aka GPCR kinases 
GSK3β Glycogen synthase kinase 3 beta 
GTP guanosine triphosphate 
GTPase Enzyme that hydrolyses guanosine triphosphate 
Gα heterotrimeric guanine nucleotide-binding proteins alpha subunit 
Gβ heterotrimeric guanine nucleotide-binding protein beta subunit 
Gγ heterotrimeric guanine nucleotide-binding protein gamma subunit 
HBC Hexabromocyclohexane 
HIF1 Hypoxia-inducible factor 1 
HIV Human Immunodeficiency Virus 
HSP Heat Shock Protein 
IBMX 3-Isobutyl-1-methylxanthine 
IC50 The half maximal inhibitory concentration 
ICL Intracellular loop  
ICL1 Intracellular Loop One  
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Abbreviation Full name 
  
IFNγ Interferon gamma 
IP Immunoprecipitation 
IP-10 Interferon gamma-induced protein 10 aka CXCL10 
IP3 Inositol 1,4,5-triphosphatase 
ITAC Interferon Inducible T-cell α Chemokine aka CXCL11 
JAK2 Janus Kinase 2 
JNK Jun amino-terminal kinases (MAPK family member) 
kDa  Kilo Dalton  
LIMK LIM Domain Kinase 
LOF Loss of function 
MAPK Mitogen-Activated Protein Kinase  
MCF7 Michigan Cancer Foundation-7 cell line 
MHC Major Histocompatibility Complex 
MCP-1 monocyte chemoattractant protein 1 aka CCL2 
MEK Mitogen-activated protein kinase kinase aka MAP2K, MAPKK 
Mfn Mitofusin 
MIF Macrophage migration inhibitory factor 
MIG Monokine induced by gamma interferon aka CXCL9 
MIP-1α Macrophage Inflammatory Protein 1 alpha aka CCL3  
MIP-1β Macrophage inflammatory protein 1-beta aka CCL4 
MiTMAB Myristyltrimethylammonium Bromide 
MLS Mitochondrial Leader Sequence 
mM Millimolar concentration 
MMP Matrix metalloproteases 
mTORC2 / mTOR Mammalian Target of Rapamicin Complex 2 
MTS Assay 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium Cell Proliferation Assay 
NADPH Nicotinamide Adenine Dinucleotide Phosphate + Hydrogen 
NFAT 
NFκB 
Nuclear Factor of Activated T-cells 
Nuclear factor kappaB   
NK cells Natural Killer cells 
nM Nano molar concentration 
NMDA receptors N-methyl-D-aspartate receptor 
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Abbreviation Full name 
  
NMR Nuclear Magnetic Resonance 
NO Nitric oxide 
NRAS Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog aka NRAS Proto-
Oncogene, GTPase 
NSAIDs Non–Steroidal Anti–Inflammatory Drugs 
Nuclear protein HMGB1 Nuclear protein High mobility group box 1  
OctMAB Octadecyltrimethyl ammonium bromide 
OPA1 Optic Atropy protein 1 
ORAL1 Calcium release-activated calcium channel protein 1 
p38 MAPK p38 Mitogen activated protein kinase 
PAK P21-activated kinases 
PAK P21-activated kinase 
Par3 Partition Defective Protein 3 
PAX3 Paired box (PAX) 3 transcription factor 
PC3 Human prostate cancer cell-line 3 
PCNA Proliferating cell nuclear antigen 
PD-1 Programmed Death Protein 1 
pDC cells Plasmacytoid dendritic cell 
PDK-1 / PDPK1 3-phosphoinositide-dependent protein kinase 1 
PD-L1 Programmed death-ligand 1 
PGE2 Prostaglandin E2 
PGH2, PGE2, PGF2 Prostaglandin H2, Prostaglandin E2, Prostaglandin F2 
PGI2 Prostacyclin 
PH domain Pleckstrin homology domain 
Pi3K Phosphoinositide-3 kinase 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PKA Protein Kinase A 
PKC Protein Kinase C 
PKD aka PKCμ Protein Kinase D aka Protein Kinase C Mu 
PLCβ Phospholipase-beta 
PLCγ Phospholipase C gamma 
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Abbreviation Full name 
  
PMA Phorbol 12-myristate 13-acetate 
PP2A Protein Phosphatase 2A 
PPARβ Peroxisome-Proliferator-Activated Receptor beta 
PRD Proline-Rich Domain 
PTD Predicted Transmembrane Domain 
PtdIns(3,4,5)P3 aka PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PtdLns(4,5)P2 aka PIP2 Phosphatidylinositol 4,5-bisphosphate 
PTEN Phosphatase and tensin homolog (a tumour suppressor) 
PTX Pertussis toxin 
Rac1 Ras-related C3 botulinum toxin substrate 1, 
RACKs Receptors for activated C-kinase 
RANTES 
Ras 
Regulated on activation, normal T cell expressed and secreted (CCL5) 
Rat Sarcoma gene 
RH Regulator of G-protein signalling homology 
Rho Ras homolog family member 
Rho GDIs Rho-specific Guanine Nucleotide Dissociation Inhibitors  
ROCC Receptor operated calcium channels 
ROS Reactive oxygen species 
RTIL Room Temperature Ionic Liquid 
SAPK Stress-activated protein kinases/( MAPK family member) 
SDF-1 Stromal Cell-Derived Factor 1 aka CXCL12 
SEM Standard Error of the Mean 
SERCAs Sarco/endoplasmic reticulum Ca2+ ATPase 
SHIP1 SH2 domain containing inositol 5-phosphatase 
SIM1 Stromal interaction molecule 1 
siRNA  Small interfering Ribonucleic Acid 
SOCC 
SOS 
Store Operated Calcium Channels 
Son of Sevenless 
SPT Serine Palmitoyltransferase 
SSH Slingshot 
STAT3 Signal transducer and activator of transcription 3 
TAM Tumour associated macrophages 
TGFα Transforming Growth Factor alpha  
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Abbreviation Full name 
  
THP-1 
Tiam1 
Human monocytic cell line from acute monocytic leukaemia 
T cell lymphoma invasion and metastasis 1 
TIMP-1 Tissue inhibitor of metalloproteinase-1 
TM3 Transmembrane helix 3 
TNFα Tumor Necrosis Factor-α 
T-reg cells Regulatory T cells aka Suppressor T cells 
TrioN Trio N-terminal DH-PH domains, a Guanine nucleotide Exchange 
Factor 
TRPM2 Transient Receptor Potential Melanostatine-2 
TRPs Transient receptor potential channels 
TRPV1 Transient receptor potential vanilloid subtype 1 
TXA2, TXB2 Thromboxane A2, Thromboxane B2. 
UV Ultra violet 
VEGF Vascular endothelial growth factor 
VGCC Voltage Gated Calcium Channels  
WASp Wiskott-Aldrich syndrome protein (actin-regulatory protein) 
WAVE WASp family Verprolin-homologous protein (actin-regulatory protein) 
WHIM Syndrome Warts Hypoammaglobulinemia Immunodeficiency and Myelokathexis 
Syndrome 
μM Micromolar concentration 
°C Degrees centigrade 
15-PGDH 15-Hydroxyprostaglandin dehydrogenase 
2D   Two-dimensional  
3D Three-dimensional 
5,15-DPP 5,15-Diphenylporphyrin 
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Appendix 4 - Small Molecule Inhibitor and Receptor Antagonist structures 
Table A4 - Small Molecule Inhibitor and Receptor Antagonist structures 
Small molecule Inhibitor Structure  
   
Dynamin Inhibitors 
MitMAB  
 
OctMAB 
 
Dynasore 
 
Dyngo 4a 
 
RTIL-13™ 
 
RhodadynC10™ 
 
Pyrimidyn-7™ 
 
PKC Inhibitors 
Rottlerin  
 
Staurosporine 
 
GF109203X  
 
PKD Inhibitor 
CID755673 
 
Raf-1 Inhibitor 
L779450 
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 Table A4 continued: Small Molecule Inhibitors and Receptor Antagonists structures   
Small molecule Inhibitor Structure 
  
cAMP Activator 
Forskolin 
 
ERK/MEK Inhibitors 
SL327 
 
PD98059 
 
Rac Inhibitors 
NSC23766   
 
EHT1864 
 
FAK/Pyk2 Inhibitors 
PF562271 
 
FAK Inhibitor PF-228 
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Table A4 continued: Small Molecule Inhibitors and Receptor Antagonists structures 
Small molecule Inhibitor Structure 
 
Kinase Inhibitors 
SB203580 
 
β-ARK-1 
 
Bosutinib 
 
H89 2HCL 
 
Y27632 
 
Pi3K Inhibitors 
AS605240 
 
LY294002 
 
GRK Inhibitor 
Ipyrimidine (4-Amino-5-
ethoxymethyl-2-methylpyrimidine) 
 
JAK2 Inhibitor 
Hexabromocyclohexane (HBC) 
 
STAT3 Inhibitors 
WP1066 
 
5,15-Diphenylporphyrin (5,15-DPP) 
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Table A4 continued: Small Molecule Inhibitors and Receptor Antagonists structures 
Small molecule Inhibitor Structure 
   
β-catenin Inhibitor 
FH535 
 
Cdc 42 Inhibitor 
ZCL278 
 
Phospholipase C Inhibitor 
U73122 
 
NSAIDs 
Celecoxib 
 
Ibuprofen 
 
Naproxen  
 
Aspirin  
 
Paracetamol  
 
CXCR4 antagonist 
ATI2341 
 
CCR1/CCR3 antagonist 
J113863 
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Table A4 continued: Small Molecule Inhibitors and Receptor Antagonists structures 
Small molecule Inhibitor                                                                     Structure 
   
CCR5 Antagonist 
Maroviroc 
 
Gβγ Inhibitor 
Gallein 
                                            
Cytoskeletal Inhibitor 
Nocodazole 
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Appendix 5 - Published Abstracts, Posters and Oral Presentations 
2014 
Poster: Chemokine receptor-induced cell migration: distinct signalling networks are used by 
different receptors. Jacques R O, Zerwes P, Fagade F, Green J, Roberts-Dalton H, Downham S, Mills 
S C, Sexton D and Mueller A. Presented: 28th – 29th April 2014, British Pharmacology Society (BPS) 
5th Focused Meeting on Cell Signalling, British Society for Immunology (BSI) Leukocyte Migration 
Affinity Group Meeting, University of Leicester.  
2015 
Abstract and Poster: The importance of signalling pathway proteins differ in CC and CXC 
chemokine-induced chemotaxis. Mills S C, Jacques R O, Zerwes P, Sexton D, and Mueller A. 
Presented: 9th – 11th February 2015, BSI Leukocyte Migration Affinity Group Meeting, “Leukocyte 
Migration in Health and Disease” at Medical School Birmingham University. Also presented: 17th 
September 2015, Annual Pharmacy Research Colloquium, John Innes Conference Centre, Norwich 
Research Park. 
Abstract and Poster: Signalling Pathway Proteins in CC and CXC Chemokine-induced Chemotaxis. 
Mills S C. Presented: 15th – 17th December 2015, BPS, Pharmacology 2015, at QEII Conference 
Centre, London.  
2016 
Abstract and Poster: Signalling Pathway Proteins in CC and CXC Chemokine-induced Chemotaxis. 
Mills S C. Presented: 18th-19th April 2016, BPS 6th Focused Meeting on Cell Signalling, BSI 
Leukocyte Migration Affinity Group Meeting, University of Leicester.  
Abstract and Poster: Cofilin: a key protein in chemokine-induced cell migration in metastasis. Mills 
S C and Mueller A. Presented: 29th May – 3rd June 2016, From Molecular Mechanisms of 
Chemokine Biology and Pathophysiology to Progress and Challenges in the Development of 
Therapeutics, Chemotactic Cytokine Gordon Research Conference, Girona, Spain. Also presented: 
13th – 15th December 2016, BPS, Pharmacology 2016, at QEII Conference Centre, London.   
Abstract and Poster: Signalling Pathway Proteins in CC and CXC Chemokine-induced Chemotaxis. 
Mills S C. Presented: 15th June 2016, School of Pharmacy Research Day, Thomas Paine Study 
Centre UEA. (won Best Pharmacology Poster Prize). 
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Oral Presentations 
3 Minute Thesis Competition, 15th June 2016, Does chemokine signalling hold the elusive silver 
bullet to beat metastasis? Single PowerPoint Slide and 3 minute oral presentation. 
School of Pharmacy Seminar, 19th September 2016, Thirty minute PowerPoint presentation and 
questions covering my research entitled: “Manipulating Chemokine Signalling to Prevent 
Metastasis”. 
Appendix 6 - Contributions to and Copies of Published Papers 
 
Published 9th September 2015: Jacques R O, Mills S C, Zerwes P, Fagade F O, Green J E, Downham 
S, Sexton D W, Mueller A. Dynamin function is important for chemokine receptor-induced cell 
migration. Cell Biochem Funct 2015 33(6):407-414.  
I contributed to writing and proof reading of paper, and undertook investigations and analysed 
data to supply figure 1 (a), (b) and (e); figure 2 (a), (c), (d); figure 3 (e), (f), (g), (h); figure 4 (a), (b). 
 
Published 21st January 2016: Mills S C, Goh P H, Kudatsih J, Ncube S, Gurung R, Maxwell W, 
Mueller A. Cell migration towards CXCL12 in leukaemic cells compared to breast cancer cells. Cell 
Signal 2016 28(4):316-324 
I contributed to writing the paper with Dr Mueller and influenced the story line. Proof read paper 
and undertook investigations and analysed data to supply following: figure 1 (g); figure 2 (a), (b), 
(c), (d), (e), (f), (g); figure 4 (a), (b), (c); figure 5 (a), (b), (c), (d), (e), (f), (g); figure 6 (a), (b), (c), (d), 
(g). 
 
Published 16th October 2017: Mills S C, Howell L, Beekman A, Stokes L, Mueller A.  Rac1 plays a 
role in CXCL12 but not CCL3-induced chemotaxis and Rac1 GEF inhibitor NSC23766 has off target 
effects on CXCR4. Cell Signal 2018 42:88-96 
I discovered and contributed paper’s story, wrote the paper with Dr Mueller, undertook 
investigations and analysed data to supply following: figure 1 (a), (b), (c), (f), (g), (h); figure 2 (a), 
(b), (c), (d), (e); figure 3 (a), (b), (c), (d); figure 4 (a), (b), (c); figure 5 (a), (b), (except EHT1864 
chemotaxis data) (c); figure 6 (a), (b), (c); figure 7(a), (b). 
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